National Cancer Institute

Division of Extramural Activities

Annual Report 2011



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Deciphering the Complexity of Drug Resistance in Cancer

For more than 30 years, the Laboratory of Cell Biology has focused on understanding the mechanisms by which cancer cells elude the toxic effects of chemotherapy. This work was initially stimulated by the observation that while some cancers go into remission following treatment with anti-cancer drugs, others fail to respond at all (intrinsic resistance), or once in remission relapse with tumors that are difficult to treat with chemotherapy (acquired resistance). New, targeted anti-cancer drugs are not exempt from the problem of both intrinsic and acquired multidrug resistance (MDR). This functional complexity of drug resistance suggests that the mechanisms underlying resistance are likely to be complex as well.

It was something of a surprise when we and others discovered in 1985 that the product of a single gene (ABCB1 or MDR1), an energy-dependent multidrug efflux pump termed P-glycoprotein (P-gp), could account for both intrinsic and acquired resistance in cultured cancer cells. We showed that at least 50 percent of drug-resistant human cancers expressed P-gp at levels sufficient to confer MDR, and strategies to inhibit P-gp in cancers and restore sensitivity to anti-cancer drugs were devised. Along the way, we discovered that common polymorphisms in the *AB*CB1 gene, including single nucleotide changes that do not alter the amino acids in P-gp (so-called "silent" mutations), can significantly alter the pattern of MDR and sensitivity to inhibitors. It soon became apparent that we were not curing most MDR cancers with strategies that inhibit P-gp, even in cases where P-gp was expressed and functional.

We decided to reconsider some of the assumptions that had gone into studies on MDR in cancer. First and foremost was the underlying hypothesis that resistance mechanisms that operated in cultured cancer cells reflected mechanisms of resistance in cancers in patients. Growth conditions of such cells differ dramatically from the environment *in vivo*. Furthermore, most cultured cancer cells have been grown outside of the body for many years and have adapted to these highly altered culture conditions by expressing many genes involved in environmental adaptation and traditionally associated with the development of drug resistance. Although cultured cells could be used to catalog *possible* mechanisms of MDR, they by no means reflected the likely mechanisms active in clinical cancers.

Using the tools of modern molecular biology, it was possible to interrogate samples from human cancers, such as ovarian cancer, acute myelogenous leukemia, and hepatoma, and correlate expression of specific drug-resistance genes with clinical outcome. This analysis of clinical cancers revealed robust, but complex, signals predicting clinical outcome involving multiple genes that could independently confer drug-resistance, but seemed to be working together in clinical cancers to thwart effective chemotherapy. P-gp expression was embedded in some of these signals as a potential predictor of poor response to chemotherapy, but was by no means the only MDR gene capable of predicting poor response. It appears that resistance derives from a reprogramming of cellular pathways that regulate growth and response to environmental adversity, and that the cancer cell can draw from many different built-in mechanisms to survive chemotherapy.

Our challenge now is to use system and computational approaches to define the pathways involved in drug resistance, and to develop better *ex vivo* systems to dissect the contribution of the many gene products and pathways involved in the development of MDR in cancer. This would allow development and testing of new approaches to circumventing or targeting resistance, such as RNAi and small molecule inhibitors of some pathways, targeting the Achilles' heel of some MDR cancers that overexpress P-gp (and other MDR cancers) with agents that specifically kill such cells, and strategies that alter resistance pathways through epigenetic changes leading to new patterns of gene expression.

References:

Shen DW, Pouliot LM, Hall MD, and Gottesman MM. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. [Review] *Pharm. Rev.* 2012:64(3);706-721.

Gillet JP, Calcagno AM, Varma S, Davidson B, Bunkholt Elstrand M, Ganapathi R, Kamat AA, Sood AK, Ambudkar SV, Seiden MV, Rueda BR, and Gottesman MM. Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. *Clin. Cancer Res.* 2012:18;3197-3206.

Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora M, Patel C, Orina JN, Eliseeva T, Singal V, Padmanabhan R, Davidson B, Ganapathi R, Sood AK, Rueda BR, Ambudkar SV, and Gottesman MM. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. *Proc. Natl. Acad. Sci. U.S.A.* 2011:108;18708-18713.

Hall MD, Handley MD, and Gottesman MM. Is resistance useless? Multidrug resistance and collateral sensitivity. [Review] *Trends Pharmacol. Sci.* 2009:30;546-555.

Fung KL and Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function. *Biochim Biophys Acta* 2009:1794;860-871.

National Cancer Institute

Division of Extramural Activities

Annual Report 2011



Cover Images: Cellular and molecular approaches to the study of multidrug resistance in cancer. The outer circle demonstrates the polarized expression of the multidrug transporter, P-glycoprotein, on the apical membrane of kidney epithelial cells. The left panel uses fluorescently labeled drug-resistant cells (green) to show how resistant ovarian cancer cells overgrow sensitive cells (red) following selection in the anti-cancer drug paclitaxel. The right panel illustrates the use of expression arrays to identify genes whose expression is associated with poor response to chemotherapy.

Images and narrative are courtesy of Michael M. Gottesman, M.D., Chief, Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Contents

Figures

Tables

Appendixes

Introduction

The Division of Extramural Activities (DEA) is the organizational component of the National Cancer Institute (NCI) responsible for coordinating the scientific review of extramural research before funding and for conducting systematic surveillance of that research after funding. The Division solicits advice from individuals and/or committees of experts on the technical and scientific merit of grants, cooperative agreements, and contracts. The peer review process is critically important to science in that it allows good ideas to surface and to be judged on their merit and promise. The peer review system is the keystone for ensuring that the best science is supported.

The DEA coordinates the activities of: (1) the National Cancer Advisory Board (NCAB), which consists of members appointed by the President, and conducts the second-level review of grants and cooperative agreements and advises the Director, NCI, on policy for the conduct of the National Cancer Program; (2) the Board of Scientific Advisors (BSA) with distinguished scientists from outside the NCI and representatives from the advocacy community advises the NCI leadership on the progress and future direction of the NCI extramural program, evaluates NCI extramural programs, and reviews NCI-initiated research concepts; and (3) extramural training opportunities for NCI program and review staff.

As a Division, we: evaluate the content of all extramural research funded by the NCI and annually track the NCI research portfolio of more than 8,055 research and training awards by using consistent budget-linked scientific information to provide a basis for budget projections; maintain extensive records of this research and provide specialized analyses of the costs, goals, and accomplishments of the research; and serve as an NCI resource to others for reporting and dissemination of the NCI's research portfolio. The DEA: monitors budgetary limitations for grant applications; participates in establishing policies to expedite funding; and initiates and implements changes to applications, guidelines, and award processes. The Division also: coordinates, for the NCI, the review and response to appeals from applicants regarding the peer review process or the subsequent disposition and management of grants, cooperative agreements, and contracts; and responds and coordinates requests from the NIH Office of Extramural Research's Agency Extramural Research Integrity Officer for information and assistance regarding scientists (or institutions) supported by NCI research funds who were the subject of allegations, inquiries, and/or investigations of possible research misconduct.

The intent of this annual report is to provide insight and useful information about the research funding process and the role of the DEA in support of NCI's mission. A comprehensive look at each of the major areas of responsibility within the Division is provided. The data presented cover Fiscal Year (FY) 2011 (1 October 2010 - 30 September 2011) and provide data comparison with previous years.

To implement a biomedical research program of the highest quality, the NCI draws on the national pool of scientists actually engaged in research for assistance in selecting the best research and training projects. We sincerely want to thank the more than 2,341 researchers, clinicians, and advocates who gave unselfishly of their time in FY2011 and have contributed to the continuing success of NCI's peer review and advisory activities.

Paulette S. Gray, Ph.D.
Director
Division of Extramural Activities

Division of Extramural Activities



Overview of the Division of Extramural Activities

The paramount goal of the National Cancer Institute (NCI) is to develop the knowledge base that will ultimately lessen the impact of cancer. Among the most important contributors to this base are the outstanding extramurally funded scientists supported by the NCI through grants, contracts, and cooperative agreements. The DEA was established within the NCI to provide the Institute and the scientific community with expert scientific review of the merits of extramural research. An important part of DEA's mission is to manage and coordinate the second level of grants review by the National Cancer Advisory Board (NCAB) and the concept review of all new and reissued Requests for Applications (RFAs) and research and development (R&D) Requests for Proposals (RFPs) with the Board of Scientific Advisors (BSA).

The **Committee Management Office** (CMO) provides oversight of all NCI-chartered advisory boards and committees, working groups, task forces, and chartered review groups, and it serves as an NIH service center for the National Center for Complementary and Alternative Medicine, the NIH Council of Councils, and a Department of Health and Human Services (HHS) chartered advisory committee. The CMO provides policy guidance and assistance to ensure that the NCI and client HHS/NIH Institutes, Centers, and Offices operate within the appropriate Federal Advisory Committee Act (FACA), the Government in Sunshine Act, and various other policies, procedures, and guidelines.

The DEA also provides effective and timely coordination of program initiatives from the initial concept stage through publication of RFAs, PAs, Notices, and RFPs, and, finally, through the peer review of grant and cooperative agreement applications and contract proposals. The **Office of Referral, Review, and Program Coordination** (ORRPC), with four branches, was established for: (1) coordination of the development and issuance of NCI program initiatives; (2) execution of grant referral; and (3) management of NCI review activities. Review activities include the organization and management of peer review for all applications and proposals received in response to RFAs, R&D RFPs, Program Announcements with Special Receipt (PARs), and multi-component grant initiatives. The program coordination responsibilities of the DEA, in cooperation with NCI extramural program divisions, offices, and centers, extend to the development of all new extramural program guidelines and funding opportunity announcements (FOAs).

Another program coordination activity is the development and maintenance of referral guidelines for assignment of grant applications to the NCI. These guidelines, included in the *Referral Guidelines for Funding Components of PHS*, are critical to the development of program initiatives across the NIH, as well as to the prompt referral of unsolicited grant applications to the NCI. These guidelines differ from the NCI Internal Referral Guidelines, which are vital to the prompt referral of grant applications to the appropriate NCI program areas.

The **Research Analysis and Evaluation Branch** (RAEB) works closely with the NCI Office of Budget and Finance to provide budget-linked portfolio data for NCI grants and contracts. In doing so, the Institute has the capability of responding expeditiously to congressional and other inquiries. This Branch has historical budget-linked portfolio data that go back to the 1930s.

The DEA conducts continual evaluation of program initiatives and coordinates policies and procedures to ensure that all aspects are as clear and accessible as possible to staff, advisory groups, and applicants. To facilitate this evaluation, the **Office of Extramural Applications** (OEA), through the **Applied Information Systems Branch** (AISB), maintains a Web-based information system to provide key information on new initiatives. This Web-based information system includes early notice of approved concepts, listings of active PAs and recently published RFAs, and policies related to the clearance of new program initiatives. This information is provided in both public Internet (**http://deainfo.nci.nih.gov/funding.htm**) and NCI limited-access Intranet versions. Both RAEB and AISB were actively involved in continuing to provide data for the NCI Funded Research Portfolio (NFRP) website (**http://fundedresearch.cancer.gov**).

Special Activities in the Office of the Director, DEA

In addition to managing and coordinating the extramural operations described in this report, the DEA Office of the Director (OD) is a focal point and repository of information and policies related to various funding mechanisms for NIH grants, staff and awardee responsibilities, eligibility requirements, receipt dates for all granting mechanisms, and special programs. The DEA OD is, for example, the coordinating center for submission of applications for special NIH-wide awards, such as the James A. Shannon Director's Award and the Institutional Development Awards (IDeAs).

The DEA OD ensures that the NCI meets the congressional mandate to promote increased participation of women, children, and members of minority and medically underserved populations in the research areas of cancer cause, prevention, control, diagnosis, and treatment. The NIH Revitalization Act of 1993 mandates that women and members of minority groups be included as subjects in each research project, unless there are clear scientific or ethical reasons that inclusion is inappropriate with respect to the health of the subject or the purpose of the research. Administrative procedures allow NCI staff to resolve inclusion problems after initial review of grant applications that are otherwise highly meritorious. In the event that a grantee believes the proposed study does not warrant or require inclusion of women or persons from minority groups, he or she can apply for a waiver of this requirement. The DEA Director is the Appeals Officer for the NCI and has the authority to grant waivers. In FY2011, 25 applications with preliminary bars to award were received by the DEA. Through corrective action, working with the applicants and program directors, all bars to award were brought into compliance before awards were made.

Additionally, the DEA Director serves as the locus for implementation and oversight of NCI policies concerning extramural research integrity and serves as a resource to all NCI staff with questions in this area. In this role, the DEA Director and designees work to address concerns about extramural research misconduct, misuse of human and animal research subjects, financial mismanagement, and financial conflict of interest involving NCI-supported research. The DEA Director functions as the NCI Research Integrity Officer (RIO) and receives from the appropriate sources all documents related to research misconduct for transmittal and reporting to relevant sources. In FY2011, 10 cases of alleged research misconduct involving NCI funding were opened and under investigation by the Office of Research Integrity, HHS, and referred to the Director, DEA. Five cases were closed, and one of the cases was found to involve research misconduct.*

Extramural Staff Training

Program and Review Extramural Staff Training Office (PRESTO)

The Program and Review Extramural Staff Training Office (PRESTO) was created in 2010 to develop and coordinate the training of scientific Program and Review Staff, and other extramural staff (e.g., members of the NIH Division of Extramural Activities Support) upon request. The mission of PRESTO, which resides in the DEA OD, is to increase the knowledge base of new and experienced staff members and optimize their effectiveness in supporting the goals of the NCI. To accomplish this mission, PRESTO staff members will: (1) design and implement a broad-based curriculum for Program and Review staff; (2) provide training on specialized topics related to understanding of and compliance with NIH

*Cases found to involve research misconduct are published in the *Federal Register* and *NIH Guide for Grants and Contracts*.

policies; and (3) identify and develop resources to facilitate individual learning and performance. PRESTO also will collaborate with the Trans-NCI Extramural Awareness Group (TEAG) and the NCI Office of Workforce Management and Development to provide customized job-related training and career development opportunities. Finally, its staff members will monitor the participation of extramural staff in NIH- and NCI-sponsored training activities as well as continuously evaluate the efficacy of these activities.

For FY2012, PRESTO plans to develop and conduct the following activities:

- Surveying NCI extramural staff to identify training needs.
- Launching a website to serve as a training resource.
- Establishing a liaison group consisting of Division/Office/Center (DOC) representatives to provide ongoing feedback to PRESTO.
- Implementing an NCI-specific curriculum for extramural staff.
- Coordinating a series of forums on core extramural staff responsibilities (e.g., NCAB Closed Sessions, Funding Opportunity Announcement Development).
- Publishing a guide for new NCI extramural staff as well as best practice handbooks for Program and Review operations.

Program Coordination: A Resource for New Funding Initiatives

The DEA performs critical functions in the development of new strategic funding initiatives at the NCI and in the coordination of their publication as Funding Opportunity Announcements, which comprise both RFAs and Program Announcements (PAs). Specifically, members of the **Program Coordination and Referral Branch** (PCRB) provide expert assistance to NCI program staff members as they work to develop and publish new (and reissue) FOAs. PCRB staff members disseminate various operating policies and procedures pertaining to extramural funding programs. To maintain consistency and completeness, all new and reissued NCI FOAs, Notices, and various associated guidelines are reviewed, edited as needed, and cleared through the DEA, under PCRB coordination, before being forwarded to the National Institutes of Health (NIH) Office of Extramural Research for approval and publication in the *NIH Guide for Grants and Contracts* and on Grants.gov. In these steps, PCRB staff members help to streamline and clarify FOA technical parameters and requirements as well as optimize accuracy, precision, and clarity of their presentation in proper format. The PCRB verifies consistency with NIH-wide requirements, provides quality control, and coordinates timelines throughout the development and publication processes. Overall, these services ensure the high quality and timely availability of NCI's funding opportunities for cancer researchers as prospective applicants.

Tables 1a and **1b** show the variety of RFAs issued by the NCI in FY2011, and **Table 2** lists RFAs issued by other NIH institutes or centers (ICs) that the NCI has joined as a participating partner. **Tables 3a** and **3b** show the variety of PAs issued by the NCI in FY2011, and **Table 4** lists PAs issued by other NIH ICs that the NCI has joined as a participating partner.

The PCRB continues to provide relevant information and timely updates to all NCI extramural staff members on activities and results related to the requirements for and uses of electronic grant applications. The Branch also serves as a direct source of guidance on this topic for program directors at the NCI and applicants in the extramural scientific community. The Referral Office (RO) staff collaborated with NCI information technology staff members and their contractors to successfully develop and deploy an improved Web-based Awaiting Receipt of Application (ARA) management system (permission for special application receipts), which contributes to an improved efficiency of use by NCI staff members and quality of service for the NCI's grant applicants and awardees. In addition to performing their program coordination and referral responsibilities, PCRB Health Scientist Administrators also served as Scientific Review Officers (SROs) in managing the reviews of 383 student loan repayment program (LRP) contract proposals in FY2011.

Grant Referral: A First Point of Contact for NCI Grant Applicants and Receipt of Applications

In FY2011, a total of 14,312 grant applications were submitted to the NCI for funding with appropriated funds (see **Figure 1** and **Table 5**). Applications for 56 different types of funding award mechanisms (see **Appendix E**), including the Investigator-Initiated Research Project (R01), Career Development Awards (K series), Research Program Project (P01), Cancer Center Support Grant (CCSG, P30), Specialized Program of Research Excellence (SPORE, P50), Small Research Project (R03), Exploratory/Developmental Project (R21), Exploratory/Developmental Phase II Project (R33), Small Business Technology Transfer (STTR) Grant (R41/R42), Small Business Innovation Research (SBIR) Grant (R43/R44), and U-series (Cooperative Agreement) mechanisms, were received.

All applications submitted to the National Institutes of Health (NIH) are assigned to an Institute or Center (IC). The IC in turn has a structure in place to address internal assignments. DEA's **Program Coordination and Referral Branch** is responsible for receipt, referral, and assignment of applications as well as for program (i.e., scientific initiative and funding opportunity) development functions. Upon receipt of primary and secondary assignments of applications to the NCI by the NIH Center for Scientific Review (CSR), the DEA Referral Officers (ROs): (1) assign all incoming applications to one of the 50 NCI extramural research program areas; (2) track program acceptance; and (3) whenever necessary, negotiate transfers of grant applications to and from other NIH ICs and even other HHS

Figure 1. Receipt and Referral of NCI Grant Applications*
FY2007 - 2011



*Includes NCI Primary and Secondary applications received and referred.

research funding agencies, such as the Agency for Healthcare Research and Quality (AHRQ) and the Centers for Disease Control and Prevention (CDC).

The ROs distribute all of the applications that are to be directly reviewed by NCI DEA-managed peer review groups. These applications include those for P01, Planning Grants (P20), Cancer Centers, Specialized Centers (P50), Conference Grants (R13), Small Grants, certain Phased Innovation Grants (R21/R33), Training Grants (T32 and R25), K-series Career Development Grants, certain R01 Research Project Grants (such as large multi-site clinical trials), and Cooperative Agreement applications.

The first point of contact for applicants is often the RO. The RO is the receipt point for Letters of Intent (LOIs) from potential applicants for multi-component P01 and R13 grants and applications for Academic Research Enhancement Award (AREA, R15) grants for research at institutions and organizations that have little or no current NIH grant award support. Additionally, applicants contact the Referral Office for information about NCI programs, their eligibility to apply the relevance of their proposed research to the missions of various NCI programs, and the names and contact information of NCI program staff members to guide them through the application process. In addition, ROs work with program staff members to determine and/or verify the responsiveness of R21 exploratory/developmental grant applications to the specific FOAs.

DEA's RO serves as the primary NCI contact locus for the extramural scientific community in need of information related to funding opportunities, mechanisms, policies, processes, procedures, new initiatives announced as RFAs or PAs, and the peer review process. In addition, the ROs assist members of the extramural community in navigating NIH and NCI Web pages to obtain current grants-related information, forms, and guidelines.

Peer Review—The Next Step

Once applications are referred to the NCI and the appropriate program, they must be reviewed. The high caliber of NCI-sponsored research is maintained through a peer review process in which experts in the appropriate fields review and score the merit of research grant applications and contract proposals. The peer review mechanism helps to ensure that the NCI uses its resources wisely and funds research that has the potential to make a significant contribution to science and medicine. The NCI's extramural programs and activities are funded primarily through peer reviewed grants and cooperative agreements. Programs that are funded through research and development contracts also are subject to peer review, including contract-supported projects conducted within the intramural research program.

The peer review system of the NIH consists of two sequential levels of review mandated by statute. The first level is of grant applications assigned to the NCI. This review is performed by either an NIH Center for Scientific Review (CSR) study section, a chartered NCI Initial Review Group (IRG) subcommittee, or an NCI Special Emphasis Panel (SEP), whose primary purpose is to review and evaluate the scientific merit/impact of research grant and cooperative agreement applications. The second level of review, which is for program relevance, is conducted by the National Cancer Advisory Board.

Most investigators are familiar with the NIH CSR study sections, which have primary responsibility for managing the peer review of R01 grant and Fellowship applications. It is less widely known, however, that grant applications representing requests for more than 50 percent of the NCI's extramural budget are reviewed by chartered IRGs and SEPs that are directly formed and managed within the NCI by the DEA. Peer review managed by either the CSR or the DEA is usually determined by the choice of grant mechanism.

The NCI has no direct input into the selection of peer reviewers who serve on CSR study sections. In contrast, members of the NCI IRG and SEPs are selected by DEA review staff, with suggestions from NCI program staff. All chartered DEA review subcommittee members are approved by the Director, DEA, based on their knowledge of the various disciplines and fields related to cancer. There are five active NCI IRG specialized review subcommittees; for example, Subcommittee A reviews Cancer Center grant applications and Subcommittee I reviews career development applications. (The membership of NCI-chartered subcommittees may be found in **Appendix C** (**pp. 104-112**) and at **http://deainfo.nci.nih.gov/advisory/irg/irg.htm.**) IRG members are appointed for varying terms of service, which may be up to 6 years. DEA SEPs may be formed to review grant applications received in response to RFAs and PARs, other specialized applications, or R&D contract proposals received in response to RFPs. Members of such panels are selected on a one-time, as-needed basis to review specific grant and cooperative agreement applications, or contract proposals. Additional information about NCI SEPs can be accessed at **http://deainfo.nci.nih.gov/advisory/sep/sep.htm**.

Both the SEPs and IRGs provide advice on the scientific and technical merit of applications for research and research training grants, cooperative agreements, and contract proposals relating to scientific areas relevant to cancer. DEA SROs manage the scientific reviews of grant applications and R&D contract proposals, including the selection of peer reviewers and the overall administration of the peer review process.

The peer review of grant applications generally occurs in the fall, winter, and spring prior to the February, June, and September NCAB meetings, respectively.

Review Workload

In FY2011, the DEA organized, managed, and reported the review of a total of 2,032 grant and cooperative agreement applications (see Table 6) **and 679 contract proposals** (see Table 12) **assigned to the NCI for funding with appropriated dollars.** The total number of grant, cooperative agreement applications, and contract proposals reviewed in FY2011 was 2,711 (see Figure 2). Table 7 provides a summary of the applications reviewed by NCI IRG subcommittees and SEPs. Fifteen meetings of the NCI IRG subcommittees and 111 SEPs were convened to review grant applications and contract proposals of various types. In addition, there were 16 site visits and 53 other review-associated meetings, such as orientation teleconferences, applicant interviews, and fact-finding review panel work groups. Approximately 2,039 peer reviewers and expert consultants served on the NCI DEA-managed IRG subcommittees, SEPs, and work groups in FY2011 (see Appendixes C and D). Members were selected because they are authorities in relevant fields of biomedical research or because they represent informed consumer perspectives.

Peer Review Functions

The Office of Referral, Review, and Program Coordination (ORRPC) is responsible for the coordination and management of the review of grant applications, cooperative agreement applications, and contract proposals for the Institute, and it includes three review branches, a referral branch, and the Office of the Associate Director. The review branches are responsible for organizing, managing, and reporting the scientific peer review of applications for a wide variety of grant

Figure 2. DEA Review Workload*
FY2007 - 2011



*Withdrawn applications are not included. LRP contracts are not included in the RFAs.

mechanisms and topics. Reviews are conducted by one of the five subcommittees of the NCI IRG or by one of the specially convened SEPs as shown in **Table 7**.

The **Research Programs Review Branch** (RPRB) and the **Resources and Training Review Branch** (RTRB) are primarily responsible for the peer review of a variety of unsolicited multi-component and career development grant applications (see **Table 6**). The RPRB has primary responsibility for review of unsolicited P01 and SPORE applications involving translational research focused on various disease sites. All of these applications are reviewed by SEPs. The RTRB manages the five active subcommittees of the NCI IRG (see **Appendix D**). Specifically, the RTRB has primary responsibility for review of applications for cancer centers, cancer training and career development, as well as for managing the corresponding five subcommittees of the NCI IRG.

The **Special Review and Logistics Branch** (SRLB) organizes and manages peer review primarily for grant applications in response to most of NCI's RFAs, specialized PARs, and R&D contract proposals submitted in response to RFPs; all of these reviews are conducted by SEPs. In addition, the **Program Coordination and Referral Branch** (PCRB) often collaborates with the review branches to assist in the review of special initiatives and also has responsibility for the review of conference grant and loan repayment program applications.

SROs in these review units prepare the summary statements, which present the peer reviewers' written evaluations of and recommendations for the applications considered at each review committee meeting. Each principal investigator (applicant) for an application also receives the summary statement as do the NCAB members for second-level review.

Reviews conducted by the RTRB, including those of the Cancer Center Support Grant (CCSG) applications, involve a two-tier initial peer review process. Normally, the first tier of the review involves a site visit to the applicant's institution by an expert review panel; these review formats provide an opportunity for the reviewers to question the applicants directly to clarify issues in the application, thereby enhancing the review process. The review panel members prepare a draft review report, which is then considered, along with the application, by the relevant subcommittee of the NCI IRG. One of the five active NCI subcommittees of the NCI IRG serves as the "parent committee" for final scoring of CCSG applications after expert panel reviews: Subcommittee A is the "parent committee" for the P30 applications. The other four subcommittees of the NCI IRG (Subcommittees F, G, I, and J) review all of the career development, training, and education grant applications submitted to the NCI.

Research Programs Review Branch

Program Project (P01) Applications

A significant proportion of the effort of the RPRB during FY2011 was associated with the review of unsolicited P01 applications. During FY2011, the SROs in the RPRB organized and managed the review of 122 new, renewal (recompeting), resubmitted (amended), and revised (competitive supplement) P01 applications (see **Table 8**), which was a higher P01 workload than the NCI has seen in the past 4 years, as shown in **Figure 3**. Approximately 53 percent of the applications were proposing new multidisciplinary research programs, and 38 percent of the applications were amended (see **Table 8**). Sixty-two (51%) of the 122 applications were referred to NCI's Division of Cancer Treatment and Diagnosis (DCTD) (see **Table 9**). The 122 applications requested approximately $312 million in total costs for the first year (see **Table 9**) and more than $1.6 billion in total costs for all years. Of the 122 P01 applications reviewed in FY2011, 21 (17%) included multiple PIs.

P01 applications are reviewed in groups of up to 10 applications by a one-tier, "paper only"

Figure 3. P01, SPORE, and Other Multi-Project Research Applications Reviewed* FY2007 - 2011



*Withdrawn applications are not included.
†Non-SPORE applications.

review process. All review panels are constituted as SEPs, with reviewers recruited based on the expertise needed for the applications being reviewed. The applications are grouped based on science, typically into four to six SEPs. Although the groupings vary depending on the applications that are received in each review round, the SEPs typically address: molecular biology; cellular and tissue biology; prevention, epidemiology, and control; discovery and development; and clinical studies. A SEP may include applications representing a continuum of research from basic through translational studies. The SEP reviewers evaluate and score projects, cores, and integration, and then assign the overall impact/priority score to each application.

Specialized Centers of Research Excellence (P50)

The other major responsibility for RPRB during FY2011 was the peer review of applications received for the NCI SPORE. These large, complex multidisciplinary P50 research center applications focus on translational research directly applicable to human disease in various organ sites. During FY2011, the RPRB organized and managed five SEPs for the review of a total of 31 SPORE applications (see **Figure 3**). These 31 applications addressed multiple organ sites, with the following distribution of applications: Brain (2); Breast (5); Gastrointestinal (GI)(3); Head and Neck (HN)(1); Leukemia (1); Lymphoma (2); Lung (4); Liver (1); Multiple Myeloma (2); Pancreatic (1); Prostate (4); Ovarian (2); Skin (2); and Genitourinary (1). Overall, 20 (65%) of the 31 applications were for new SPOREs, and 11 (35%) of the 31 applications were renewal applications. The applications requested $84,221,617 in total costs for the first year of support and more than $402,500,000 in total costs for all years.

The disease sites addressed in SPORE applications for each review round continue to be very varied. Five applications addressing four different disease sites were reviewed for the February 2011 NCAB meeting, 21 applications addressing 12 disease sites were reviewed for the June 2011 NCAB meeting, and five applications addressing five disease sites were reviewed for the September 2011 NCAB meeting.

The large number of new and resubmitted (amended) applications related to multiple disease sites resulted in increased complexity for the SROs who manage the reviews of the SPORE applications. Due to the complexity of the review, the special review criteria, and the large number of reviewers required for the research proposed, the SROs who organize the SPORE reviews routinely conduct orientation conference calls with all of the reviewers 3 to 4 weeks before the review meeting to explain the special features of this program and the associated special review criteria.

Potential applicants for both P01 and SPORE grants are strongly encouraged to have pre-submission conferences with the appropriate NCI program (and review) staff members so that they fully understand the guidelines, requirements, and goals of these complex applications. SROs from RPRB routinely participate in these pre-submission conferences to ensure that applicants also understand the formatting requirements, the review process, the special review criteria, and the special scoring paradigms for these applications.

Resources and Training Review Branch

In FY2011, the Resources and Training Review Branch administered five NCI IRG subcommittees (A, F, G, I, and J). This Branch has the responsibility for the reviews of applications for cancer centers, institutional training and education programs, and career development awards. Its staff members also participate in the reviews of applications for other funding mechanisms handled by the DEA.

The reviews conducted by the RTRB subcommittees are of two types: (1) the complex, multidisciplinary applications, such as the CCSG; and (2) single component training and career development applications. The review formats for the Cancer Center Support Grant applications generally involve a two-step initial review. The first step of the review involves a site visit to the applicant institution. Each group of experts serves as a fact-finding body to clarify any information or issues related to the application through discussion with the applicants. This site visit committee prepares a draft report that is presented, with the full application, for discussion, evaluation, and final scoring by the parent subcommittee, NCI IRG Subcommittee A. Scoring by a parent subcommittee provides a more uniform evaluation of applications than scoring by individual review teams. The single component applications are reviewed by a chartered subcommittee. Please note that the NCI's clinical trial enterprise is undergoing review, and changes in clinical trial approval and funding are expected in the future.

NCI Cancer Centers

The CCSG Funding Opportunity Announcement (FOA) was released in conjunction with revisions to the guidelines and other supporting documents in October 2010. The SRO for NCI-Subcommittee A played a major role in drafting the CCSG FOA and the subsequent drafting of guidelines for both applicants and reviewers. During FY2011, Subcommittee A reviewed 16 applications.

Training and Career Development

Between 2007 and 2009, the number of applications for career development awards had declined. The significant increase from 385 applications in 2009 to 474 in 2010, however, was stabilized to 438 in 2011. The number of training grant applications was 142 in 2011 (see **Figure 4**).

National Clinical Trials Network

Late in FY2010, the NCI initiated a new effort entitled "Transforming the NCI Clinical Trials

**Figure 4. Numbers of Career Development (CD) and Training and Education (T&E) Applications Reviewed*
FY2007 - 2011**



CD Mechanisms: K01, K07, K08, K18, K22, K23, K24, K25, K99. T&E Mechanisms: K12, R25, T32.
*Withdrawn applications are not included.

Enterprise," to fully evaluate and upgrade the Clinical Cooperative Group Program. Although this process is ongoing, and until a new FOA and Guidelines document for the National Clinical Trials Network (NCTN) are written and approved, the NCI is not accepting new or competing U10 Cooperative Agreement applications that request funding. It is anticipated that the NCI will again be receiving applications for NCTN review in FY2013.

Other RTRB Activities

To assist reviewers in preparing for their participation in peer review, Reviewer Guides are maintained for all of the application types reviewed by the RTRB. These Reviewer Guides were updated for the newly reissued FOAs and for electronic receipt. This resource was especially helpful for the subcommittee members who evaluate Training and Career Development grant applications because most reviewers on each subcommittee review several types of applications. The Reviewer Guides contain general information on peer review and NIH rules regarding the use of human subjects in research, as well as specific instructions for each of the mechanisms to be reviewed by that subcommittee. These mechanism-specific guides have been completed for all education, training, and career development types of applications that are reviewed in the RTRB, and for the Cancer Centers applications that are evaluated by Subcommittee A.

Special Review and Logistics Branch

The SRLB organizes and manages peer review primarily for grant applications submitted in response to NCI RFAs and specialized PARs as well as for contract proposals submitted in response to specific RFPs. The reviews are conducted with SEPs and involve recruiting scientists with the appropriate expertise for each review meeting. During FY2011, the DEA reviewed

2,025 applications received in response to 22 RFAs and 40 PAs/PARs.

Following approval of RFA concepts by the NCI Scientific Program Leaders (SPL) and the BSA, program staff members prepare RFAs for publication in the *NIH Guide for Grants and Contracts*. DEA staff members, including members of the SRLB, assist in critically reading the draft documents and in providing recommendations for clarity relative to application requirements and review criteria. In an RFA, a specific, published dollar amount is set aside by the Institute and approved by the BSA, whereas for a PAR, there is no dollar set-aside and no requirement for BSA review. **Table 10** lists the RFAs and number of related applications that were reviewed by the DEA in FY2011. **Table 11** presents the number of applications submitted in response to PAs or PARs, the review of which is shared by the SRLB, the RPRB, and the RTRB. The Institute also issues RFP solicitations seeking offers for contracts to support activities targeted to highly specific Institute goals.

Technology Research Applications

The majority of technology research initiatives use the R21 Exploratory/Developmental award mechanism and the R33 Exploratory/Developmental Phase II award mechanism. The R21 mechanism is intended to encourage exploratory/developmental research by providing support for exploratory pilot projects in the early stages of project development. The R33 mechanism is suitable for projects where "proof-of-principle" of the proposed technology or methodology already has been established and supportive preliminary data are available. Both of these mechanisms are well suited for technology development. In FY2011, 191 technology applications for Exploratory/Developmental grants (R21) and Exploratory/Developmental Phase II grants (R33) were reviewed under five RFAs. In addition, 25 cooperative agreement (U24) applications were reviewed for "Clinical Proteomic Technologies for Cancer (CPTC) Initiative: Proteome Characterization Centers" and seven P50 applications for "*In Vivo* Cellular and Molecular Imaging Centers." Furthermore, 44 R01 applications were submitted in response to an RFA entitled "Advanced *In Vivo* Imaging to Understand Cancer Systems."

The Small Business Innovation Research (SBIR) program supports Phase I feasibility applications (R43), Phase II applications (R44), and Fast-Track applications (R43/R44). In 2009, there was the first issuance of the SBIR Phase II Bridge Award RFA designed to "bridge the gap" between the end of the Phase II award and commercial development. That program continued in 2011. As shown in **Figure 5**, the total number of SBIR applications received and reviewed in 2011 (130) represents a fivefold increase from the number submitted in 2010 (25).

Multi-Component Research Applications

Figure 3 describes the historic and current workload for multi-component grant applications. In addition to the FOAs for SPORE (peer reviewed in RPRB) and Cancer Centers (peer reviewed in RTRB), there were an additional five multi-component initiatives: Barrett's Esophagus Translational Research Network (RFA-CA-10-014); Tumor Microenvironment Network (TMEN) (RFA CA-10-021); Comprehensive Partnerships to Reduce Cancer Health Disparities (RFA CA-11-001); Population-based Research Optimizing Screening Through Personalized Regimens (RFA CA11-003); and *In Vivo* Cellular and Molecular Imaging Centers (ICMICs) (PAR09-157).

Small Grant Programs

Several small grant (R03) PAR program initiatives stimulated increased interest in the applicant community. These initiatives provided support for many new investigators and pilot studies in cancer prevention (PAR-08-055); cancer epidemiology (PAR-08-237); and behavior research in cancer control (PAR-09-003). In FY2010, there were 351 applications submitted in response to the three initiatives. In FY2011, those same initiatives attracted 428 applications, a significant increase. In FY2011, an additional 139 R03

Figure 5. Technology Initiatives Applications Reviewed* FY2007 - 2011



*Withdrawn applications are not included.
†2011 includes: R01, R21, R33, P50, U01, U24.

applications were submitted under other Program Announcements and were reviewed in CSR.

Research and Development Contract Proposals

The DEA SRLB and PCRB reviewed 679 R&D contract proposals (including 386 Loan Repayment Program applications) received in response to 38 RFPs. Of those 38 RFPs, 35 were part of the Omnibus Solicitation for SBIR published each fall (Phase I and II topics) (see Table 12). During review, several elements of each proposal are individually evaluated and scored, with the combined score indicating the overall merit. After negotiations, contract awards result from the RFP solicitation. Phase II SBIR proposals can be submitted only at the request of the Institute. To facilitate the contract review process, the SRLB has been working with the staff of DEA's Applied Information Systems Branch to develop a series of Web-based documents to be used for contract peer review.

NCI Grant and RFA Funding

The Board of Scientific Advisors (BSA) is responsible for advising the NCI Director on the extramural program and the future direction and funding of each Division's extramural research. As such, it provides concept review for NCI-sponsored RFAs. **Figures 6** and **7** show total NCI Grant and RFA funding according to scientific concept area in FY2010 and FY2011. **Figure 8** shows RFA concepts that the BSA approved from FY2008 through FY2011 according to the sponsoring NCI Division, Office, and Center.

Table 13 presents a summary of total funding of NCI grant awards by mechanism for FY2011. In **Table 14**, a comparison is made of the average cost and number of NCI R01, P01, R03, R13, R21, P30, P50, U01, U10, and U19 grants and cooperative agreements awarded in FY2007 through FY2011 according to the extramural divisions, offices, and centers.

Trends in grant funding according to scientific discipline and organ site are provided in **Tables 15** and **16**. **Table 17** reports NCI's funding of foreign research grants in FY2011, and **Table 18** reports foreign components of U.S. domestic research grants in FY2011. **Note:** Some grant awards made during a fiscal year may have been for grant applications reviewed in a prior fiscal year.

Figure 6. NCI Grant and RFA Funding Percentages by Concept Area FY2010



Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants.
Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 7. NCI Grant and RFA Funding Percentages by Concept Area FY2011



Percents represent Total Funding and RFA Funding for the Concept Area as a percentage of Total NCI Grants.
Concept Area (% of Total Funding to Total NCI Grants; % of RFA Funding to Total NCI Grants)

Figure 8. BSA Approved RFA Concept Set-Asides by Division/Office/Center



Legend:

DCB	Division of Cancer Biology
DCCPS	Division of Cancer Control and Population Sciences
DCP	Division of Cancer Prevention
DCTD	Division of Cancer Treatment and Diagnosis
OD	Office of the Director
OD-OCTR	Office of the Director - Office of Centers, Training, and Resources
OD-OCG	Office of the Director - Office of Cancer Genomics
OD-CRCHD	Office of the Director - Center to Reduce Cancer Health Disparities
OD-OHAM	Office of the Director - Office of HIV and AIDS Malignancy
OD-CSSI	Office of the Director - Center for Strategic Scientific Initiatives
OD-OBBR	Office of the Director - Office of Biorepositories and Biospecimen Research
OD-SBIRDC	Office of the Director - Small Business Innovation Research Development Center
TRANS	NCI (DCTD), Trans-NIH

* Indicates co-funding among NCI Divisions/Offices/Centers.

Supporting Peer Review Consultants

Ensuring that highly qualified individuals are available for expert review of grant applications and contract proposals requires an efficient administrative support system. The DEA's **Scientific Review and Evaluation Activities** (SREA) unit, residing within the NCI **Committee Management Office** (CMO), supports the NCI peer review process by compensating consultants for their services on the NCI IRG subcommittees or SEPs and by reimbursing for their travel and other expenses (see **Appendixes C** and **D**). The SREA staff also approves and processes payments for other activities related to review, including hotel contracts, teleconferencing services, and contract-supported ticketing services.

The NCI SREA program is a multi-million dollar program. The staff members of CMO continue to oversee the successful reconciliation of peer review costs charged against the SREA account, identify erroneous charges, and keep an extensive tracking sheet on all costs related to approximately 135 peer review-associated meetings, which all contribute to successfully managing the budget. The CMO is able to provide the DEA Director with a clear picture of funds spent against the SREA budget throughout the year to ensure there are enough funds to cover all NCI peer review activities.

During FY2011, approximately 2,039 consultants were paid honoraria and a flat-rate reimbursement for meals and incidental expenses for serving at more than 135 peer review meetings (**Appendix D**). There were 4,083 instances of honoraria and flat rate payments to NCI's peer review consultants. The SREA staff works diligently to ensure reviewers are reimbursed in a timely manner and, when appropriate, contacts every reviewer with an unpaid or returned reimbursement status. The SROs have expressed their gratitude to the members of the SREA team for tracking the reviewers' payments and, when necessary, helping reviewers complete their Secure Payee Registration System (SPRS) registration. Due to these proactive efforts by the SREA staff, only 21 of 4,083 instances of honoraria and flat-rate payments owed to NCI peer review consultants were not paid in FY2011.

The NCI continued to be a participant in the Hotel Centralization Program with the NIH SREA Management and Service Center in FY2011. The NIH SREA Management and Service Center conducts the final review and processing of all NCI peer review meeting hotel contracts and invoices. The SREA staff, however, is responsible for ensuring all hotel charges are valid and accurate before all hotel invoices are processed for payment by the NIH SREA Management and Service Center. Teleconference meeting costs and airline tickets were paid expeditiously throughout the year, and SREA staff ensured the timely review and approval of 105 hotel contracts and 96 hotel invoices.

The CMO and its SREA program created new training materials and conducted training sessions for NCI DEA staff. These training sessions encompass all facets of the peer review process as it relates to the CMO and SREA. The Committee Management Activities section includes the specific training sessions that were held in FY2011.

The SREA staff collaborates with the Associate Director, ORRPC, NCI DEA Branch Chiefs, and SROs on the development of NCI SREA policies and procedures. On an ongoing basis, they monitor and evaluate current SREA activities, and they initiate changes and improvements whenever warranted. The NCI Committee Management Procedures for Peer Review Meetings training book, which contains detailed guidelines, policies, and procedures for all aspects of SREA activities, is updated as needed. This training book is given to all NCI SROs and Extramural Support Assistants (ESAs) as a reference guide for important CMO and SREA policies and procedures that are integral to the peer review process and the NCI's mission.

DEA's Role in Advisory Activities

Beyond its central role in coordinating the referral of grants and peer review, perhaps the most far-reaching role the DEA plays across the NCI is the coordination and administration of NCI's nine chartered Federal advisory committees (see **Appendix C**). The memberships and activities of these advisory bodies are coordinated by the **Office of the Director**, DEA, and the **Committee Management Office**, DEA, in consultation with the **NCI Director**. A primary responsibility of the DEA is coordination of the activities of the NCAB, whose members are appointed by the President and whose responsibilities include conducting the second-level review of grant and cooperative agreement applications, as well as advising the NCI Director on policy for the conduct of the National Cancer Program. The DEA also coordinates administration of the Board of Scientific Advisors (BSA), the body responsible for the oversight and concept review of the extramural programs and initiatives of the NCI. Under the various chartered committees, working groups are formed to address and make recommendations on several important areas of cancer research related to basic research, clinical trials, diverse populations, cancer advocacy, treatment, cancer control, drug development, prevention, communication, education, and so on. As such, the DEA plays a major role in the development and issuance of PAs, PARs, and RFAs, the major extramural program initiatives used by the NCI to fund extramural research. The DEA Director serves as Executive Secretary to the NCAB and the BSA. (See **Appendixes A** and **B** for highlights of the activities of these Boards in FY2011 and **Appendix C** for a list of current chartered committee members.)

Major NCI Advisory Bodies Administered by the DEA

National Cancer Advisory Board (NCAB). NCI's principal advisory body is the Presidentially appointed **NCAB**. The Board advises the Department of Health and Human Services (HHS) Secretary and the NCI Director on issues related to the entire National Cancer Program and provides a second level of review for grant applications referred to the NCI and for the U.S. Food and Drug Administration (FDA) (see **Appendix A**).

President's Cancer Panel (PCP). The **PCP** consists of three members appointed by the President, who by virtue of their training, experience, and background, are exceptionally qualified to appraise the National Cancer Program. At least two members of the Panel are distinguished scientists or physicians, and the third member is a nationally recognized cancer research advocate. The Panel monitors the development and execution of the activities of the National Cancer Program, and reports directly to the President. Any delays or hindrances in the rapid execution of the Program are immediately brought to the attention of the President.

Board of Scientific Advisors (BSA). The **BSA** represents the scientific community's voice in NCI-supported extramural science. The Board, composed of distinguished scientists from outside the NCI and representatives from the advocacy community, advises the NCI leadership on the progress and future direction of the Institute's Extramural Research Program. The Board evaluates NCI extramural programs and policies, and it reviews concepts for new research opportunities and solicitations to ensure that those concepts are meritorious and consistent with the Institute's mission (see **Appendix B**).

Boards of Scientific Counselors (BSCs) for Basic Sciences, and for Clinical Sciences and Epidemiology. The two **BSCs**, managed through the Office of the Director (OD), NCI, advise the Institute leadership on the progress and future direction of NCI's Intramural Research Program residing in the Center for Cancer Research (CCR) and the Division of Cancer Epidemiology and Genetics (DCEG). These groups of scientific experts from outside the NCI evaluate the performance and productivity of NCI staff sci-

NCI Advisory Boards

BSA New Members

Dr. Sangeeta N. Bhatia
Massachusetts Institute of Technology

Dr. Brian J. Druker
Oregon Health and Science University

Dr. Karen M. Emmons
Harvard School of Public Health

Dr. Stanton L. Gerson
Case Western Reserve University

Dr. Theodore S. Lawrence
University of Michigan Medical School

NCI Advisory Boards (continued)

BSA New Members

Dr. Francis Ali-Osman
Duke University School of Medicine

Dr. Luis F. Parada
University of Texas Southwestern Medical Center

Dr. Lincoln Stein
Ontario Institute for Cancer Research

Dr. Gregory L. Verdine
Harvard University

entists through periodic site visits to intramural laboratories and provide evaluation and advice on the course of research for each Laboratory and Branch.

Director's Consumer Liaison Group (DCLG). The DCLG advises the NCI Director with respect to promoting research outcomes that are in the best interest of cancer patients. To this end, the DCLG will conduct these activities with the intent to identify new approaches, promote innovation, recognize unforeseen risks or barriers, and identify unintended consequences that could result from NCI decisions or actions. Additionally, the DCLG will provide insight into enhancing input, optimizing outreach, and promoting strong collaborations, all with respect to non-scientist stakeholders.

Clinical Trials and Translational Research Advisory Committee (CTAC). The CTAC advises and makes recommendations to the NCI Director, NCI Deputy Directors, and the NCI Division/Office/Center (DOC) Directors on the NCI-supported national clinical trials enterprise to build a strong scientific infrastructure by bringing together a broadly developed and engaged coalition of stakeholders involved in the clinical trials process. In addition, the Committee makes recommendations regarding the effectiveness of NCI's translational research management and administration program, including needs and opportunities across disease sites, patient populations, translational developmental pathways, and the range of molecular mechanisms responsible for cancer development. The CTAC also will advise on the appropriate magnitude for dedicated translational research priorities and recommend allocation of translational research operations across organizational units, programs, disease sites, populations, developmental pathways, and molecular mechanisms. This responsibility encompasses oversight of all clinical trials, both extramural and intramural. The Committee provides broad scientific and programmatic advice on the investment of taxpayer dollars in clinical trials and related science.

NCI Frederick Advisory Committee (NFAC). The NFAC will provide advice and make recommendations to the Director, NCI, and the Associate Director, NCI-Frederick, on the optimal use of the NCI-Frederick facility to rapidly meet the most urgent needs of the Institute. The NCI facility in Frederick, Maryland, was established in 1972 as a Government-owned Contractor-operated facility. In 1975, the facility was designated as a Federally Funded Research and Development Center (FFRDC) to provide a unique national resource for the development of new technologies and the translation of basic science discoveries into novel agents for the prevention, diagnosis and treatment of cancer and AIDS. The Committee will review major new projects proposed to be performed at NCI-Frederick and advise the Director, NCI, and Associate Director, NCI-Frederick, about the intrinsic merit of the projects and about whether they should be done at the Frederick facility.

NCI Initial Review Group (IRG). The IRG, composed of five active subcommittees, reviews grants for centers, research projects, and research training activities in the areas of cancer cause, prevention, diagnosis, treatment, and control. Members may be appointed as standing committee members with overlapping terms of up to 6 years, or as "temporary" members with all of the rights and obligations of committee membership, including the right to vote on recommendations in which the individual fully participated as a reviewer for a specific meeting. Consultants also may be invited to serve as special experts or *ad hoc* members to provide information or advice. These individuals generally serve on site visit groups or work groups providing critical information to the chartered advisory subcommittees responsible for initial peer review.

NCI Special Emphasis Panels (SEPs). The SEPs advise the NCI Director and the DEA Director regarding research grant and cooperative agreement applications, contract proposals, as well as concept reviews relating to basic and clinical sciences, and applied research and development programs of special relevance to the NCI. Membership of a SEP is fluid, with individuals designated to serve for individual meetings rather than for fixed terms. These individuals have all of the rights and obligations of committee membership, including the right to vote on recommendations.

Committee Management Activities

The NCI Committee Management Office (CMO) is critical to the continued success of all NCI Federal advisory committee activities, including Boards, Advisory Committees, subcommittees, working groups, review panels, and so on. The CMO is located in in the Office of the Director, DEA, NCI. This office continues to provide expert advice to the NCI Director, NCI Deputy Directors, the NCI DEA Director, and other senior-level Institute/Center/Client staff persons on all rules, regulations, guidelines, policies, procedures, etc., governing the Federal Advisory Committee Act (FACA). The CMO also is an established service center for the management of other Institute's Federal advisory committees. Service Center Clients include the following: NIH Council of Councils (CoC), National Center for Complementary and Alternative Medicine (NCCAM)(Note: this agreement was terminated in October 2011 for budgetary reasons); and the Secretary's Advisory Committee on Genetics, Health and Society (SACGHS)(Note: this agreement was terminated in February 2011 when the Committee was dissolved per an HHS directive).

As a service center for the Office of the Director, NIH, and NCCAM, the NCI CMO continued to provide exceptional service to these Client-Institutes on the management of their Federal advisory committees. The CMO effectively managed a comprehensive ethics program in support of NCCAM and CoC. Ethics services include review of OGE-450s of new NCCAM Council and CoC advisory committee members. For all NCI Service Center advisory committees, the CMO also provides the following committee management services: charter renewals, analysis of potential nominees, and preparation of nomination slates, *Federal Register* notices, annual and fiscal year reports, and so on.

In March 2011, the CMO worked closely with the Director, DEA, NCI, to expeditiously establish the NCI-Frederick Advisory Committee (NFAC). With the addition of this Federal advisory committee, the CMO successfully manages 14 Federal advisory committees and numerous subcommittees and working groups. The Office also is responsible for providing logistical planning and support of the four National Cancer Advisory Board meetings, three Board of Scientific Advisors meetings, and three NCI-Frederick Advisory Committee meetings as well as several subcommittees and working groups.

Highlights of FY2011 CMO activities include the following:

- Provided training on the following topics at Brown Bag sessions and Retreats for DEA staff:
  - Overview of the FACA
  - Temporary Member & SEP Waiver Policy and Procedures
  - Pre & Post Peer Review Meeting Activities for Committee Management
  - Peer Review Meeting Logistics for Committee Management
    - Hotel contract review and processing procedures
    - Components of the NIH Reimbursement Process
  - Coding of Meeting Attendees in the CM IMPAC II Module

- At the request of the Assistant Director, DEA, the CMO reviewed various DEA guidelines throughout the year to determine whether they were correct and consistent with FACA regulations. The documents reviewed were the *DEA Consumer Guide*, *NCAB Orientation Book*, and *BSA Orientation Book*.

- CMO staff members constantly keep abreast of potential legislation as it relates to Federal advisory committees, and they communicate any concerns to the NCI DEA Director. In terms of major policy changes, the Office of Management and Budget issued Final

Guidance on Appointment of Lobbyists to Federal Boards and Commissions. This guidance affected not only SGE advisory boards/councils but also peer review committees. The CMO was called upon by the Office of Federal Advisory Committee Policy (OFACP) Director to help develop policy and procedure guidance for the NIH community. As a result, CMO suggestions were incorporated into the OFACP Policy: Implementing Ban on Lobbyists Serving on Advisory Committees, which was issued in December 2011.

- Met with the acting ORRPC Associate Director on several occasions to discuss SREA issues and met with several Executive Secretaries to orient them on their roles and responsibilities related to the advisory committees and discuss the policies and procedures. The CMO also participated in several conference calls to discuss various topics, such as NIH Ethics procedures for SGEs.

- In terms of FACA guidance, worked with NCI's Division of Cancer Control and Population Sciences on appropriate language in support of their "Health 2.0 Developer Challenge."

- Participated in several Program Review and Extramural Staff Training Office (PRESTO) meetings to advise PRESTO staff on the placement of CMO and SREA documents on their new website.

- Responded to several FOIA requests, initiated a cleanup of SEP female/minority data, and oversaw travel authorizations and vouchers for more than 100 Special Government Employee (SGE) travel instances.

- The Committee Management IMPAC II Module is an integral part of the day-to-day activities in the management of advisory committees. As such, the CMO regularly provides feedback to the Committee Management Users Group Representative on potential modifications to the Module. NCI CMO staff also participated in piloting several NIH projects throughout the year.

- Participated in the following NIH/NCI working groups:
  - Food Service Working Group—tasked to make recommendations on healthy food choices, cafeteria space, and meeting room space.
  - Shady Grove Facilities Working Group—tasked to review required Branch space to ensure it meets the needs of current office space.
  - OFACP 1810 Working Group—The purpose of this working group is to rewrite the NIH 1810-1 Procedures for Avoiding Conflict of Interest for NIH SGE Advisory Committee Members Manual Issuance and develop new and innovative practices for ensuring SGEs are in compliance with all conflict of interest and ethics regulations.

- Served in numerous meetings to provide advice on working groups, FACA, and SGE rules and regulations.

- Responded to requests from senior NCI and Client staff about various non-FACA meetings and working group concerns.

Portfolio Tracking and Analysis

The DEA's Research Analysis and Evaluation Branch (RAEB) is the officially designated contact for scientific information on NCI-supported research. The NCI needs to collect and maintain consistent budget-linked scientific information across all of its scientific programs to analyze the Institute's research funding portfolio, make budget projections, and disseminate information about cancer. The DEA conducts analyses to project future NCI research expenditures and to provide budget justifications to Congress. The work of the RAEB allows the DEA to respond immediately to requests for information from NCI staff, the broader NIH community, and requesters nationally and worldwide regarding the NCI Funded Research Portfolio (**http://fundedresearch.cancer.gov**). The RAEB reviews both unfunded applications and funded extramural grants supported by the NCI to consistently link scientific categories to budget categories on all Institute programs. These capabilities are based on a sophisticated system of indexing in which research documentation staff members analyze grant applications to classify each project for its degree of relevance to Special Interest Category (SIC) and Organ Site Codes (SITE). SIC Codes are meant to describe in a consistent way the major scientific disciplines that are of stated or growing interest to the NIH, HHS, Congress, and the public. A critical characteristic of these data is comparability from one fiscal year to the next.

Trends in funding from FY2007 through FY2011 for selected organ sites and SIC Codes are presented in **Tables 15** and **16**. In addition, RAEB staff members serve as DEA or NCI representatives on NCI or NIH-wide scientific reporting initiatives. These groups and committees deal with various aspects of NIH grants and contracts or tracking and reporting on areas of special interest to the NIH, NCI, and/or Congress.

FY2011 Highlights

- Provided portfolio analyses for congressional requests, including one on pediatric cancer and for numerous requesters. For example: Provided analyses to Program Directors for research on early life exposure and cancer, Ductal Carcinoma *In Situ*, and NCI-sponsored research in China. Provided NCI analysis for Dr. Francis Collins' contribution to the HIRO World RePORT Database on NIH research in Sub-Saharan Africa.
- Indexed and coded nearly 16,000 funded and unfunded applications.
- Supported the NCI-Funded Research Portfolio (NFRP) website by providing scientific indexing for NCI-funded extramural projects (**http://fundedresearch.cancer.gov**).
- Supported the ICR Partners (ICRP), a group of international cancer funding organizations, by coding NCI extramural projects to the common scientific outline (CSO) and participating in the ICRP.
- Continued coordination with the NCI Office of Budget and Finance (OBF) to update and align budget reporting categories.
- Chaired the NCI Accrual Working Group to prepare data for biennial reporting of NCI compliance with Congressional Health Disparities reporting requirements, and represented the NCI on the NIH Population Tracking Users Group. Served as NCI Subject Matter Experts on the Population Tracking Redesign Working Group.
- Served as DEA representative to the NCI Communications Committee.
- Served as DEA representative to the NCI Planning and Evaluation Special Interest Group (SIG).
- Continued data quality comparison checks with DCTD program staff for RAEB multi-project clinical trials coding.

Extramural Research by Foreign Research Institutions and Extramural NCI Research Grants With a Foreign Research Component

In FY2011, the NCI allocated $20.7 million to support 58 grants received by foreign research institutions. These foreign grants are listed by country, mechanism, disease area, and total funding support in Table 17. Canadian institutions received the most funding from the NCI, with 26 grants totaling $9.3 million. R01 is the most common mechanism funded, with 32 grants receiving $12.6 million. Disease areas receiving the most NCI funding to foreign institutions were Lung ($4.4 million), Breast ($2.6 million), Colon ($3 million), and Kidney ($1.3 million).

FY2011 Funding of Foreign Institutions

*(See **Table 17** for more information.)*

Country	Grants #	Funding $
Canada	26	$9,260,672
France	3	$3,820,749
Australia	6	$2,450,009
United Kingdom	8	$2,232,776
Israel	6	$1,389,516
Switzerland	2	$355,057
Belgium	1	$232,518
Netherlands	1	$217,378
India	1	$195,671
Ireland	1	$187,983
Korea	1	$170,273
Spain	2	$149,495

In FY2011, the NCI supported 228 U.S. Domestic grants with 391 foreign components. These grants are listed in Table 18 by country, mechanism, and number of grants. Because many grants have multiple foreign contributors, the total count is greater than the total number of grants. Canadian and United Kingdom institutions are the NCI's most frequent collaborators, with 50 and 43 grants, respectively. R01 is the most common mechanism used for collaborations, with 209 grants.

Success Rates of Extramural Science Categories

The RAEB assigns scientific indexing to both funded and unfunded applications, so it is possible to calculate success rates for funding in scientific categories. For example, the following graphs and tables illustrate success rates for selected Special Interest Categories (SIC) and for the highest incidence cancers (see Figures 9 and 10). The highest incidence cancer rankings are from the SEER rank of top 15 cancer sites, 2004-2008, age-adjusted incidence for all races and sexes.

Success rates were calculated by dividing the total number of applications newly funded in 2011 (type 1 and 2 grants) for that research category (SIC or Organ Site) by the total number of applications for that research category.

Figure 9. FY2011 Success Rates for Applications in High Incidence Cancers*

Sorted by Success Rate



Cancer Organ Site	SEER Rank*	Types 1 & 2 Funded in 2011 for This Site	Total Applications Received in 2011 for This Site	2011 Success Rate for This Site	Total Funding for Types 1 & 2 in 2011 for This Site
Stomach	14	9	35	25.71%	$777,428
Kidney	8	37	156	23.72%	$7,310,916
Non-Hodgkins Lymphoma	7	72	306	23.53%	$19,682,105
Leukemia	10	141	613	23.00%	$37,226,907
Colon and Rectum	4	167	863	19.35%	$46,910,052
Uterus	9	13	69	18.84%	$1,342,345
Lung	3	168	910	18.46%	$56,305,735
Prostate	1	197	1,069	18.43%	$52,756,440
Bladder	5	32	186	17.20%	$4,478,854
Breast	2	372	2,172	17.13%	$119,146,667
Thyroid	12	10	60	16.67%	$2,095,530
Pancreas	11	90	567	15.87%	$20,659,104
Melanoma	6	66	419	15.75%	$18,188,846
Liver	15	48	336	14.29%	$11,014,551
Oral Cavity and Pharynx	13	8	82	9.76%	$1,295,763

*SEER rank of top 15 cancer sites 2004-2008 age-adjusted incidence for all races and sexes.

Figure 10. FY2011 Success Rates for Applications in Selected Special Interest Categories

Sorted by Success Rate



Special Interest Category	Types 1 & 2 Funded in 2011 for This SIC	Total Applications Received in 2011 for This SIC	2011 Success Rate for This SIC	Total Funding for Types 1 & 2 in 2011 for This SIC
Genomics	209	748	27.94%	$80,074,084
Inflammation	106	424	25.00%	$25,370,685
Oncogenes	275	1,198	22.95%	$80,472,422
Prevention	221	969	22.81%	$68,614,209
Obesity	49	220	22.27%	$16,799,728
Angiogenesis	94	447	21.03%	$23,247,468
Metastasis	279	1,372	20.34%	$77,102,659
Early Detection	154	807	19.08%	$61,236,904
Biomarkers	366	1,977	18.51%	$112,370,701
Diagnosis	377	2,162	17.44%	$145,229,794
Therapy	691	4,447	15.54%	$235,433,481

Information Resources Management

The Applied Information Systems Branch (AISB) provides integrated computer support, information technology expertise, and information systems development for the DEA. The AISB maintains and monitors the DEA Internet and Intranet websites; designs, develops, and maintains Division-specific software applications; administers and maintains various DEA servers; provides help desk support; provides oversight of hardware and connectivity; and serves as a liaison with the NIH Center for Information Technology (CIT) and the NCI Center for Biomedical Informatics and Information Technology (CBIIT). Its mission is critical to the Division in communicating current information technology activities and new developments to all components of the NCI and NIH as well as to external reviewer and applicant communities.

DEA's Information Technology and Information Systems contracts are managed by the AISB. The AISB has a computer support team to track staff requests, manage the Division's computer equipment inventory, and provide computer-related training, as needed. Specific projects utilizing the technologies and services provided by the AISB are described under the appropriate functions of the DEA throughout this report. For FY2011, specific AISB accomplishments are highlighted below.

System Administration and Desktop Support

- Created and administered five new Microsoft SharePoint websites.
- Planned and performed extraordinary provisions to secure servers for power disruptions due to natural disaster events (i.e., Hurricane Irene, Virginia earthquake) and anticipated government shutdowns.
- Performed additional server room environment and intrusion detection improvements.
- Implemented improved structured workflows for application life-cycle development, testing, and deployment to production.
- Arranged and coordinated DEA Personal Identity Verification (PIV) card personal identification number (PIN) reset stations with CBIIT in preparation for the implementation of PIV card login.
- Performed FY2011 Annual Assessment (AA)/ Continuous Monitoring for Certification and Accreditation (C&A) of the Fiscal Linked Analysis of Research Emphasis (FLARE) application, which included remediation of system control deficiencies, fulfilling Plan of Actions and Milestones (POA&M), contingency plans, and required system table-top exercises.
- Completed submission of C&A for the DEA GSS (General Support System) applications, which resulted in the Authorization To Operate (ATO) from the NCI Information Systems Security Officer.
- Collaborated with NCI CIO and CBIIT staff to identify and resolve problems associated with purchased equipment processed through NCI's Central Receiving.

Major DEA Internet/Intranet Development

- Developed and deployed new Intranet pages for the new NCI Program and Review Extramural Training Office (PRESTO).
- Redesigned and deployed DEA's Intranet site with an improved interface and navigation.

Application Development Projects

- Implemented the NIH Login for application development and test environments; production environment scheduled for deployment in 2012.
- Developed and tested a new Web-based peer review scoring (PRS) application.
- Developed, tested, and scheduled an application to replace the existing FedEX Shipping application for production in 2012.
- Migrated the application environment to the latest Java JDK and Tomcat 6.

- Established integration of data collection and sharing in Funding Opportunity Announcements (FOA) applications between the DEA's Program Coordination and Referral Branch (PCRB) and NCI's Office of Extramural Finance and Information Analysis (OEFIA).
- Implemented meeting information distribution via the Internet for Board of Scientific Advisors (BSA) and BSA workgroup members.
- Initiated work and collaboration with the NIH eRA on the migration of the NCAB early concurrence application to the Electronic Council Book module.
- Coordinated the Glossary business owner transition, led discussions for business case, purpose, ideas for further development and enhancement.
- Completed development and implementation of new Staff Listing application using XSL and XML, which included the migration of SQL Server to Oracle database.

Development and Support of Software Applications for the Research Analysis and Evaluation Branch's Scientific Coding and Analysis

- Coordinated user support, application enhancement and environment management, scientific coding data management, dissemination and reporting to FLARE. Major enhancements included: New Women's Health Report; New Audit Report Module; New Biomarker Coding Module; FLARE running under SSL; FLARE running under NIH Login/PIV (Test environment); Separation of FLARE application server from database server; Principal Investigator Module enhancements; and Translational Research Module enhancements.

User Training

AISB staff provided user training and ongoing support for Adobe Connect Web Conferencing, Microsoft SharePoint services, and NIH Secure Email Transfer utility to promote increased usage of collaborative tools in the work environment. Other user training performed by AISB staff included the Review Material Preparation application and other AISB developed applications.

AISB Staff Involvement

AISB staff members were involved with many NCI and NIH information systems and information technology groups and organizations, including:

- International Cancer Research Portfolio (ICRP) Data Meetings;
- NCI Change Management Group;
- NCI Coding QA/QC Team;
- NCI Division, Office, and Centers IT Contacts Group;
- NCI Science Management Workspace;
- NCI Subproject Re-engineering Users Group;
- NIH CIT Architecture Review Board;
- NIH SharePoint Users Forum;
- NIH Server Consolidation Planning Team;
- NIH Electronic Council Book and Query View Reporting Steering Committee;
- NIH eRA RCDC Data Analysis Working Group/Power User Group;
- NIH eRA Review Users Group (RUG);
- NIH eRA Subproject Re-engineering Focus Group; and
- NIH eRA Technical Coordinators Group.

Organizational Structure of the Division of Extramural Activities

Office of the Director

- Directs and administers the operations of the Division, including those activities relating to grant review and administration, contract review, and Advisory Committee and Board activities.
- Directly coordinates and manages the NCAB and the BSA.
- Coordinates coding of NCI's grant portfolio.
- Initiates, coordinates, and implements Institute policies and procedures relating to grants and contracts reviews.
- Oversees the NCI's Committee Management Office.
- Implements NCI policies regarding extramural research integrity.
- Advises the Scientific Program Leadership (SPL) Committee, NCI, on extramural guidelines, review, advisory activities, and implementation strategies.
- Coordinates NCI extramural staff training requirements with the NIH.
- Represents the NCI on the NIH-wide Extramural Program Management Committee (EPMC) with responsibility for development of extramural policy and procedures across all NIH Institutes and Centers.
- Oversees inclusion of gender, minority, and children.
- Serves as the NCI Research Integrity Office.
- Coordinates, develops, and implements extramural policy.

Paulette Gray, Ph.D. ..... **Director**
Vacant ..... **Deputy Director**
Cedric Long, Ph.D. ..... **Assistant Director**
Patricia Marek, M.B.A. ..... **Special Assistant to the Director**
Barbara Hider ..... **Secretary**
Judi Ziegler ..... **Secretary**

Committee Management Office, OD

- Coordinates functionally related Federal advisory committee activities across the Institute and its client-Institutes. The office manages NCI advisory committees, and serves as an NIH service center for the NIH National Center for Complementary and Alternative Medicine (NCCAM), the NIH Council of Councils, and a HHS chartered advisory committee to ensure that appropriate policies and procedures are in place to conduct the designated mission of each committee.
- Acts as a Service Center to provide advisory committee policy and management services to the Office of Biotechnology Activities, Office of the Director, NIH, and the NCCAM.
- Provides policy guidance to the NCI and client-Institute staff on administrative and technical aspects of Federal advisory committees; coordinates activities with all other NCI advisory committees; implements policies and procedures designed to avoid conflicts in the nomination, selection, and recruitment of board members; implements CM Module guidelines and procedures to ensure that all committee-related data are correctly entered into the database for preparation and submission of required annual reports to the President of the United States, HHS, and NIH; provides logistical support for NCAB, NFAC, and BSA meetings, subcommittees, and work groups; and facilitates NCAB and BSA committee-related travel.
- Researches and evaluates conflict of interest and foreign activities issues for client-Institutes and provides advice on resolutions affecting advisory committee members serving as special government employees.
- Provides administrative support for the peer review system by compensating consultants for their services on NCI IRG subcommittees and SEPs, reimbursing consultants for travel and other expenses, and approving and processing payments for other activities related to review such as hotel contracts and teleconferencing.

Claire Harris ..... **Committee Management Officer**
Andrea Collins ..... **Deputy Committee Management Officer**
Linda Southworth ..... **Senior Committee Management Specialist**
Malaika Staff ..... **Senior Committee Management Specialist**
Natasha Copeland ..... **Committee Management Specialist**
Hing Lee ..... **Committee Management Specialist**
Alonda Lord ..... **Committee Management Specialist**
Ricardo Rawle ..... **Committee Management Specialist**
Kate Reardon ..... **Committee Management Specialist**
Kimberly Taylor ..... **Committee Management Specialist**

Program and Review Extramural Staff Training Office

- Develops and implements both broad-based and focused curricula for NCI Program and Review staff.
- Coordinates training for other extramural staff (e.g., in the Division of Extramural Activities Support) upon request.
- Identifies and develops resources (electronic and human) to facilitate learning and optimal individual, group, and organizational performance.
- Collaborates with other entities (including NCI Office of Workforce Management and Development) to provide customized job-related training and career development opportunities.
- Monitors participation of extramural staff in NIH- and NCI-sponsored training activities.

Michael Small, Ph.D.	**Chief**
Ivan Ding, M.D.	**Health Scientist Administrator**
Peter Wirth, Ph.D.	**Health Scientist Administrator**
Gregory Jones	**Program Analyst**
Elena Kusterer	**Program Analyst**
Cecily Nelson, M.S.	**Program Analyst**
Denise Santeufemio	**Program Analyst**

Office of Referral, Review, and Program Coordination

- Coordinates program concept development; publication functions; and receipt, referral, and assignment of all NCI applications.
- Coordinates review activities of the SRLB, RTRB, RPRB, and PCRB.

Shamala Srinivas, Ph.D	**Acting Associate Director**
Catherine Battistone	**Program Analyst**
Linda Brown	**Program Specialist**
Linda Coleman	**Committee Management Specialist**

Special Review and Logistics Branch

- Plans, manages, and assists in the scientific merit review of special grant and cooperative agreement applications (received in response to RFAs and PARs) and the technical merit review of contract proposals (received in response to RFPs).
- Identifies and recommends appropriate review committee members and site visitors, as required for the review of assigned applications and proposals.
- Provides the SROs and other support staff for the technical review committees.
- Serves as the information and coordination center for all grant applications and contract proposals pending review by the Branch.
- Provides input and advice on grant and contract review policy and procedures, application and proposal patterns, and research trends and other related information, as required.
- Coordinates second-level review activities of the NCAB with staff of other NCI Divisions, other Branches of the Division, and the NCI Office of Grants Administration.
- Provides logistical support for primary- and second-level review activities in support of other Division and Institute units.

Kirt Vener, Ph.D. ..... Chief
Thomas Vollberg, Ph.D. ..... Deputy Chief

Special Review Unit

Kenneth Bielat, Ph.D. ..... Scientific Review Officer
Eun-Ah Cho, Ph.D.* ..... Scientific Review Officer
Donald Coppock, Ph.D. ..... Scientific Review Officer
Jeffrey DeClue, Ph.D. ..... Scientific Review Officer
Irina Gordienko, Ph.D.† ..... Scientific Review Officer
Gerald Lovinger, Ph.D. ..... Scientific Review Officer
Savvas Makrides, Ph.D. ..... Scientific Review Officer
Isis Mikhail, Ph.D.‡ ..... Scientific Review Officer
Thu Nguyen ..... Program Analyst
Lalita Palekar, Ph.D. ..... Scientific Review Officer
Joyce Pegues, Ph.D. ..... Scientific Review Officer
Marvin Salin, Ph.D. ..... Scientific Review Officer
Ellen Schwartz, Ph.D.* ..... Scientific Review Officer
Cliff Schweinfest, Ph.D.* ..... Scientific Review Officer
Viatcheslav Soldatenkov, Ph.D. ..... Scientific Review Officer
Adriana Stoica, Ph.D. ..... Scientific Review Officer
Zhiqiang Zou, Ph.D.* ..... Scientific Review Officer

Review Processing and Distribution Unit

Adrian Bishop ..... Mail and File Clerk
Sanjeeb Choudhry ..... Mail and File Clerk
Robert Kruth ..... Mail and File Clerk
Clara Murphy ..... Program Assistant

*Joined in 2011.
†Passed away February 2011.
‡On detail from February to September 2011.

Program Coordination and Referral Branch

- Serves as the information and coordination point within the NCI for the development, clearance, publication, and tracking of all NCI extramural program (funding) initiatives, which include all RFAs, PAs, and Notices submitted for publication in the *NIH Guide for Grants and Contracts*, and also on Grants.gov, which is a Federal-wide online portal for electronic submission of grant applications.
- Coordinates the development and periodic revision of referral (i.e., application assignment) guidelines within the NCI for both external and internal use.
- Coordinates the development of shared (referral) interest statements with other NIH Institutes and Centers (ICs) so that grant applications of possible or real mutual interest can be properly assigned for receipt, review, and/or funding.
- Serves as liaison to the Center for Scientific Review (CSR), NIH, to ensure the appropriate referrals (i.e., assignments) of grant applications to the Institute and the transfers of grant applications between the NCI and other NIH ICs.
- Refers new (Type 1) applications to the appropriate cancer activity area(s) according to the NCI Internal Referral Guidelines that define the program interests of each of the 50 cancer activity areas (which typically represent program branches in the NCI extramural divisions).
- Semi-automatically refers resubmission (amended) and renewal (competing continuation, Type 2) applications to the cancer activity area that accepted the previously submitted application (with quality control measures performed to ensure the accuracy of referrals).
- Coordinates requests from program staff for application status changes (including corrections of application assignments and numbers, which is done in collaboration with NCI program staff, CSR referral staff, and referral staff of other ICs and agencies) and for acceptance of grant assignments.
- Serves as the NCI contact point and liaison to involved parties at the NIH for approval of the use of cooperative agreement mechanisms and for conversion of grants to cooperative agreements.
- Works with NCI program and review staff and with NIH referral liaisons to address unresolved referral and review issues with the CSR and other NIH ICs.
- Receives and distributes advance copies of applications to review and program staff.
- Receives Letters of Intent from applicants (principal investigators) intending to submit large budget grants (including, but not limited to, program projects and cooperative agreements for clinical trials).
- By handling communications with applicants and NCI program staff members, coordinates approvals (and disapprovals) of the NCI to sponsor the submission of individual conference (R13) grant applications.
- Serves as the primary point of contact and assistance at the NCI for applicants who want to apply for an Academic Research Enhancement Award (i.e., the NIH R15 AREA grant mechanism).
- Processes and tracks requests for submissions of large-budget grant applications that allow them to be received at the NIH, peer reviewed, and possibly awarded by the NCI.
- Maintains database records of prospective large-budget grant and conference grant applications for each council round.
- Serves as the primary NCI information and referral point for the extramural scientific community on a broad range of subjects, including grant guidelines, application information, new initiatives announced as RFAs or PAs, and the review process.

- Assists the extramural community in navigating the NIH and NCI Web pages to help users obtain current information, forms, and guidelines.
- Directs applicants to the appropriate SROs and Program Directors for information regarding the status of the review and award of their grant applications.
- Tracks and analyzes trends of CSR referral to study sections and resultant review outcomes.
- Provides data and data analyses on funding opportunities and on the receipt and referral of grant applications to NCI senior staff members and committees.

Christopher L. Hatch, Ph.D.	**Chief**
David Contois	**Referral Officer, NCI/NIH Referral Liaison**
Anandarup Gupta, Ph.D.	**RFA/PA Coordinator, Scientific Review Officer**
Leota Hall	**Referral Officer, NCI/NIH Referral Liaison**
Natacha P. Lassègue	**Program Analyst**
Bratin Saha, Ph.D.	**Referral Officer, Scientific Review Officer**
Jan Woynarowski, Ph.D.	**RFA/PA Coordinator, Scientific Review Officer**

Research Programs Review Branch

- Plans, coordinates, and manages the scientific merit review of program project grants, specialized centers, and other grant mechanisms, as necessary, by chartered review committees and Special Emphasis Panels.
- Arranges for and participates in onsite assessments of the research capabilities and facilities of selected applicants.
- Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, research trends, and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers and other DEA Branches.

Olivia Bartlett, Ph.D.	**Chief**
Virginia Wray, Ph.D.	**Deputy Chief**
Shakeel Ahmad, Ph.D.	**Scientific Review Officer**
Monica Congo	**Program Specialist**
Majed Hamawy, Ph.D., M.B.A.	**Scientific Review Officer**
Wlodek Lopaczynski, M.D., Ph.D.	**Scientific Review Officer**
Caron Lyman, Ph.D.	**Scientific Review Officer**
David Ransom, Ph.D.	**Scientific Review Officer**
Delia Tang, Ph.D.	**Scientific Review Officer**
Shamala Srinivas, Ph.D.*	**Scientific Review Officer**
Peter Wirth, Ph.D.†	**Scientific Review Officer**

*Moved to ORRPC in FY2011.
†Moved to PRESTO in FY2011.

Resources and Training Review Branch

- Plans, coordinates, and manages the scientific merit review of cancer center, training, education, and career development grant and cooperative agreement applications by chartered review committees and Special Emphasis Panels.
- Arranges for and participates in onsite assessments of the research capabilities and facilities of selected applicants.
- Identifies and recommends appropriate review committee members and site visitors, as required, for the review of assigned applications.
- Provides input and advice on grant review policy and procedures, application patterns, and research trends and other related information, as required.
- Coordinates grant review activities with staff of other NCI Divisions/Offices/Centers, other DEA Branches, and the Center for Scientific Review.

Robert E. Bird, Ph.D. ..... Chief
Lynn Amende, Ph.D. ..... Scientific Review Officer
Gail Bryant, M.D. ..... Scientific Review Officer
Jeannette Korczak, Ph.D. ..... Scientific Review Officer
Ilda McKenna, Ph.D. ..... Scientific Review Officer
Timothy Meeker, M.D. ..... Scientific Review Officer
Sergei Radaev, Ph.D. ..... Scientific Review Officer
Sonya Roberson, Ph.D. ..... Scientific Review Officer
Denise M. Santeufemio*..... Program Specialist

Office of Extramural Applications

- Coordinates activities of the Research Analysis and Evaluation Branch and the Applied Information Systems Branch.
- Provides budget-linked research portfolio data and coordinates the information management of extramural NCI-supported research.

Amir Sahar-Khiz, Ph.D., M.B.A., PMP..... Associate Director
Justin Rhoderick ..... Program Analyst

Research Analysis and Evaluation Branch

- Serves as the Institute's officially designated, centralized source of scientific information and science-based budget information on NCI-supported research.
- Analyzes and classifies the science content of all Institute-supported research projects.
- Analyzes the distribution of funds among research areas; these analyses serve as a basis for budget projections.
- Reports and answers inquiries on the scientific and budgetary aspects of Institute-funded research, including research grants, center grants, training grants, and research contracts.
- Maintains liaisons with other organizations involved in related classification activities.
- Documents the need for proposed RFAs by comparing RFA concepts with existing NCI-supported research and with unsolicited applications.

Marilyn Gaston..... Chief
Edward Kyle..... Deputy Chief

*Moved to PRESTO in FY2011.

Research Documentation

- Analyzes and indexes grants and contracts for the Branch's computerized systems.
- Analyzes extramural projects for relevance to SICs and Anatomic Sites to determine the officially reported figures for Institute support and to provide a basis for budget projections.
- Maintains liaison with other offices within the Institute to ensure consistent reporting of data.
- Monitors the results of NCI's grant-supported research.
- Assists other NCI organizations by indexing NCI research projects for attributes other than SICs and Sites, for example, Common Scientific Outline (CSO) Codes and AIDS Categories.

Edward Kyle	**Lead Biologist/Team Leader**
Beth Buschling	**Biologist**
Beverly Johnson, M.S.	**Biologist**
Ernestyne Watkins, M.S.	**Biologist**
Bernard Whitfield	**Biologist**
Tyrone Wilson	**Biologist**

Technical Operations, Inquiry, and Reporting

- Provides specialized data querying, archiving, and reporting functions for the Division and the Institute.
- Coordinates Institute data reporting with the NCI Office of Budget and Financial Management, NIH Population Tracking and Inclusion Committee, and others.
- Answers inquiries from Congress, the public, the press, and others concerning any phase of Institute-supported work.
- Conducts indepth analyses of extramural research data, including trends analyses.
- Identifies emerging priority areas for data collection and analysis.
- Ensures that terms and categories for indexing are updated and reflect current trends in cancer research, and maintains a thesaurus of term definitions.
- Manages RAEB's FLARE grants documentation and indexing database, ensuring reliability and completeness of its contents.
- Maintains and updates archival document files.
- Works with contractors and the AISB to refine RAEB's computer applications to meet the Branch's needs and resolve FLARE computer application problems for the Branch.
- Represents the DEA as its communications coordinator in the Office of Communications and Education Steering Committee.

Gail Blaufarb, M.S.	**Lead Biologist/Team Leader**
Clarissa Douglas	**Program Specialist**
William Clark, M.S.	**Biologist**
Rajasri Roy, Ph.D.	**Epidemiologist**
Vacant	**Biological Statistician**

Applied Information Systems Branch

- Fulfills the information technology (IT) requirements of the Division by coordinating information resources management (IRM) activities with other relevant NCI and NIH units, and by providing high-quality information analysis, design, development, and coordination of applications in support of the Division's business processes.
- Serves as the focal point for the Division in the development, deployment, and application of specialized software and databases required for the conduct of review, referral, coding, advisory, and other extramural applications.
- Serves as the liaison with the NCI Center for Biomedical Informatics and Information Technology (CBIIT) staff; NCI computer professionals; NCI units charged with execution of extramural IRM functions; trans-NIH functional units such as the CSR, Office of Policy for Extramural Research Administration (OPERA), and Office of Extramural Research (OER); and the IMPAC II and NIH eRA (electronic Research Administration) staff and systems.
- Supports connectivity and design of Internet and Intranet applications.
- Establishes, administers, and monitors commercial support contracts to provide design, production, and maintenance for microcomputer equipment and information storage and retrieval systems that are not covered by CBIIT.
- Formulates DEA-specific office automation policy.
- Provides staff/lead users with technical support and training for DEA IT applications.
- Coordinates general user support and training with NCI and NIH services.
- Provides Division-specific applications of video teleconferencing and audiovisual services in support of review and Board activities.
- Provides management with recommendations for establishing and implementing policies for conducting Division computer-assisted presentations, as necessary.
- Reviews user-created applications and recommends and/or designs changes to improve efficiency and effectiveness.

Gregory Fischetti ..... **Chief**

Application Development and Operations Team

- Analyzes and coordinates life-cycle development of software for the Division.
- Develops and designs applications to support the Division's business practices, including user guides.
- Develops, administers, and monitors contracts for acquisition, support, and maintenance of database systems.
- Administers office automation contracts as well as DEA-wide Blanket Purchase Agreements for computer equipment maintenance and supplies.
- Formulates office automation policy, system development, and eRA/IMPAC II operations for the Division.
- Coordinates internal user groups and the provision of training for specific DEA applications and the use of office automation equipment technology.

Todd Hardin ..... **Team Leader**
Deborah Buranich* ..... **Information Technology Specialist**
Richard Florence ..... **Information Technology Specialist**
Roderick James ..... **Information Technology Specialist**
Teresa Park ..... **Information Technology Specialist**
Raymond Vidal ..... **Information Technology Specialist**

*Left in 2011.

Information Management Team

- Designs and maintains the Division's Intranet and Internet sites and pages, and identifies documents to be placed on the NCI website to make Division information more accessible to the public.
- Develops new Web-based software applications that will enhance the productivity and efficiency of extramural processes within the DEA and the distribution of Division information throughout the NCI.
- Coordinates application development and supports the Research Analysis and Evaluation Branch in the areas of scientific coding and analysis.
- Establishes partnerships and ongoing communications with staff and external customers to foster openness and collaboration in accomplishing the information initiatives of the Division.
- Works with DEA staff to ensure the current utility and linkages of documents placed on the Web.

Elaine Taylor ..... **Team Leader**
Michael Hu ..... **Information Technology Specialist**
Joshua Rhoderick ..... **Information Technology Specialist**
Lorrie Smith ..... **Information Technology Specialist**

Table 1a. Requests for Applications (RFAs) Published by the NCI in FY2011

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division, Office, and Center
10/14/2010	CA11-001	U54	Comprehensive Partnerships to Reduce Cancer Health Disparities	CRCHD
11/12/2010	CA11-003	U54	Population-based Research Optimizing Screening through Personalized Regimens (PROSPR)	DCCPS
	CA11-004	U01	Statistical Coordination Center for the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR)	
12/8/2010	CA11-005	R01	Advanced *In Vivo* Imaging to Understand Cancer Systems	DCTD
2/3/2011	CA11-002	R44	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	SBIRDC
02/17/2011	CA11-501	U24	Childhood Cancer Survivor Study (CCSS) (Limited Competition)	DCTD
05/24/2011	CA11-006	U10	Community Clinical Oncology Program Groups	DCP
	CA11-007		Community Clinical Oncology Program Research Bases	
	CA11-008		Minority-Based Community Clinical Oncology Program Groups	
05/26/2011	CA11-010	U01	Cancer Target Discovery and Development (CTDD) Network	CSSI
07/28/2011	CA11-009	U01	Alliance of Glycobiologists for Detection of Cancer	DCP
08/25/2011	CA11-011	R01	Research Answers to NCI's Provocative Questions	*
	CA11-012	R21		
09/29/2011	CA11-502	U24	Cancer Research Network: A Research Resource Within Health Care Delivery System (Limited Competition)	DCCPS

*All Divisions, Centers, and Offices may participate.
Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11).

Table 1b. Requests for Applications (RFAs) Published by the NCI in FY2011

Sorted by Division, Office, and Center

Division, Office, and Center	RFA	Mechanism	Title	Date of Publication
CRCHD	CA11-001	U54	Comprehensive Partnerships to Reduce Cancer Health Disparities	10/14/2010
CSSI	CA11-010	U01	Cancer Target Discovery and Development (CTDD) Network	05/26/2011
DCCPS	CA11-003	U54	Population-based Research Optimizing Screening through Personalized Regimens (PROSPR)	11/12/2010
	CA11-004	U01	Statistical Coordination Center for the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR)	
DCCPS	CA11-502	U24	Cancer Research Network: A Research Resource Within Health Care Delivery System (Limited Competition)	09/29/2011
DCP	CA11-006	U10	Community Clinical Oncology Program Groups	05/24/2011
	CA11-007		Community Clinical Oncology Program Research Bases	
	CA11-008		Minority-Based Community Clinical Oncology Program Groups	
DCP	CA11-009	U01	Alliance of Glycobiologists for Detection of Cancer	07/28/2011
DCTD	CA11-005	R01	Advanced *In Vivo* Imaging to Understand Cancer Systems	12/8/2010
	CA11-501	U24	Childhood Cancer Survivor Study (CCSS) (Limited Competition)	02/17/2011
SBIRDC	CA11-002	R44	SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	2/3/2011
*	CA11-011	R01	Research Answers to NCI's Provocative Questions	08/25/2011
	CA11-012	R21		

*All Divisions, Centers, and Offices may participate.
Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11).

Table 2. NCI Participation in Trans-NIH Requests for Applications (RFAs) in FY2011

Sorted by Date of Publication

Date of Publication	RFA	Mechanism	Title	Division
10/6/2010	RM10-019	DP5	NIH Director's Early Independence Awards	*
10/29/2010	ES11-006	U19	Deepwater Horizon Disaster Research Consortia: Health Impacts and Community Resiliency	DCCPS
11/12/2010	RM11-001	R21	Integrating Comparative Effectiveness Research Findings Into Care Delivery Through Economic Incentives	DCCPS
11/12/2010	RM11-002	R01	The Market for Long-Term Care Insurance	DCCPS
11/16/2010	RM10-020	U54	Institutional Clinical and Translational Science Award	*
11/24/2010	DE11-003	K18	Short-Term Mentored Career Development Awards in the Basic Behavioral and Social Sciences for Mid-Career and Senior Investigators	CCT
01/20/2011	ES11-002	R21	Dietary Influence on the Human Health Effects of Environmental Exposures	DCCPS
2/2/2011	OD11-001	SI2	Lasker Clinical Research Scholars Program	CCT
02/17/2011	RM11-003	U54	Limited Competition: NIH-HMO Collaboratory Coordinating Center	DCCPS
4/5/2011	AI11-003	R01	NIH/PEPFAR Collaboration for Implementation Science and Impact Evaluation	OHAM
5/4/2011	OD11-004	R25	Limited Competition: Strengthening Behavioral and Social Science in Medical School Education	CCT
07/12/2011	TW11-003	R01	International Tobacco and Health Research and Capacity Building Program	DCCPS
07/18/2011	HD12-204	R21	Sleep and Social Environment: Basic Biopsychosocial Processes	DCCPS
07/21/2011	OD11-002	K12	Building Interdisciplinary Research Careers in Women's Health	CCT
8/5/2011	RM11-004	DP1	2012 NIH Director's Pioneer Award Program	*
08/10/2011	RM11-005	DP2	2012 NIH Director's New Innovator Award Program	*
08/16/2011	TW11-001	R25	Limited Competition: Global Health Program for Fellows and Scholars (Global Health Fellows)	CCT
08/22/2011	RM11-012	R01	Economic Research on Incentives for Efficient Use of Preventive Services	DCCPS
08/23/2011	RM11-010	U41	Human Heredity and Health in Africa (H3Africa): Bioinformatics Network	OD
9/2/2011	MH12-130	R01	Basic Research on Decision Making: Cognitive, Affective, and Developmental Perspectives	DCCPS
09/14/2011	RM11-011	UH2, UH3	Human Heredity and Health in Africa (H3Africa): H3Africa Biorepository Grants	OD
09/21/2011	ES11-010	R21	Environmental Influences on Stem Cells in Development, Health, and Disease	DCB
09/21/2011	RM11-006	R01	NIH Director's Transformative Research Awards	*
09/22/2011	HL12-037	R01	Mechanistic Pathways Linking Psychosocial Stress and Behavior	DCCPS

*All Divisions, Centers, and Offices may participate.

Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11).

Table 3a. Program Announcements (PAs) Published by the NCI in FY2011

Sorted by Date of Publication

Date of Publication	PA/PAR	Mechanism	Title	Division, Office, and Center
10/12/2010	PAR11-005	P30	Cancer Center Support Grants (CCSGs) for NCI-Designated Cancer Centers	OCC
12/3/2010	PAR11-079	R03	Cancer Prevention Research Small Grant Program	DCP
12/9/2010	PA11-073	R01	Mitochondria in Cancer Epidemiology, Detection, Diagnosis, and Prognosis	DCCPS, DCP, DCTD
	PA11-074	R21		
3/14/2011	PAR11-150	U01	Quantitative Imaging for Evaluation of Responses to Cancer Therapies	DCTD
	PAR11-151	U01	Strategic Partnering to Evaluate Cancer Signatures (SPECS II)	DCTD
3/15/2011	PAR11-152	U01	The Role of Microbial Metabolites in Cancer Prevention and Etiology	DCP
3/16/2011	PAR11-146	U01	Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment	DCB
	PAR11-156	U01	Basic Cancer Research in Cancer Health Disparities	DCB, DCP, CRCHD
3/17/2011	PA11-158	R01	Biomarkers of Infection-Associated Cancers	DCP
	PA11-159	R21		
	PA11-160	R01	Enhancing Tumoricidal Activity of Natural Killer (NK) Cells by Dietary Components for Cancer Prevention	DCP
	PA11-161	R21		
	PA11-162	R01	The Effect of Racial and Ethnic Discrimination/Bias on Health Care Delivery	DCCPS
	PA11-163	R21		
	PA11-164	R03		
	PAR11-167	UM1	Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	DCCPS
5/24/2011	PAR11-216	R21	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	DCTD
6/17/2011	PA11-238	R01	Spatial Uncertainty: Data, Modeling, and Communication	DCP
	PA11-239	R21		
	PA11-240	R03		
8/9/2011	PA11-297	R21	Pilot Studies in Pancreatic Cancer	DCCPS
	PA11-298	R03		
9/22/2011	PAR11-346	R01	Interventions for Health Promotion and Disease Prevention in Native American Populations	DCCPS

Source: Office of Referral, Review and Program Coordination.

Table 3b. Program Announcements (PAs) Published by the NCI in FY2011

Sorted by Division, Office, and Center

Division, Office, and Center	PA/PAR	Mechanism	Title	Date of Publication
OCC	PAR11-005	P30	Cancer Center Support Grants (CCSGs) for NCI-Designated Cancer Centers	10/12/2010
DCB	PAR11-146	U01	Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment	3/16/2011
DCB, DCP, CRCHD	PAR11-156	U01	Basic Cancer Research in Cancer Health Disparities	
DCCPS, DCP, DCTD	PA11-073	R01	Mitochondria in Cancer Epidemiology, Detection, Diagnosis, and Prognosis	12/9/2010
	PA11-074	R21		
DCCPS	PA11-162	R01	The Effect of Racial and Ethnic Discrimination/Bias on Health Care Delivery	3/17/2011
	PA11-163	R21		
	PA11-164	R03		
DCCPS	PAR11-167	UM1	Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	3/17/2011
DCCPS	PA11-297	R21	Pilot Studies in Pancreatic Cancer	8/9/2011
	PA11-298	R03		
DCCPS	PAR11-346	R01	Interventions for Health Promotion and Disease Prevention in Native American Populations	9/22/2011
DCP	PAR11-079	R03	Cancer Prevention Research Small Grant Program	12/3/2010
DCP	PAR11-152	U01	The Role of Microbial Metabolites in Cancer Prevention and Etiology	3/15/2011
DCP	PA11-158	R01	Biomarkers of Infection-Associated Cancers	3/17/2011
	PA11-159	R21		
DCP	PA11-160	R01	Enhancing Tumoricidal Activity of Natural Killer (NK) Cells by Dietary Components for Cancer Prevention	3/17/2011
	PA11-161	R21		
DCP	PA11-238	R01	Spatial Uncertainty: Data, Modeling, and Communication	6/17/2011
	PA11-239	R21		
	PA11-240	R03		
DCTD	PAR11-150	U01	Quantitative Imaging for Evaluation of Responses to Cancer Therapies	3/14/2011
DCTD	PAR11-151	U01	Strategic Partnering to Evaluate Cancer Signatures (SPECS II)	
DCTD	PAR11-216	R21	Early Phase Clinical Trials in Imaging and Image-Guided Interventions	5/24/2011

Source: Office of Referral, Review and Program Coordination.

Table 4. NCI Participation in Trans-NIH Program Announcements (PA/PARs) in FY2011

Sorted by Date of Publication

Date of Publication	PA/PAR	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
10/14/2010	PA11-009	K23	Translational Scholar Career Awards in Pharmacogenomics and Personalized Medicine	CCT	NCRR
11/12/2010	PAR11-028	R01	Continued Development and Maintenance of Software	DCB	NCRR
	PAR11-032	R21	Methods and Approaches for Detection of Gene-Environment Interactions in Human Disease	DCCPS	NIEHS
11/17/2010	PAR11-036	R03	Fogarty International Research Collaboration—Behavioral and Social Sciences (FIRCA-BSS) Research Award	DCCPS	FIC
	PAR11-037	R03	Fogarty International Research Collaboration—Basic Biomedical (FIRCA-BB) Research Award		FIC
12/03/2010	PAR11-057	R01	Developmental Pharmacology	DCTD	NICHD
	PAR11-058	R03			
	PAR11-059	R21			
12/7/2010	PA11-063	R01	Translating Basic Behavioral and Social Science Discoveries Into Interventions to Improve Health-Related Behaviors	DCCPS	OBSSR
1/24/2011	PA11-096	R43, R44	PHS 2011-02 Omnibus Solicitation of the NIH, CDC, FDA, and ACF for Small Business Innovation Research Grant Applications (Parent SBIR)	SBIRDC	NIH
	PA11-097	R41, R42	PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR)		
02/09/2011	PAR11-108	P30	Centers for AIDS Research and Developmental Centers for AIDS Research	OHAM	NIAID
02/10/2011	PA11-110	F30	Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Predoctoral M.D./Ph.D. and Other Dual Doctoral Degree Fellows (Parent F30)	CCT	NIH
	PA11-111	F31	Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Predoctoral Fellows (Parent F31)	CCT	NIH
	PA11-112	F31	Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Predoctoral Fellowships to Promote Diversity in Health-Related Research (Parent - Diversity)	CCT	NIH
	PA11-113	F32	Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Postdoctoral Fellows (Parent F32)	CCT	NIH
	PA11-114	F33	Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Senior Fellows (Parent F33)	CCT	NIH
3/14/2011	PA11-148	R01	Nanoscience and Nanotechnology in Biology and Medicine	CSSI	NIBIB
	PA11-149	R21			
3/24/2011	PA11-180	R01	Research on Ethical Issues in Biomedical, Social, and Behavioral Research	DCTD	NIH
	PA11-181	R03			
	PA11-182	R21			

continued

Source: Office of Referral, Review and Program Coordination.

Table 4. NCI Participation in Trans-NIH Program Announcements (PA/PARs) in FY2011

Sorted by Date of Publication

Date of Publication	PA/PAR	Mechanism	Title	Division, Office, and Center	Issuing NIH-IC
3/25/2011	PA11-184	T32	Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (Parent T32)	CCT	NIH
3/30/2011	PAR11-130	R01	Genetic Screens to Enhance Zebrafish Research	DCB	NICHD
	PAR11-131	R01	Enhancing Zebrafish Research With Research Tools and Techniques	DCB	NIDDK
4/8/2011	PA11-193	K08	Mentored Clinical Scientist Research Career Development Award (Parent K08)	CCT	NIH
	PA11-194	K23	Mentored Patient-Oriented Research Career Development Award (Parent K23)	CCT	NIH
	PA11-195	K24	Midcareer Investigator Award in Patient-Oriented Research (Parent K24)	CCT	NIH
	PA11-196	K25	Mentored Quantitative Research Development Award (Parent K25)	CCT	NIH
	PA11-197	K99, R00	NIH Pathway to Independence Award (Parent K99/R00)	CCT	NIH
4/15/2011	PAR11-203	U01	Predictive Multiscale Models for Biomedical, Biological, Behavioral, Environmental, and Clinical Research	DCB	NIBIB
04/29/2011	PAR11-210	X01	Center for Inherited Disease Research (CIDR) High Throughput Genotyping and Sequencing Resource Access	CSSI	NIH
7/18/2011	PA11-250	R01	Ethical, Legal, and Social Implications (ELSI) of Genomic Research Regular Research Program	DCCPS	NIH
7/22/2011	PA11-260	R01	Research Project Grant (Parent R01)	*	NIH
08/17/2011	PAR11-314	R01	Systems Science and Health in the Behavioral and Social Sciences	DCCPS	OBSSR
09/01/2011	PAR11-325	R25	Clinical Research Education and Career Development (CRECD) in Minority Institutions	CCT	NCRR

*All NCI Divisions, Offices, and Centers may participate.
Source: Office of Referral, Review and Program Coordination.

Table 5. Applications Received for Referral by the NCI/DEA in FY2011*†

Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by Board				Total Costs Requested First Year
			Feb	June	Aug	Sept	
International Training Grants in Epidemiology (FIC)	D43	9	9	0	0	0	$4,864,003
Individual Predoctoral National Research Service Award (NRSA) for M.D./Ph.D. Fellowships (ADAMHA)	F30	43	0	0	0	43	$0 ‡
Predoctoral Individual National Research Service Award (NRSA)	F31	222	46	34	0	142	$0 ‡
Postdoctoral Individual National Research Service Award (NRSA)	F32	429	117	167	0	145	$0 ‡
National Research Service Award (NRSA) for Senior Fellows	F33	2	0	1	0	1	$0 ‡
Research Scientist Development Award – Research and Training	K01	31	8	16	0	7	$3,733,741
Research Scientist Award	K05	8	3	2	0	3	$1,214,935
Academic/Teacher Award	K07	80	27	21	0	32	$11,483,231
Clinical Investigator Award	K08	89	24	44	0	21	$14,057,060
Physician Scientist Award (Program)	K12	11	11	0	0	0	$5,599,443
Career Enhancement Award	K18	4	2	1	0	1	$557,347
Career Transition Award	K22	48	10	19	0	19	$8,010,577
Mentored Patient-Oriented Research Development Award	K23	47	17	13	0	17	$7,677,567
Midcareer Investigator Award in Patient-Oriented Research	K24	7	0	3	0	4	$1,215,582
Mentored Quantitative Research Career Development	K25	27	14	6	0	7	$3,841,387
Career Transition Award	K99	204	64	64	0	76	$21,958,086
Research Program Projects	P01	127	35	45	0	47	$324,501,470
Exploratory Grants	P20	26	0	1	0	25	$7,134,156
Center Core Grants	P30	23	12	5	0	6	$101,982,068
Specialized Center	P50	38	5	28	0	5	$90,232,268
Research Project	R01	6,485	2,070	2,321	76	2,018	$3,109,129,921
Small Research Grants	R03	566	163	193	0	210	$44,276,298
Conferences	R13	203	74	87	0	42	$8,092,766
Academic Research Enhancement Awards (AREA)	R15	255	97	82	0	76	$103,772,697
Exploratory/Developmental Grants	R21	2,995	1,035	1,107	2	851	$697,020,889
Resource-Related Research Projects	R24	1	0	1	0	0	$423,810
Education Projects	R25	72	39	18	0	15	$21,466,909
Exploratory/Developmental Grants Phase II	R33	48	17	29	0	2	$20,998,973
Method to Extend Research in Time (MERIT) Award	R37	5	3	1	0	1	$3,086,852

continued

*Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11). Includes NCI Primary and Secondary assigned applications and withdrawn applications. Excludes deleted applications.

†Of the applications received during the year, 6,192 were not recommended for further consideration by the initial review committee, and an additional 6,641 received scores in the bottom 33 percent and were not submitted for NCAB action.

‡NRSA Stipend Levels include: (Pre-doc = $21,180) and (Post-doc Level 0 through Level 7 = $37,740 - $52,068)

Table 5. Applications Received for Referral by the NCI/DEA in FY2011*†

Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by Board				Total Costs Requested First Year
			Feb	June	Aug	Sept	
Small Business Technology Transfer (STTR) Grants – Phase I	R41	143	42	61	0	40	$26,407,253
Small Business Technology Transfer (STTR) Grants – Phase II	R42	29	9	13	0	7	$13,368,937
Small Business Innovation Research Grants (SBIR) – Phase I	R43	1,228	363	436	54	375	$250,865,513
Small Business Innovation Research Grants (SBIR) – Phase II	R44	246	68	90	19	69	$146,129,773
High Priority, Short Term Project Award	R56	9	4	5	0	0	$0 ‡
Research and Institutional Resources Health Disparities Endowment Grants – Capacity Building	S21	1	0	0	1	0	$25,000,000
Research Enhancement Award	SC1	25	5	4	0	16	$7,518,299
Pilot Research Project	SC2	12	3	5	0	4	$1,660,106
Intramural Clinical Scholar Research Award	SI2	20	0	0	20	0	$0 ‡
Institutional National Research Service Award (NRSA)	T32	82	24	34	0	24	$28,042,893
Research Project (Cooperative Agreements)	U01	194	77	61	31	25	$196,059,520
Cooperative Clinical Research (Cooperative Agreements)	U10	38	11	27	0	0	$19,069,525
Conference (Cooperative Agreement)	U13	1	0	1	0	0	$29,907
Research Program (Cooperative Agreements)	U19	4	0	4	0	0	$6,866,988
Resource-Related Research Project (Cooperative Agreements)	U24	26	25	0	0	1	$85,727,009
Biotechnology Resource (Cooperative Agreements)	U41	1	0	0	0	1	$818,146
Animal (Mammalian and Nonmammalian) Model, and Animal and Biological Materials Resource Cooperative Agreements (NCRR)	U42	1	0	1	0	0	$12,400,000
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase I	U43	46	0	2	0	44	$8,749,249
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase II	U44	2	0	0	1	1	$938,896
Specialized Center (Cooperative Agreements)	U54	93	0	3	90	0	$271,147,594
Academic Research Enhancement Awards (AREA) Cooperative Agreements	UA5	1	0	1	0	0	$380,871
Exploratory/Developmental Cooperative Agreement – Phase I	UH2	5	1	4	0	0	$1,242,042
Totals		**14,312**	**4,534**	**5,061**	**294**	**4,423**	**$5,718,754,557**

*Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11). Includes NCI Primary and Secondary assigned applications and withdrawn applications. Excludes deleted applications.

†Of the applications received during the year, 6,192 were not recommended for further consideration by the initial review committee, and an additional 6,641 received scores in the bottom 33 percent and were not submitted for NCAB action.

‡NRSA Stipend Levels include: (Pre-doc = $21,180) and (Post-doc Level 0 through Level 7 = $37,740 - $52,068)

Table 6. Grant and Cooperative Agreement Applications Reviewed by the NCI/DEA in FY2011*†

Sorted by Mechanism

Mechanism	Activity Code	Total by Activity	Applications by Board				Total Costs Requested First Year
			Feb	June	Aug	Sept	
Research Scientist Development Award – Research and Training	K01	30	8	15	0	7	$3,653,408
Research Scientist Award	K05	8	3	2	0	3	$1,214,935
Academic/Teacher Award	K07	73	26	19	0	28	$11,304,323
Clinical Investigator Award	K08	76	21	38	0	17	$11,900,835
Physician Scientist Award (Program)	K12	9	9	0	0	0	$5,599,443
Career Enhancement Award	K18	4	2	1	0	1	$557,347
Career Transition Award	K22	44	9	18	0	17	$8,010,577
Mentored Patient-Oriented Research Development Award	K23	35	12	11	0	12	$6,675,203
Midcareer Investigator Award in Patient-Oriented Research	K24	7	0	3	0	4	$1,215,582
Mentored Quantitative Research Career Development	K25	26	14	5	0	7	$3,691,432
Career Transition Award	K99	165	62	47	0	56	$18,596,133
Research Program Projects	P01	122	32	43	0	47	$320,181,263
Exploratory Grants	P20	25	0	1	0	24	$7,134,156
Center Core Grants	P30	16	5	5	0	6	$89,181,482
Specialized Center	P50	37	5	27	0	5	$88,777,479
Research Project	R01	99	3	50	44	2	$66,544,517
Small Research Grants	R03	427	117	152	0	158	$35,108,815
Conferences	R13	121	41	54	0	26	$5,282,894
Exploratory/Developmental Grants	R21	158	55	102	0	1	$55,368,865
Education Projects	R25	60	30	15	0	15	$20,306,052
Exploratory/Developmental Grants – Phase II	R33	33	13	20	0	0	$16,270,835
Small Business Innovation Research Grants (SBIR) – Phase I	R43	64	0	20	44	0	$11,626,568
Small Business Innovation Research Grants (SBIR) – Phase II	R44	21	0	2	19	0	$16,066,366
Institutional National Research Service Award	T32	73	22	31	0	20	$27,393,895
Research Project (Cooperative Agreements)	U01	129	57	28	21	23	$146,208,021
Cooperative Clinical Research (Cooperative Agreements)	U10	11	11	0	0	0	$8,700,720
Resource-Related Research Project (Cooperative Agreements)	U24	26	25	0	0	1	$85,727,009
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase I	U43	43	0	0	0	43	$8,749,249
Small Business Innovation Research (SBIR) Cooperative Agreements – Phase II	U44	2	0	0	1	1	$938,896
Specialized Center (Cooperative Agreements)	U54	88	0	0	88	0	$256,526,326
Totals		**2,032**	**582**	**709**	**217**	**524**	**$1,338,512,626**

*Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11). Includes NCI Primary and Secondary assigned applications and withdrawn applications. Excludes deleted applications. Withdrawn applications have been subtracted from the total count.

†Of the applications received during the year, 161 were withdrawn, 676 were not recommended for further consideration by the initial review committee, and an additional 838 received scores in the bottom 33 percent and were not submitted for NCAB action.

Table 7. Applications Reviewed by NCI IRG Subcommittees and Special Emphasis Panels (SEPs) in FY2011*

NCI IRG Subcommittee	Types of Applications Reviewed	Number of Applications	Total Costs Requested First Year
A - Cancer Centers	P30	16	$89,181,482
F - Manpower and Training	K99, T32	228	$43,195,843
G - Education	K01, K05, K07, K12, K22, K24, R01, R25	91	$27,041,208
I - Career Development	K01, K08, K18, K22, K25	162	$25,051,148
J - Population and Patient-Oriented Training	K07, K23, R25	109	$18,115,540
Totals - NCI IRG Subcommittees		**606**	**202,585,221**
Total SEPs	K01, K07, K12, K22, K23, K99, P01, P20, P50, R01 R03, R21, R25, R33, R43, R44, T32, U01, U10, U24, U43, U44, U54	**1,426**	**$1,135,927,405**
Totals		**2,032**	**$1,338,512,626**

*Source: Office of Referral, Review and Program Coordination. IMPACII. Application count includes Secondary assignments. There were 18 withdrawn applications that have been subtracted from the total count.

Table 8. Summary of Investigator-Initiated P01 Applications Reviewed in FY2011*

Type of Application	Applications by Board			FY 2011 Total
	February 2011	June 2011	September 2011	
New	8	14	23	45
Resubmitted New	7	11	6	24
Renewal	10	9	10	29
Resubmitted Renewal	7	8	7	22
Revisions			2	2
Total	**32**	**42**	**48**	**122**

*Source: Office of Referral, Review and Program Coordination.

Table 9. Summary of Investigator-Initiated P01 Applications Reviewed, Sorted by NCI Program Division, in FY2011*

Program Division	Number of Applications	Total Costs Requested First Year	Total Costs for Requested Period
Division of Cancer Biology (DCB)	35	$77,066,588	$397,863,927
Division of Cancer Control and Population Sciences (DCCPS)	17	$66,008,510	$349,825,742
Division of Cancer Prevention (DCP)	8	$16,280,214	$83,879,567
Division of Cancer Treatment and Diagnosis (DCTD)	62	$152,323,000	$809,368,019
Grand Total	**122**	**$311,678,312**	**$1,640,937,255**

*Source: Office of Referral, Review and Program Coordination.

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2011*

Title of Initiative	RFA Number	Activity Code	Applications by Board					Total Costs Requested First Year
			Totals	Feb	June	Aug	Sept	
The Early Detection Research Network: Biomarker Developmental Laboratories	CA09-017	U01	3	3	0	0	0	$2,352,163
Innovative and Early-Stage Development of Emerging Technologies in Biospecimen Science	CA10-001	R21	16	3	13	0	0	$3,811,958
Validation and Advanced Development of Emerging Technologies in Biospecimen Science	CA10-002	R33	8	6	2	0	0	$3,688,115
Application and Early Stage Development of Emerging Technologies in Cancer Research	CA10-003	R21	41	15	26	0	0	$16,010,939
Validation and Advanced Development of Emerging Technologies for Cancer Research	CA10-004	R33	26	7	19	0	0	$12,927,538
Innovative Technology Development for Cancer Research	CA10-005	R21	100	37	63	0	0	$35,307,063
Community Clinical Oncology Program Groups	CA10-010	U10	6	6	0	0	0	$4,729,892
Community Clinical Oncology Program Research Bases	CA10-011	U10	1	1	0	0	0	$1,492,608
Minority-Based Community Clinical Oncology Program Groups	CA10-012	U10	3	3	0	0	0	$1,967,603
Innovative Emerging Molecular Analysis Technologies (SBIR)	CA10-013	R43	64	0	20	44	0	$11,626,568
		R44	3	0	2	1	0	$428,827
Barrett's Esophagus Translational Research Network	CA10-014	U54	10	0	0	10	0	$156,905,142
Coordinating Center for the Barrett's Esophagus Translational Research Network	CA10-015	U01	3	0	0	3	0	$1,490,669
Clinical Proteomic Technologies for Cancer Initiative (CPTC): Proteome Characterization Centers	CA10-016	U24	25	25	0	0	0	$81,348,033
Scientific Meetings for Creating Interdisciplinary Research Teams in Basic Behavioral and Social Science Research	CA10-017	R13	26	0	26	0	0	$1,676,320
Tumor Microenvironment Network (TMEN)	CA10-021	U54	41	0	0	41	0	$45,466,301
Comprehensive Partnerships to Reduce Cancer Health Disparities	CA11-001	U54	16	0	0	16	0	$22,715,205
SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer Therapeutics, Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization	CA11-002	R44	18	0	0	18	0	$15,637,539
		U44	1	0	0	1	0	$323,069
Population-Based Research Optimizing Screening Through Personalized Regimens	CA11-003	U54	21	0	0	21	0	$31,439,678

continued

*Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11). Includes NCI Primary and Secondary assigned applications and withdrawn applications. Excludes deleted applications. There were 114 withdrawn applications that have been subtracted from the total count.

Table 10. Requests for Applications (RFAs) Reviewed by the NCI/DEA in FY2011*

Title of Initiative	RFA Number	Activity Code	Applications by Board					Total Costs Requested First Year
			Totals	Feb	June	Aug	Sept	
Population-Based Research Optimizing Screening Through Personalized Regimens Statistical Coordination Center	CA11-004	U01	7	0	0	7	0	$13,757,814
Advanced *In Vivo* Imaging to Understand Cancer Systems	CA11-005	R01	44	0	0	44	0	$31,605,780
Childhood Cancer Survivor Study (CCSS)	CA11-501	U24	1	0	0	0	1	$4,378,976
Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA)	GM11-003	R01	45	0	45	0	0	$15,460,067
Totals			**529**	**106**	**216**	**206**	**1**	**$516,547,867**

*Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11). Includes NCI Primary and Secondary assigned applications and withdrawn applications. Excludes deleted applications. There were 114 withdrawn applications that have been subtracted from the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2011*

Title of Initiative	PA/PAR Number	Activity Code	Applications by Board					Total Costs Requested First Year
			Totals	Feb	June	Aug	Sept	
Decision Making in Cancer: Single-Event Decisions	PA08-063	R01	1	1	0	0	0	$1,041,897
Career Enhancement Award for Stem Cell Research	PA09-110	K18	4	2	1	0	1	$557,347
Research on Clinical Decision Making in People With or At Risk for Life-Threatening Illness	PA09-122	R01	1	0	0	0	1	$804,493
Exploratory Grants for Behavioral Research in Cancer Control	PA09-130	R21	1	0	0	0	1	$238,905
Development, Application, and Evaluation of Prediction Models for Cancer Risk and Prognosis	PA10-025	R01	1	1	0	0	0	$351,435
Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants	PA10-036	T32	73	22	31	0	20	$27,393,895
Mentored Clinical Scientist Research Career Development Award (Parent)	PA10-059	K08	70	20	35	0	15	$10,985,952
Mentored Patient-Oriented Research Career Development Award (Parent)	PA10-060	K23	31	11	9	0	11	$5,904,635
Midcareer Investigator Award in Patient-Oriented Research (Parent)	PA10-061	K24	7	0	3	0	4	$1,215,582

continued

*Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11). Includes NCI Primary and Secondary assigned applications and withdrawn applications. Excludes deleted applications. There were 69 withdrawn applications that have been subtracted from the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2011*

Title of Initiative	PA/PAR Number	Activity Code	Applications by Board					Total Costs Requested First Year
			Totals	Feb	June	Aug	Sept	
Mentored Quantitative Research Development Award (Parent)	PA10-062	K25	26	14	5	0	7	$3,691,432
NIH Pathway to Independence Award (Parent)	PA10-063	K99	165	62	47	0	56	$18,596,133
Research Project Grant (Parent)	PA10-067	R01	5	1	3	0	1	$15,278,997
NIH Support for Conferences and Scientific Meetings (Parent)	PA10-071	R13	93	40	28	0	25	$3,573,824
Scientific Meetings for Creating Interdisciplinary Research Teams	PA10-106	R13	3	1	1	0	1	$82,750
Cancer Prevention Research Small Grant Program	PAR08-055	R03	105	49	56	0	0	$8,692,910
	PAR11-079		91	0	0	0	91	$7,996,528
NCI Cancer Education and Career Development Program	PAR08-120	R25	36	17	8	0	11	$12,250,756
	PAR10-165		24	13	7	0	4	$8,055,296
Quantitative Imaging for Evaluation of Responses to Cancer Therapies	PAR08-225	U01	27	9	11	0	7	$18,242,979
Small Grants Program for Cancer Epidemiology	PAR08-237	R03	141	36	60	0	45	$11,200,973
		U01	1	1	0	0	0	$70,404
Small Grants for Behavioral Research in Cancer Control	PAR09-003	R03	91	32	36	0	23	$7,290,314
NCI Program Project Applications	PAR09-025	P01	118	30	43	0	45	$312,371,355
Collaborative Research in Integrative Cancer Biology and the Tumor Microenvironment	PAR09-026	U01	17	0	6	11	0	$12,279,925
NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity	PAR09-050	K08	6	1	3	0	2	$914,883
NCI Mentored Patient-Oriented Research Career Development Award to Promote Diversity	PAR09-051	K23	4	1	2	0	1	$770,568
NCI Mentored Research Scientist Development Award to Promote Diversity	PAR09-052	K01	30	8	15	0	7	$3,653,408
NCI Transition Career Development Award to Promote Diversity	PAR09-069	K22	20	3	8	0	9	$3,266,660
Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award	PAR09-078	K07	73	26	19	0	28	$11,304,323
Established Investigator Award in Cancer Prevention and Control	PAR09-088	K05	8	3	2	0	3	$1,214,935
The NCI Transition Career Development Award	PAR09-089	K22	24	6	10	0	8	$4,743,917

continued

*Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11). Includes NCI Primary and Secondary assigned applications and withdrawn applications. Excludes deleted applications. There were 69 withdrawn applications that have been subtracted from the total count.

Table 11. Program Announcements (PAs) Reviewed by the NCI/DEA in FY2011*

Title of Initiative	PA/PAR Number	Activity Code	Applications by Board					Total Costs Requested First Year
			Totals	Feb	June	Aug	Sept	
Etiology, Prevention, and Treatment of Hepatocellular Carcinoma	PAR09-147	P01	2	0	0	0	2	$4,090,759
In Vivo Cellular and Molecular Imaging Centers (ICMICs)	PAR09-157	P50	7	0	7	0	0	$13,931,599
Feasibility Studies for Collaborative Interaction for Minority Institution/Cancer Center Partnership	PAR09-201	P20	24	0	0	0	24	$4,634,156
Specialized Programs of Research Excellence (SPOREs) in Human Cancer for Years 2010, 2011, and 2012	PAR10-003	P20	1	0	1	0	0	$2,500,000
		P50	30	5	20	0	5	$74,845,880
Strategic Partnering to Evaluate Cancer Signatures	PAR10-126	U01	44	44	0	0	0	$52,837,105
Paul Calabresi Career Development Award for Clinical Oncology	PAR10-155	K12	9	9	0	0	0	$5,599,443
The Role of Microbial Metabolites in Cancer Prevention and Etiology	PAR10-208	U01	11	0	11	0	0	$8,847,827
Core Infrastructure and Methodological Research for Cancer Epidemiology Cohorts	PAR10-283	U01	16	0	0	0	16	$36,329,135
Cancer Diagnostic and Therapeutic Agents Enabled by Nanotechnology (SBIR)	PAR10-286	U43	43	0	0	0	43	$8,749,249
		U44	1	0	0	0	1	$615,827
Cancer Center Support Grants (CCSGs) for NCI-designated Cancer Centers	PAR11-005	P30	11	0	5	0	6	$73,695,474
Totals			**1,496**	**468**	**493**	**11**	**524**	**$800,713,865**

*Source: Office of Referral, Review and Program Coordination. IMPACII (Retrieved 11/15/11). Includes NCI Primary and Secondary assigned applications and withdrawn applications. Excludes deleted applications. There were 69 withdrawn applications that have been subtracted from the total count.

Table 12. Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2011*

Announcement/ Topic Number	Announcement Title	Workload Round	No. of Proposals
N01-CM01018-83	Early Therapeutics Development With Phase II Emphasis	Feb-11	12
Topic 268 (Phase II)	Novel Antibody Epitope Mapping Techologies	Feb-11	1
Topic 255	Development of Anticancer Agents	Jun-11	45
Topic 277 (FT) (Phase I: 13) (Phase I & II: 2)	Companion Diagnostics: Predictive and Prognostic Tests Enabling Personalized Medicine in Cancer Therapy	Jun-11	17
Topic 283	Development of a Molecular Diagnostic Assay to Detect Basal-Like Breast Cancer	Jun-11	7
Topic 284	Alternative Biospecimen Stabilization and Storage Solutions	Jun-11	5
Topic 291 (FT) (Phase I: 11) (Phase I & II: 1)	Radioprotector/Mitigator Development to Decrease Normal Tissue Injury During Radiotherapy	Jun-11	13
Topic 292 (FT) (Phase I: 2) (Phase I & II: 1)	Development of Molecular Pharmacodynamic Assays for Targeted Therapies	Jun-11	4
Topic 293 (FT) (Phase I: 24) (Phase I & II: 3)	Development of Devices for Point of Care Analysis of Circulating Tumor Cells	Jun-11	30
Topic 294	Development of Glycosylation-Specific Research Reagents (Antibodies and Aptamers)	Jun-11	14
Topic 295	Algorithms for Automated Quantitative Imaging of Tumor Microenvironment	Jun-11	1
Topic 296	Systems for Automated Storage, Analysis, and Reporting of Objective Behavioral Exposures	Jun-11	15
Topic 297	Methods and Tools for Quantitatively Measuring Non-Coding RNAs in Cancer Early Detection, Prediction, and Diagnosis	Jun-11	8
Topic 298	Low-Field Electron Paramagnetic Resonance Imaging Device to Optimize Development of Anti-Angiogenic Therapeutics in Cancer Animal Models (NIH TT)	Jun-11	3
Topic 299	A New Type of Vaccine for Prevention of HIV Infection and HIV-Associated Cancers (NIH TT)	Jun-11	1
Topic 300 (FT) (Phase I: 18) (Phase I & II: 2)	Therapeutics and Theranostics Based on Nanotechnology	Jun-11	22
Topic 301 (FT) (Phase I: 15) (Phase I & II: 2)	Nanotechnology Sensing Platforms for Improved Diagnosis of Cancer	Jun-11	19
Topic 302 (FT) (Phase I: 9) (Phase I & II:1)	Development of Clinical Automated Multiplex Affinity Capture Technology for Detecting Low Abundance Cancer-Related Proteins/Peptides	Jun-11	11

continued

*The NCI reviewed a total of 679 proposals. The proposals were in response to SBIR Contract Solicitations – Phase I (139) and Fast Track Phase I/II (116), Phase II (26), RFP (12), and Loan Repayment (386).
Source: Office of Referral, Review and Program Coordination.

Table 12. Requests for Proposals (RFPs) and SBIR Topics Reviewed by the NCI/DEA in FY2011*

Announcement/ Topic Number	Announcement Title	Workload Round	No. of Proposals
Topic 304	Development of Blood-Based Methods for the Detection of Cancer Recurrence in Post-Therapy Breast Cancer Patients	Jun-11	6
Topic 305	Novel Digital X-Ray Sources for Cancer Imaging Applications	Jun-11	7
Topic 306	Development of Innovative Algorithms/Software for Processing and Analysis of *In Vivo* Images in Oncology	Jun-11	11
Topic 307	Novel Imaging Agents to Expand the Clinical Toolkit for Cancer Diagnosis, Staging, and Treatment	Jun-11	16
Topic 256 (Phase II)	Innovative Methods for Manufacturing Safe, Effective Cancer Therapeutics	Jun-11	1
Topic 264 (Phase II)	Novel and Improved Methods for Detecting Epigenetic Modifications	Jun-11	2
Topic 259 (Phase II)	Quantitative Tissue Imaging for Clinical Diagnosis and Treatment	Jun-11	1
Topic 242 (Phase II)	Biosensors for Early Cancer Detection and Risk Assessment	Jun-11	1
Topic 260 (Phase II)	High Level Programming Language to Expedite Development of User Interfaces	Jun-11	1
Topic 261 (Phase II)	Mobile Computing for Consumer-Centered Cancer Prevention and Control	Jun-11	2
Topic 262 (Phase II)	Health Information Technology to Facilitate Patient-Centered Communication in Cancer-Related Care	Jun-11	2
Topic 249 (Phase II)	System to Analyze and Support Biomarker Research and Development Strategies	Jun-11	1
Topic 246 (Phase II)	Integrating Patient-Reported Outcomes in Hospice and Palliative Care Practices	Jun-11	1
Topic 266 (Phase II)	Nanotechnology Imaging and Sensing Platforms for Improved Diagnosis of Cancer	Jun-11	2
Topic 229 (Phase II)	Developmnet of Molecular Pharmacodynamic Assays for Targeted Therapies	Oct-11	1
Topic 255 (Phase II)	Development of Anticancer Agents	Oct-11	5
Topic 269 (Phase II)	Development of Novel Protein Expression Technologies for Glycosylated Cancer-Related Proteins	Oct-11	1
Topic 267 (Phase II)	Multifunctional Therapeutics Based on Nanotechnology	Oct-11	4
L30	Loan Repayment	Oct-11	288
L40		Oct-11	98
Total			**679**

*The NCI reviewed a total of 679 proposals. The proposals were in response to SBIR Contract Solicitations – Phase I (139) and Fast Track Phase I/II (116), Phase II (26), RFP (12), and Loan Repayment (386).
Source: Office of Referral, Review and Program Coordination.

Table 13. Summary of NCI Grant Awards by Mechanism in FY2011*†

Fund Type: Appropriated Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	% of NCI Total Grants		Competing Requested	Competing Awarded	Success Rate
				Number	Dollars			
Research Project Grants								
Traditional Research Grants – R01/ RL1	3,648	1,331,624,576	365,029	56.5%	40.9%	4,497	655	14.6%
Program Projects – P01	129	259,232,124	2,009,551	2.0%	8.0%	108	22	20.3%
Small Grants – R03	127	9,646,392	75,956	2.0%	0.3%	427	72	16.9%
Exploratory/Developmental Research – R21	442	88,480,688	200,183	6.8%	2.7%	2,240	223	10.0%
Phased Innovation Grant (Phase 2) – R33	9	3,165,203	351,689	0.1%	0.1%	9	2	22.2%
Pathway to Independence – R00	71	17,238,093	242,790	1.1%	0.5%	0	0	0.0%
Exploratory/Development Coop Agreements – UH2/UH3	1	254,808	254,808	0.0%	0.0%	3	1	33.3%
Merit Awards – R37	59	30,327,664	514,028	0.9%	0.9%	8	7	87.5%
NIH Director Pioneer Award (NDPA) – DP1	8	7,639,418	954,927	0.1%	0.2%	0	0	0.0%
Academic Research Enhancement Awards (AREA) – R15	24	9,564,898	398,537	0.4%	0.3%	186	24	12.9%
Request for Applications	159	51,662,462	324,921	2.5%	1.6%	387	57	14.7%
Cooperative Agreements – RFA-U01/ U19	131	142,484,439	1,087,667	2.0%	4.4%	22	11	50.0%
Cooperative Agreements – U01/U19	67	52,976,533	790,695	1.0%	1.6%	151	32	21.2%
Small Business Innovation Research	123	72,253,449	587,426	1.9%	2.2%	1,038	53	5.1%
Small Business Technology Transfer – R41/R42	21	11,801,000	561,952	0.3%	0.4%	154	7	4.6%
Program Evaluation – R01	0	75,329,000	75,329,000	0.0%	2.3%	0	0	0.0%
Subtotal Research Project Grants	**5,019**	**2,163,680,747**	**431,098**	**77.7%**	**66.5%**	**9,230**	**1,166**	**12.6%**
Other Research								
Clinical Cooperative Groups	135	239,990,437	1,777,707	2.1%	7.4%	14	9	64.3%
Clinical Cooperative Groups – U10 Specials	0	3,590,000	3,590,000	0.0 %	0.1%	0	0	0.0%
Clinical Cooperative Groups – CCCT	0	299,979	299,979	0.0%	0.0%	0	0	0.0%
Cooperative Conference Grants – U13	0	2,500	2,500	0.0%	0.0%	0	0	0.0%
Conference Grants – D43/R13	92	5,934,287	64,503	1.4%	0.2%	109	56	51.3%
Training Conference Grants – T15/ RL9	3	259,560	86,520	0.1%	0.0%	0	0	0.0%
Cancer Education Awards – R25	90	32,589,783	362,109	1.4%	1.0%	62	21	33.9%
Research/Resource Grant – R24/ U24	50	68,416,186	1,368,324	0.8%	2.1%	35	15	42.9%
Research Enhancement Award – SC1	2	633,050	316,525	0.0%	0.0%	0	0	0.0%
Pilot Research Project – SC2	0	0	0	0.0%	0.0%	0	0	0.0%
Exploratory Grants - Cooperative Agreement (NCI)-U56	0	299,999	299,999	0.0%	0.0%	0	0	0.0%
Subtotal Other Research	**372**	**352,015,781**	**946,279**	**5.8%**	**10.8%**	**220**	**101**	**45.9%**

continued

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† Courtesy of the Office of Extramural Finance and Information Analysis.

Table 13. Summary of NCI Grant Awards by Mechanism in FY2011*†

Fund Type: Appropriated Cost Centers Mechanisms	Awards Count	Awards Dollars	Average Cost	% of NCI Total Grants		Competing Requested	Competing Awarded	Success Rate
				Number	Dollars			
Centers								
Core	82	269,467,323	3,286,187	1.3%	8.3%	31	17	54.8%
Core – CCCT	0	4,556,664	4,556,664	0.0%	0.1%	0	0	0.0%
Center for AIDS Research – CFAR – OHAM – P30	0	4,320,870	4,320,870	0.0%	0.1%	0	0	0.0%
Spore Grants	61	121,867,640	1,997,830	0.9%	3.7%	38	7	18.4%
Other P50/P20	22	35,172,495	1,598,750	0.3%	1.1%	4	3	75.0%
Specialized Center (Cooperative Agreement)	111	162,652,253	1,465,336	1.7%	5.0%	91	30	33.0%
Subtotal Centers	**276**	**598,037,245**	**2,166,802**	**4.3%**	**18.4%**	**164**	**57**	**34.8%**
NRSA								
NRSA Institution	172	59,515,764	346,022	2.7%	1.8%	66	37	56.1%
NRSA Fellowships	184	8,138,094	44,229	2.9%	0.3%	347	81	23.%
Subtotal NRSA	**356**	**67,653,858**	**190,039**	**5.5%**	**2.1%**	**413**	**118**	**28.6%**
Careers								
Career Enhancement Award for Stem Cell Research – K18	1	117,208	117,208	0.0%	0.0%	3	1	33.3%
Mentored Clinical Scientist – K08	91	14,128,973	155,263	1.4%	0.4%	77	29	37.7%
Preventive Oncology Award – K07	88	12,257,057	139,285	1.4%	0.4%	65	17	26.2%
Mentored Career Award – K12	18	12,423,662	690,203	0.3%	0.4%	9	4	44.4%
Mentored Research Scientist Development Awards, Mentored Career Development to Promote Diversity/ Temin – K01	56	7,377,036	131,733	0.9%	0.2%	27	11	40.7%
Clinical Research Track – K22	28	4,826,847	172,387	0.4%	0.2%	39	9	23.1%
Mentored Patient – Oriented Research Career Development Award – K23	38	5,936,804	156,232	1.0%	0.2%	45	12	26.7%
Mid-Career Investigator in Patient-Oriented Research Award – K24	16	2,859,540	178,721	0.3%	0.1%	4	1	25.0%
Mentored Quantitative Research Career Development Award – K25	21	2,867,576	136,551	0.3%	0.1%	25	2	8.0%
Established Investigator Award in Cancer Prevention & Control – K05	25	3,740,870	149,635	0.4%	0.1%	8	5	62.5%
Pathway to Independence – K99	56	7,079,750	126,424	0.9%	0.2%	141	32	22.7%
Subtotal Careers	**438**	**73,615,323**	**168,072**	**6.8%**	**2.3%**	**443**	**123**	**27.8%**
Total	**6,461**	**3,255,002,954**	**503,792**	**100.0%**	**100.0%**	**10,470**	**1,565**	**15.0%**

* A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

† Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2007 - FY2011‡

	FY 2007		FY 2008		FY 2009		FY 2010		FY 2011		Percent Change 2007 - 2011	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
R01 Average Cost of Award												
NCI Overall	3,849	329	3,732	335	3,573	350	3,655	362	3,648	365	-5.22%	10.94%
DCB	2,050	294	1,923	298	1,792	308	1,783	313	1,748	317	-14.7%	7.8%
DCP	231	392	247	368	246	388	261	399	258	400	11.7%	2.0%
DCTD	1,083	308	1,055	317	1,042	327	1,107	336	1,141	343	5.4%	11.4%
DCCPS	478	474	490	484	478	515	486	561	485	553	1.5%	16.7%
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	7	1,751	17	917	15	977	18	911	16	901	128.6%	-48.5%
P01 Average Cost of Award												
NCI Overall	172	1,901	158	1,932	151	2,002	140	2,004	129	2,010	-25.0%	5.73%
DCB	65	1,584	58	1,675	60	1,729	56	1,783	53	1,804	-18.5%	13.9%
DCP	13	2,047	11	1,916	9	1,931	7	1,737	8	1,814	-38.5%	-11.4%
DCTD	84	2,067	77	2,069	69	2,215	64	2,188	58	2,164	-31.0%	4.7%
DCCPS	9	2,367	11	2,306	12	2,174	12	2,161	10	2,298	11.1%	-2.9%
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	1	2,442	1	2,397	1	2,220	1	2,576	0	638	-100.0%	-73.9%
R03 Average Cost of Award												
NCI Overall	284	76	256	77	239	77	181	78	127	76	-55.28%	0.0%
DCB	5	73	9	75	15	76	8	78	3	75	-40.0%	2.7%
DCP	122	77	107	78	91	78	56	78	38	75	-68.9%	-2.6%
DCTD	8	78	9	73	12	76	10	77	6	76	-25.0%	-2.6%
DCCPS	149	76	131	75	119	77	107	79	80	77	-46.3%	1.3%
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	0	0	0	47	2	47	0	0	0	0	0.0%	0.0%
R21 Average Cost of Award												
NCI Overall	437	180	466	198	447	205	415	202	442	200	1.14%	11.11%
DCB	64	161	74	183	75	193	77	188	79	181	23.4%	12.4%
DCP	48	163	55	169	50	174	50	187	51	183	6.3%	12.3%
DCTD	250	194	248	214	236	218	198	218	207	220	-17.2%	13.4%
DCCPS	75	158	87	180	85	195	82	185	80	178	6.7%	12.7%
OD (CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	0	160	2	230	1	204	8	217	25	205	100.0%	28.1%

continued

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

†In thousands.

‡Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2007 - FY2011‡

	FY 2007		FY 2008		FY 2009		FY 2010		FY 2011		Percent Change 2007 - 2011	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
U01/U19 Average Cost of Award												
NCI Overall	145	1,010	125	906	110	1,035	131	1,091	130	1,062	-10.34%	5.15%
DCB	26	850	23	870	28	776	28	776	29	721	11.5%	-15.2%
DCP	15	469	9	402	7	366	35	741	35	671	133.3%	43.1%
DCTD	61	1,293	56	1,051	39	1,417	28	1,461	26	1,313	-57.4%	1.5%
DCCPS	43	886	32	564	32	678	23	1,598	23	1,752	-46.5%	97.8%
OD(CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	0	307	5	2,534	4	3,159	17	1,039	17	1,135	100.0%	269.7%
R13 Average Cost of Award												
NCI Overall	81	15	92	34	80	36	95	76	92	65	13.58%	333.33%
DCB	42	8	40	9	33	10	36	9	35	4	-16.7%	-50.0%
DCP	8	18	4	12	8	15	8	12	9	15	12.5%	-16.7%
DCTD	16	12	24	11	19	13	19	12	16	11	0.0%	-8.3%
DCCPS	10	29	11	30	14	24	17	20	17	14	70.0%	-51.7%
OD(CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	5	52	13	162	6	307	15	418	15	349	200.0%	571.2%
U10 Average Cost of Award												
NCI Overall	138	1,728	133	1,773	134	1,750	131	1,937	135	1,801	-2.17%	4.22%
DCP	72	1,250	72	1,275	73	1,254	71	1,330	77	1,160	6.9%	-7.2%
DCTD	66	2,246	61	2,360	61	2,344	60	2,655	58	2,653	-12.1%	18.1%
OD(CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	0	147	0	0	0	0	0	0	0	0	0.0%	-100.0%
P30 Average Cost of Award												
NCI Overall	63	4,229	64	4,217	65	4,337	66	4,446	66	4,168	4.76%	-1.44%
DCTD	0	5,215	0	0	0	0	0	0	0	0	0.0%	-100.0%
DCCPS	0	319	0	0	0	0	0	0	0	0	0.0%	-100.0%
OD(CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	63	4,141	64	4,217	65	4,337	66	4,446	66	4,168	4.8%	0.7%

continued

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

†In thousands.

‡Courtesy of the Office of Extramural Finance and Information Analysis.

Table 14. Average Total Cost*† and Number of Research Project Grant Awards Sorted by Division, Office, Center, and Mechanism From FY2007 - FY2011‡

	FY 2007		FY 2008		FY 2009		FY 2010		FY 2011		Percent Change 2007 - 2011	
	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost	No.	Avg. Cost
P50 Average Cost of Award												
NCI Overall	80	1,957	60	2,055	71	1,967	75	2,081	74	1,979	-7.5%	1.12%
DCP	0	0	0	0	0	0	0	400	0	400	0.0%	100.0%
DCTD	9	1,591	60	2,051	64	2,025	65	2,101	64	1,999	611.1%	25.6%
DCCPS	12	1,746	0	0	7	1,334	10	1,847	10	1,739	-16.7%	-0.4%
OD(CRCHD, OCAM, CSSI, CCT, OHAM, etc.)	59	2,056	0	262	0	766	0	617	0	701	-100.0%	-65.9%
SBIR Average Cost of Award												
NCI Overall	231	356	274	314	219	367	180	411	123	587	-46.75%	64.89%
CRCHD	0	0	0	0	0	0	0	85	0	83	0.0%	100.0%
CSSI	1	250	0	0	0	0	0	0	0	0	-100.0%	-100.0%
DCB	33	284	23	268	0	0	0	0	0	0	-100.0%	-100.0%
DCP	14	341	16	318	0	0	0	0	0	0	-100.0%	-100.0%
DCTD	163	378	165	342	4	318	0	0	0	0	-100.0%	-100.0%
DCCPS	20	314	13	326	0	0	0	0	0	32	-100.0%	-89.8%
SBIRDC	0	0	57	251	215	368	180	411	123	586	100.0%	100.0%
STTR Average Cost of Award												
NCI Overall	47	242	38	297	42	277	27	431	21	562	-55.32%	132.23%
DCB	2	292	3	189	0	0	0	0	0	0	-100.0%	-100.0%
DCP	3	300	3	325	0	0	0	0	0	0	-100.0%	-100.0%
DCTD	41	238	27	297	1	138	0	0	0	0	-100.0%	-100.0%
DCCPS	1	107	2	301	0	0	0	0	0	0	-100.0%	-100.0%
SBIRDC	0	0	0	0	0	0	0	0	21	562	100.0%	100.0%
STTRDC	0	0	3	368	41	280	27	431	0	0	0.0%	0.0%
U54 Average Cost of Award												
NCI Overall	42	1,778	44	1,802	56	1,939	93	1,453	101	1,523	140.48%	-14.34%
CRCHD	15	961	17	1,161	21	1,274	51	1,066	47	1,152	213.3%	19.9%
CSSI	8	3,635	8	3,683	16	3,311	18	2,776	21	2,468	162.5%	-32.1%
DCB	15	1,483	15	1,407	15	1,327	20	1,492	22	1,400	46.7%	-5.6%
DCCPS	4	2,236	4	2,242	4	2,238	4	230	11	1,551	175.0%	-30.6%

*A grant award count of zero showing a dollar amount represents either administrative supplements to existing grants, which are not factored into the grant count but are factored into the average cost of an award, or co-funded grants, which are not factored into the grant count for the NCI but are factored into the average cost of an award.

†In thousands.

‡Courtesy of the Office of Extramural Finance and Information Analysis.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Adrenal	***Number of Grants***	***14***	***9***	***7***	***9***	***6***	
	Relevant Grant Dollars	1,795,342	490,757	443,049	908,434	557,086	
	Total Count	***14***	***9***	***7***	***9***	***6***	
	Total Relevant Dollars	1,795,342	490,757	443,049	908,434	557,086	**-4.01**
Anus	***Number of Grants***	***16***	***13***	***17***	***14***	***16***	
	Relevant Grant Dollars	1,605,089	1,717,104	2,585,470	1,996,111	2,740,690	
	Number of Contracts	***5***	***5***	***5***	‡	***3***	
	Relevant Contract Dollars	794,336	744,588	778,300	‡	446,435	
	Total Count	***21***	***18***	***22***	***14***	***19***	
	Total Relevant Dollars	2,399,425	2,461,692	3,363,770	1,996,111	3,187,125	**14.56**
Bladder	***Number of Grants***	***261***	***230***	***219***	***208***	***176***	
	Relevant Grant Dollars	17,496,016	20,612,527	20,834,546	18,941,518	15,777,763	
	Number of Contracts	***18***	***17***	***16***	***3***	***1***	
	Relevant Contract Dollars	580,571	417,443	340,792	25,113	176,266	
	Total Count	***279***	***247***	***235***	***211***	***177***	
	Total Relevant Dollars	18,076,587	21,029,970	21,175,338	18,966,631	15,954,029	**-2.32**
Bone Marrow	***Number of Grants***	***138***	***101***	***75***	***92***	***76***	
	Relevant Grant Dollars	23,646,795	15,453,422	16,586,714	13,124,422	17,343,897	
	Total Count	***138***	***101***	***75***	***92***	***76***	
	Total Relevant Dollars	23,646,795	15,453,422	16,586,714	13,124,422	17,343,897	**-4.01**
Bone, Cartilage	***Number of Grants***	***131***	***110***	***84***	***98***	***90***	
	Relevant Grant Dollars	20,571,396	16,585,539	16,835,159	18,014,359	14,539,162	
	Number of Contracts	***1***	***1***	‡	‡	‡	
	Relevant Contract Dollars	10,124	10,529	‡	‡	‡	
	Total Count	***132***	***111***	***84***	***98***	***90***	
	Total Relevant Dollars	20,581,520	16,596,068	16,835,159	18,014,359	14,539,162	**-7.55**
Brain	***Number of Grants***	***534***	***536***	***464***	***498***	***500***	
	Relevant Grant Dollars	118,668,961	121,777,889	125,530,253	131,178,363	143,786,108	
	Number of Contracts	***15***	***15***	***14***	***3***	***3***	
	Relevant Contract Dollars	322,417	436,218	215,004	217,734	698,895	
	Total Count	***549***	***551***	***478***	***501***	***503***	
	Total Relevant Dollars	118,991,378	122,214,107	125,745,257	131,396,097	144,485,003	**5.01**
Breast	***Number of Grants***	***2,041***	***1,999***	***1,958***	***1,934***	***1,859***	
	Relevant Grant Dollars	532,031,369	517,943,650	542,409,702	569,062,367	552,999,395	
	Number of Contracts	***44***	***44***	***36***	***32***	***20***	
	Relevant Contract Dollars	8,013,038	6,480,995	7,420,959	7,908,595	9,370,644	
	Total Count	***2,085***	***2,043***	***1,994***	***1,966***	***1,879***	
	Total Relevant Dollars	540,044,407	524,424,645	549,830,661	576,970,962	562,370,039	**1.09**
Central Nervous System	***Number of Grants***	***82***	***70***	***42***	***43***	***35***	
	Relevant Grant Dollars	12,808,969	8,892,769	5,765,488	6,255,071	5,370,246	
	Number of Contracts	***1***	***1***	***1***	‡	‡	
	Relevant Contract Dollars	150,000	450,000	374,998	‡	‡	
	Total Count	***83***	***71***	***43***	***43***	***35***	
	Total Relevant Dollars	12,958,969	9,342,769	6,140,486	6,255,071	5,370,246	**-14.42**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Cervix	***Number of Grants***	***343***	***321***	***298***	***298***	***295***	
	Relevant Grant Dollars	68,615,877	57,532,246	51,605,675	61,579,940	60,341,462	
	Number of Contracts	***23***	***23***	***23***	***5***	***4***	
	Relevant Contract Dollars	6,467,605	5,783,915	7,479,618	4,759,619	4,729,585	
	Total Count	***366***	***344***	***321***	***303***	***299***	
	Total Relevant Dollars	75,083,482	63,316,161	59,085,293	66,339,559	65,071,047	**-3.00**
Childhood Leukemia	***Number of Grants***	***125***	***131***	***123***	***148***	***157***	
	Relevant Grant Dollars	40,753,571	43,226,882	42,335,965	49,924,922	33,329,128	
	Total Count	***125***	***131***	***123***	***148***	***157***	
	Total Relevant Dollars	40,753,571	43,226,882	42,335,965	49,924,922	33,329,128	**2.83**
Colon, Rectum	***Number of Grants***	***1,037***	***1,011***	***963***	***984***	***951***	
	Relevant Grant Dollars	241,436,522	242,315,525	237,991,020	245,295,756	242,486,775	
	Number of Contracts	***44***	***46***	***38***	***16***	***11***	
	Relevant Contract Dollars	8,736,401	8,206,006	7,934,699	6,412,331	4,299,256	
	Total Count	***1,081***	***1,057***	***1,001***	***1,000***	***962***	
	Total Relevant Dollars	250,172,923	250,521,531	245,925,719	251,708,087	246,786,031	**-0.32**
Connective Tissue	***Number of Grants***	***83***	***70***	***55***	***51***	***56***	
	Relevant Grant Dollars	10,865,081	12,574,363	10,709,782	10,417,011	9,999,338	
	Total Count	***83***	***70***	***55***	***51***	***56***	
	Total Relevant Dollars	10,865,081	12,574,363	10,709,782	10,417,011	9,999,338	**-1.46**
Embryonic Tissue, Cells	***Number of Grants***	***20***	***9***	***6***	***10***	***8***	
	Relevant Grant Dollars	3,170,012	1,779,062	694,792	1,477,847	1,325,565	
	Total Count	***20***	***9***	***6***	***10***	***8***	
	Total Relevant Dollars	3,170,012	1,779,062	694,792	1,477,847	1,325,565	**-0.61**
Esophagus	***Number of Grants***	***155***	***133***	***129***	***100***	***118***	
	Relevant Grant Dollars	20,497,757	18,768,511	24,435,190	25,599,073	28,238,207	
	Number of Contracts	***3***	***3***	‡	‡	***1***	
	Relevant Contract Dollars	349,150	258,939	‡	‡	20,000	
	Total Count	***158***	***136***	***129***	***100***	***119***	
	Total Relevant Dollars	20,846,907	19,027,450	24,435,190	25,599,073	28,258,207	**8.71**
Eye	***Number of Grants***	***17***	***13***	***11***	***13***	***12***	
	Relevant Grant Dollars	2,134,820	1,850,716	1,910,869	2,168,685	2,161,882	
	Total Count	***17***	***13***	***11***	***13***	***12***	
	Total Relevant Dollars	2,134,820	1,850,716	1,910,869	2,168,685	2,161,882	**0.78**
Gall Bladder	***Number of Grants***	***9***	***3***	***4***	***1***	***16***	
	Relevant Grant Dollars	997,955	462,516	372,129	212,356	199,485	
	Total Count	***9***	***3***	***4***	***1***	***16***	
	Total Relevant Dollars	997,955	462,516	372,129	212,356	199,485	**-30.55**
Gastrointestinal Tract	***Number of Grants***	***86***	***68***	***62***	***51***	***48***	
	Relevant Grant Dollars	13,865,217	9,411,464	9,143,226	8,649,596	8,306,179	
	Number of Contracts	***4***	***2***	‡	‡	‡	
	Relevant Contract Dollars	176,140	‡	‡	‡	‡	
	Total Count	***90***	***70***	***62***	***51***	***48***	
	Total Relevant Dollars	14,041,357	9,411,464	9,143,226	8,649,596	8,306,179	**-11.30**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Genital System, Female	***Number of Grants***	***32***	***15***	***9***	***12***	***19***	
	Relevant Grant Dollars	1,885,968	1,408,356	578,518	1,255,368	1,708,702	
	Number of Contracts	**5**	**5**	**5**	**5**	**1**	
	Relevant Contract Dollars	735,936	651,232	666,439	336,493	187,496	
	Total Count	***37***	***20***	***14***	***17***	***20***	
	Total Relevant Dollars	2,621,904	2,059,588	1,244,957	1,591,861	1,896,198	**-3.50**
Genital System, Male	***Number of Grants***	***10***	***7***	***6***	***6***	***5***	
	Relevant Grant Dollars	1,329,596	1,304,477	1,466,575	549,031	334,581	
	Number of Contracts	***6***	***5***	***5***	***5***	‡	
	Relevant Contract Dollars	745,318	651,232	666,439	336,493	‡	
	Total Count	***16***	***12***	***11***	***11***	***5***	
	Total Relevant Dollars	2,074,914	1,955,709	2,133,014	885,524	334,581	**-29.35**
Head and Neck	***Number of Grants***	***241***	***234***	***214***	***204***	***201***	
	Relevant Grant Dollars	37,004,472	42,337,050	41,932,591	41,468,691	39,623,318	
	Number of Contracts	***4***	***4***	***5***	***7***	***3***	
	Relevant Contract Dollars	2,272,727	2,252,606	1,433,714	1,897,174	1,337,385	
	Total Count	***245***	***238***	***219***	***211***	***204***	
	Total Relevant Dollars	39,277,199	44,589,656	43,366,305	43,365,865	40,960,703	**1.31**
Heart	***Number of Grants***	***31***	***24***	***20***	***15***	***16***	
	Relevant Grant Dollars	3,186,004	2,919,031	2,361,956	2,148,483	1,737,287	
	Total Count	***31***	***24***	***20***	***15***	***16***	
	Total Relevant Dollars	3,186,004	2,919,031	2,361,956	2,148,483	1,737,287	**-13.98**
Hodgkins Lymphoma	***Number of Grants***	***90***	***91***	***72***	***54***	***77***	
	Relevant Grant Dollars	15,324,741	15,616,622	13,631,008	9,846,229	8,994,562	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***90***	***91***	***72***	***54***	***77***	
	Total Relevant Dollars	15,324,741	15,616,622	13,631,008	9,846,229	8,994,562	**-11.81**
Kaposi Sarcoma	***Number of Grants***	***110***	***99***	***81***	***92***	***87***	
	Relevant Grant Dollars	20,905,539	20,543,363	18,551,830	17,444,041	20,205,869	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***111***	***99***	***81***	***92***	***87***	
	Total Relevant Dollars	20,905,539	20,543,363	18,551,830	17,444,041	20,205,869	**-0.39**
Kidney	***Number of Grants***	***224***	***209***	***210***	***226***	***241***	
	Relevant Grant Dollars	23,713,721	26,064,122	26,856,193	26,734,935	29,194,089	
	Number of Contracts	***3***	***2***	***1***	***2***	***2***	
	Relevant Contract Dollars	74,757	‡	47,891	274,436	390,889	
	Total Count	***227***	***211***	***211***	***228***	***243***	
	Total Relevant Dollars	23,788,478	26,064,122	26,904,084	27,009,371	29,584,978	**5.68**
Larynx	***Number of Grants***	***7***	***4***	***5***	***3***	***4***	
	Relevant Grant Dollars	333,234	94,951	387,226	99,159	203,215	
	Total Count	***7***	***4***	***5***	***3***	***4***	
	Total Relevant Dollars	333,234	94,951	387,226	99,159	203,215	**66.71**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Leukemia	***Number of Grants***	***800***	***735***	***703***	***680***	***683***	
	Relevant Grant Dollars	190,978,673	187,378,267	192,236,365	210,799,140	199,610,401	
	Number of Contracts	***3***	***3***	***2***	***3***	***4***	
	Relevant Contract Dollars	55,441	159,480	228,944	1,495,139	1,098,646	
	Total Count	***803***	***738***	***705***	***683***	***687***	
	Total Relevant Dollars	191,034,114	187,537,747	192,465,309	212,294,279	200,709,047	**1.41**
Liver	***Number of Grants***	***307***	***303***	***280***	***294***	***302***	
	Relevant Grant Dollars	60,837,509	60,131,598	58,730,034	60,616,338	54,071,410	
	Number of Contracts	***4***	***2***	***1***	‡	***1***	
	Relevant Contract Dollars	160,124	46,630	124,807	‡	299,353	
	Total Count	***311***	***305***	***281***	***294***	***303***	
	Total Relevant Dollars	60,997,633	60,178,228	58,854,841	60,616,338	54,370,763	**-2.71**
Lung	***Number of Grants***	***1,010***	***966***	***961***	***965***	***968***	
	Relevant Grant Dollars	205,648,922	211,422,479	210,440,490	243,602,747	260,155,893	
	Number of Contracts	***37***	***42***	***35***	***23***	***16***	
	Relevant Contract Dollars	8,081,836	8,194,888	7,217,782	7,815,307	4,919,129	
	Total Count	***1,047***	***1,008***	***996***	***988***	***984***	
	Total Relevant Dollars	213,730,758	219,617,367	217,658,272	251,418,054	265,075,022	**5.70**
Lymph Node	***Number of Grants***	***26***	***23***	***18***	***15***	***13***	
	Relevant Grant Dollars	4,278,957	5,090,890	4,206,917	2,542,477	2,017,737	
	Total Count	***26***	***23***	***18***	***15***	***13***	
	Total Relevant Dollars	4,278,957	5,090,890	4,206,917	2,542,477	2,017,737	**-14.65**
Lymphatic System	***Number of Grants***	***8***	***9***	***9***	***4***	***5***	
	Relevant Grant Dollars	868,599	1,008,473	972,288	472,471	788,609	
	Total Count	***8***	***9***	***9***	***4***	***5***	
	Total Relevant Dollars	868,599	1,008,473	972,288	472,471	788,609	**7.01**
Melanoma	***Number of Grants***	***502***	***506***	***454***	***457***	***435***	
	Relevant Grant Dollars	88,841,117	91,542,259	86,581,615	85,429,532	96,537,993	
	Number of Contracts	***2***	***2***	***2***	***4***	***1***	
	Relevant Contract Dollars	261,078	‡	276,130	698,413	50,000	
	Total Count	***504***	***508***	***456***	***461***	***436***	
	Total Relevant Dollars	89,102,195	91,542,259	86,857,745	86,127,945	96,587,993	**2.23**
Mesothelioma	***Number of Grants***	‡	***19***	***18***	***15***	***16***	
	Relevant Grant Dollars	‡	5,258,514	4,954,819	5,530,460	3,457,493	
	Total Count	‡	***19***	***18***	***15***	***16***	
	Total Relevant Dollars	‡	5,258,514	4,954,819	5,530,460	3,457,493	**-10.55**
Muscle	***Number of Grants***	***56***	***42***	***37***	***37***	***48***	
	Relevant Grant Dollars	7,555,840	7,152,012	6,535,783	6,049,875	8,018,193	
	Total Count	***56***	***42***	***37***	***37***	***48***	
	Total Relevant Dollars	7,555,840	7,152,012	6,535,783	6,049,875	8,018,193	**2.78**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Myeloma	***Number of Grants***	***224***	***197***	***234***	***234***	***242***	
	Relevant Grant Dollars	28,812,062	34,920,892	40,008,777	41,740,236	48,195,056	
	Number of Contracts	***1***	***2***	‡	***1***	‡	
	Relevant Contract Dollars	‡	28,000	‡	199,860	‡	
	Total Count	***225***	***199***	***234***	***235***	***242***	
	Total Relevant Dollars	28,812,062	34,948,892	40,008,777	41,940,096	48,195,056	**13.88**
Nervous System	***Number of Grants***	***29***	***33***	***29***	***30***	***28***	
	Relevant Grant Dollars	4,185,349	5,617,294	4,847,016	5,271,048	6,787,090	
	Number of Contracts	‡	‡	‡	‡	***1***	
	Relevant Contract Dollars	‡	‡	‡	‡	8,250	
	Total Count	***29***	***33***	***29***	***30***	***29***	
	Total Relevant Dollars	4,185,349	5,617,294	4,847,016	5,271,048	6,795,340	**14.54**
Neuroblastoma	***Number of Grants***	***87***	***95***	***100***	***98***	***98***	
	Relevant Grant Dollars	16,114,373	16,372,549	17,189,208	17,861,575	20,974,714	
	Total Count	***87***	***95***	***100***	***98***	***98***	
	Total Relevant Dollars	16,114,373	16,372,549	17,189,208	17,861,575	20,974,714	**6.98**
Non-Hodgkins Lymphoma	***Number of Grants***	***589***	***570***	***523***	***455***	***472***	
	Relevant Grant Dollars	103,225,943	102,077,543	100,604,178	97,937,059	101,566,115	
	Number of Contracts	‡	‡	‡	‡	***1***	
	Relevant Contract Dollars	‡	‡	‡	‡	1,500,000	
	Total Count	***589***	***570***	***523***	***455***	***473***	
	Total Relevant Dollars	103,225,943	102,077,543	100,604,178	97,937,059	103,066,115	**0.01**
Nose, Nasal Passages	***Number of Grants***	***11***	***10***	***10***	***14***	***8***	
	Relevant Grant Dollars	786,737	835,744	676,153	1,627,236	904,491	
	Total Count	***11***	***10***	***10***	***14***	***8***	
	Total Relevant Dollars	786,737	835,744	676,153	1,627,236	904,491	**20.84**
Not Site Specific§	***Number of Grants***	***2,243***	***2,304***	***2,196***	***2,079***	***1,952***	
	Relevant Grant Dollars	578,625,792	595,117,368	604,058,911	608,746,346	573,631,342	
	Number of Contracts	***213***	***214***	***186***	***162***	***166***	
	Relevant Contract Dollars	186,310,560	357,711,859	432,722,194	191,360,124	192,657,199	
	Total Count	***2,456***	***2,518***	***2,382***	***2,241***	***2,118***	
	Total Relevant Dollars	764,936,352	952,829,227	1,036,781,105	800,106,470	766,288,541	**1.58**
Oral Cavity	***Number of Grants***	‡	***43***	***49***	***52***	***49***	
	Relevant Grant Dollars	‡	5,505,263	8,783,998	11,138,288	8,209,050	
	Number of Contracts	‡	***1***	‡	‡	‡	
	Relevant Contract Dollars	‡	1,188,000	‡	‡	‡	
	Total Count	‡	***44***	***49***	***52***	***49***	
	Total Relevant Dollars	‡	6,693,263	8,783,998	11,138,288	8,209,050	**10.58**
Ovary	***Number of Grants***	***438***	***419***	***398***	***413***	***413***	
	Relevant Grant Dollars	85,320,484	81,047,163	92,438,385	96,565,010	96,600,440	
	Number of Contracts	***14***	***16***	***16***	***11***	***6***	
	Relevant Contract Dollars	5,595,233	5,782,543	6,099,306	5,217,503	2,015,726	
	Total Count	***452***	***435***	***414***	***424***	***419***	
	Total Relevant Dollars	90,915,717	86,829,706	98,537,691	101,782,513	98,616,166	**2.29**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.
§Not Site Specific = no specific site specified in application, applicable to many sites.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Pancreas	***Number of Grants***	***377***	***405***	***401***	***424***	***417***	
	Relevant Grant Dollars	71,482,007	81,507,036	83,917,076	90,502,908	91,095,822	
	Number of Contracts	***1***	***4***	***1***	***1***	***3***	
	Relevant Contract Dollars	10,124	358,204	124,807	159,140	673,594	
	Total Count	***378***	***409***	***402***	***425***	***420***	
	Total Relevant Dollars	71,492,131	81,865,240	84,041,883	90,662,048	91,769,416	**6.57**
Parathyroid	***Number of Grants***	***3***	***3***	***4***	***2***	***1***	
	Relevant Grant Dollars	195,111	167,518	103,991	‡	‡	
	Total Count	***3***	***3***	***4***	***2***	***1***	
	Total Relevant Dollars	195,111	167,518	103,991	‡	‡	**-26.03**
Penis	***Number of Grants***	***6***	***7***	***4***	***5***	***6***	
	Relevant Grant Dollars	2,720,503	3,031,187	752,499	2,667,920	2,249,216	
	Total Count	***6***	***7***	***4***	***5***	***6***	
	Total Relevant Dollars	2,720,503	3,031,187	752,499	2,667,920	2,249,216	**43.77**
Pharynx	***Number of Grants***	***36***	***32***	***52***	***14***	***18***	
	Relevant Grant Dollars	2,833,144	2,785,503	4,449,521	1,521,576	1,692,375	
	Number of Contracts	***1***	***1***	‡	‡	‡	
	Relevant Contract Dollars	1,162,260	1,188,000	‡	‡	‡	
	Total Count	***37***	***33***	***52***	***14***	***18***	
	Total Relevant Dollars	3,995,404	3,973,503	4,449,521	1,521,576	1,692,375	**-10.79**
Pituitary	***Number of Grants***	***9***	***6***	***7***	***7***	***7***	
	Relevant Grant Dollars	920,804	606,496	482,208	627,219	1,032,440	
	Total Count	***9***	***6***	***7***	***7***	***7***	
	Total Relevant Dollars	920,804	606,496	482,208	627,219	1,032,440	**10.01**
Prostate	***Number of Grants***	***1,139***	***1,101***	***1,028***	***1,030***	***960***	
	Relevant Grant Dollars	267,487,905	252,666,154	250,572,712	265,054,420	254,592,786	
	Number of Contracts	***41***	***46***	***38***	***24***	***13***	
	Relevant Contract Dollars	9,212,924	9,220,125	8,857,832	8,108,959	5,670,388	
	Total Count	***1,180***	***1,147***	***1,066***	***1,054***	***973***	
	Total Relevant Dollars	276,700,829	261,886,279	259,430,544	273,163,379	260,263,174	**-1.43**
Reticuloendothelial System	***Number of Grants***	***64***	***49***	***30***	***24***	***23***	
	Relevant Grant Dollars	12,745,312	8,704,661	7,424,753	4,220,047	4,207,337	
	Total Count	***64***	***49***	***30***	***24***	***23***	
	Total Relevant Dollars	12,745,312	8,704,661	7,424,753	4,220,047	4,207,337	**-22.47**
Respiratory System	***Number of Grants***	***4***	***5***	***3***	***3***	***5***	
	Relevant Grant Dollars	400,761	448,324	484,204	400,921	433,241	
	Total Count	***4***	***5***	***3***	***3***	***5***	
	Total Relevant Dollars	400,761	448,324	484,204	400,921	433,241	**2.68**
Retinoblastoma	***Number of Grants***	***24***	***25***	***23***	***20***	***14***	
	Relevant Grant Dollars	3,691,685	4,536,603	3,582,106	2,599,952	2,291,465	
	Total Count	***24***	***25***	***23***	***20***	***14***	
	Total Relevant Dollars	3,691,685	4,536,603	3,582,106	2,599,952	2,291,465	**-9.36**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Salivary Glands	***Number of Grants***	***4***	***4***	***4***	***5***	***2***	
	Relevant Grant Dollars	166,982	216,951	219,489	281,931	122,931	
	Total Count	***4***	***4***	***4***	***5***	***2***	
	Total Relevant Dollars	166,982	216,951	219,489	281,931	122,931	**0.79**
Skin	***Number of Grants***	***301***	***274***	***243***	***227***	***206***	
	Relevant Grant Dollars	56,840,776	48,382,761	44,850,024	43,190,271	39,781,606	
	Number of Contracts	‡	‡	***1***	‡	***1***	
	Relevant Contract Dollars	‡	‡	200,000	‡	999,000	
	Total Count	***301***	***274***	***244***	***227***	***207***	
	Total Relevant Dollars	56,840,776	48,382,761	45,050,024	43,190,271	40,780,606	**-7.87**
Small Intestine	***Number of Grants***	***28***	***23***	***21***	***19***	***21***	
	Relevant Grant Dollars	3,616,287	1,913,855	2,322,269	2,154,757	2,523,663	
	Total Count	***28***	***23***	***21***	***19***	***21***	
	Total Relevant Dollars	3,616,287	1,913,855	2,322,269	2,154,757	2,523,663	**-3.96**
Spleen	***Number of Grants***	***7***	***5***	***4***	***3***	***1***	
	Relevant Grant Dollars	553,101	579,727	190,652	243,170	41,226	
	Total Count	***7***	***5***	***4***	***3***	***1***	
	Total Relevant Dollars	553,101	579,727	190,652	243,170	41,226	**-29.45**
Stomach	***Number of Grants***	***82***	***74***	***64***	***65***	***58***	
	Relevant Grant Dollars	10,528,229	8,736,659	11,212,686	10,776,732	9,227,080	
	Number of Contracts	***2***	***2***	‡	‡	‡	
	Relevant Contract Dollars	20,391	21,086	‡	‡	‡	
	Total Count	***84***	***76***	***64***	***65***	***58***	
	Total Relevant Dollars	10,548,620	8,757,745	11,212,686	10,776,732	9,227,080	**-1.80**
Testis	***Number of Grants***	***49***	***39***	***30***	***27***	***23***	
	Relevant Grant Dollars	7,845,968	6,649,429	4,704,354	4,216,762	2,966,075	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***49***	***39***	***30***	***27***	***23***	
	Total Relevant Dollars	7,845,968	6,649,429	4,704,354	4,216,762	2,966,075	**-21.13**
Thymus	***Number of Grants***	***12***	***9***	***6***	***4***	***4***	
	Relevant Grant Dollars	1,140,409	944,461	702,233	397,192	504,940	
	Total Count	***12***	***9***	***6***	***4***	***4***	
	Total Relevant Dollars	1,140,409	944,461	702,233	397,192	504,940	**-14.79**
Thyroid	***Number of Grants***	***47***	***50***	***47***	***52***	***51***	
	Relevant Grant Dollars	7,167,262	9,785,919	10,773,542	10,900,704	10,394,218	
	Number of Contracts	***1***	***2***	‡	‡	‡	
	Relevant Contract Dollars	20,248	161,058	‡	‡	‡	
	Total Count	***48***	***52***	***47***	***52***	***51***	
	Total Relevant Dollars	7,187,510	9,946,977	10,773,542	10,900,704	10,394,218	**10.81**
Trachea, Bronchus	***Number of Grants***	***3***	***3***	***3***	***2***	***4***	
	Relevant Grant Dollars	256,970	283,631	332,875	112,364	927,176	
	Total Count	***3***	***3***	***3***	***2***	***4***	
	Total Relevant Dollars	256,970	283,631	332,875	112,364	927,176	**171.66**

continued

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 15. NCI Organ and Related Site-Specific Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Anatomical Site	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Uterus	***Number of Grants***	***112***	***109***	***107***	***80***	***90***	
	Relevant Grant Dollars	16,188,704	14,240,551	14,708,946	12,006,415	13,617,358	
	Number of Contracts	***2***	***2***	‡	‡	‡	
	Relevant Contract Dollars	37,500	‡	‡	‡	‡	
	Total Count	***114***	***111***	***107***	***80***	***90***	
	Total Relevant Dollars	16,226,204	14,240,551	14,708,946	12,006,415	13,617,358	**-3.48**
Vagina	***Number of Grants***	***4***	***5***	***3***	***4***	***5***	
	Relevant Grant Dollars	485,811	395,049	374,910	275,471	284,762	
	Total Count	***4***	***5***	***3***	***4***	***5***	
	Total Relevant Dollars	485,811	395,049	374,910	275,471	284,762	**-11.73**
Vascular	***Number of Grants***	***130***	***96***	***65***	***55***	***48***	
	Relevant Grant Dollars	24,320,429	16,401,823	13,022,343	12,429,452	11,108,479	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***130***	***96***	***65***	***55***	***48***	
	Total Relevant Dollars	24,320,429	16,401,823	13,022,343	12,429,452	11,108,479	**-17.09**
Wilms Tumor	***Number of Grants***	***17***	***17***	***16***	***15***	***17***	
	Relevant Grant Dollars	3,686,340	3,748,439	4,249,920	3,792,626	3,166,418	
	Total Count	***17***	***17***	***16***	***15***	***17***	
	Total Relevant Dollars	3,686,340	3,748,439	4,249,920	3,792,626	3,166,418	**-3.05**

*Some categories are not mutually exclusive, resulting in overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific site.
‡Coding not required or requested.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Adoptive Cell Immunotherapy	***Number of Grants***	***266***	***264***	***250***	***249***	***226***	
	Relevant Grant Dollars	78,652,209	74,709,142	65,455,904	71,169,780	68,415,543	
	Number of Contracts	***1***	‡	‡	‡	***1***	
	Relevant Contract Dollars	149,291	‡	‡	‡	247,568	
	Total Count	***267***	***264***	***250***	***249***	***227***	
	Total Relevant Dollars	78,801,500	74,709,142	65,455,904	71,169,780	68,663,021	**-3.78**
Advanced Manufacturing Technology	***Number of Grants***	***36***	***26***	***16***	***15***	***13***	
	Relevant Grant Dollars	8,330,740	4,715,021	3,032,054	3,285,087	2,770,889	
	Number of Contracts	***8***	***6***	***7***	***1***	‡	
	Relevant Contract Dollars	2,507,029	796,198	2,189,910	106,000	‡	
	Total Count	***44***	***32***	***23***	***16***	***13***	
	Total Relevant Dollars	10,837,769	5,511,219	5,221,964	3,391,087	2,770,889	**-43.62**
Aging	***Number of Grants***	***1,587***	***1,511***	***1,311***	***1,066***	***854***	
	Relevant Grant Dollars	162,147,038	152,249,919	135,080,359	113,349,368	99,438,832	
	Number of Contracts	***34***	***39***	***26***	***7***	***5***	
	Relevant Contract Dollars	4,441,352	5,277,985	4,221,489	2,424,616	631,073	
	Total Count	***1,621***	***1,550***	***1,337***	***1,073***	***859***	
	Total Relevant Dollars	166,588,390	157,527,904	139,301,848	115,773,984	100,069,905	**-13.18**
AIDS	***Number of Grants***	***657***	***492***	***413***	***412***	***65***	
	Relevant Grant Dollars	113,664,239	103,344,122	98,869,614	91,837,776	13,092,878	
	Number of Contracts	***11***	***8***	***10***	***3***	‡	
	Relevant Contract Dollars	2,534,209	2,461,012	4,070,295	504,083	‡	
	Total Count	***668***	***500***	***423***	***415***	***65***	
	Total Relevant Dollars	116,198,448	105,805,134	102,939,909	92,341,859	13,092,878	**-27.48**
Alternative Medicine, Direct	***Number of Grants***	***339***	***369***	***371***	***373***	***347***	
	Relevant Grant Dollars	74,353,346	97,318,620	85,029,188	89,420,040	83,106,708	
	Number of Contracts	***6***	***4***	***3***	***2***	‡	
	Relevant Contract Dollars	763	791	610	1,149,412	‡	
	Total Count	***345***	***373***	***374***	***375***	***347***	
	Total Relevant Dollars	74,354,109	97,319,411	85,029,798	90,569,452	83,106,708	**1.76**
Alternative Medicine, Indirect	***Number of Grants***	***76***	***57***	***48***	***44***	***47***	
	Relevant Grant Dollars	20,093,511	13,189,399	8,017,376	8,714,472	8,363,143	
	Total Count	***76***	***57***	***48***	***44***	***47***	
	Total Relevant Dollars	20,093,511	13,189,399	8,017,376	8,714,472	8,363,143	**-28.22**
Alzheimers Dementia	***Number of Grants***	***8***	***6***	***7***	***4***	***4***	
	Relevant Grant Dollars	688,918	519,280	643,620	508,810	565,699	
	Total Count	***8***	***6***	***7***	***4***	***4***	
	Total Relevant Dollars	688,918	519,280	643,620	508,810	565,699	**-7.17**
Arctic Research	***Number of Grants***	***8***	***7***	***5***	***3***	***3***	
	Relevant Grant Dollars	708,426	965,121	593,726	684,462	692,817	
	Total Count	***8***	***7***	***5***	***3***	***3***	
	Total Relevant Dollars	708,426	965,121	593,726	684,462	692,817	**-5.37**
Arthritis	***Number of Grants***	***9***	***4***	***6***	***4***	***5***	
	Relevant Grant Dollars	675,986	558,858	269,326	400,562	396,477	
	Total Count	***9***	***4***	***6***	***4***	***5***	
	Total Relevant Dollars	675,986	558,858	269,326	400,562	396,477	**-24.18**
Asbestos	***Number of Grants***	***16***	***14***	***10***	***11***	***12***	
	Relevant Grant Dollars	2,167,075	3,033,759	2,598,119	3,428,084	2,591,109	
	Total Count	***16***	***14***	***10***	***11***	***12***	
	Total Relevant Dollars	2,167,075	3,033,759	2,598,119	3,428,084	2,591,109	**2.90**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Ataxia Telangiectasia	***Number of Grants***	***23***	***23***	***21***	***19***	***17***	
	Relevant Grant Dollars	3,510,779	3,327,580	3,679,780	2,938,837	1,769,222	
	Total Count	***23***	***23***	***21***	***19***	***17***	
	Total Relevant Dollars	3,510,779	3,327,580	3,679,780	2,938,837	1,769,222	**-15.24**
Autoimmune Diseases	***Number of Grants***	***61***	***55***	***45***	***37***	***35***	
	Relevant Grant Dollars	6,772,469	6,844,086	5,221,927	4,320,535	4,076,442	
	Total Count	***61***	***55***	***45***	***37***	***35***	
	Total Relevant Dollars	6,772,469	6,844,086	5,221,927	4,320,535	4,076,442	**-14.13**
Behavior Research	***Number of Grants***	***984***	***1,072***	***1,093***	***1,104***	***769***	
	Relevant Grant Dollars	300,881,659	280,067,448	297,188,165	314,205,359	237,545,358	
	Number of Contracts	***20***	***18***	***14***	***10***	***9***	
	Relevant Contract Dollars	7,837,430	7,038,853	4,360,635	3,248,062	4,368,885	
	Total Count	***1,004***	***1,090***	***1,108***	***1,116***	***778***	
	Total Relevant Dollars	308,719,089	287,106,301	301,598,796	318,626,425	241,914,243	**-5.36**
Bioengineering	***Number of Grants***	***648***	***661***	***593***	***543***	***478***	
	Relevant Grant Dollars	169,947,069	166,106,195	146,299,426	143,101,038	136,659,850	
	Number of Contracts	***33***	***43***	***19***	***19***	***28***	
	Relevant Contract Dollars	23,767,460	23,284,472	9,802,298	5,212,765	7,104,296	
	Total Count	***681***	***704***	***612***	***562***	***506***	
	Total Relevant Dollars	193,714,529	189,390,667	156,101,724	148,313,803	143,764,146	**-7.98**
Bioinformatics	***Number of Grants***	***625***	***647***	***609***	***613***	***620***	
	Relevant Grant Dollars	146,352,339	153,069,578	162,286,911	175,538,540	195,579,757	
	Number of Contracts	***31***	***35***	***21***	***16***	***20***	
	Relevant Contract Dollars	44,985,173	61,976,197	23,191,871	18,412,975	20,328,761	
	Total Count	***656***	***682***	***630***	***629***	***640***	
	Total Relevant Dollars	191,337,512	215,045,775	185,478,782	193,951,515	215,908,518	**2.69**
Biological Carcinogenesis Non-Viral	***Number of Grants***	***56***	***61***	***68***	***65***	***68***	
	Relevant Grant Dollars	10,156,057	10,028,377	13,031,273	13,043,584	14,509,921	
	Number of Contracts	***1***	***1***	‡	‡	‡	
	Relevant Contract Dollars	11,790	11,788	‡	‡	‡	
	Total Count	***57***	***62***	***68***	***65***	***68***	
	Total Relevant Dollars	10,167,847	10,040,165	13,031,273	13,043,584	14,509,921	**8.25**
Biologics/Biological Response Modifiers	***Number of Grants***	***2,467***	***2,415***	***2,122***	***1,900***	***1,668***	
	Relevant Grant Dollars	848,648,865	770,905,944	696,719,623	670,058,289	603,303,533	
	Number of Contracts	***45***	***35***	***36***	***22***	***15***	
	Relevant Contract Dollars	36,827,103	49,274,072	42,544,872	21,405,546	16,939,205	
	Total Count	***2,512***	***2,450***	***2,158***	***1,922***	***1,683***	
	Total Relevant Dollars	885,475,968	820,180,016	739,264,495	691,463,835	620,242,738	**-9.03**
Biomaterials Research	***Number of Grants***	***144***	***156***	***131***	***141***	***114***	
	Relevant Grant Dollars	28,978,407	29,002,753	27,561,068	21,212,069	17,519,246	
	Number of Contracts	***7***	***9***	‡	***4***	‡	
	Relevant Contract Dollars	220,708	876,528	‡	1,548,783	‡	
	Total Count	***151***	***165***	***131***	***145***	***114***	
	Total Relevant Dollars	29,199,115	29,879,281	27,561,068	22,760,852	17,519,246	**-12.56**
Biomedical Computing	***Number of Grants***	***296***	***430***	***467***	***532***	***542***	
	Relevant Grant Dollars	62,125,716	91,622,068	113,451,117	137,845,989	144,567,142	
	Number of Contracts	***36***	***52***	***21***	***19***	***30***	
	Relevant Contract Dollars	45,656,485	62,638,913	61,682,516	61,163,296	76,247,799	
	Total Count	***332***	***482***	***488***	***551***	***572***	
	Total Relevant Dollars	107,782,201	154,260,981	175,133,633	199,009,285	220,814,941	**16.25**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Birth Defects	***Number of Grants***	***83***	***75***	***61***	***64***	***56***	
	Relevant Grant Dollars	12,986,117	12,667,124	11,547,343	12,310,466	10,773,700	
	Total Count	***83***	***75***	***61***	***64***	***56***	
	Total Relevant Dollars	12,986,117	12,667,124	11,547,343	12,310,466	10,773,700	**-4.63**
Bone Marrow Transplantation	***Number of Grants***	***149***	***140***	***146***	***140***	***146***	
	Relevant Grant Dollars	57,685,687	47,434,124	52,111,916	54,507,621	50,005,537	
	Number of Contracts	‡	‡	***1***	‡	‡	
	Relevant Contract Dollars	‡	‡	49,496	‡	‡	
	Total Count	***149***	***140***	***147***	***140***	***146***	
	Total Relevant Dollars	57,685,687	47,434,124	52,161,412	54,507,621	50,005,537	**-4.13**
Breast Cancer Detection	***Number of Grants***	***528***	***525***	***508***	***498***	***458***	
	Relevant Grant Dollars	106,217,059	108,220,945	104,769,617	99,759,605	91,023,962	
	Number of Contracts	***25***	***28***	***22***	***13***	***15***	
	Relevant Contract Dollars	3,226,170	2,767,443	2,928,506	3,632,816	6,478,783	
	Total Count	***553***	***553***	***530***	***511***	***473***	
	Total Relevant Dollars	109,443,229	110,988,388	107,698,123	103,392,421	97,502,745	**-2.88**
Breast Cancer Early Detection	***Number of Grants***	***251***	***240***	***219***	***225***	***196***	
	Relevant Grant Dollars	55,363,825	53,893,623	45,876,009	47,143,457	48,915,492	
	Number of Contracts	***5***	***6***	***1***	***3***	***4***	
	Relevant Contract Dollars	677,184	470,851	420,996	1,506,703	2,561,486	
	Total Count	***256***	***246***	***220***	***228***	***200***	
	Total Relevant Dollars	56,041,009	54,364,474	46,297,005	48,650,160	51,476,978	**-2.47**
Breast Cancer Education	***Number of Grants***	***154***	***144***	***142***	***149***	***131***	
	Relevant Grant Dollars	19,875,523	16,003,803	17,412,166	16,743,662	16,114,826	
	Total Count	***154***	***144***	***142***	***149***	***131***	
	Total Relevant Dollars	19,875,523	16,003,803	17,412,166	16,743,662	16,114,826	**-5.96**
Breast Cancer Epidemiology	***Number of Grants***	***200***	***191***	***182***	***189***	***195***	
	Relevant Grant Dollars	57,628,754	54,730,727	54,666,482	64,674,588	67,767,559	
	Number of Contracts	***4***	***3***	***1***	***5***	***1***	
	Relevant Contract Dollars	775,166	308,692	51,500	336,493	1,620,669	
	Total Count	***204***	***194***	***183***	***194***	***196***	
	Total Relevant Dollars	58,403,920	55,039,419	54,717,982	65,011,081	69,388,228	**3.97**
Breast Cancer Genetics	***Number of Grants***	***427***	***429***	***429***	***453***	***482***	
	Relevant Grant Dollars	96,343,475	97,895,528	104,276,046	116,708,177	116,790,479	
	Number of Contracts	***3***	***3***	***8***	***5***	***6***	
	Relevant Contract Dollars	1,110,467	1,064,606	2,655,595	2,418,766	2,277,691	
	Total Count	***430***	***432***	***437***	***458***	***488***	
	Total Relevant Dollars	97,453,942	98,960,134	106,931,641	119,126,943	119,068,170	**4.79**
Breast Cancer Prevention	***Number of Grants***	***252***	***237***	***223***	***211***	***193***	
	Relevant Grant Dollars	33,900,951	24,443,078	23,625,542	20,573,617	19,425,993	
	Number of Contracts	‡	‡	‡	‡	***2***	
	Relevant Contract Dollars	‡	‡	‡	‡	161745	
	Total Count	***252***	***237***	***223***	***211***	***195***	
	Total Relevant Dollars	33,900,951	24,443,078	23,625,542	20,573,617	19,587,738	**-15.44**
Breast Cancer Rehabilitation	***Number of Grants***	***159***	***157***	***156***	***165***	***180***	
	Relevant Grant Dollars	19,883,798	18,496,683	22,053,106	23,414,402	23,491,341	
	Number of Contracts	***1***	‡	‡	‡	‡	
	Relevant Contract Dollars	149,973	‡	‡	‡	‡	
	Total Count	***160***	***157***	***156***	***165***	***180***	
	Total Relevant Dollars	20,033,771	18,496,683	22,053,106	23,414,402	23,491,341	**3.49**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Breast Cancer Screening	***Number of Grants***	***194***	***190***	***182***	***194***	***178***	
	Relevant Grant Dollars	25,068,440	22,935,243	21,132,490	22,564,554	24,098,034	
	Number of Contracts	***1***	‡	‡	‡	***1***	
	Relevant Contract Dollars	18,848	‡	‡	‡	1,599,992	
	Total Count	***195***	***190***	***182***	***194***	***179***	
	Total Relevant Dollars	25,087,288	22,935,243	21,132,490	22,564,554	25,698,026	**0.58**
Breast Cancer Treatment	***Number of Grants***	***712***	***715***	***676***	***699***	***671***	
	Relevant Grant Dollars	157,072,191	159,717,667	175,287,152	191,699,483	182,244,051	
	Number of Contracts	***18***	***17***	***20***	***11***	***3***	
	Relevant Contract Dollars	3,175,991	2,845,506	2,908,754	1,962,093	461,244	
	Total Count	***730***	***732***	***696***	***710***	***674***	
	Total Relevant Dollars	160,248,182	162,563,173	178,195,906	193,661,576	182,705,295	**3.13**
Breast Cancer-Basic	***Number of Grants***	***855***	***807***	***773***	***781***	***758***	
	Relevant Grant Dollars	157,238,472	152,092,109	161,805,933	168,864,512	168,911,481	
	Number of Contracts	***8***	***8***	***9***	***9***	***2***	
	Relevant Contract Dollars	685,736	559,354	1,532,199	1,977,194	648,203	
	Total Count	***863***	***815***	***782***	***790***	***760***	
	Total Relevant Dollars	157,924,208	152,651,463	163,338,132	170,841,706	169,559,684	**1.68**
Cancer Survivorship	***Number of Grants***	***593***	***604***	***596***	***627***	***669***	
	Relevant Grant Dollars	188,415,629	189,504,238	197,965,376	233,784,991	244,829,411	
	Number of Contracts	***27***	***26***	***22***	***7***	***11***	
	Relevant Contract Dollars	4,021,835	3,743,947	2,901,978	2,202,035	10,974,854	
	Total Count	***620***	***630***	***618***	***634***	***680***	
	Total Relevant Dollars	192,437,464	193,248,185	200,867,354	235,987,026	255,804,265	**6.87**
Carcinogenesis, Environmental	***Number of Grants***	***1,591***	***1,478***	***1,407***	***1,316***	***1,237***	
	Relevant Grant Dollars	478,853,048	416,898,310	388,760,406	395,790,431	384,795,833	
	Number of Contracts	***34***	***34***	***26***	***19***	***9***	
	Relevant Contract Dollars	18,994,043	16,619,490	10,219,303	7,165,859	3,411,768	
	Total Count	***1,625***	***1,512***	***1,433***	***1,335***	***1,246***	
	Total Relevant Dollars	497,847,091	433,517,800	398,979,709	402,956,290	388,207,601	**-6.54**
Cervical Cancer Education	***Number of Grants***	***38***	***48***	***42***	***49***	***44***	
	Relevant Grant Dollars	6,476,819	6,078,672	5,288,307	6,669,506	6,289,116	
	Total Count	***38***	***48***	***42***	***49***	***44***	
	Total Relevant Dollars	6,476,819	6,078,672	5,288,307	6,669,506	6,289,116	**-1.62**
Chemoprevention	***Number of Grants***	***595***	***603***	***581***	***554***	***513***	
	Relevant Grant Dollars	147,147,622	127,214,057	122,199,190	110,809,302	110,334,008	
	Number of Contracts	***36***	***26***	***20***	***9***	***9***	
	Relevant Contract Dollars	31,817,172	30,237,119	34,586,263	14,907,908	12,224,778	
	Total Count	***631***	***629***	***601***	***563***	***522***	
	Total Relevant Dollars	178,964,794	157,451,176	156,785,453	125,717,210	122,558,786	**-10.33**
Chemoprevention, Clinical	***Number of Grants***	***140***	***130***	***134***	***136***	***129***	
	Relevant Grant Dollars	40,528,158	33,077,734	32,365,770	31,292,583	30,974,445	
	Number of Contracts	***19***	***12***	***7***	***2***	***4***	
	Relevant Contract Dollars	12,265,652	11,367,607	11,187,869	1,568,183	6,660,343	
	Total Count	***159***	***142***	***141***	***138***	***133***	
	Total Relevant Dollars	52,793,810	44,445,341	43,553,639	32,860,766	37,634,788	**-9.71**
Chemotherapy	***Number of Grants***	***1,338***	***1,350***	***1,318***	***1,265***	***1,268***	
	Relevant Grant Dollars	497,798,503	474,245,547	491,407,371	486,445,892	487,783,247	
	Number of Contracts	***37***	***31***	***24***	***23***	***23***	
	Relevant Contract Dollars	24,643,133	23,279,025	18,985,236	16,237,585	15,509,777	
	Total Count	***1,375***	***1,381***	***1,342***	***1,288***	***1,291***	
	Total Relevant Dollars	522,441,636	497,524,572	510,392,607	502,683,477	503,293,024	**-0.97**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Child Health	***Number of Grants***	***226***	***208***	***173***	***180***	***146***	
	Relevant Grant Dollars	62,633,467	55,722,419	41,893,936	35,485,301	30,619,348	
	Number of Contracts	***3***	***1***	***1***	***1***	***1***	
	Relevant Contract Dollars	10,124	10,529	94,045	100,000	500,000	
	Total Count	***229***	***209***	***174***	***181***	***147***	
	Total Relevant Dollars	62,643,591	55,732,948	41,987,981	35,585,301	31,119,348	**-18.92**
Childhood Cancers	***Number of Grants***	***500***	***504***	***477***	***495***	***517***	
	Relevant Grant Dollars	159,209,507	164,775,607	163,353,861	166,272,586	165,281,278	
	Number of Contracts	***5***	***5***	***1***	***1***	***1***	
	Relevant Contract Dollars	3,801,832	1,431,001	1,990,858	2,938,868	2,791,925	
	Total Count	***505***	***509***	***478***	***496***	***518***	
	Total Relevant Dollars	163,011,339	166,206,608	165,344,719	169,211,454	168,073,203	**0.75**
Chronic Myeloproliferative Disorders	***Number of Grants***	***130***	***124***	***115***	***129***	***143***	
	Relevant Grant Dollars	37,298,741	31,066,792	31,864,056	33,259,274	40,413,091	
	Total Count	***130***	***124***	***115***	***129***	***143***	
	Total Relevant Dollars	37,298,741	31,066,792	31,864,056	33,259,274	40,413,091	**2.04**
Clinical Trials, Diagnosis	***Number of Grants***	***193***	***180***	***177***	***158***	***157***	
	Relevant Grant Dollars	60,241,052	52,919,647	46,050,747	49,365,161	50,104,212	
	Number of Contracts	***17***	***20***	***15***	***14***	***3***	
	Relevant Contract Dollars	23,143,799	22,227,173	20,599,926	21,295,518	4,929,393	
	Total Count	***210***	***200***	***192***	***172***	***160***	
	Total Relevant Dollars	83,384,851	75,146,820	66,650,673	70,660,679	55,033,605	**-10.04**
Clinical Trials, Other	***Number of Grants***	***213***	***202***	***196***	***231***	***220***	
	Relevant Grant Dollars	55,628,143	57,804,488	55,185,455	64,532,028	69,256,696	
	Number of Contracts	***5***	***5***	***2***	***3***	***4***	
	Relevant Contract Dollars	27,588,310	35,442,454	1,800,000	2,199,778	5,627,105	
	Total Count	***218***	***207***	***198***	***234***	***224***	
	Total Relevant Dollars	83,216,453	93,246,942	56,985,455	66,731,806	74,883,801	**-6.51**
Clinical Trials, Prevention	***Number of Grants***	***127***	***152***	***160***	***162***	***227***	
	Relevant Grant Dollars	51,851,105	51,014,829	52,476,013	56,851,445	142,302,439	
	Number of Contracts	***19***	***14***	***10***	***4***	***6***	
	Relevant Contract Dollars	18,950,376	17,487,767	17,750,174	10,044,105	11,401,878	
	Total Count	***146***	***166***	***170***	***166***	***233***	
	Total Relevant Dollars	70,801,481	68,502,596	70,226,187	66,895,550	153,704,317	**30.97**
Clinical Trials, Therapy	***Number of Grants***	***707***	***709***	***657***	***636***	***523***	
	Relevant Grant Dollars	426,525,232	394,416,421	381,371,267	383,892,811	321,816,935	
	Number of Contracts	***16***	***16***	***16***	***17***	***20***	
	Relevant Contract Dollars	24,919,354	20,555,120	45,809,933	43,398,794	57,748,533	
	Total Count	***723***	***725***	***673***	***653***	***543***	
	Total Relevant Dollars	451,444,586	414,971,541	427,181,200	427,291,605	379,565,468	**-4.27**
Combined Treatment Modalities	***Number of Grants***	***558***	***572***	***601***	***679***	***769***	
	Relevant Grant Dollars	336,759,452	329,900,253	330,893,890	366,302,744	388,561,125	
	Number of Contracts	***1***	***1***	***1***	***4***	***7***	
	Relevant Contract Dollars	2,404,801	1,141,539	1,990,858	3,372,144	6,442,620	
	Total Count	***559***	***573***	***602***	***683***	***776***	
	Total Relevant Dollars	339,164,253	331,041,792	332,884,748	369,674,888	395,003,745	**3.73**
Cost Effectiveness	***Number of Grants***	***176***	***177***	***172***	***173***	***177***	
	Relevant Grant Dollars	25,250,379	27,408,881	27,223,170	27,186,831	29,938,700	
	Number of Contracts	***6***	***5***	***3***	***2***	***1***	
	Relevant Contract Dollars	149,213	791	610	186,230	248,461	
	Total Count	***182***	***182***	***175***	***175***	***178***	
	Total Relevant Dollars	25,399,592	27,409,672	27,223,780	27,373,061	30,187,161	**4.37**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Diabetes	***Number of Grants***	***64***	***59***	***53***	***47***	***36***	
	Relevant Grant Dollars	7,129,217	7,044,678	6,202,451	3,530,526	4,851,425	
	Total Count	***64***	***59***	***53***	***47***	***36***	
	Total Relevant Dollars	7,129,217	7,044,678	6,202,451	3,530,526	4,851,425	**-13.26**
Diagnosis	***Number of Grants***	***1,918***	***1,985***	***1,911***	***1,855***	***1,779***	
	Relevant Grant Dollars	575,537,825	573,452,204	559,042,065	553,036,713	559,531,772	
	Number of Contracts	***78***	***94***	***71***	***66***	***51***	
	Relevant Contract Dollars	37,162,748	48,739,504	36,236,631	38,373,345	24,273,760	
	Total Count	***1,996***	***2,079***	***1,982***	***1,921***	***1,830***	
	Total Relevant Dollars	612,700,573	622,191,708	595,278,696	591,410,058	583,805,532	**-1.23**
Diethylstilbestrol	***Number of Grants***	***3***	***3***	‡	***2***	***3***	
	Relevant Grant Dollars	399,512	405,296	‡	210,443	330,257	
	Number of Contracts	***5***	***5***	***5***	***5***	‡	
	Relevant Contract Dollars	1,471,870	1,302,461	1,332,877	1,345,965	‡	
	Total Count	***8***	***8***	***5***	***7***	***3***	
	Total Relevant Dollars	1,871,382	1,707,757	1,332,877	1,556,408	330,257	**-25.53**
Dioxin	***Number of Grants***	***13***	***10***	***10***	***12***	***13***	
	Relevant Grant Dollars	1,284,000	1,364,134	1,268,488	1,736,256	869,725	
	Total Count	***13***	***10***	***10***	***12***	***13***	
	Total Relevant Dollars	1,284,000	1,364,134	1,268,488	1,736,256	869,725	**-6.16**
DNA Repair	***Number of Grants***	***716***	***699***	***633***	***600***	***555***	
	Relevant Grant Dollars	157,601,803	135,428,622	122,923,808	128,813,944	122,952,777	
	Number of Contracts	‡	‡	‡	***2***	‡	
	Relevant Contract Dollars	‡	‡	‡	399,599	‡	
	Total Count	***716***	***699***	***633***	***602***	***555***	
	Total Relevant Dollars	157,601,803	135,428,622	122,923,808	129,213,543	122,952,777	**-6.63**
Drug Development	***Number of Grants***	***1,941***	***2,077***	***2,087***	***2,091***	***2,095***	
	Relevant Grant Dollars	528,991,781	526,752,390	538,758,282	550,899,818	582,044,480	
	Number of Contracts	***100***	***86***	***75***	***82***	***84***	
	Relevant Contract Dollars	59,479,332	89,847,891	51,239,667	50,932,059	44,439,383	
	Total Count	***2,041***	***2,163***	***2,162***	***2,173***	***2,179***	
	Total Relevant Dollars	588,471,113	616,600,281	589,997,949	601,831,877	626,483,863	**1.53**
Drug Discovery	***Number of Grants***	***308***	***366***	***364***	***377***	***380***	
	Relevant Grant Dollars	74,279,785	79,667,568	81,268,839	74,170,074	71,551,561	
	Number of Contracts	***23***	***18***	***11***	***18***	***11***	
	Relevant Contract Dollars	9,753,535	9,345,219	13,478,230	11,779,829	2,805,286	
	Total Count	***331***	***384***	***375***	***395***	***391***	
	Total Relevant Dollars	84,033,320	89,012,787	94,747,069	85,949,903	74,356,847	**-3.02**
Drug Resistance	***Number of Grants***	***627***	***646***	***631***	***634***	***638***	
	Relevant Grant Dollars	117,103,635	109,833,907	111,827,085	117,323,805	126,166,864	
	Number of Contracts	‡	‡	***1***	***2***	***2***	
	Relevant Contract Dollars	‡	‡	37,181	395,550	388,667	
	Total Count	***627***	***646***	***632***	***636***	***640***	
	Total Relevant Dollars	117,103,635	109,833,907	111,864,266	117,719,355	126,555,531	**1.92**
Drugs – Natural Products	***Number of Grants***	***630***	***647***	***634***	***640***	***603***	
	Relevant Grant Dollars	143,442,656	134,532,430	150,196,945	143,114,167	140,027,475	
	Number of Contracts	***13***	***5***	***4***	***4***	***5***	
	Relevant Contract Dollars	1,026,873	240,346	593,175	1,375,565	1,298,440	
	Total Count	***643***	***652***	***638***	***644***	***608***	
	Total Relevant Dollars	144,469,529	134,772,776	150,790,120	144,489,732	141,325,915	**-0.78**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Early Detection	***Number of Grants***	***949***	***936***	***869***	***839***	***799***	
	Relevant Grant Dollars	265,030,226	240,604,537	222,168,970	227,060,938	231,169,872	
	Number of Contracts	***31***	***40***	***20***	***17***	***10***	
	Relevant Contract Dollars	23,894,581	23,057,128	21,156,276	21,353,066	9,463,743	
	Total Count	***980***	***976***	***889***	***856***	***809***	
	Total Relevant Dollars	288,924,807	263,661,665	243,325,246	248,414,004	240,633,615	**-4.76**
Effectiveness Research	***Number of Grants***	***174***	***135***	***156***	***199***	***241***	
	Relevant Grant Dollars	48,830,097	38,991,088	52,087,249	59,933,366	88,645,132	
	Number of Contracts	***5***	***4***	***1***	***2***	***2***	
	Relevant Contract Dollars	435,033	216,123	252,597	560,081	303,094	
	Total Count	***179***	***139***	***157***	***201***	***243***	
	Total Relevant Dollars	49,265,130	39,207,211	52,339,846	60,493,447	88,948,226	**14.99**
Endocrinology	***Number of Grants***	***880***	***846***	***787***	***716***	***669***	
	Relevant Grant Dollars	172,460,886	152,810,901	160,349,292	144,586,939	134,691,456	
	Number of Contracts	***8***	***8***	***6***	***5***	***2***	
	Relevant Contract Dollars	1,710,706	1,442,461	2,042,874	1,345,965	365,780	
	Total Count	***888***	***854***	***793***	***721***	***671***	
	Total Relevant Dollars	174,171,592	154,253,362	162,392,166	145,932,904	135,057,236	**-6.66**
Energy Balance	***Number of Grants***	***128***	***117***	***109***	***104***	***105***	
	Relevant Grant Dollars	39,387,827	37,250,439	34,684,820	30,844,556	33,474,016	
	Number of Contracts	***4***	***5***	***2***	***1***	‡	
	Relevant Contract Dollars	1,047,129	1,916,049	1,575,000	4,885	‡	
	Total Count	***132***	***122***	***111***	***105***	***105***	
	Total Relevant Dollars	40,434,956	39,166,488	36,259,820	30,849,441	33,474,016	**-5.07**
Epid.-Biochemical	***Number of Grants***	***584***	***581***	***560***	***544***	***513***	
	Relevant Grant Dollars	191,467,862	187,522,766	186,146,991	207,004,532	196,371,213	
	Number of Contracts	***13***	***10***	***11***	***9***	***10***	
	Relevant Contract Dollars	12,716,700	13,132,622	22,350,084	22,230,209	27,302,955	
	Total Count	***597***	***591***	***571***	***553***	***523***	
	Total Relevant Dollars	204,184,562	200,655,388	208,497,075	229,234,741	223,674,168	**2.16**
Epidemiology	***Number of Grants***	***154***	***184***	***203***	***238***	***248***	
	Relevant Grant Dollars	30,658,644	35,362,320	48,391,387	58,955,769	58,456,327	
	Number of Contracts	***14***	***12***	***11***	***12***	***9***	
	Relevant Contract Dollars	3,123,091	40,155,271	6,923,651	7,967,822	6,370,296	
	Total Count	***168***	***196***	***214***	***250***	***257***	
	Total Relevant Dollars	33,781,735	75,517,591	55,315,038	66,923,591	64,826,623	**8.24**
Epidemiology, Environmental	***Number of Grants***	***571***	***534***	***518***	***487***	***442***	
	Relevant Grant Dollars	177,174,581	165,826,605	157,183,612	169,765,154	158,195,340	
	Number of Contracts	***27***	***24***	***21***	***16***	***10***	
	Relevant Contract Dollars	17,552,030	16,439,893	24,581,051	24,953,396	22,833,401	
	Total Count	***598***	***558***	***539***	***503***	***452***	
	Total Relevant Dollars	194,726,611	182,266,498	181,764,663	194,718,550	181,028,741	**-1.87**
Epigenetics	***Number of Grants***	***642***	***699***	***722***	***771***	***859***	
	Relevant Grant Dollars	121,281,851	115,349,385	139,887,622	161,834,223	182,952,932	
	Number of Contracts	***1***	***2***	***4***	***3***	‡	
	Relevant Contract Dollars	144,400	302,567	653,292	549,598	‡	
	Total Count	***643***	***701***	***726***	***774***	***859***	
	Total Relevant Dollars	121,426,251	115,651,952	140,540,914	162,383,821	182,952,932	**9.71**
Gene Mapping, Human	***Number of Grants***	***655***	***554***	***493***	***436***	***402***	
	Relevant Grant Dollars	138,302,632	119,648,785	153,658,315	158,894,763	149,903,735	
	Total Count	***655***	***554***	***493***	***436***	***402***	
	Total Relevant Dollars	138,302,632	119,648,785	153,658,315	158,894,763	149,903,735	**1.04**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Gene Mapping, Non-Human	***Number of Grants***	***358***	***327***	***274***	***243***	***215***	
	Relevant Grant Dollars	57,173,146	49,897,071	40,329,713	37,746,569	35,807,176	
	Total Count	***358***	***327***	***274***	***243***	***215***	
	Total Relevant Dollars	57,173,146	49,897,071	40,329,713	37,746,569	35,807,176	**-12.57**
Gene Transfer, Clinical	***Number of Grants***	***81***	***58***	***37***	***28***	***33***	
	Relevant Grant Dollars	16,880,605	9,063,499	11,261,635	8,086,568	8,242,594	
	Total Count	***81***	***58***	***37***	***28***	***33***	
	Total Relevant Dollars	16,880,605	9,063,499	11,261,635	8,086,568	8,242,594	**-26.02**
Genetic Testing Research, Human	***Number of Grants***	***470***	***460***	***380***	***335***	***286***	
	Relevant Grant Dollars	175,117,006	153,581,370	128,833,823	115,367,220	97,622,451	
	Number of Contracts	***4***	***4***	***3***	***3***	***4***	
	Relevant Contract Dollars	1,210,690	1,064,606	1,308,355	1,325,744	1,531,022	
	Total Count	***474***	***464***	***383***	***338***	***290***	
	Total Relevant Dollars	176,327,696	154,645,976	130,142,178	116,692,964	99,153,473	**-14.85**
Genomics	***Number of Grants***	***360***	***603***	***758***	***837***	***936***	
	Relevant Grant Dollars	93,564,965	160,617,624	233,634,493	276,653,749	312,504,344	
	Number of Contracts	***6***	***7***	***11***	***9***	***10***	
	Relevant Contract Dollars	248,376	37,387,078	2,893,716	2,573,478	3,992,902	
	Total Count	***366***	***610***	***769***	***846***	***946***	
	Total Relevant Dollars	93,813,341	198,004,702	236,528,209	279,227,227	316,497,246	**24.39**
Health Literacy	***Number of Grants***	***54***	***74***	***78***	***93***	***104***	
	Relevant Grant Dollars	9,318,204	14,713,919	19,259,445	21,151,000	23,322,845	
	Number of Contracts	***3***	***6***	***2***	***1***	***1***	
	Relevant Contract Dollars	494,973	462,228	2,242,507	2,225,682	2,034,678	
	Total Count	***57***	***80***	***80***	***94***	***105***	
	Total Relevant Dollars	9,813,177	15,176,147	21,501,952	23,376,682	25,357,523	**20.31**
Health Promotion	***Number of Grants***	***575***	***567***	***550***	***535***	***492***	
	Relevant Grant Dollars	216,311,569	188,789,768	189,856,649	156,169,759	158,653,454	
	Number of Contracts	***30***	***31***	***29***	***12***	***5***	
	Relevant Contract Dollars	17,599,722	17,490,115	12,155,514	8,239,835	4,853,740	
	Total Count	***605***	***598***	***579***	***547***	***497***	
	Total Relevant Dollars	233,911,291	206,279,883	202,012,163	164,409,594	163,507,194	**-9.73**
Health Care Delivery	***Number of Grants***	***177***	***233***	***260***	***323***	***361***	
	Relevant Grant Dollars	46,244,456	58,703,422	79,491,611	99,249,496	111,213,954	
	Number of Contracts	***15***	***19***	***7***	***9***	***10***	
	Relevant Contract Dollars	5,067,214	4,471,971	4,206,677	4,637,640	6,239,884	
	Total Count	***192***	***252***	***267***	***332***	***371***	
	Total Relevant Dollars	51,311,670	63,175,393	83,698,288	103,887,136	117,453,838	**18.95**
Helicobacter	***Number of Grants***	***39***	***39***	***39***	***34***	***33***	
	Relevant Grant Dollars	7,219,894	5,876,269	8,224,164	8,078,008	8,081,826	
	Number of Contracts	***1***	***1***	‡	‡	‡	
	Relevant Contract Dollars	11,790	11,788	‡	‡	‡	
	Total Count	***40***	***40***	***39***	***34***	***33***	
	Total Relevant Dollars	7,231,684	5,888,057	8,224,164	8,078,008	8,081,826	**0.96**
Hematology	***Number of Grants***	***1,729***	***1,646***	***1,531***	***1,472***	***465***	
	Relevant Grant Dollars	479,959,002	468,003,334	451,773,304	466,847,932	122,611,326	
	Number of Contracts	***11***	***10***	***6***	***6***	‡	
	Relevant Contract Dollars	1,466,168	1,465,173	906,834	1,967,879	‡	
	Total Count	***1,740***	***1,656***	***1,537***	***1,478***	***465***	
	Total Relevant Dollars	481,425,170	469,468,507	452,680,138	468,815,811	122,611,326	**-19.17**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Hematopoietic Stem Cell Research	***Number of Grants***	***496***	***486***	***467***	***396***	***465***	
	Relevant Grant Dollars	117,664,534	114,552,753	114,121,151	113,380,226	122,611,326	
	Number of Contracts	***5***	***5***	***5***	***1***	‡	
	Relevant Contract Dollars	1,345,185	1,177,713	727,386	999,936	‡	
	Total Count	***501***	***491***	***472***	***397***	***465***	
	Total Relevant Dollars	119,009,719	115,730,466	114,848,537	114,380,162	122,611,326	**0.80**
Hormone Replacement Therapy	***Number of Grants***	***61***	***49***	***41***	***33***	***31***	
	Relevant Grant Dollars	10,834,905	6,714,658	7,098,888	3,175,346	3,987,675	
	Total Count	***61***	***49***	***41***	***33***	***31***	
	Total Relevant Dollars	10,834,905	6,714,658	7,098,888	3,175,346	3,987,675	**-38.48**
Hospice	***Number of Grants***	***72***	***57***	***45***	***45***	***33***	
	Relevant Grant Dollars	13,724,054	9,075,982	8,363,251	9,344,380	8,276,000	
	Number of Contracts	‡	***4***	‡	***1***	‡	
	Relevant Contract Dollars	‡	612,259	‡	999,998	‡	
	Total Count	***72***	***61***	***45***	***46***	***33***	
	Total Relevant Dollars	13,724,054	9,688,241	8,363,251	10,344,378	8,276,000	**-14.59**
Human Genome	***Number of Grants***	‡	***219***	***408***	***533***	***631***	
	Relevant Grant Dollars	‡	72,721,075	157,617,076	224,387,803	262,277,096	
	Number of Contracts	‡	***1***	***3***	***2***	***2***	
	Relevant Contract Dollars	‡	149,975	2,392,888	2,260,666	1,398,722	
	Total Count	‡	***220***	***411***	***535***	***633***	
	Total Relevant Dollars	‡	72,871,050	160,009,964	226,648,469	263,675,818	**59.19**
Iatrogenesis	***Number of Grants***	***245***	***288***	***275***	***257***	***247***	
	Relevant Grant Dollars	50,173,643	55,716,691	65,399,334	61,577,955	62,271,326	
	Number of Contracts	***5***	***6***	***7***	***5***	***3***	
	Relevant Contract Dollars	1,471,870	2,202,346	2,532,672	1,345,965	487,983	
	Total Count	***250***	***294***	***282***	***262***	***250***	
	Total Relevant Dollars	51,645,513	57,919,037	67,932,006	62,923,920	62,759,309	**4.34**
Imaging	***Number of Grants***	***1,058***	***1,100***	***1,047***	***1,045***	***1,012***	
	Relevant Grant Dollars	299,804,703	300,082,605	289,428,387	298,744,722	309,142,019	
	Number of Contracts	***30***	***40***	***27***	***32***	***20***	
	Relevant Contract Dollars	19,391,655	32,833,674	18,714,802	21,851,672	7,316,896	
	Total Count	***1,088***	***1,140***	***1,074***	***1,077***	***1,032***	
	Total Relevant Dollars	319,196,358	332,916,279	308,143,189	320,596,394	316,458,915	**-0.33**
Immunization	***Number of Grants***	‡	***477***	***420***	***442***	***449***	
	Relevant Grant Dollars	‡	116,732,773	109,830,817	116,267,543	122,814,703	
	Number of Contracts	‡	***1***	***2***	‡	***4***	
	Relevant Contract Dollars	‡	14,808,841	1,370,729	‡	3,429,651	
	Total Count	‡	***478***	***422***	***442***	***453***	
	Total Relevant Dollars	‡	131,541,614	111,201,546	116,267,543	126,244,354	**-0.78**
Inflammation	***Number of Grants***	‡	***328***	***365***	***418***	***467***	
	Relevant Grant Dollars	‡	59,043,221	66,040,358	81,746,863	99,553,973	
	Number of Contracts	‡	***1***	***1***	‡	‡	
	Relevant Contract Dollars	‡	7,404,421	98,991	‡	‡	
	Total Count	‡	***329***	***366***	***418***	***467***	
	Total Relevant Dollars	‡	66,447,642	66,139,349	81,746,863	99,553,973	**14.97**
Information Dissemination	***Number of Grants***	***945***	***902***	***853***	***861***	***835***	
	Relevant Grant Dollars	275,833,072	246,350,342	247,182,186	231,787,714	237,305,178	
	Number of Contracts	***76***	***72***	***57***	***38***	***36***	
	Relevant Contract Dollars	75,698,744	74,153,319	72,776,903	72,642,039	70,246,091	
	Total Count	***1,021***	***974***	***910***	***899***	***871***	
	Total Relevant Dollars	351,531,816	320,503,661	319,959,089	304,429,753	307,551,269	**-3.48**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Metastasis	***Number of Grants***	***1,546***	***1,585***	***1,574***	***1,527***	***1,534***	
	Relevant Grant Dollars	345,942,774	346,736,699	365,861,233	361,870,802	381,229,457	
	Number of Contracts	***6***	***8***	***8***	***7***	***6***	
	Relevant Contract Dollars	868,175	1,033,247	1,183,914	1,325,290	1,024,332	
	Total Count	***1,552***	***1,593***	***1,582***	***1,534***	***1,540***	
	Total Relevant Dollars	346,810,949	347,769,946	367,045,147	363,196,092	382,253,789	**2.43**
Mind/Body Research	***Number of Grants***	***103***	***83***	***82***	***75***	***83***	
	Relevant Grant Dollars	15,650,555	13,979,085	14,158,379	17,883,028	16,149,064	
	Total Count	***103***	***83***	***82***	***75***	***83***	
	Total Relevant Dollars	15,650,555	13,979,085	14,158,379	17,883,028	16,149,064	**0.11**
Molecular Disease	***Number of Grants***	***4,845***	***4,996***	***5,003***	***4,962***	***4,879***	
	Relevant Grant Dollars	1,577,174,333	1,563,937,623	1,615,324,573	1,670,263,492	1,660,747,605	
	Number of Contracts	***24***	***23***	***35***	***31***	***35***	
	Relevant Contract Dollars	8,406,934	7,309,485	12,253,807	9,144,621	14,337,338	
	Total Count	***4,869***	***5,019***	***5,038***	***4,993***	***4,914***	
	Total Relevant Dollars	1,585,581,267	1,571,247,108	1,627,578,380	1,679,408,113	1,675,084,943	**1.34**
Molecular Imaging	***Number of Grants***	***333***	***523***	***617***	***650***	***701***	
	Relevant Grant Dollars	105,359,905	147,326,896	174,956,716	164,707,342	181,500,075	
	Number of Contracts	***4***	***9***	***11***	***15***	***15***	
	Relevant Contract Dollars	1,013,254	1,650,977	2,239,610	4,042,324	5,602,005	
	Total Count	***337***	***532***	***628***	***665***	***716***	
	Total Relevant Dollars	106,373,159	148,977,873	177,196,326	168,749,666	187,102,080	**12.60**
Molecular Targeted Prevention	***Number of Grants***	***159***	***219***	***237***	***252***	***248***	
	Relevant Grant Dollars	34,942,948	39,335,671	46,986,672	39,235,184	47,765,297	
	Number of Contracts	‡	***1***	‡	***1***	***1***	
	Relevant Contract Dollars	‡	74,930	‡	74,750	248,461	
	Total Count	***159***	***220***	***237***	***253***	***249***	
	Total Relevant Dollars	34,942,948	39,410,601	46,986,672	39,309,934	48,013,758	**7.52**
Molecular Targeted Therapy	***Number of Grants***	***1,149***	***1,405***	***1,483***	***1,515***	***1,577***	
	Relevant Grant Dollars	312,853,050	393,453,935	404,674,238	407,096,513	442,319,529	
	Number of Contracts	***13***	***19***	***9***	***21***	***18***	
	Relevant Contract Dollars	3,032,933	2,742,385	2,305,444	6,175,491	7,588,080	
	Total Count	***1,162***	***1,424***	***1,492***	***1,536***	***1,595***	
	Total Relevant Dollars	315,885,983	396,196,320	406,979,682	413,272,004	449,907,609	**8.33**
Nanotechnology	***Number of Grants***	***492***	***496***	***430***	***461***	***444***	
	Relevant Grant Dollars	116,707,923	114,866,489	113,651,594	122,072,696	119,336,493	
	Number of Contracts	***14***	***22***	***10***	***20***	***11***	
	Relevant Contract Dollars	910,600	38,850,232	3,523,067	7,338,362	5,161,598	
	Total Count	***506***	***518***	***440***	***481***	***455***	
	Total Relevant Dollars	117,618,523	153,716,721	117,174,661	129,411,058	124,498,091	**-0.51**
Neurofibromatosis	***Number of Grants***	***30***	***27***	***26***	***34***	***15***	
	Relevant Grant Dollars	4,151,165	4,166,356	6,209,557	7,560,557	2,915,817	
	Total Count	***30***	***27***	***26***	***34***	***15***	
	Total Relevant Dollars	4,151,165	4,166,356	6,209,557	7,560,557	2,915,817	**-2.57**
Nursing Research	***Number of Grants***	***86***	***71***	***58***	***54***	***49***	
	Relevant Grant Dollars	17,454,501	14,422,508	12,056,800	13,918,717	11,599,142	
	Total Count	***86***	***71***	***58***	***54***	***49***	
	Total Relevant Dollars	17,454,501	14,422,508	12,056,800	13,918,717	11,599,142	**-10.98**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Nutrition-Fiber	***Number of Grants***	***36***	***29***	***21***	***19***	***19***	
	Relevant Grant Dollars	9,144,679	7,461,435	6,750,851	2,058,728	3,019,322	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***36***	***29***	***21***	***19***	***19***	
	Total Relevant Dollars	9,144,679	7,461,435	6,750,851	2,058,728	3,019,322	**-53.58**
Nutrition	***Number of Grants***	***914***	***887***	***866***	***830***	***779***	
	Relevant Grant Dollars	230,745,569	208,303,563	202,932,362	198,165,748	201,597,394	
	Number of Contracts	***19***	***19***	***16***	***14***	***5***	
	Relevant Contract Dollars	4,126,230	4,410,022	13,115,073	13,792,873	9,069,226	
	Total Count	***933***	***906***	***882***	***844***	***784***	
	Total Relevant Dollars	234,871,799	212,713,585	216,047,435	211,958,621	210,666,620	**-2.85**
Nutrition Monitoring	***Number of Grants***	***76***	***52***	***46***	***45***	***42***	
	Relevant Grant Dollars	22,183,358	12,732,118	14,363,776	11,311,406	15,194,549	
	Number of Contracts	***4***	***4***	***3***	‡	‡	
	Relevant Contract Dollars	596,492	898,128	800,214	‡	‡	
	Total Count	***80***	***56***	***49***	***45***	***42***	
	Total Relevant Dollars	22,779,850	13,630,246	15,163,990	11,311,406	15,194,549	**-14.19**
Obesity	***Number of Grants***	***236***	***235***	***232***	***251***	***251***	
	Relevant Grant Dollars	54,166,986	49,154,604	52,150,701	47,992,367	58,308,346	
	Number of Contracts	***6***	***7***	***5***	‡	***3***	
	Relevant Contract Dollars	447,594	899,253	801,220	‡	689394	
	Total Count	***242***	***242***	***237***	***251***	***254***	
	Total Relevant Dollars	54,614,580	50,053,857	52,951,921	47,992,367	59,006,740	**2.24**
Occupational Cancer	***Number of Grants***	***66***	***64***	***51***	***57***	***49***	
	Relevant Grant Dollars	8,696,174	9,326,436	8,119,594	10,901,093	8,727,377	
	Number of Contracts	***5***	***6***	***3***	***2***	‡	
	Relevant Contract Dollars	2,524,418	1,695,741	850,154	224,000	‡	
	Total Count	***71***	***70***	***54***	***59***	***49***	
	Total Relevant Dollars	11,220,592	11,022,177	8,969,748	11,125,093	8,727,377	**-6.72**
Oncogenes	***Number of Grants***	***2,477***	***2,354***	***2,194***	***2,031***	***1,934***	
	Relevant Grant Dollars	621,281,231	552,856,295	518,552,721	515,190,558	498,144,267	
	Number of Contracts	***5***	***4***	***6***	***3***	***5***	
	Relevant Contract Dollars	1,438,471	1,347,905	2,229,506	2,074,867	1,072,456	
	Total Count	***2,482***	***2,358***	***2,200***	***2,034***	***1,939***	
	Total Relevant Dollars	622,719,702	554,204,200	520,782,227	517,265,425	499,216,723	**-5.74**
Organ Transplant Research	***Number of Grants***	***203***	***199***	***192***	***182***	***194***	
	Relevant Grant Dollars	74,100,547	64,935,205	65,966,217	66,404,117	67,155,158	
	Number of Contracts	‡	‡	***1***	‡	‡	
	Relevant Contract Dollars	‡	‡	49,496	‡	‡	
	Total Count	***203***	***199***	***193***	***182***	***194***	
	Total Relevant Dollars	74,100,547	64,935,205	66,015,713	66,404,117	67,155,158	**-2.69**
Osteoporosis	***Number of Grants***	***7***	***8***	***9***	***8***	***6***	
	Relevant Grant Dollars	1,291,894	1,596,851	913,593	411,172	317,668	
	Total Count	***7***	***8***	***9***	***8***	***6***	
	Total Relevant Dollars	1,291,894	1,596,851	913,593	411,172	317,668	**-50.16**
Pain	***Number of Grants***	***189***	***170***	***161***	***147***	***152***	
	Relevant Grant Dollars	19,956,772	16,642,839	16,576,535	16,468,439	16,300,996	
	Number of Contracts	‡	***2***	‡	***2***	‡	
	Relevant Contract Dollars	‡	230,355	‡	1,299,610	‡	
	Total Count	***189***	***172***	***161***	***149***	***152***	
	Total Relevant Dollars	19,956,772	16,873,194	16,576,535	17,768,049	16,300,996	**-5.40**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Palliative Care	***Number of Grants***	***211***	***186***	***167***	***161***	***153***	
	Relevant Grant Dollars	31,002,487	24,209,640	22,111,289	20,897,707	21,247,383	
	Number of Contracts	***2***	***5***	‡	***2***	***1***	
	Relevant Contract Dollars	247,473	612,259	‡	2,198,445	52,655	
	Total Count	***213***	***191***	***167***	***163***	***154***	
	Total Relevant Dollars	31,249,960	24,821,899	22,111,289	23,096,152	21,300,038	**-10.42**
PAP Testing	***Number of Grants***	***123***	***117***	***105***	***106***	***105***	
	Relevant Grant Dollars	16,109,246	13,323,361	10,352,147	10,627,523	11,695,680	
	Number of Contracts	‡	‡	‡	***1***	‡	
	Relevant Contract Dollars	‡	‡	‡	45,000	‡	
	Total Count	***123***	***117***	***105***	***107***	***105***	
	Total Relevant Dollars	16,109,246	13,323,361	10,352,147	10,672,523	11,695,680	**-9.26**
Pediatric Research	***Number of Grants***	***763***	***685***	***685***	***685***	***581***	
	Relevant Grant Dollars	233,892,539	208,184,370	212,351,643	212,337,590	146,844,741	
	Number of Contracts	***6***	***6***	***3***	***7***	***2***	
	Relevant Contract Dollars	3,811,957	1,471,436	2,134,899	4,384,833	3,291,925	
	Total Count	***769***	***691***	***688***	***692***	***583***	
	Total Relevant Dollars	237,704,496	209,655,806	214,486,542	216,722,423	150,136,666	**-10.20**
Personlized Health Care	***Number of Grants***	***589***	***652***	***632***	***630***	***638***	
	Relevant Grant Dollars	225,012,995	214,006,481	199,252,033	183,230,229	180,445,101	
	Number of Contracts	***13***	***15***	***17***	***21***	***17***	
	Relevant Contract Dollars	31,772,058	33,822,151	35,742,085	37,543,010	32,351,821	
	Total Count	***602***	***667***	***649***	***651***	***655***	
	Total Relevant Dollars	256,785,053	247,828,632	234,994,118	220,773,239	212,796,922	**-4.78**
Pesticides	***Number of Grants***	***25***	***21***	***14***	***12***	***13***	
	Relevant Grant Dollars	1,414,843	1,508,700	909,530	531,371	471,294	
	Number of Contracts	***2***	***2***	***2***	***2***	‡	
	Relevant Contract Dollars	1,528,886	845,205	701,197	224,000	‡	
	Total Count	***27***	***23***	***16***	***14***	***13***	
	Total Relevant Dollars	2,943,729	2,353,905	1,610,727	755,371	471,294	**-55.51**
Pharmacogenetics	***Number of Grants***	***268***	***319***	***310***	***312***	***276***	
	Relevant Grant Dollars	62,777,011	74,057,323	70,646,463	53,813,379	52,795,552	
	Number of Contracts	‡	***3***	***2***	‡	***1***	
	Relevant Contract Dollars	149,518	1,039,064	150,000	‡	193,637	
	Total Count	***269***	***322***	***312***	***312***	***277***	
	Total Relevant Dollars	62,926,529	75,096,387	70,796,463	53,813,379	52,989,189	**-5.74**
Prevention	***Number of Grants***	***1,273***	***1,293***	***1,294***	***1,246***	***1,220***	
	Relevant Grant Dollars	390,136,455	356,228,797	346,953,036	324,621,692	332,988,470	
	Number of Contracts	***51***	***43***	***36***	***20***	***23***	
	Relevant Contract Dollars	42,187,416	41,680,021	46,984,156	28,993,208	30,211,780	
	Total Count	***1,324***	***1,336***	***1,330***	***1,266***	***1,243***	
	Total Relevant Dollars	432,323,871	397,908,818	393,937,192	353,614,900	363,200,250	**-4.59**
Proteomics	***Number of Grants***	***441***	***542***	***543***	***564***	***648***	
	Relevant Grant Dollars	83,307,623	99,199,104	98,691,096	105,713,144	128,504,517	
	Number of Contracts	***17***	***23***	***14***	***13***	***12***	
	Relevant Contract Dollars	1,967,090	39,204,878	4,666,075	3,710,715	2,364,169	
	Total Count	***458***	***565***	***557***	***577***	***660***	
	Total Relevant Dollars	85,274,713	138,403,982	103,357,171	109,423,859	130,868,686	**7.41**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Radiation, Electromagnetic Fields	***Number of Grants***	***7***	***7***	***5***	***5***	***5***	
	Relevant Grant Dollars	1,246,146	821,382	235,460	794,902	274,880	
	Total Count	***7***	***7***	***5***	***5***	***5***	
	Total Relevant Dollars	1,246,146	821,382	235,460	794,902	274,880	**-73.90**
Radiation, Ionizing	***Number of Grants***	***219***	***192***	***143***	***137***	***118***	
	Relevant Grant Dollars	36,870,333	31,992,559	24,747,402	24,942,689	22,587,580	
	Number of Contracts	***5***	***6***	***1***	‡	‡	
	Relevant Contract Dollars	1,290,859	940,864	200,000	‡	‡	
	Total Count	***224***	***198***	***144***	***137***	***118***	
	Total Relevant Dollars	38,161,192	32,933,423	24,947,402	24,942,689	22,587,580	**-14.34**
Radiation, Ionizing Diagnosis	***Number of Grants***	***176***	***231***	***236***	***284***	***288***	
	Relevant Grant Dollars	45,615,274	50,150,240	60,711,962	67,228,830	83,355,570	
	Number of Contracts	***4***	***5***	***3***	***2***	***6***	
	Relevant Contract Dollars	1,203,666	270,167	465,803	1,127,414	3,682,723	
	Total Count	***180***	***236***	***239***	***286***	***294***	
	Total Relevant Dollars	46,818,940	50,420,407	61,177,765	68,356,244	86,038,293	**15.27**
Radiation, Ionizing Radiotherapy	***Number of Grants***	***696***	***680***	***635***	***605***	***594***	
	Relevant Grant Dollars	216,965,316	207,665,565	199,422,427	197,773,842	215,668,304	
	Number of Contracts	***6***	***4***	***4***	***3***	***6***	
	Relevant Contract Dollars	985,654	47,500	545,157	226,116	852,523	
	Total Count	***702***	***684***	***639***	***608***	***600***	
	Total Relevant Dollars	217,950,970	207,713,065	199,967,584	197,999,958	216,520,827	**-0.11**
Radiation, Low-Level Ionizing	***Number of Grants***	***31***	***23***	***20***	***16***	***15***	
	Relevant Grant Dollars	6,781,869	6,004,368	6,500,454	3,564,004	2,684,415	
	Number of Contracts	‡	‡	***1***	‡	‡	
	Relevant Contract Dollars	‡	‡	200,000	‡	‡	
	Total Count	***31***	***23***	***21***	***16***	***15***	
	Total Relevant Dollars	6,781,869	6,004,368	6,700,454	3,564,004	2,684,415	**-28.81**
Radiation, Magnetic Resonance Imaging	***Number of Grants***	***327***	***360***	***324***	***309***	***311***	
	Relevant Grant Dollars	78,242,316	80,540,821	75,059,941	71,053,694	72,516,747	
	Number of Contracts	***3***	***3***	***3***	***2***	***3***	
	Relevant Contract Dollars	366,699	217,673	416,415	625,760	810,966	
	Total Count	***330***	***363***	***327***	***311***	***314***	
	Total Relevant Dollars	78,609,015	80,758,494	75,476,356	71,679,454	73,327,713	**-1.83**
Radiation, Mammography	***Number of Grants***	***223***	***205***	***203***	***211***	***186***	
	Relevant Grant Dollars	28,018,078	28,042,754	31,642,663	26,824,376	30,249,026	
	Number of Contracts	***2***	***2***	***1***	***1***	***2***	
	Relevant Contract Dollars	442	452	464	999,985	1,845,486	
	Total Count	***225***	***207***	***204***	***212***	***188***	
	Total Relevant Dollars	28,018,520	28,043,206	31,643,127	27,824,361	32,094,512	**3.27**
Radiation, Non-Ionizing	***Number of Grants***	***259***	***219***	***177***	***167***	***160***	
	Relevant Grant Dollars	38,486,311	32,101,143	27,357,488	26,918,563	26,910,915	
	Number of Contracts	‡	‡	‡	***3***	***1***	
	Relevant Contract Dollars	‡	‡	‡	476,414	999,000	
	Total Count	***259***	***219***	***177***	***170***	***161***	
	Total Relevant Dollars	38,486,311	32,101,143	27,357,488	27,394,977	27,909,915	**-8.80**
Radiation, Non-Ionizing Diagnosis	***Number of Grants***	***443***	***514***	***502***	***471***	***467***	
	Relevant Grant Dollars	116,159,136	132,398,533	136,372,426	125,702,669	131,948,820	
	Number of Contracts	***3***	***4***	***3***	***9***	***5***	
	Relevant Contract Dollars	308,514	446,969	416,415	1,675,452	1,260,269	
	Total Count	***446***	***518***	***505***	***480***	***472***	
	Total Relevant Dollars	116,467,650	132,845,502	136,788,841	127,378,121	133,209,089	**3.10**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.

Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Radiation, Non-Ionizing Radiotherapy	***Number of Grants***	***117***	***152***	***161***	***195***	***190***	
	Relevant Grant Dollars	21,061,866	31,373,416	41,460,636	40,077,552	48,439,155	
	Number of Contracts	***1***	***1***	***1***	***3***	‡	
	Relevant Contract Dollars	191,815	181,796	199,735	599,386	‡	
	Total Count	***118***	***153***	***162***	***198***	***190***	
	Total Relevant Dollars	21,253,681	31,555,212	41,660,371	40,676,938	48,439,155	**18.39**
Radiation, Ultraviolet	***Number of Grants***	***224***	***189***	***152***	***149***	***144***	
	Relevant Grant Dollars	31,886,944	27,465,174	23,732,686	23,686,597	24,555,465	
	Number of Contracts	‡	‡	‡	***3***	***1***	
	Relevant Contract Dollars	‡	‡	‡	476,414	‡	
	Total Count	***224***	***189***	***152***	***152***	***145***	
	Total Relevant Dollars	31,886,944	27,465,174	23,732,686	24,163,011	25,554,465	**-6.07**
Radon	***Number of Grants***	***9***	***6***	***5***	***2***	***3***	
	Relevant Grant Dollars	1,928,547	2,177,728	1,976,301	48,624	326,441	
	Total Count	***9***	***6***	***5***	***2***	***3***	
	Total Relevant Dollars	1,928,547	2,177,728	1,976,301	48,624	326,441	**-847.96**
Rare Diseases	***Number of Grants***	***220***	***183***	***138***	***140***	***119***	
	Relevant Grant Dollars	37,126,604	30,770,735	26,634,147	29,192,350	23,592,946	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***220***	***183***	***138***	***140***	***119***	
	Total Relevant Dollars	37,126,604	30,770,735	26,634,147	29,192,350	23,592,946	**-11.65**
Rehabilitation	***Number of Grants***	***232***	***215***	***221***	***221***	***230***	
	Relevant Grant Dollars	36,209,824	33,557,701	37,960,259	38,584,600	40,748,671	
	Number of Contracts	***16***	***16***	***14***	***2***	***1***	
	Relevant Contract Dollars	2,094,384	1,508,881	1,131,599	76,452	52,655	
	Total Count	***248***	***231***	***235***	***223***	***231***	
	Total Relevant Dollars	38,304,208	35,066,582	39,091,858	38,661,052	40,801,326	**1.37**
Rural Populations	***Number of Grants***	***112***	***106***	***95***	***103***	***103***	
	Relevant Grant Dollars	36,914,134	35,317,988	38,996,059	35,157,309	34,658,560	
	Number of Contracts	***13***	***13***	***12***	***12***	***10***	
	Relevant Contract Dollars	10,687,353	11,397,326	9,846,502	10,416,108	8,535,867	
	Total Count	***125***	***119***	***107***	***115***	***113***	
	Total Relevant Dollars	47,601,487	46,715,314	48,842,561	45,573,417	43,194,427	**-2.48**
Sexually Transmitted Diseases	***Number of Grants***	***232***	***215***	***192***	***183***	***185***	
	Relevant Grant Dollars	43,581,416	35,502,090	31,951,321	30,488,788	29,789,110	
	Number of Contracts	***1***	***1***	***1***	***2***	***1***	
	Relevant Contract Dollars	3,893,007	3,621,135	3,701,779	4,439,576	3,836,717	
	Total Count	***233***	***216***	***193***	***185***	***186***	
	Total Relevant Dollars	47,474,423	39,123,225	35,653,100	34,928,364	33,625,827	**-9.22**
Sleep Disorders	***Number of Grants***	***67***	***65***	***54***	***70***	***64***	
	Relevant Grant Dollars	7,121,771	7,576,158	7,775,308	9,183,149	7,810,486	
	Total Count	***67***	***65***	***54***	***70***	***64***	
	Total Relevant Dollars	7,121,771	7,576,158	7,775,308	9,183,149	7,810,486	**2.24**
Small Molecules	***Number of Grants***	***439***	***429***	***386***	***407***	***416***	
	Relevant Grant Dollars	77,439,195	77,887,805	73,465,245	70,693,138	81,708,151	
	Number of Contracts	***6***	***4***	***1***	***10***	***9***	
	Relevant Contract Dollars	784,713	843,000	30,860	2,203,593	3,726,105	
	Total Count	***445***	***433***	***387***	***417***	***425***	
	Total Relevant Dollars	78,223,908	78,730,805	73,496,105	72,896,731	85,434,256	**2.47**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Smokeless Tobacco	***Number of Grants***	***24***	***24***	***26***	***34***	***19***	
	Relevant Grant Dollars	3,306,451	3,957,700	5,933,701	6,896,702	4,743,669	
	Number of Contracts	***2***	***1***	‡	***1***	***1***	
	Relevant Contract Dollars	1,761,000	1,800,000	‡	453,965	385,000	
	Total Count	***26***	***25***	***26***	***35***	***20***	
	Total Relevant Dollars	5,067,451	5,757,700	5,933,701	7,350,667	5,128,669	**1.00**
Smoking, Passive	***Number of Grants***	***34***	***32***	***30***	***24***	***15***	
	Relevant Grant Dollars	5,124,660	4,887,736	3,425,541	3,459,579	2,250,884	
	Number of Contracts	‡	‡	‡	***1***	***1***	
	Relevant Contract Dollars	‡	‡	‡	453,965	385,000	
	Total Count	***35***	***32***	***30***	***25***	***16***	
	Total Relevant Dollars	5,124,660	4,887,736	3,425,541	3,913,544	2,635,884	**-16.93**
Structural Biology	***Number of Grants***	***1,750***	***1,610***	***1,456***	***1,337***	***1,242***	
	Relevant Grant Dollars	358,120,437	310,422,424	280,014,980	269,191,027	258,099,045	
	Number of Contracts	***18***	***16***	***17***	***11***	***15***	
	Relevant Contract Dollars	2,971,719	39,571,941	2,434,109	1,512,388	1,522,607	
	Total Count	***1,768***	***1,626***	***1,473***	***1,348***	***1,257***	
	Total Relevant Dollars	361,092,156	349,994,365	282,449,089	270,703,415	259,621,652	**-8.88**
Surgery	***Number of Grants***	***409***	***390***	***352***	***327***	***333***	
	Relevant Grant Dollars	67,021,084	66,059,380	63,498,562	72,591,577	85,655,815	
	Number of Contracts	‡	‡	‡	***2***	***2***	
	Relevant Contract Dollars	‡	‡	‡	1,200,000	373,417	
	Total Count	***409***	***390***	***352***	***329***	***335***	
	Total Relevant Dollars	67,021,084	66,059,380	63,498,562	73,791,577	86,029,232	**6.26**
Taxol	***Number of Grants***	***304***	***290***	***284***	***305***	***285***	
	Relevant Grant Dollars	69,172,683	62,261,243	68,741,615	73,441,347	70,198,681	
	Number of Contracts	‡	‡	‡	***1***	‡	
	Relevant Contract Dollars	‡	‡	‡	50,000	‡	
	Total Count	***304***	***290***	***284***	***306***	***285***	
	Total Relevant Dollars	69,172,683	62,261,243	68,741,615	73,491,347	70,198,681	**0.08**
Telehealth	***Number of Grants***	***428***	***399***	***364***	***351***	***311***	
	Relevant Grant Dollars	85,583,070	74,370,113	76,214,970	83,738,070	76,191,259	
	Number of Contracts	***34***	***39***	***26***	***10***	***11***	
	Relevant Contract Dollars	28,625,864	24,501,587	15,922,057	12,502,513	11,912,660	
	Total Count	***462***	***438***	***390***	***361***	***322***	
	Total Relevant Dollars	114,208,934	98,871,700	92,137,027	96,240,583	88,103,919	**-6.75**
Therapy	***Number of Grants***	***3,695***	***3,842***	***3,736***	***3,668***	***3,626***	
	Relevant Grant Dollars	1,273,381,182	1,256,647,167	1,253,530,990	1,289,919,675	1,295,238,778	
	Number of Contracts	***122***	***112***	***104***	***102***	***94***	
	Relevant Contract Dollars	80,366,537	68,675,001	100,995,788	97,314,391	93,641,732	
	Total Count	***3,817***	***3,954***	***3,840***	***3,770***	***3,720***	
	Total Relevant Dollars	1,353,747,719	1,325,322,168	1,354,526,778	1,387,234,066	1,388,880,510	**0.62**
Tobacco	***Number of Grants***	***494***	***465***	***493***	***470***	***449***	
	Relevant Grant Dollars	110,296,415	107,012,253	106,446,317	121,389,946	127,614,366	
	Number of Contracts	***6***	***5***	***7***	***8***	***4***	
	Relevant Contract Dollars	3,240,062	2,762,640	804,235	2,479,840	1,419,652	
	Total Count	***500***	***470***	***500***	***478***	***453***	
	Total Relevant Dollars	113,536,477	109,774,893	107,250,552	123,869,786	129,034,018	**2.95**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Tobacco Use Behavior	***Number of Grants***	***221***	***219***	***250***	***250***	***239***	
	Relevant Grant Dollars	57,580,022	61,173,821	65,696,233	81,176,603	83,456,895	
	Number of Contracts	‡	‡	***2***	***4***	***2***	
	Relevant Contract Dollars	‡	‡	144,041	1,868,571	1,320,000	
	Total Count	***221***	***219***	***252***	***254***	***241***	
	Total Relevant Dollars	57,580,022	61,173,821	65,840,274	83,045,174	84,776,895	**8.94**
Tropical Diseases	***Number of Grants***	***48***	***36***	***31***	***29***	***25***	
	Relevant Grant Dollars	8,793,217	8,218,552	7,697,801	6,535,704	5,619,635	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***48***	***36***	***31***	***29***	***25***	
	Total Relevant Dollars	8,793,217	8,218,552	7,697,801	6,535,704	5,619,635	**-11.39**
Tumor Markers	***Number of Grants***	***1,134***	***996***	***846***	***731***	***626***	
	Relevant Grant Dollars	319,367,043	252,452,493	218,547,902	189,955,095	161,691,676	
	Number of Contracts	***25***	***29***	***19***	***12***	***4***	
	Relevant Contract Dollars	5,365,228	4,923,691	6,788,354	4,365,645	2,569,530	
	Total Count	***1,159***	***1,025***	***865***	***743***	***630***	
	Total Relevant Dollars	324,732,271	257,376,184	225,336,256	194,320,740	164,531,206	**-17.92**
Underserved Populations	***Number of Grants***	***562***	***568***	***563***	***607***	***595***	
	Relevant Grant Dollars	184,506,681	173,480,427	193,637,731	210,560,355	210,385,470	
	Number of Contracts	***41***	***38***	***34***	***21***	***16***	
	Relevant Contract Dollars	18,594,280	15,803,363	14,072,123	12,245,405	10,306,244	
	Total Count	***603***	***606***	***597***	***628***	***611***	
	Total Relevant Dollars	203,100,961	189,283,790	207,709,854	222,805,760	220,691,714	**1.85**
Vaccine Development	***Number of Grants***	***173***	***171***	***168***	***163***	***159***	
	Relevant Grant Dollars	27,285,816	25,020,169	27,688,541	21,218,754	21,105,678	
	Number of Contracts	***1***	‡	***2***	‡	***1***	
	Relevant Contract Dollars	74,646	‡	1,370,729	‡	199,988	
	Total Count	***174***	***171***	***170***	***163***	***160***	
	Total Relevant Dollars	27,360,462	25,020,169	29,059,270	21,218,754	21,305,666	**-8.00**
Vaccine Production	***Number of Grants***	***9***	***8***	***4***	***8***	***6***	
	Relevant Grant Dollars	2,813,459	1,733,938	1,679,991	1,046,919	661,049	
	Number of Contracts	‡	‡	‡	‡	***1***	
	Relevant Contract Dollars	‡	‡	‡	‡	1,499,001	
	Total Count	***9***	***8***	***4***	***8***	***7***	
	Total Relevant Dollars	2,813,459	1,733,938	1,679,991	1,046,919	2,160,050	**-4.90**
Vaccine Research	***Number of Grants***	***208***	***211***	***201***	***201***	***195***	
	Relevant Grant Dollars	36,637,670	34,486,715	37,047,110	33,377,072	34,117,779	
	Number of Contracts	***2***	***2***	***1***	***1***	***2***	
	Relevant Contract Dollars	132,329	14,808,841	30,860	23,100	1,502,003	
	Total Count	***210***	***213***	***202***	***202***	***197***	
	Total Relevant Dollars	36,769,999	49,295,556	37,077,970	33,400,172	34,619,782	**-3.73**
Vaccine Testing	***Number of Grants***	***156***	***151***	***138***	***130***	***111***	
	Relevant Grant Dollars	39,939,724	34,603,697	29,771,312	21,759,604	18,745,944	
	Number of Contracts	***1***	***1***	***1***	***1***	***1***	
	Relevant Contract Dollars	3,893,007	3,621,135	3,701,779	4,394,576	3,836,717	
	Total Count	***157***	***152***	***139***	***131***	***112***	
	Total Relevant Dollars	43,832,731	38,224,832	33,473,091	26,154,180	22,582,661	**-17.63**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Virus – Cancer Research	***Number of Grants***	***652***	***613***	***558***	***541***	***505***	
	Relevant Grant Dollars	172,868,916	158,577,860	151,074,096	153,628,908	142,438,045	
	Number of Contracts	***4***	***3***	***3***	***3***	***1***	
	Relevant Contract Dollars	4,042,298	18,429,976	5,230,139	4,549,461	3,836,717	
	Total Count	***656***	***616***	***561***	***544***	***506***	
	Total Relevant Dollars	176,911,214	177,007,836	156,304,235	158,178,369	146,274,762	**-4.88**
Virus – Epstein-Barr	***Number of Grants***	***116***	***115***	***110***	***110***	***104***	
	Relevant Grant Dollars	21,411,991	26,897,323	26,563,416	24,362,117	24,499,924	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***116***	***115***	***110***	***110***	***104***	
	Total Relevant Dollars	21,411,991	26,897,323	26,563,416	24,362,117	24,499,924	**2.67**
Virus – Genital Herpes	***Number of Grants***	***7***	***6***	***4***	***4***	***4***	
	Relevant Grant Dollars	496,778	540,230	477,647	379,575	372,188	
	Total Count	***7***	***6***	***4***	***4***	***4***	
	Total Relevant Dollars	496,778	540,230	477,647	379,575	372,188	**-8.21**
Virus – Hepatitis B	***Number of Grants***	***51***	***50***	***54***	***51***	***50***	
	Relevant Grant Dollars	11,410,102	11,387,036	12,166,996	11,337,066	6,370,613	
	Total Count	***51***	***50***	***54***	***51***	***50***	
	Total Relevant Dollars	11,410,102	11,387,036	12,166,996	11,337,066	6,370,613	**-11.23**
Virus – Hepatitis C	***Number of Grants***	***41***	***38***	***35***	***34***	***31***	
	Relevant Grant Dollars	6,769,322	5,322,764	6,405,143	5,719,779	4,600,379	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***41***	***38***	***35***	***34***	***31***	
	Total Relevant Dollars	6,769,322	5,322,764	6,405,143	5,719,779	4,600,379	**-10.46**
Virus – Herpes	***Number of Grants***	***225***	***228***	***208***	***206***	***190***	
	Relevant Grant Dollars	51,242,661	56,793,367	54,527,236	47,274,246	48,127,519	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***225***	***228***	***208***	***206***	***190***	
	Total Relevant Dollars	51,242,661	56,793,367	54,527,236	47,274,246	48,127,519	**-1.98**
Virus – HHV8	***Number of Grants***	***100***	***94***	***81***	***87***	***78***	
	Relevant Grant Dollars	21,779,525	23,036,760	19,737,355	18,532,843	17,725,584	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***100***	***94***	***81***	***87***	***78***	
	Total Relevant Dollars	21,779,525	23,036,760	19,737,355	18,532,843	17,725,584	**-5.53**
Virus – HTLV-I	***Number of Grants***	***31***	***27***	***23***	***22***	***24***	
	Relevant Grant Dollars	8,125,525	6,797,477	7,313,840	6,183,612	6,171,762	
	Number of Contracts	‡	‡	‡	‡	‡	
	Relevant Contract Dollars	‡	‡	‡	‡	‡	
	Total Count	***31***	***27***	***23***	***22***	***24***	
	Total Relevant Dollars	8,125,525	6,797,477	7,313,840	6,183,612	6,171,762	**-7.74**
Virus – HTLV-II	***Number of Grants***	***5***	***4***	***1***	‡	***2***	
	Relevant Grant Dollars	286,731	409,579	135,552	‡	2,000	
	Total Count	***5***	***4***	***1***	‡	***2***	
	Total Relevant Dollars	286,731	409,579	135,552	‡	2,000	**-99.30**

continued

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 16. NCI Special Interest Category (SIC) Dollars for FY2007 - FY2011 – Annual Percent Change*

(This table reports funding for grants and contracts only; intramural projects are excluded.)

Special Interest Categories	Counts and Relevant Dollars†	2007	2008	2009	2010	2011	Average Percent Change/Yr.
Virus – Papilloma	***Number of Grants***	***191***	***178***	***166***	***169***	***168***	
	Relevant Grant Dollars	50,026,145	43,565,517	39,602,459	46,214,177	43,559,761	
	Number of Contracts	***1***	***1***	***3***	***1***	***1***	
	Relevant Contract Dollars	3,893,007	3,621,135	5,230,139	4,394,576	3,836,717	
	Total Count	***192***	***179***	***169***	***170***	***169***	
	Total Relevant Dollars	53,919,152	47,186,652	44,832,598	50,608,753	47,396,478	**-3.61**
Virus – Papova	***Number of Grants***	***238***	***221***	***206***	***207***	***200***	
	Relevant Grant Dollars	62,029,169	54,680,936	49,970,034	55,528,827	52,541,742	
	Number of Contracts	***1***	***1***	***3***	***2***	***1***	
	Relevant Contract Dollars	3,893,007	3,621,135	5,230,139	4,544,576	3,836,717	
	Total Count	***239***	***222***	***209***	***209***	***201***	
	Total Relevant Dollars	65,922,176	58,302,071	55,200,173	60,073,403	56,378,459	**-4.18**
Virus – SV40	***Number of Grants***	***46***	***40***	***36***	***29***	***25***	
	Relevant Grant Dollars	8,818,318	7,172,313	5,967,645	5,171,617	5,163,432	
	Total Count	***46***	***40***	***36***	***29***	***25***	
	Total Relevant Dollars	8,818,318	7,172,313	5,967,645	5,171,617	5,163,432	**-14.67**
Vitamin A	***Number of Grants***	***109***	***102***	***89***	***66***	***55***	
	Relevant Grant Dollars	19,640,820	16,421,451	11,622,987	8,863,103	9,150,008	
	Number of Contracts	***1***	***1***	***1***	***1***	***1***	
	Relevant Contract Dollars	306,833	178,904	300,000	391,285	99,917	
	Total Count	***110***	***103***	***90***	***67***	***56***	
	Total Relevant Dollars	19,947,653	16,600,355	11,922,987	9,254,388	9,249,925	**-22.07**
Vitamin C	***Number of Grants***	***31***	***26***	***24***	***21***	***15***	
	Relevant Grant Dollars	2,781,603	2,020,753	2,234,318	1,843,823	1,106,973	
	Total Count	***31***	***26***	***24***	***21***	***15***	
	Total Relevant Dollars	2,781,603	2,020,753	2,234,318	1,843,823	1,106,973	**-22.31**
Vitamin D	***Number of Grants***	‡	‡	***32***	***45***	***70***	
	Relevant Grant Dollars	‡	‡	9,218,013	11,837,723	20,457,495	
	Number of Contracts	‡	‡	***1***	‡	‡	
	Relevant Contract Dollars	‡	‡	200,000	‡	‡	
	Total Count	‡	‡	***33***	***45***	***70***	
	Total Relevant Dollars	‡	‡	9,418,013	11,837,723	20,457,495	**49.25**
Vitamins, Other	***Number of Grants***	***104***	***103***	***72***	***55***	***44***	
	Relevant Grant Dollars	22,228,099	20,299,917	15,499,403	12,310,882	10,076,781	
	Total Count	***104***	***103***	***72***	***55***	***44***	
	Total Relevant Dollars	22,228,099	20,299,917	15,499,403	12,310,882	10,076,781	**-21.13**

*Some categories are not mutually exclusive, resulting in an overlap in reported funding; dollar totals, therefore, exceed 100 percent of the extramural budget.
†Relevant Dollars = portion of the funded amount relevant to a specific SIC.
‡Coding not required or requested.
Source: Research Analysis and Evaluation Branch.

Table 17. NCI Funding of Foreign Research Grants in FY2011

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country/Cancer Site	Mechanism								
AUSTRALIA	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*6*	*1*		*5*			*1*	*13*
Funding $		*683,390*	*52,380*		*230,201*			*1,510,087*	*2,476,058*
Colon, Rectum		212,181						1,510,087	1,722,268
Hodgkins Lymphoma					39,134				39,134
Leukocytes					115,101				115,101
Liver		26,049							26,049
Lung		260,491							260,491
Melanoma		184,669							184,669
Myeloma					36,832				36,832
Neuroblastoma			52,380						52,380
Non-Hodgkins Lymphoma					39,134				39,134
BELGIUM	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #							*18*		*18*
Funding $							*255,770*		*255,770*
Bone Marrow							4,650		4,650
Brain							6,976		6,976
Breast							97,658		97,658
Cervix							2,325		2,325
Childhood Leukemia							25,577		25,577
Colon, Rectum							18,601		18,601
Esophagus							2,325		2,325
Kidney							6,976		6,976
Leukemia							25,577		25,577
Lung							11,626		11,626
Muscle							2,325		2,325
Myeloma							9,301		9,301
Neuroblastoma							6,976		6,976
Non-Hodgkins Lymphoma							2,325		2,325
Ovary							13,951		13,951
Prostate							11,626		11,626
Urinary System							2,325		2,325
Uterus							4,650		4,650
CANADA	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*28*	*4*	*4*	*4*	*3*	*18*	*3*	*64*
Funding $		*4,034,458*	*94,644*	*430,489*	*334,064*	*1,000,380*	*594,199*	*2,816,241*	*9,304,475*
Bladder		54,139							54,139
Bone Marrow		192,346							192,346
Breast		938,287		107,723	167,032		426,425		1,639,467
Cervix							3,518		3,518
Colon, Rectum							1,883	848,869	850,752
Connective Tissue			47,322						47,322
Gall Bladder							1,883		1,883
Hodgkins Lymphoma							1,883		1,883
Kidney							7,532		7,532
Leukemia		942,515					1,883		944,398
Liver		51,225							51,225
Lung		1,192,495			167,032		16,947		1,376,474
Melanoma		122,465							122,465

continued

Table 17. NCI Funding of Foreign Research Grants in FY2011

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country/Cancer Site	Mechanism								
CANADA *(continued)*	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Muscle		59,605							59,605
Myeloma							37,661		37,661
Non-Hodgkins Lymphoma			23,661				1,883		25,544
Not Site Specific		122,465	23,661	103,078		736,347	11,298	1,967,372	2,964,221
Ovary						264,033	15,954		279,987
Pancreas		51,225							51,225
Prostate		248,086		219,688			59,800		527,574
Skin		59,605							59,605
Urinary System							5,649		5,649
Childhood Leukemia									
Leukemia									
FRANCE	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #						*5*			*5*
Funding $						*3,820,750*			*3,820,750*
Bladder						124,963			124,963
Kidney						1,235,811			1,235,811
Lung						1,876,817			1,876,817
Not Site Specific*						583,159			583,159
Ovary									
INDIA	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*2*							*2*
Funding $		*391,342*							*391,342*
Breast		195,671							195,671
Cervix		195,671							195,671
IRELAND	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*2*							*2*
Funding $		*187,983*							*187,983*
Neuroblastoma		187,983							187,983
ISRAEL	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		11			3				14
Funding $		933,588			455,927				1,389,515
Breast		63,235			230,202				293,437
Colon, Rectum		84,354			56,431				140,785
Lung		61,375			169,294				230,669
Myeloma		61,375							61,375
Not Site Specific*		476,124							476,124
Ovary		102,771							102,771
Prostate		84,354							84,354
KOREA, REPUBLIC OF	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*1*							*1*
Funding $		*170,273*							*170,273*
Lung		170,273							170,273

continued

*Not Site Specific denotes research NOT on a particular type of cancer/cancer site (e.g., basic research examining a role of a protein in cellular DNA damage in a bacteria/worm/fruit fly/non-cancer cell system).
Source: Research Analysis and Evaluation Branch.

Table 17. NCI Funding of Foreign Research Grants in FY2011

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country/Cancer Site	Mechanism								
NETHERLANDS	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*2*							*2*
Funding $		*217,378*							*217,378*
Colon, Rectum		217,378							217,378
SPAIN	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		4							4
Funding $		149,495							149,495
Melanoma		27,667							27,667
Pancreas		121,828							121,828
SWITZERLAND	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #		*5*							*5*
Funding $		*355,057*							*355,057*
Non-Hodgkins Lymphoma		88,481							88,481
Nose, Nasal Passages		44,240							44,240
Not Site Specific*		178,096							178,096
Pharynx		44,240							44,240
UNITED KINGDOM	**F31**	**R01**	**R03**	**R21**	**R37**	**U01**	**U10**	**U24**	**Totals**
Grants #	*1*	*8*	*1*			*2*		*3*	*15*
Funding $	*41,800*	*1,297,640*	*49,327*			*614,408*		*229,602*	*2,232,777*
Brain		403,962							403,962
Breast	41,800		49,327			307,204			398,331
Colon, Rectum		97,820							97,820
Lung		459,288							459,288
Melanoma		97,820							97,820
Myeloma		238,750							238,750
Prostate						307,204			307,204
Thyroid								229,602	229,602
Total Grants	**1**	**69**	**6**	**4**	**12**	**10**	**36**	**7**	**145**
Total $ Per Grant type	**41,800**	**8,420,604**	**196,351**	**430,489**	**1,020,192**	**5,435,538**	**849,969**	**4,555,930**	**20,950,873**

*Not Site Specific denotes research NOT on a particular type of cancer/cancer site (e.g., basic research examining a role of a protein in cellular DNA damage in a bacteria/worm/fruit fly/non-cancer cell system).
Source: Research Analysis and Evaluation Branch.

Table 18. Foreign Components of U.S. Domestic Research Grants in FY2011

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country	Funding Mechanism																				Sub-total
	D43	F32	K01	K07	K25	P01	P50	R01	R03	R13	R21	R24	R25	R33	R37	R44	T15	U01	U19	U24	U54	
Africa (not-specified)																		1				**1**
Argentina																		1		1		**2**
Australia			1			1		13	1									4		3		**23**
Austria								4												1		**5**
Bangladesh								2														**2**
Barbados								2														**2**
Belgium																				1		**1**
Brazil								3									1	3		1		**8**
Cameroon	1																	1				**2**
Canada						1	1	23	2	5	3				1	1		9		4		**50**
Chile										1												**1**
China								15	1	1					1				1	2		**21**
Colombia		1				1														1		**3**
Costa Rica																		1				**1**
Czech Republic								3												1		**4**
Denmark							1	6			1									1		**9**
Dominican Republic								1														**1**
Egypt								3					1							1		**5**
Finland								4	1											1		**6**
France								8	1											1		**10**
Germany					1			12		1		1					1	2		2		**20**
Greece								1														**1**
Haiti								1														**1**
Honduras				1																		**1**
Hungary																				2		**2**
India							1	2										1		1		**5**
Iran																				1		**1**
Ireland								2												1		**3**
Israel								11	1						1		1			2		**16**
Italy								7	1	3	1				1					2		**15**
Japan								5		1								1		1		**8**
Kenya	1							3										2				**6**
Kuwait																				1		**1**
Latvia								1														**1**
Malawi																		1				**1**
Malaysia																				1		**1**
Mexico								2												1		**3**
Moldova															1							**1**
Morocco								1														**1**
Netherlands								9							1			4		1	1	**16**
New Zealand								3			1									2		**6**
Nigeria	1							1										1				**3**

continued

Source: Research Analysis and Evaluation Branch.

Table 18. Foreign Components of U.S. Domestic Research Grants in FY2011

(This table reports extramural grants only; intramural grants and contracts are excluded.)

Country	Funding Mechanism																				Sub-total
	D43	F32	K01	K07	K25	P01	P50	R01	R03	R13	R21	R24	R25	R33	R37	R44	T15	U01	U19	U24	U54	
Norway								1									1					**2**
Pakistan																				1		**1**
Panama																				1		**1**
Peru																					2	**2**
Philippines								1			1											**2**
Poland								1												1		**2**
Portugal																				1		**1**
Russia								2												2		**4**
Rwanda	1																					**1**
Saudi Arabia																				1		**1**
Senegal								2														**2**
Singapore				1				2												1		**4**
Slovenia																				1		**1**
South Africa	1							1										1		2		**5**
South Korea								2												1		**3**
Spain								6		1								1		2		**10**
Sweden								9		1				1						2		**13**
Switzerland						1												1		2		**4**
Taiwan								1												1		**2**
Tanzania	1																					**1**
Thailand																		1				**1**
Turkey						1		1												1		**3**
Uganda	2							1	1									2				**6**
United Kingdom						1		29	1	1	1			1			2	5		1	1	**43**
Uruguay																				1		**1**
Venezuela																				1		**1**
Vietnam								1														**1**
Zambia	1							1														**2**
Zimbabwe																		1				**1**
	D43	**F32**	**K01**	**K07**	**K25**	**P01**	**P50**	**R01**	**R03**	**R13**	**R21**	**R24**	**R25**	**R33**	**R37**	**R44**	**T15**	**U01**	**U19**	**U24**	**U54**	**391***
Totals	**9**	**1**	**1**	**2**	**1**	**6**	**3**	**209**	**10**	**15**	**8**	**1**	**1**	**2**	**6**	**1**	**6**	**44**	**1**	**60**	**4**	

*Because many grants have multiple foreign contributors, the total count (391) is greater than the total number of grants (245).

Appendix A: Activities of the National Cancer Advisory Board

Originally established as the National Advisory Cancer Council in 1937, the NCAB consists of 18 members who are appointed by the President and 12 nonvoting *ex officio* members. The NCAB advises, assists, consults with, and makes recommendations to the Secretary, HHS, and to the NCI Director with respect to the activities carried out by and through the Institute and on policies pertaining to these activities. It is authorized to recommend support for grants and cooperative agreements following technical and scientific peer review. The Director of the DEA serves as Executive Secretary of the NCAB. In fulfilling its role as the locus for second-level review of all peer reviewed applications, the Board reviewed a total of 12,920 applications in 2011 requesting $3,606,059,525 in direct costs with appropriated funds.

The Board heard presentations, discussed, and provided advice on a variety of topics and NCI activities in FY2011, such as:

- NCI Director's Report
- President's Cancer Panel Report
- Legislative Update
- *Ad Hoc* Working Group to Create a Strategic Scientific Vision for the National Cancer Program and Review Progress of the National Cancer Institute Report
- Operational Efficiency Working Group (OEWG) Demo
- Center for Cancer Research: Update on Prostate Cancer Imaging
- Status Report: Division of Cancer Epidemiology and Genetics
- Status Report: Implementation of the Institute of Medicine Clinical Trials Report Recommendations, Pharmacodynamics and Therapeutics Functional Working Group, and Center for Cancer Research
- NCI Biennial Report: Inclusion of Women and Minorities in Clinical Research
- Conflict of Interest: Facilitation of Industry Interactions
- Annual Delegations of Authority
- Bypass Budget Overview
- Update: 12th Report on Carcinogenesis
- NCAB Subcommittee Reports: Facilitation of Industry Interactions, Clinical Investigations, and Global Cancer Research
- New Regulation on Managing Financial Conflict of Interest of NIH-Supported Grantees
- Provocative Questions: Status and Future Plans
- Overview: NCI's Small Business Innovation Research (SBIR) Program and Center for Cancer Genomics
- NCI Intramural Clinical Research Program: Utilization of the Clinical Center
- Developing a Report Card for the Clinical Trial Activation Timelines: Initial Implementation of the OEWG Report Recommendations
- NCAB *Ad Hoc* Working Group Report

As part of its mandate for oversight of NCI activities, the NCAB receives regular updates from the NCI Director, the NCI Office of Legislation and Congressional Activities, and the President's Cancer Panel.

Another major role of the Board is to monitor the overall advisory and oversight activities of the NCI as a whole. In that regard, it annually reviews the site visit outcomes of intramural review and the extramural RFA and RFP concepts acted on by the BSA. The NCAB also participates in the framing of the annual NCI Bypass Budget and considers the impact of actualized priorities as expressed by the allocation of the annual operating budget.

The full text of recent NCAB meeting summaries is available on the NCI website at **http://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm**.

Appendix B: Activities of the Board of Scientific Advisors

The BSA provides scientific advice on a wide variety of matters concerning scientific program policy, progress, and future direction of NCI's extramural research programs, and concept review of extramural program initiatives.

In addition to approving a number of extramural program initiatives (see below), the BSA also heard presentations on the following in FY2011:

- Report of the NCI Director
- NCI/Congressional Relations
- Perspectives on the BSA
- BSA RFA Annual Concept Report
- Drug Scarcity Problem
- Status Report: Implementation of the Institute of Medicine (IOM) Clinical Trials Report Recommendations
- Overview: NCI Center for Global Health
- Cancer Bioinformatics Grid (caBIG®) Working Group Report
- Implementation Plan: cancer Bioinformatics Grid (caBIG®)
- Status Report: caBIG® Oversight *Ad Hoc* Subcommittee
- Update: The Chernobyl Tissue Bank

RFA/Cooperative Agreements Approved

Office of the Director

- Cancer Target Discovery and Development Network Centers
- Research Answers to NCI's Provocative Questions
- SBIR Phase II Bridge Awards to Accelerate the Development of Cancer Therapeutics Imaging Technologies, Interventional Devices, Diagnostics, and Prognostics Toward Commercialization
- Innovative Molecular Analysis Technologies Program
- Commercial Application and Use of Emerging Molecular Analysis Technologies
- Clinical Proteomic Technologies for Cancer
- Comprehensive Partnership to Reduce Cancer Health Disparities

Division of Cancer Biology

- NCI Tumor Microenvironment Network

Division of Cancer Control and Population Sciences

- HMO Cancer Research Network Research Resources

Division of Cancer Prevention

- Alliance of Glycobiologists for Detection of Cancer: A Trans-NIH Program

Division of Cancer Treatment and Diagnosis

- National Specimen Banks to Support NCI Clinical Trial Networks
- Data Resource for Blood and Marrow Transplants
- Pediatric Phase I/Pilot Consortium
- NCI Clinical Trials Network

Appendix C: List of Chartered Committees

President's Cancer Panel

Chair

LaSalle D. Leffall, Jr., M.D. ..... Howard University

Member

Margaret L. Kripke, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center

Executive Secretary

Abby B. Sandler, Ph.D. ..... National Cancer Institute

National Cancer Advisory Board

Chair

Bruce A. Chabner, M.D. ..... Massachusetts General Hospital Cancer Center

Members

Anthony Atala, M.D. ..... Wake Forest University School of Medicine
Victoria L. Champion, D.N.S. ..... Indiana University School of Nursing
Donald S. Coffey, Ph.D. ..... The Johns Hopkins University School of Medicine
Marcia R. Cruz-Correa, M.D., Ph.D. ..... University of Puerto Rico
Kevin J. Cullen, M.D. ..... Marlene and Stuart Greenebaum Cancer Center
William H. Goodwin, Jr., M.B.A. ..... CCA Industries, Inc.
Waun Ki Hong, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Mr. Robert A. Ingram ..... Hatteras Venture Partners
Tyler E. Jacks, Ph.D. ..... Massachusetts Institute of Technology
Judith S. Kaur, M.D. ..... Mayo Comprehensive Cancer Center
Ms. Mary Vaughan Lester ..... University of California, San Francisco Foundation
H. Kim Lyerly, M.D. ..... Duke University
Karen M. Meneses, Ph.D. ..... University of Alabama at Birmingham
Olufunmilayo F. Olopade, M.B.B.S., F.A.C.P. ..... The University of Chicago
Jennifer A. Pietenpol, Ph.D. ..... Vanderbilt University Medical Center
Jonathan M. Samet, M.D., M.S. ..... University of Southern California, Keck School of Medicine
William R. Sellers, M.D. ..... Novartis Institutes for Biomedical Research, Inc.

Ex Officio Members of the National Cancer Advisory Board

Linda S. Birnbaum, Ph.D., D.A.B.T., A.T.S. ..... National Institute of Environmental Health Sciences, NIH
Francis S. Collins, M.D., Ph.D. ..... National Institutes of Health
Margaret A. Hamburg, M.D. ..... U.S. Food and Drug Administration

John P. Holdren, Ph.D. ..... Office of Science and Technology Policy
John Howard, M.D., M.P.H., J.D., L.L.M. ..... National Institute for Occupational Safety and Health
Lisa P. Jackson, M.S. .....U.S. Environmental Protection Agency
The Honorable Dr. Michael J. Kussman ..... U.S. Department of Veterans Affairs
Anna Palmisano, Ph.D. ..... U.S. Department of Energy
The Honorable Kathleen Sebelius, M.P.A. .....U.S. Department of Health and Human Services
The Honorable Hilda L. Solis .....U.S. Department of Labor
Inez Tenenbaum, M.Ed. .....U.S. Consumer Product Safety Commission
Jonathan Woodson, M.D. ..... The Pentagon

Alternates to *Ex Officio* Members of the National Cancer Advisory Board

Michael A. Babich, Ph.D. .....U.S. Consumer Product Safety Commission
Patricia Bray, M.D., M.P.H. .....OSHA/U.S. Department of Labor
Michael Kelley, M.D., F.A.C.P. ..... U.S. Department of Veterans Affairs
Aubrey Miller, M.D. .....National Institute of Environmental Health Sciences, NIH
Richard Pazdur, M.D. ..... U.S. Food and Drug Administration
John F. Potter, M.D. .....Walter Reed Army Medical Center
R. Julian Preston, Ph.D. .....U.S. Environmental Protection Agency
Michael Stebbins, Ph.D. ..... Office of Science and Technology Policy
Marie H. Sweeney, Ph.D., M.P.H. ..... National Institute for Occupational Safety and Health
Lawrence A. Tabak, D.D.S., Ph.D. .....National Institutes of Health
Sharlene Weatherwax, Ph.D. ..... U.S. Department of Energy

Executive Secretary

Paulette S. Gray, Ph.D. ..... National Cancer Institute

NCI – Frederick Advisory Committee

Chair

Zach H. Hall, Ph.D. .....University of California, San Francisco

Members

J. Carl Barrett, Ph.D. .....AstraZeneca
David Botstein, Ph.D. .....Princeton University
Levi A. Garraway, M.D., Ph.D. ..... Harvard Medical School
Beatrice Hahn, M.D. .....The University of Pennsylvania
Monica J. Justice, Ph.D. ..... Baylor College of Medicine
Lawrence J. Marnett, Ph.D. .....Vanderbilt University
Jill P. Mesirov, Ph.D. .....The Broad Institute of MIT and Harvard University
Garry P. Nolan, Ph.D. .....Stanford University
Kenneth Olden, Ph.D., Sc.D., L.H.D. ..... Hunter College
Steven T. Rosen, M.D., F.A.C.P.*.....Northwestern University

*Pending.

Representatives

Joe W. Gray, Ph.D. ..... Oregon Health and Science University
Thomas A. Look, M.D. ..... Dana-Farber Cancer Insitutute
Jennifer A. Pietenpol, Ph.D. ..... Vanderbilt University
Cheryl Willman, M.D. ..... The University of New Mexico

Ex Officio Members of the NCI – Frederick Advisory Committee

John Czajkowski, M.P.A. ..... National Cancer Institute
James H. Doroshow, M.D. ..... National Cancer Institute
Joseph F. Fraumeni, Jr., M.D. ..... National Cancer Institute
Paulette S. Gray, Ph.D. ..... National Cancer Institute
Douglas R. Lowy, M.D. ..... National Cancer Institute
Alan Rabson, M.D. ..... National Cancer Institute
Craig W. Reynolds, Ph.D. ..... National Cancer Institute
Robert H. Wiltrout, Ph.D. ..... National Cancer Institute

Executive Secretary

Thomas M. Vollberg, Ph.D. ..... National Cancer Institute

NCI Board of Scientific Advisors

Chair

Todd R. Golub, M.D. ..... Dana-Farber Cancer Institute

Members

Francis Ali-Osman, D.Sc. ..... Duke University Medical Center
Paul M. Allen, Ph.D. ..... Washington University School of Medicine
Christine B. Ambrosone, Ph.D. ..... Roswell Park Cancer Institute
Sangeeta N. Bhatia, M.D., Ph.D. ..... Massachusetts Institute of Technology
Andrea Califano, Ph.D. ..... Columbia University Medical Center
Michael A. Caligiuri, M.D. ..... Ohio State University Comprehensive Cancer Center
Arul M. Chinnaiyan, M.D., Ph.D. ..... University of Michigan Medical School
Curt I. Civin, M.D. ..... University of Maryland School of Medicine
Chi V. Dang, M.D., Ph.D. ..... The Johns Hopkins University
Ronald A. DePinho, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Robert B. Diasio, M.D. ..... Mayo Clinic Cancer Center
Jeffrey A. Drebin, M.D., Ph.D., F.A.C.S. ..... Hospital of the University of Pennsylvania
Brian J. Druker, M.D.* ..... Oregon Health and Science University
Karen M. Emmons, Ph.D. ..... Dana-Farber Cancer Institute
Betty Ferrell, Ph.D., R.N., F.A.A.N. ..... City of Hope National Medical Center
Kathleen M. Foley, M.D. ..... Memorial Sloan-Kettering Cancer Center
Sanjiv S. Gambhir, M.D., Ph.D. ..... Stanford University

*Pending.

Stanton L. Gerson, M.D. ..... Case Western Reserve University
Joe W. Gray, Ph.D. ..... Oregon Health and Science University
Mary J.C. Hendrix, Ph.D. ..... Northwestern University
Timothy J. Kinsella, M.D. ..... Rhode Island Hospital
Joshua LaBaer, M.D., Ph.D. ..... Arizona State University
Theodore S. Lawrence, M.D., Ph.D. ..... University of Michigan
Mr. Don Listwin ..... Canary Foundation
Christopher J. Logothetis, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Maria E. Martinez, Ph.D., M.P.H. ..... The University of Arizona
James L. Omel, M.D. ..... Volunteer
Luis F. Parada, Ph.D. ..... The University of Texas Southwestern Medical Center
Edith A. Perez, M.D. ..... Mayo Clinic
Stuart L. Schreiber, Ph.D. ..... The Broad Institute of MIT and Harvard University
Lincoln Stein, M.D., Ph.D. ..... Ontario Institute for Cancer Research
Bruce W. Stillman, Ph.D. ..... Cold Spring Harbor Laboratory
Victor J. Strecher, Ph.D., M.P.H. ..... University of Michigan School of Public Health
Louise C. Strong, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Frank M. Torti, M.D., M.P.H. ..... Wake Forest University School of Medicine
Gregory L. Verdine, Ph.D.* ..... Harvard University
Jean Y. Wang, Ph.D. ..... University of California, San Diego School of Medicine
Irving L. Weissman, M.D. ..... Stanford University
James K. Willson, M.D. ..... University of Texas Southwestern Medical Center

Executive Secretary

Paulette S. Gray, Ph.D. ..... National Cancer Institute

*Pending.

Clinical Trials and Translational Research Advisory Committee

Chair

James L. Abbruzzese, M.D., F.A.C.P. ..... The University of Texas M.D. Anderson Cancer Center

Members

Peter C. Adamson, M.D. ..... The University of Pennsylvania
Susan G. Arbuck, M.D., M.Sc., F.A.C.P.† ..... Susan G. Arbuck M.D., LLC
Monica M. Bertagnolli, M.D. ..... Dana-Farber Cancer Institute
Deborah W. Bruner, Ph.D., R.N., F.A.A.N. ..... The University of Pennsylvania
Curt I. Civin, M.D. ..... University of Maryland School of Medicine
Kenneth H. Cowan, M.D., Ph.D. ..... University of Nebraska Medical Center
Mr. Everett E. Dodson ..... Lombardi Comprehensive Cancer Center
Olivera J. Finn, Ph.D. ..... University of Pittsburgh School of Medicine
Stephen S. Grubbs, M.D.* ..... Medical Oncology Hematology Consultants, PA
Sandra J. Horning, M.D. ..... Genentech, Inc.
Scott M. Lippman, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Nancy P. Mendenhall, M.D. ..... University of Florida Health Science Center
Lisa A. Newman, M.D., M.P.H., F.A.C.S. ..... University of Michigan Comprehensive Cancer Center
David R. Parkinson, M.D.* ..... Nodality, Inc.
Edith A. Perez, M.D. ..... Mayo Clinic Foundation
Ms. Nancy Roach ..... C3: Colorectal Cancer Coalition
Daniel J. Sargent, Ph.D. ..... Mayo Clinic Foundation
Mitchell D. Schnall, M.D., Ph.D. ..... The University of Pennsylvania Medical Center
Peter G. Shields, M.D. ..... Georgetown University Medical Center
Joel E. Tepper, M.D. ..... Lineberger Comprehensive Cancer Center
James L. Wade III, M.D. ..... Decatur Memorial Hospital Cancer Care Institute

Ex Officio Members

James H. Doroshow, Ph.D. ..... National Cancer Institute
Paulette S. Gray, Ph.D. ..... National Cancer Institute
Rosemarie Hakim, Ph.D., M.S. ..... Centers for Medicare and Medicaid Services
Lee Helman, M.D. ..... National Cancer Institute
Michael J. Kelley, M.D., F.A.C.P. ..... Veterans Health Administration
Richard Pazdur, M.D., F.A.C.P. ..... U.S. Food and Drug Administration
John F. Potter, M.D. ..... Walter Reed Army Medical Center
Alan Rabson, M.D. ..... National Cancer Institute

Executive Secretary

Sheila A. Prindiville, M.D., M.P.H. ..... National Cancer Institute

*Extended.
†Pending Clearance.

Board of Scientific Counselors for Clinical Sciences and Epidemiology, NCI

Chair

Ethan Dmitrovsky, M.D. ..... Dartmouth Medical School

Members

Wadih Arap, M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Edgar Ben-Josef, M.D. ..... University of Michigan
Arthur W. Blackstock, Jr., M.D.* ..... Wake Forest University
Bruce Blazar, M.D. ..... University of Minnesota
Tim Byers, M.D. ..... University of Colorado Cancer Center
William Cance, M.D. ..... Roswell Park Cancer Institute
Susan Chang, M.D. ..... University of California, San Francisco School of Medicine
William Evans, Pharm.D. ..... St. Jude Children's Research Hospital
Jo Freudenheim, Ph.D. ..... State University of New York
Judy Garber, M.D. ..... Dana-Farber Cancer Institute
Marc Goodman, Ph.D. ..... University of Hawaii
Bernard Harlow, Ph.D. ..... University of Minnesota
Carl June, M.D. ..... The University of Pennsylvania School of Medicine
Karen Kelly, M.D. ..... University of California, Davis Medical Center
Alexandra Levine, M.D., M.A.C.P. ..... City of Hope National Medical Center
Sanford Markowitz, M.D., Ph.D.* ..... Case Western Reserve University
Augusto Ochoa, M.D. ..... Louisiana State University Health Science Center
Kenneth Offit, M.D., M.P.H.* ..... Memorial Sloan-Kettering Cancer Center
David Poplack, M.D. ..... Baylor College of Medicine
Ms. Nancy Roach ..... C3: Colorectal Cancer Coalition
Thomas Rohan, M.D., Ph.D. ..... Albert Einstein College of Medicine
Daniel Schaid, Ph.D. ..... Mayo Clinic
Thomas Sellers, Ph.D. ..... H. Lee Moffitt Cancer Center and Research Institute
Darryl Shibata, M.D. ..... University of Southern California
Robert Tigelaar, M.D. ..... Yale University School of Medicine
Walter Urba, M.D., Ph.D. ..... Providence Portland Medical Center
Elizabeth Ward, Ph.D. ..... American Cancer Society
George Wilding, M.D.* ..... University of Wisconsin
Cheryl Willman, M.D. ..... University of New Mexico Cancer Research and Treatment Center

Executive Secretary

Brian Wojcik, Ph.D. ..... National Cancer Institute

*Pending.

Board of Scientific Counselors for Basic Sciences, NCI

Chair

Joan W. Conaway, Ph.D. ..... Stowers Institute for Medical Research

Past Chair

Laurence Hurley, Ph.D. ..... University of Arizona

Members

Cory Abate-Shen, Ph.D. ..... Columbia University
Dafna Bar-Sagi, Ph.D. ..... New York University School of Medicine
Paul Bieniasz, Ph.D. ..... Aaron Diamond AIDS Research Center
John Cambier, Ph.D. ..... University of Colorado Denver School of Medicine and National Jewish Health
Selina Chen-Kiang, Ph.D. ..... Weill Medical College of Cornell University
Lawrence Corey, M.D. ..... Fred Hutchinson Cancer Research Center
Sara A. Courtneidge, Ph.D.* ..... Sanford-Burnham Medical Research Institute
Norman Drinkwater, Ph.D. ..... University of Wisconsin-Madison
Nelson Fausto, M.D. ..... University of Washington School of Medicine
Errol Friedberg, M.D. ..... University of Texas Southwestern Medical Center
Joanna Groden, Ph.D.* ..... The Ohio State University
Thomas Hamilton, Ph.D. ..... Cleveland Clinic Foundation
Daria Hazuda, Ph.D. ..... Merck and Company, Inc.
Eric Hunter, Ph.D. ..... Emory Vaccine Center
Chris Ireland, Ph.D. ..... University of Utah
Marc Jenkins, Ph.D. ..... University of Minnesota Medical School
Alexandra Joyner, Ph.D.* ..... Memorial Sloan-Kettering Cancer Center
Marcelo Kazanietz, Ph.D. ..... The University of Pennsylvania School of Medicine
Robert E. Lewis, Ph.D.* ..... University of Nebraska Medical Center
Jonathan Licht, M.D. ..... Northwestern University Feinberg School of Medicine
Wendell Lim, Ph.D. ..... University of California, San Francisco
A. Thomas Look, M.D. ..... Dana-Farber Cancer Institute
Ian Macara, Ph.D. ..... University of Virginia Health Sciences Center
Nita Maihle, Ph.D. ..... Yale University School of Medicine
Lynn Matrisian, Ph.D. ..... Vanderbilt University School of Medicine
Suzanne Ostrand-Rosenberg, Ph.D. ..... University of Maryland, Baltimore
Ann Marie Pendergast, Ph.D. ..... Duke University Medical Center
Thomas Poulos, Ph.D. ..... University of California, Irvine
James Prestegard, Ph.D. ..... University of Georgia
Kenneth Rock, M.D. ..... University of Massachusetts Medical School
James A. Wells, Ph.D.* ..... University of California, San Francisco
Wayne M. Yokoyama, M.D.* ..... Washington University
Ming You, M.D., Ph.D. ..... Medical College of Wisconsin
Virginia Zakian, Ph.D. ..... Princeton University

Executive Secretary

Florence E. Farber, Ph.D. ..... National Cancer Institute

*Pending.

NCI Director's Consumer Liaison Group

Chair

Ms. Gwen Darien ..... Samuel Waxman Cancer Research Foundation

Vice-Chair

Mr. Everett E. Dodson ..... Georgetown Lombardi Cancer Center

Members

Jeffrey Allen, Ph.D. ..... Friends of Cancer Research
Susan G. Braun, M.A. ..... Commonweal
Adam M. Clark, Ph.D. ..... Medtran Health Strategies, LLC
Marie E. Dahlstrom, M.A. ..... De La Mano Frente Al Cancer: Latino Cancer Coalition
Joyce Wilcox Graff, M.A. ..... VHL Family Alliance
Joya Delgado Harris, M.P.H. ..... Advocate
Linda S. House, M.S., R.N. ..... Cancer Support Community
Cheryl Jernigan, C.P.A., FACHE ..... Susan G. Komen for the Cure
Jeffrey A. Kaufman, M.B.A. ..... Adenoid Cystic Carcinoma Research
Michelle McMurry-Heath, M.D., Ph.D. ..... Health, Biomedical Science, and Society Initiative
Deborah Morosini, M.D. ..... AstraZeneca Pharmaceuticals
Phyllis Pettit Nassi, M.S.W. ..... University of Utah
Jon G. Retzlaff, M.P.A., M.B.A. ..... American Association for Cancer Research
Ms. Wendy K.D. Selig ..... Melanoma Research Alliance
Mr. Josh Sommer ..... The Chordoma Foundation
Andrea E. Ferris Stern, M.B.A. ..... LUNGevity Foundation
Ms. Arlene Wahwasuck ..... Four Tribes Women's Wellness Coalition
Max N. Wallace, J.D. ..... Accelerate Brain Cancer Cure, Inc.

Executive Secretary

Shannon K. Bell, M.S.W. ..... National Cancer Institute

NCI Initial Review Group Scientific Review Committees

Subcommittee A—Cancer Centers

Chair

Edward Chu, M.D. ..... University of Pittsburgh

Past Chair

Stanton L. Gerson, M.D. ..... Case Western Reserve University

Members

Terrance L. Albrecht, Ph.D. ..... Wayne State University School of Medicine
Howard H. Bailey, M.D. ..... University of Wisconsin at Madison
Robert C. Bast, Jr., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Barbara J. Beckwith, M.A. ..... The Ohio State University Medical Center
Marianne Berwick, Ph.D., M.P.H. ..... The University of New Mexico
William E. Carson III, M.D. ..... The Ohio State University
Moon Shao-Chuang, Jr., Ph.D., M.P.H. ..... University of California, Davis
S. Gail Eckhardt, M.D. ..... University of Colorado
Susan M. Gapstur, Ph.D., M.P.H. ..... Northwestern University
Robert J. Gillies, Ph.D. ..... H. Lee Moffitt Cancer Center and Research Institute
Terry Hyslop, Ph.D. ..... Thomas Jefferson University
Mark A. Israel, M.D. ..... Dartmouth-Hitchcock Medical Center
Richard Jove, Ph.D. ..... City of Hope Comprehensive Cancer Center
Russel E. Kaufman, M.D., F.A.C.S. ..... The Wistar Institute
Linda Malkas, Ph.D. ..... City of Hope
Beverly S. Mitchell, M.D. ..... Stanford University
Motomi Mori, Ph.D. ..... Oregon Health and Science Center
Timothy L. Ratliff, Ph.D. ..... Purdue University
Jerome Ritz, M.D. ..... Harvard Medical School
Victoria L. Seewaldt, M.D. ..... Duke University Medical School
Richard L. Seither, Ph.D., M.B.A. ..... Albert Einstein College of Medicine of Yeshiva University
Jill M. Siegfried, Ph.D. ..... University of Pittsburgh, Hillman Cancer Center
Eric J. Small, M.D. ..... University of California, San Francisco
Kenneth D. Tew, Ph.D., D.Sc. ..... Medical University of South Carolina
Geoffrey R. Weiss, M.D. ..... University of Virginia
Bamarese Wheatley, Dr.Ed., M.P.H. ..... BPW Consulting Services
Douglas Yee, M.D. ..... The University of Minnesota

Scientific Review Officer

Gail J. Bryant, M.D. ..... National Cancer Institute

Subcommittee F—Manpower and Training

Chair

Mark A. Nelson, Ph.D. ..... The University of Arizona

Members

Vicki V. Baker, M.D. ..... Independent Consultant
Steven P. Balk, M.D., Ph.D. ..... Harvard Medical School
David L. Bartlett, M.D. ..... University of Pittsburgh School of Medicine
Moray J. Campbell, Ph.D. ..... Roswell Park Cancer Institute
Cathy S. Carlson, Ph.D., D.V.M. ..... University of Minnesota
Herbert Chen, M.D. ..... University of Wisconsin
Fong-Fong Chu, Ph.D. ..... Beckman Research Institute of City of Hope
Craig M. Crews, Ph.D. ..... Yale University
Daniel Donoghue, Ph.D. ..... University of California, San Diego
Henry S. Friedman, M.D. ..... Duke University Medical Center
Juan Fueyo-Margareto, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Rebecca S. Hartley, Ph.D. ..... The University of New Mexico Health Sciences Center
Marlene L. Hauck, Ph.D., D.V.M. ..... North Carolina State University
Mark R. Kelley, Ph.D. ..... Indiana University School of Medicine
Annette R. Khaled, Ph.D. ..... University of Central Florida
Molly F. Kulesz-Martin, Ph.D. ..... Oregon Health and Science University
Deborah A. Lannigan, Ph.D. ..... University of Virginia
Edmund C. Lattime, Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Christopher I. Li, M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Nipun B. Merchant, M.D., F.A.C.S. ..... Vanderbilt University Medical Center
Babatunde O. Oyajobi, M.D., Ph.D. ..... The University of Texas Health Sciences Center, San Antonio
Janet S. Rader, M.D., F.A.C.O.G. ..... Medical College of Wisconsin
Gavin P. Robertson, Ph.D. ..... The Pennsylvania State University
Mary Beth Terry, Ph.D. ..... Columbia University Mailman School of Public Health
Yu-Chung Yang, Ph.D. ..... Case Western Reserve University
Kenneth S. Zuckerman, M.D. ..... University of South Florida College of Medicine

Scientific Review Officer

Lynn M. Amende, Ph.D. ..... National Cancer Institute

Subcommittee G—Education

Chair

Georgia Robins Sadler, Ph.D. .....University of California, San Diego

Past Chair

Robert M. Chamberlain, Ph.D. .....The University of Texas M.D. Anderson Cancer Center

Members

Lucile L. Adams-Campbell, Ph.D. .....Georgetown University Medical Center
Barbara L. Anderson, Ph.D. .....The Ohio State University
Dee M. Baldwin, Ph.D., R.N., F.A.A.N. .....University of North Carolina at Charlotte
Deborah J. Bowen, Ph.D. .....Boston University
John C. Byrd, M.D. .....The Ohio State University Comprehensive Cancer Center
Shine Chang, Ph.D. .....The University of Texas M.D. Anderson Cancer Center
Concepcion R. Diaz-Arrastia, M.D. .....The University of Texas Medical Branch
Phyllis A. Gimotty, Ph.D. .....The University of Pennsylvania
Gail G. Harrison, Ph.D. .....University of California, Los Angeles
Judy Kasey Houlette, M.A. .....Friend for Life Cancer Support Network
Chanita A. Hughes-Halbert, Ph.D. .....The University of Pennsylvania
Daniel C. Hughes, Ph.D. .....The University of Texas Health Science Center
Aminah Jatoi, M.D. .....Mayo Clinic
Lovell A. Jones, Ph.D. .....The University of Texas M.D. Anderson Cancer Center
E. Melinda Mahabee-Gitthens, M.D. .....Cinicinnati Children's Hospital Medical Center
Gertraud Maskarinec, M.D., Ph.D. .....University of Hawaii Cancer Research Center
Arthur M. Michalek, Ph.D. .....State University of New York at Buffalo
R. Sean Morrison, M.D. .....Mount Sinai School of Medicine
Polly A. Newcomb, Ph.D. .....Fred Hutchinson Cancer Research Center
Joseph F. O'Donnell, M.D. .....Dartmouth Medical School
Jamie S. Ostroff, Ph.D. .....Memorial Sloan-Kettering Cancer Center
Timothy Pearman, Ph.D. .....Tulane University School of Medicine
Mark P. Pfeifer, M.D. .....University of Louisville Hospital
Edward A. Sausville, M.D., Ph.D. .....University of Maryland
Peter C. Trask, Ph.D. .....Pfizer, Inc.

Scientific Review Officer

Jeannette F. Korczak, Ph.D. .....National Cancer Institute

Subcommittee H—Clinical Trials*

Chair

Jacqueline K. Benedetti, Ph.D. ..... Fred Hutchinson Cancer Research Center

Members

Karla V. Ballman, Ph.D. ..... Mayo Clinic, College of Medicine
Claudia R. Baquet, M.D. ..... University of Maryland School of Medicine
Debra L. Barton, Ph.D., R.N., A.O.C.N. ..... Mayo Clinic, College of Medicine
Arthur W. Blackstock, Jr., M.D. ..... Wake Forest University School of Medicine
John A. Blessing, Ph.D. ..... Roswell Park Cancer Institute
Debra W. Christie, M.B.A. ..... University of Mississippi Medical Center
Susan Devine, C.C.R.P. ..... The Hospital for Sick Children, Toronto
Joshua D.I. Ellenhom, M.D., F.A.C.S. ..... City of Hope National Medical Center
Leonard G. Gomella, M.D. ..... Thomas Jefferson University
Ramaswamy Govindan, M.D. ..... Washington University School of Medicine
Julie R. Gralow, M.D. ..... University of Washington School of Medicine
Stanford E. Jeames, D.H.A. ..... University of Massachusetts, Donahue Institute
Gregory P. Kalemkerian, M.D. ..... University of Michigan Health System
Merrill S. Kies, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Jeanette Y. Lee, Ph.D. ..... University of Arkansas for Medical Sciences
Neyssa M. Marina, M.D. ..... Stanford University Medical Center
Elizabeth Poplin, M.D. ..... The Cancer Institute of New Jersey
David I. Quinn, Ph.D. ..... University of Southern California, Keck School of Medicine
William F. Regine, M.D. ..... University of Maryland School of Medicine
Denise Reinke, M.S. ..... University of Michigan Comprehensive Cancer Center
William H. Rodgers, M.D., Ph.D. ..... Lenox Hill Hospital
Melanie E. Royce, M.D., Ph.D. ..... The University of New Mexico Cancer Research Center
Mary Scroggins, M.A. ..... In My Sister's Care
Elin R. Sigurdson, M.D., Ph.D. ..... Fox Chase Cancer Center
Alan P. Venook, M.D. ..... University of California, San Francisco
Mary K. Washington, M.D., Ph.D. ..... Vanderbilt University Medical Center
Mark A. Watson, M.D., Ph.D. ..... Washington University School of Medicine

Scientific Review Officer

Timothy C. Meeker, M.D. ..... National Cancer Institute

*Subcommittee H was inactivated on April 1, 2011.

Subcommittee I—Career Development

Chair

William E. Gillanders, M.D. ..... Washington University School of Medicine

Members

Deepak Bastia, Ph.D. ..... Medical University of South Carolina
Sujit Basu, M.D., Ph.D. ..... The Ohio State University
Soldano Ferrone, M.D., Ph.D. ..... University of Pittsburgh Cancer Institute
James M. Ford, M.D. ..... Stanford University School of Medicine
Roland G. Henry, Ph.D. ..... University of California, San Francisco
Jessica J. Kandel, M.D. ..... Columbia University
Charles Keller, M.D. ..... Oregon Health and Science University
Marilyn L.G. Lamm, Ph.D. ..... Northwestern University Feinberg School of Medicine
John M. Lehman, Ph.D. ..... East Carolina University
Sophie A. Lelievre, D.V.M., Ph.D. ..... Purdue Center for Cancer Research
Anna E. Loshkin, Ph.D. ..... University of Pittsburgh School of Medicine
Daniela E. Matei, M.D. ..... Indiana University School of Medicine
Carlos S. Moreno, Ph.D. ..... Emory University, Winship Cancer Institute
Neil Osheroff, Ph.D. ..... Vanderbilt University School of Medicine
Mauel L. Penichet, Ph.D. ..... University of California, Los Angeles
Rajagopal Ramesh, Ph.D. ..... University of Oklahoma Health Sciences Center
Wolfram E. Samlowski, M.D. ..... University of Nevada School of Medicine
Richard D. Schulick, M.D. ..... The Johns Hopkins University School of Medicine
Robert A. Winn, M.D. ..... University of Colorado School of Medicine
Wen-Cheng Xiong, M.D., Ph.D. ..... Medical College of Georgia

Scientific Review Officer

Sergei Radaev, Ph.D. ..... National Cancer Institute

Subcommittee J—Population and Patient-Oriented Training

Chair

Johanna W. Lampe, Ph.D. ..... Fred Hutchinson Cancer Research Center

Past Chair

Michael A. Andrykowski, Ph.D. ..... University of Kentucky

Members

Virginia F. Borges, M.D., M.M.Sc. ..... University of Colorado, Denver School of Medicine
Michael Bouvet, M.D. ..... University of California, San Diego–Moores Cancer Center
Malcolm V. Brock, M.D. ..... The Johns Hopkins Hospital
Mary E. Cooley, Ph.D. ..... Dana-Farber Cancer Institute
Michael E. Hagansee, M.D., Ph.D. ..... Louisiana State University
Raymond J. Hohl, M.D., Ph.D. ..... The University of Iowa
Shawna V. Hudson, Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Paul B. Jacobson, Ph.D. ..... H. Lee Moffitt Cancer Center and Research Institute
Beverly L. Laird, Ph.D. ..... 3D Medical Concepts, LLC
Christopher H. Lowrey, M.D. ..... Dartmouth College School of Medicine
Guy H. Montgomery, Ph.D. ..... Mount Sinai School of Medicine
Chaya S. Moskowitz, Ph.D. ..... Memorial Sloan-Kettering Cancer Center
Kristen B. Moysich, Ph.D. ..... Roswell Park Cancer Institute
C. Daniel Mullins, Ph.D. ..... University of Maryland
Frank J. Penedo, Ph.D. ..... University of Miami
Lillian L. Siu, M.D. ..... Princess Margaret Hospital
Scott A. Waldman, M.D., Ph.D. ..... Thomas Jefferson University
Cary A.C. Zahbrock, M.S.W. ..... National Coalition for Cancer Survivorship
Zuo-Feng Zhang, M.D., Ph.D. ..... University of California, Los Angeles School of Public Health

Scientific Review Officer

Ilda M. McKenna, Ph.D. ..... National Cancer Institute

Initial Review Group Subcommittees

Cancer Centers

Institutional Training and Education

Initial Review Group Subcommittees (continued)

Transition to Independence

Special Emphasis Panels

Program Project Review Panel Meeting I

Special Emphasis Panels (continued)

SPORE in Breast, Prostate, and Thyroid Cancers

SPORE in Lymphoma, Leukemia, Brain, Esophageal, and Gastrointestinal Cancers

Appendix D: NCI Initial Review Group Consultants

1. Consultants Serving as Temporary Members on IRG Subcommittees in FY2011

A

Aguiar, Ricardo C., M.D., Ph.D. ..... The University of Texas Health Science Center, San Antonio
Akman, Steven A., M.D. ..... Wake Forest University Health Sciences
Alberg, Anthony J., Ph.D., M.P.H. ..... Medical University of South Carolina
Ali-Osman, Francis, D.Sc. ..... Duke University
Ambinder, Richard F., M.D., Ph.D. ..... The Johns Hopkins University
Arenberg, Douglas A., M.D. ..... University of Michigan, Ann Arbor
Arteaga, Carlos L., M.D. ..... Vanderbilt University
Augenlicht, Leonard H., Ph.D. ..... Montefiore Medical Center, New York

B

Bailey, Howard H., M.D. ..... University of Wisconsin, Madison
Bandera, Elisa V., M.D., Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Bangia, Naveen, Ph.D. ..... Roswell Park Cancer Institute Corporation
Bennett, Anton M., Ph.D. ..... Yale University
Bergan, Raymond C., M.D. ..... Northwestern University, Chicago
Bergen, Andrew W., Ph.D. ..... SRI International
Berger, Franklin G., Ph.D. ..... The University of South Carolina, Columbia
Biondi, Andrea, M.D. ..... University of Milano-Bicocca
Bishop, Maria C., M.D. ..... The University of Arizona
Bjornsti, Mary-Ann, Ph.D. ..... University of Alabama at Birmingham
Blackstock, Arthur W., M.D. ..... Wake Forest University Health Sciences
Boise, Lawrence H., Ph.D. ..... Emory University
Bolwell, Brian, M.D. ..... Cleveland Clinic Foundation
Bost, James E., Ph.D. ..... The University of Pittsburgh
Bradbury, Michelle S., M.D., Ph.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Brard, Laurent, M.D., Ph.D. ..... Southern Illinois University School of Medicine
Buchsbaum, Donald J., Ph.D. ..... University of Alabama at Birmingham
Busch, Theresa M., Ph.D. ..... University of Rochester

C

Carlson, Cathy S., D.V.M., Ph.D. ..... The University of Minnesota, Twin Cities
Carroll, William L., M.D. ..... New York University School of Medicine
Carson, William E., M.D. ..... The Ohio State University
Chang, Shine, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Chao, Chun, Ph.D. ..... Kaiser Foundation Research Institute
Chen, Moon Shao-Chuang., Ph.D., M.P.H. ..... University of California, Davis
Clarke, Jennifer P., Ph.D. ..... University of Miami School of Medicine
Cleaver Tallchief, Vicki L., Ed.D. ..... Oklahoma University Medical Center

Cody, Vivian, Ph.D. ..... Hauptman-Woodward Medical Research Institute
Cooney, Kathleen A., M.D. ..... University of Michigan, Ann Arbor
Craft, Alan W., M.D. ..... Royal Victoria Infirmary
Cullen, Bryan R., Ph.D. ..... Duke University

D

DeClerck, Yves A., M.D. ..... University of Southern California
Di Cristofano, Antonio, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Dowlati, Afshin, M.D. ..... H. Lee Moffitt Cancer Center & Research Institute

E

El-Deiry, Wafik S., M.D., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center
Elmer, Patricia J., Ph.D. ..... National College of Naturopathic Medicine at Dallas
Evans, Sydney M., M.D. ..... The University of Pennsylvania

F

Figlin, Robert A., M.D. ..... Cedars-Sinai Medical Center
Fingeroth, Joyce D., M.D. ..... Beth Israel Deaconess Medical Center

G

Graf, Norbert, M.D. ..... University of Saarlandes
Grandis, Jennifer R., M.D. ..... The University of Pittsburgh
Grufferman, Seymour, M.D., Ph.D. ..... The University of New Mexico
Grunberg, Steven M., M.D. ..... The University of Vermont & State Agricultural College

H

Hande, Kenneth R., M.D. ..... Vanderbilt University
Hatcher, Jennifer, Ph.D. ..... University of Kentucky
Hauck, Marlene L., D.V.M., Ph.D. ..... North Carolina State University, Raleigh
Hubbard, Karen, Ph.D. ..... City College of New York
Hughes, Daniel C., Ph.D. ..... The University of Texas Health Science Center, San Antonio

J

Jacobsen, Paul B., Ph.D. ..... University of South Florida
Jones, Richard J., M.D. ..... The Johns Hopkins University
Jove, Richard, Ph.D. ..... Beckman Research Institute of City of Hope

K

Keller, Charles, M.D. ..... Oregon Health and Science University
Kinney, Anita Y., Ph.D., R.N. ..... University of Utah
Kitchell, Barbara E., D.V.M., Ph.D. ..... Michigan State University
Kushi, Lawrence H., Sc.D. ..... Kaiser Foundation Research Institute

L

LaFlamme, Susan, Ph.D. ..... Albany Medical College
Laird, Beverly L., Ph.D. ..... American Cancer Society, Inc.
Lampson, Lois A., Ph.D. ..... Brigham and Women's Hospital
Lattime, Edmund C., Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Le Beau, Michelle M., Ph.D. ..... The University of Chicago
Lelievre, Sophie A., D.V.M., Ph.D. ..... Purdue University, West Lafayette
Lenkinski, Robert E., Ph.D. ..... University of Texas Southwestern Medical Center at Dallas
Li, Jian J., M.D., Ph.D. ..... Purdue University, West Lafayette
Lokshin, Anna E., Ph.D. ..... The University of Pittsburgh

M

Mahabee-Gittens, E. Melinda, M.D. ..... Children's Hospital Medical Center, Cincinnati
Malkas, Linda H., Ph.D. ..... Beckman Research Institute of City of Hope
Mandal, Diptasri M., Ph.D. ..... Louisiana State University Health Sciences Center, New Orleans
Manning, Henry C., Ph.D. ..... Vanderbilt University
Marshall, James, Ph.D. ..... Roswell Park Cancer Institute
Martin, Brian J., M.P.A. ..... University of Rochester
Maskarinec, Gertraud, M.D., Ph.D., M.P.H. ..... University of Hawaii, Manoa
Matei, Daniela E., M.D. ..... Indiana University-Purdue University Indianapolis
Meric-Bernstam, Funda, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Mermelstein, Robin J., Ph.D. ..... University of Illinois at Chicago
Meyers, Craig M., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center
Mori, Motomi, Ph.D. ..... Oregon Health and Science University
Moskowitz, Chaya, Ph.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Mukherji, Bijay, M.D. ..... University of Connecticut School of Medicine & Dentistry
Mukhtar, Hasan, Ph.D. ..... University of Wisconsin, Madison
Mullins, C. Daniel., Ph.D. ..... University of Maryland, Baltimore
Myers, Chad L., Ph.D. ..... The University of Minnesota, Twin Cities

O

Olshan, Andrew, Ph.D. ..... The University of North Carolina at Chapel Hill
Osheroff, Neil, Ph.D. ..... Vanderbilt University
Ostroff, Jamie S., Ph.D. ..... Memorial Sloan-Kettering Institute for Cancer Research

P

Pearson, Andrew D., Ph.D. ..... Royal Marsden Hospital
Penichet, Manuel L., M.D., Ph.D. ..... University of California, Los Angeles
Pieper, Russell O., Ph.D. ..... University of California, San Francisco
Plon, Sharon E., M.D., Ph.D. ..... Baylor College of Medicine

R

Radivoyevitch, Tomas, Ph.D. ..... Medical University of South Carolina
Reitz, Marvin S., Ph.D. ..... University of Maryland, Baltimore
Riegel, Anna T., Ph.D. ..... Georgetown University
Rincon, Mercedes, Ph.D. ..... The University of Vermont & State Agricultural College

S

Sanchez, Irma, Ph.D. ..... Harvard Medical School
Santana, Victor M., M.D. ..... St. Jude Children's Research Hospital
Schuchter, Lynn M., M.D. ..... The University of Pennsylvania
Shen, Zhiyuan, M.D., Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Shields, Anthony F., M.D., Ph.D. ..... Wayne State University
Siegfried, Jill M., Ph.D. ..... The University of Pittsburgh
Smith, David I., Ph.D. ..... Mayo Clinic
Sorensen, Glorian C., Ph.D, M.P.H. ..... Dana-Farber Cancer Institute
Sugden, William M., Ph.D. ..... University of Wisconsin, Madison

T

Tan, Ming T., Ph.D. ..... University of Maryland, Baltimore
Tannous, Bakhos A., Ph.D. ..... Massachusetts General Hospital
Terry, Michael A., B.S. ..... University of Rochester
Tiwari, Hemant K., Ph.D. ..... University of Alabama at Birmingham
Tsodikov, Alexander, Ph.D. ..... University of Michigan, Ann Arbor

V

Van Etten, Richard A., M.D., Ph.D. ..... Tufts Medical Center

W

Waller, Edmund K., M.D., Ph.D. ..... Emory University
Wang, Shizhen E., Ph.D. ..... Beckman Research Institute of City of Hope
Warnecke, Richard, Ph.D. ..... University of Illinois at Chicago
Weaver, Valerie M., Ph.D. ..... University of California, San Francisco
Wiley, Patti, M.B.A. ..... On the Wings of Angels
Willett, Christopher G., M.D. ..... Duke University
Wilson, Bridget S., Ph.D. ..... The University of New Mexico Health Sciences Center
Wilson, David L., Ph.D. ..... Case Western Reserve University
Wilson, David M., Ph.D. ..... National Institute on Aging
Wilson-Sanders, Susan E., D.V.M. ..... The University of Arizona
Winn, Robert A., M.D. ..... University of Colorado, Denver
Winter, Jane N., M.D. ..... Northwestern University
Woloschak, Gayle E., Ph.D. ..... Northwestern University

X

Xiong, Wen-Cheng, M.D., Ph.D. ..... Medical College of Georgia School of Medicine

Y

Yang, Yu-Chung, Ph.D. ..... Case Western Reserve University

Total number of Reviewers: 129

2. Consultants Serving as *Ad Hoc* Committee Members on IRG Site Visit Teams in FY2011

A

Alberg, Anthony J., Ph.D., M.P.H. ..... Medical University of South Carolina
Albrecht, Terrance L., Ph.D. ..... Wayne State University
Ali-Osman, Francis, D.Sc. ..... Duke University
Ambinder, Richard F., M.D., Ph.D. ..... The Johns Hopkins University
Andrykowski, Michael A., Ph.D. ..... University of Kentucky
Arteaga, Carlos L., M.D. ..... Vanderbilt University
Augenlicht, Leonard H., Ph.D. ..... Montefiore Medical Center, New York

B

Bailey, Howard H., M.D. ..... University of Wisconsin, Madison
Bast, Robert C., M.D. ..... Harvard University Medical School
Bastia, Deepak, Ph.D. ..... Medical University of South Carolina
Baum, Linda L., Ph.D. ..... Rush University Medical Center
Beckwith, Barbara J., M.A. ..... The Ohio State University
Belk, Bonnie F., M.P.A., M.A. ..... Private Practice
Benovic, Jeffrey L., Ph.D. ..... Thomas Jefferson University
Bergan, Raymond C., M.D. ..... Northwestern University
Berwick, Marianne, Ph.D., M.P.H. ..... The University of New Mexico
Bickell, Nina A., M.D., M.P.H. ..... Mount Sinai School of Medicine
Bjornsti, Mary-Ann, Ph.D. ..... University of Alabama at Birmingham
Bond, Jeffrey P., Ph.D. ..... The University of Vermont & State Agricultural College
Boothman, David A., Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Boyett, James M., Ph.D. ..... St. Jude Children's Research Hospital
Bruchez, Marcel P., Ph.D. ..... Carnegie-Mellon University
Buchsbaum, Donald J., Ph.D. ..... University of Alabama at Birmingham

C

Carbone, Michele, M.D., Ph.D. ..... University of Hawaii Cancer Center
Carducci, Michael A., M.D. ..... The Johns Hopkins University
Carroll, William L., M.D. ..... New York University School of Medicine
Carson, William E., M.D. ..... The Ohio State University
Chen, Moon S., Ph.D., M.P.H. ..... University of California, Davis
Chow, Samson A., Ph.D. ..... University of California, Los Angeles
Chu, Edward, M.D. ..... University of Pittsburgh
Clurman, Bruce E., M.D, Ph.D. ..... Fred Hutchinson Cancer Research Center
Cody, Vivian, Ph.D. ..... Hauptman-Woodward Medical Research Institute
Cooney, Kathleen A., M.D. ..... University of Michigan, Ann Arbor
Crawford, Jeffrey C., M.D. ..... Duke University
Creek, Kim E., Ph.D. ..... The University of South Carolina, Columbia
Curley, Robert W., Ph.D. ..... The Ohio State University

D

Davis, Jerry K., D.V.M., Ph.D. ..... University of Florida
Davisson, Vincent J., Ph.D. ..... Purdue University, West Lafayette
DeClerck, Yves A., M.D. ..... University of Southern California
DiGiovanni, John, Ph.D. ..... The University of Texas, Austin
DiMaio, Daniel C., M.D., Ph.D. ..... Yale University
DiPaola, Robert S., M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Djeu, Julie Y., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Dowlati, Afshin, M.D. ..... Case Western Reserve University
Duli, Anne M., M.P.A. ..... Case Western Reserve University

E

Eckhardt, Sue G., M.D. ..... University of Colorado, Denver
Edgerton, Mary E., M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
El-Deiry, Wafik S., M.D., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center
Ellerbeck, Edward F., M.D., M.P.H. ..... University of Kansas Medical Center
Engelhard, Victor H., Ph.D. ..... University of Virginia, Charlottesville
Erlichman, Charles, M.D. ..... Mayo Clinic
Erwin, Deborah O., Ph.D. ..... Roswell Park Cancer Institute
Euhus, David M., M.D. ..... The University of Texas Southwestern Medical Center, Dallas

F

Ferrara, James L., M.D. ..... University of Michigan, Ann Arbor
Ferrell, Betty R., Ph.D., R.N., F.A.A.N. ..... Beckman Research Institute of City of Hope
Ferrone, Soldano, M.D., Ph.D. ..... University of Pittsburgh
Figlin, Robert A., M.D. ..... Cedars-Sinai Medical Center
Fingeroth, Joyce D., M.D. ..... Beth Israel Deaconess Medical Center
Fontham, Elizabeth H., Ph.D. ..... Louisiana State University Health Sciences Center, New Orleans
Futscher, Bernard W., Ph.D. ..... The University of Arizona

G

Gapstur, Susan M., Ph.D., M.P.H. ..... American Cancer Society, Inc.
Gasson, Judith C., M.D., Ph.D. ..... University of California, Los Angeles
Gerlach, Robert W., M.A. ..... Dartmouth College
Gerson, Stanton L., M.D. ..... Case Western Reserve University
Gewirtz, David A., Ph.D. ..... Virginia Commonwealth University
Gibbs, Richard A., Ph.D. ..... Purdue University, West Lafayette
Gillies, Robert J., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Grant, Marcia L., D.N.Sc., F.A.A.N. ..... City of Hope National Medical Center
Graves, Barbara J., Ph.D. ..... University of Utah
Gruber, Stephen B., M.D., Ph.D., M.P.H. ..... University of Michigan, Ann Arbor
Grufferman, Seymour, M.D. ..... The University of New Mexico

H

Hackett, Lauren E., M.P.A. ..... New York University
Haffty, Bruce G., M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Hanash, Samir M., M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Hansen, Marc F., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Harrison, Anita L., M.A. ..... Medical University of South Carolina
Hawthorn, Lesleyann, Ph.D. ..... Georgia Health Sciences University
Herbst, Roy S., M.D., Ph.D. ..... Yale University
Hess, Kenneth R., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Hilsenbeck, Susan G., Ph.D. ..... Baylor College of Medicine
Hoopes, P. Jack, D.V.M., Ph.D. ..... Dartmouth College
Howell, Stephen B., M.D. ..... University of California, San Diego
Hsu, Edward W., Ph.D. ..... University of Utah
Huang, Tim H.-M., Ph.D. ..... The Ohio State University
Hudis, Clifford A., M.D. ..... Sloan-Kettering Institute for Cancer Research
Hughes-Halbert, Chanita A., Ph.D. ..... The University of Pennsylvania
Hwang, Lu-Yu, M.D. ..... The University of Texas Health Science Center, Houston
Hyslop, Terry M., Ph.D. ..... Thomas Jefferson University

I

Iglehart, James D., M.D. ..... Dana-Farber Cancer Institute
Iritani, Brian M., D.V.M., Ph.D. ..... University of Washington
Israel, Mark A., M.D. ..... Dartmouth College

J

Jacobs, Lisa K., M.D. ..... The Johns Hopkins University
Jacobsen, Paul B., Ph.D. ..... University of South Florida
Jenkins, Robert B., M.D., Ph.D. ..... Mayo Clinic
Johnson, Candace S., Ph.D. ..... Roswell Park Cancer Institute Corporation
Jones, Judy A., M.A. ..... Cutaneous Lymphoma Foundation
Jones, Richard J., M.D. ..... The Johns Hopkins University
Jove, Richard, Ph.D. ..... Beckman Research Institute of City of Hope

K

Kane, Madeleine A., M.D., Ph.D. ..... University of Colorado, Denver
Kaufman, Howard L., M.D. ..... Rush University Medical Center
Kaufman, Russel E., M.D. ..... Wistar Institute
Kelly, William K., D.O. ..... Jefferson Medical College
Kerr, William G., Ph.D. ..... State University of New York at Oneonta
Khuri, Fadlo R., M.D. ..... Emory University
Kinney, Anita Y., R.N., Ph.D. ..... University of Utah
Kipps, Thomas J., M.D., Ph.D. ..... University of California, San Diego

Kleinman, Nanette R., D.V.M. ..... Case Western Reserve University
Kong, Ah-Ng T., Ph.D. ..... Rutgers University
Kung, Hsing-Jien, Ph.D. ..... University of California, Davis

L

Lairmore, Michael D., D.V.M., Ph.D. ..... The Ohio State University
Lannin, Donald R., M.D. ..... Yale University
Le, Chap T., Ph.D. ..... University of Minnesota, Twin Cities
Le Beau, Michelle M., Ph.D. ..... The University of Chicago
LeBien, Tucker W., Ph.D. ..... University of Minnesota, Twin Cities
Lee, Terry D., Ph.D. ..... Beckman Research Institute of City of Hope
Lenkinski, Robert E., Ph.D. ..... The University of Texas Southwestern Medical Center
Li, King C., M.D., M.B.A. ..... Methodist Hospital Research Institute
Lichtor, Terence R., M.D., Ph.D. ..... Rush University Medical Center
Lin, Weili, Ph.D. ..... The University of North Carolina at Chapel Hill
Lowe, Val J., M.D. ..... Mayo Clinic
Lu, Karen H., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Lynch, Thomas J., M.D. ..... Yale University

M

Macoska, Jill A., Ph.D. ..... University of Michigan, Ann Arbor
Malkas, Linda H., Ph.D. ..... Beckman Research Institute of City of Hope
Marshall, James R., Ph.D. ..... Roswell Park Cancer Institute
Matei, Daniela E., M.D. ..... Indiana University-Purdue University Indianapolis
Mayne, Susan T., Ph.D. ..... Yale University
McCarthy, James B., Ph.D. ..... University of Minnesota, Twin Cities
McConkey, David J., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
McCormick, Frank P., Ph.D. ..... University of California, San Francisco
McWeeney, Shannon K., Ph.D. ..... Oregon Health and Science University
Mehta, Minesh P., M.D. ..... Northwestern University
Mermelstein, Robin J., Ph.D. ..... University of Illinois at Chicago
Mesecar, Andrew D., Ph.D. ..... Purdue University, West Lafayette
Meyn, Raymond E., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Miller, Kathy D., M.D. ..... Indiana University-Purdue University Indianapolis
Mitchell, Beverly S., M.D. ..... Stanford University
Moley, Jeffrey F., M.D. ..... Washington University
Moore, Anna, Ph.D. ..... Massachusetts General Hospital
Mori, Motomi, Ph.D. ..... Oregon Health and Science University
Mukherji, Bijay, M.D. ..... University of Connecticut School of Medicine & Dentistry
Muller, Carolyn Y., M.D. ..... The University of New Mexico

N

Naeve, Clayton W., Ph.D. ..... St. Jude Children's Research Hospital
Nalcioglu, Orhan, Ph.D. ..... University of California, Irvine

O

Ochs, Michael F., Ph.D. ..... The Johns Hopkins University

P

Pakes, Steven P., D.V.M., Ph.D. ..... The University of Texas Southwestern Medical Center
Pasick, Rena J., Dr.P.H. ..... University of California, San Francisco
Patterson, Ruth E., Ph.D. ..... University of California, San Diego
Perez, Raymond P., M.D. ..... University of Kansas Medical Center
Perez-Soler, Roman, M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Pieper, Russell O., Ph.D. ..... University of California, San Francisco
Plate, Janet, M.D., Ph.D. ..... Rush University Medical Center
Porter, Peggy L., M.D. ..... Fred Hutchinson Cancer Research Center

Q

Quaranta, Vito, M.D. ..... Vanderbilt University

R

Rademaker, Alfred W., Ph.D. ..... Northwestern University
Rader, Janet S., M.D. ..... Medical College of Wisconsin
Ratliff, Timothy L., Ph.D. ..... Purdue University, West Lafayette
Reid, Mary E., Ph.D. ..... Roswell Park Cancer Institute
Remick, Scot C., M.D. ..... West Virginia University
Ritz, Jerome, M.D. ..... Dana-Farber Cancer Institute
Roberson, Paula K., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Rosenblatt, Joseph D., M.D. ..... University of Miami School of Medicine
Ryan, James C., M.D. ..... Northern California Institute of Research & Education

S

Sacks, Peter G., Ph.D. ..... New York University
Santana, Victor M., M.D. ..... St. Jude Children's Research Hospital
Sarkaria, Jann N., M.D. ..... Mayo Clinic
Schiller, Joan H., M.D. ..... The University of Texas, Dallas
Schuchter, Lynn M., M.D. ..... The University of Pennsylvania
Schwartz, Ann G., Ph.D., M.P.H. ..... Wayne State University
Seewaldt, Victoria L., M.D. ..... Duke University
Seither, Richard L., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Serody, Jonathan S., M.D. ..... The University of North Carolina at Chapel Hill
Shimizu, Yoji, Ph.D. ..... University of Minnesota, Twin Cities
Showe, Louise C., Ph.D. ..... Wistar Institute
Shull, James D., Ph.D. ..... University of Wisconsin, Madison
Shyr, Yu, Ph.D. ..... Vanderbilt University
Siegfried, Jill M., Ph.D. ..... University of Pittsburgh at Pittsburgh
Slovin, Susan F., M.D, Ph.D. ..... Sloan-Kettering Institute for Cancer Research
Small, Eric J., M.D. ..... University of California, San Francisco

Smith, David I., Ph.D. ..... Mayo Clinic
Speicher, David W., Ph.D. ..... Wistar Institute
Stadler, Walter M., M.D. ..... The University of Chicago
Stahl, Douglas C., Ph.D. ..... City of Hope National Medical Center
Stauffacher, Cynthia V., Ph.D. ..... Purdue University, West Lafayette
Sukumar, Saraswati, Ph.D. ..... The Johns Hopkins University

T

Tew, Kenneth D., Ph.D. ..... Medical University of South Carolina
Thomas, Melanie B., M.D. ..... Medical University of South Carolina
Trimble, Cornelia L., M.D. ..... The Johns Hopkins University
Tycko, Benjamin, M.D, Ph.D. ..... Gordon Research Conferences

V

Vail, David M., D.V.M. ..... University of Wisconsin, Madison
Van Breemen, Richard B., Ph.D. ..... University of Illinois at Chicago
Van Etten, Richard A., M.D., Ph.D. ..... Tufts Medical Center
Vannier, Michael W., M.D. ..... The University of Chicago
Villalona-Calero, Miguel A., M.D. ..... The Ohio State University

W

Waller, Edmund K., M.D., Ph.D. ..... Emory University
Wang, Jean Y.J., Ph.D. ..... Kosan Biosciences, Inc.
Wei, Wei-Zen, Ph.D. ..... Wayne State University
Weichert, Jamey P., Ph.D. ..... University of Wisconsin, Madison
Weiner, George J., M.D. ..... University of Iowa
Weiner, Louis M., M.D. ..... Georgetown University
Weiss, Geoffrey R., M.D. ..... University of Virginia, Charlottesville
Welch, Danny R., Ph.D. ..... University of Kansas Medical Center
Wetzler, Meir, M.D. ..... Roswell Park Cancer Institute
Wheatley, Bonnie P., Ed.D. ..... Alameda County Medical Center
Wheeler, David A., Ph.D. ..... Baylor College of Medicine
Wicha, Max S., M.D. ..... University of Michigan, Ann Arbor
Wilburn, Louella S., M.A. ..... People Living With Cancer
Wilding, George, M.D. ..... University of Wisconsin, Madison
Wiley, Patti, M.B.A. ..... On the Wings of Angels
Willett, Christopher G., M.D. ..... Duke University
Wilson-Sanders, Susan E., D.V.M. ..... The University of Arizona

Y

Yee, Douglas, M.D. ..... The University of Minnesota
Yen, Yun, M.D., Ph.D. ..... Beckman Research Institute of City of Hope

Total number of Reviewers: 213

3. Consultants Serving on Special Emphasis Panels (SEPs) in FY2011

A

Aagaard-Tillery, Kjersti M., M.D., Ph.D. ..... Baylor College of Medicine
Abdulkadir, Sarki A., M.D., Ph.D. ..... Vanderbilt University
Abounader, Roger, M.D., Ph.D. ..... University of Virginia
Adams, Mary L., Ph.D. ..... The University of Texas, Austin
Adams, Swann A., Ph.D. ..... University of South Carolina, Columbia
Adams-Campbell, Lucile L., Ph.D. ..... Georgetown University
Agarwal, Rajesh, Ph.D. ..... University of Colorado, Denver
Aguilar-Cordova, Estuardo, Ph.D. ..... Advantagene, Inc.
Agus, David B., M.D. ..... The University of Southern California
Ahmed, Farid E., Ph.D. ..... GEM Tox Consultants & Labs, Inc.
Ahsan, Habibul, M.D. ..... Columbia University
Ain, Kenneth B., M.D. ..... University of Kentucky
Ajani, Jaffer A., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Akala, Emmanuel O., Ph.D. ..... The University of Utah
Akman, Steven A., M.D. ..... Wake Forest University
Al'Absi, Mustafa N., Ph.D. ..... The University of Minnesota, Twin Cities
Albertson, Donna G., Ph.D. ..... University of California, San Francisco
Albright, Lisa C., Ph.D. ..... The University of Utah
Alexandrow, Mark G., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Alfred, Lawrence, Ph.D. ..... San Diego State University
Ali, M.D. Meser, Ph.D. ..... Henry Ford Health System
Ali-Osman, Francis, D.Sc. ..... Duke University School of Medicine
Alter, Orly, Ph.D. ..... The University of Utah
Altomare, Deborah A., Ph.D. ..... University of Central Florida
Anandasabapathy, Sharmila, M.D. ..... Mount Sinai School of Medicine
Anant, Shrikant, Ph.D. ..... The University of Kansas Medical Center
Andersen, Barbara L., Ph.D. ..... The Ohio State University
Anderson, Garth R., Ph.D. ..... Roswell Park Cancer Institute
Anderson, James K., M.D. ..... The University of Minnesota, Twin Cities
Anderson, Michael E., Ph.D. ..... University of Hartford
Anderson, Richard A., Ph.D. ..... University of Wisconsin, Madison
Anderson, Roger T., Ph.D. ..... The Pennsylvania State University
Anderson, Stewart J., Ph.D. ..... The University of Pittsburgh
Andrisani, Ourania M., Ph.D. ..... Indiana University-Purdue University Indianapolis
Aplin, Andrew E., Ph.D. ..... Thomas Jefferson University
Applegate, Bradford W., Ph.D. ..... Personal Improvement Computer Systems
Arceci, Robert J., M.D., Ph.D. ..... The Johns Hopkins University
Archer, Donald G., Ph.D. ..... National Institute of Standards and Technology
Archer, Kellie J., Ph.D. ..... Virginia Commonwealth University
Arenaz, Pablo, Ph.D. ..... Texas A&M International University
Argenbright, Keith E., M.D. ..... The University of Texas Southwestern Medical School, Dallas
Armato, Samuel G., Ph.D. ..... The University of Chicago
Arnold, Connie L., Ph.D. ..... Louisiana State University, Shreveport

Ashendel, Curtis L., Ph.D. ..... Purdue University, West Lafayette
Ashikaga, Takamaru, Ph.D. ..... The University of Vermont
Ashing-Giwa, Kimlin T., Ph.D. ..... University of California, Los Angeles
Ashktorab, Hassan, Ph.D. ..... Howard University
Asmann, Yan W., Ph.D. ..... Mayo Clinic
Aspinall, Mara G., M.B.A. ..... On-Q-Ity
Assoian, Richard, Ph.D. ..... The University of Pennsylvania
Asthagiri, Anand R., Ph.D. ..... Northeastern University
Atasoy, Ulus, M.D. ..... University of Missouri, Columbia
Au, Jessie L.S., Pharm.D., Ph.D. ..... Optimum Therapeutics, LLC
Auerbach, Robert, Ph.D. ..... University of Wisconsin, Madison
Augenlicht, Leonard H., Ph.D. ..... Montefiore Medical Center
Austin, Robert H., Ph.D. ..... Princeton University
Ayala, Gustavo, M.D. ..... The University of Texas Health Science Center, Houston

B

Bachmann, Andre S., Ph.D. ..... University of Hawaii at Hilo
Backman, Vadim, Ph.D. ..... Northwestern University
Badawi, Ramsey D., Ph.D. ..... University of California, Davis
Badger, Terry A., R.N., Ph.D. ..... The University of Arizona
Baehrecke, Eric H., Ph.D. ..... University of Massachusetts Medical School, Worcester
Baer, Maria R., M.D. ..... University of Maryland, Baltimore
Bahjat, Keith, Ph.D. ..... Providence Portland Medical Center
Bailey, Howard H., M.D. ..... University of Wisconsin, Madison
Bailey-Wilson, Joan E., Ph.D. ..... National Human Genome Research Institute
Bains, Sarjit S. ..... MarkPap India, LLC
Baker, David C., M.D., Ph.D. ..... The University of Tennessee, Knoxville
Baker, Dewleen G., M.D. ..... Veterans Medical Research Foundation
Balazsi, Gabor, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Balch, Royal C., Ph.D. ..... Indiana University
Baldwin, Dee M., Ph.D., R.N., F.A.A.N. ..... University of North Carolina at Charlotte
Balgley, Brian M., Ph.D. ..... Bioproximity, LLC
Ballman, Karla V., Ph.D. ..... Mayo Clinic
Balogh, Lajos P., Ph.D. ..... Roswell Park Cancer Institute
Bandos, Andriy, Ph.D. ..... The University of Pittsburgh
Banerjee, Sushanta K., Ph.D. ..... Kansas City VA Medical Center
Bankson, James A., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Bansal, Navin, Ph.D. ..... Indiana University-Purdue University Indianapolis
Baranowski, Tom, Ph.D. ..... Baylor College of Medicine
Barcellos-Hoff, Mary H., Ph.D. ..... New York University School of Medicine
Barker, Peter E., Ph.D. ..... National Institute of Standards and Technology
Barrett, Michael T., Ph.D. ..... Translational Genomics Research Institute
Barrett, Terrence A., M.D. ..... Northwestern University
Bar-Sagi, Dafna, Ph.D. ..... New York University School of Medicine
Bartolomei, Marisa S., Ph.D. ..... The University of Pennsylvania
Barton, Jennifer K., Ph.D. ..... The University of Arizona
Basu, Hirak S., Ph.D. ..... University of Wisconsin, Madison

Batra, Surinder K., Ph.D. ..... University of Nebraska Medical Center
Baumann, William T., Ph.D. ..... Virginia Technologies, Inc.
Baxter, Nancy N., M.D., Ph.D. ..... St. Michael's Hospital
Baxter-Lowe, Lee A., Ph.D. ..... Palmetto Health, Richland
Beck, John R., M.D. ..... Fox Chase Cancer Center
Beck, William T., Ph.D. ..... University of Illinois at Chicago
Becker, Dorothea, Ph.D. ..... The University of Pittsburgh
Beckman, Robert A., M.D., Ph.D. ..... Daiichi-Sankyo Pharma Development
Bednar, Bohumil, Ph.D. ..... Merck Research Laboratories
Beemon, Karen L., Ph.D. ..... The Johns Hopkins University
Belbin, Thomas J., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Belfort, Marlene, Ph.D. ..... The State University of New York, Albany
Bellamy, Scarlett, Sc.D. ..... The University of Pennsylvania
Bellen, Hugo J., D.V.M., Ph.D. ..... Baylor College of Medicine
Bemis, Lynne T., Ph.D. ..... University of Colorado, Denver
Benchimol, Samuel, Ph.D. ..... York University
Beningo, Karen A., Ph.D. ..... Wayne State University
Bennett, Charles L., M.D., Ph.D. ..... University of South Carolina, Columbia
Berens, Michael E., Ph.D. ..... Translational Genomics Research Institute
Berenson, James R., M.D. ..... Cedars-Sinai Medical Center
Beretta, Laura, Ph.D. ..... Fred Hutchinson Cancer Research Center
Berezin, Mikhail Y., Ph.D. ..... Washington University
Bergen, Harold R., Ph.D. ..... Mayo Proteomic Research Center
Berger, Franklin G., Ph.D. ..... University of South Carolina, Columbia
Berger, Mitchel S., M.D. ..... University of California, San Francisco
Berger, Nathan A., D.V.M., M.D. ..... Case Western Reserve University
Berget, Peter B., Ph.D. ..... University of the Sciences, Philadelphia
Berry, Donna L., M.S.N., R.N., Ph.D. ..... Dana-Farber Cancer Institute
Bhowmick, Neil A., Ph.D. ..... Cedars-Sinai Medical Center
Bible, Keith C., M.D., Ph.D. ..... Mayo Clinic
Bickell, Nina A., M.D. ..... Mount Sinai School of Medicine
Bigatti, Silvia M., Ph.D. ..... Indiana University-Purdue University Indianapolis
Bikram, Malavosklish, Ph.D. ..... University of Houston
Bishayee, Anupam, Ph.D. ..... American University of Health Sciences
Blackstock, Arthur W., M.D. ..... Wake Forest University Health Sciences
Blezek, Daniel, Ph.D. ..... Mayo Clinic
Bloom, Joan R., Ph.D. ..... University of California, Berkeley
Bocan, Thomas M., Ph.D. ..... Pfizer, Inc.
Bock, Beth C., Ph.D. ..... Miriam Hospital
Bock, Cathryn H., Ph.D., M.P.H. ..... Wayne State University
Bogdanov, Alexei A., D.Sc., Ph.D. ..... University of Massachusetts Medical School, Worcester
Bogen, Steven A., M.D., Ph.D. ..... Medical Discovery Partners, LLC
Bolick, Michael, B.S. ..... Selah Technologies, LLC
Bolton, Philip H., Ph.D. ..... Wesleyan University
Bolwell, Brian, M.D. ..... Cleveland Clinic Foundation
Boman, Bruce M., M.D., Ph.D. ..... Christiana Care Health Services, Inc.

Boothman, David A., Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Bosenberg, Marcus W., M.D., Ph.D. ..... Yale University
Boucher, Yves, Ph.D. ..... Massachusetts General Hospital
Bowers, William J., Ph.D. ..... Vaccinex, Inc.
Boyd, Jeffrey, Ph.D. ..... Fox Chase Cancer Center
Boyd, Norman F., Sc.D., M.D. ..... Ontario Cancer Institute
Boysen, Gunnar, Ph.D. ..... University of Arkansas, Little Rock
Brace, Christopher L., Ph.D. ..... University of Wisconsin, Madison
Braithwaite, Dejana K., Ph.D. ..... University of California, San Francisco
Bram, Richard J., M.D., Ph.D. ..... Mayo Clinic
Brat, Daniel J., M.D., Ph.D. ..... Emory University
Braun, Latoya J., Ph.D. ..... University of Colorado, Denver
Brem, Steven, M.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Brenan, Colin J.H., Ph.D. ..... CB Bioventures, LLC
Brent, Roger, Ph.D. ..... Fred Hutchinson Cancer Research Center
Brewer, Molly A., D.V.M., M.D. ..... University of Connecticut Health Center
Bridges, John F.P., Ph.D. ..... The Johns Hopkins University
Briley, Margaret E., Ph.D. ..... The University of Texas, Austin
Broaddus, William C., M.D., Ph.D. ..... Virginia Commonwealth University
Broccoli, Dominique, Ph.D. ..... Memorial Health University Medical Center, Inc.
Brockbank, Kelvin G.M., Ph.D. ..... Cell and Tissue Systems, Inc.
Brockhausen, Inka, Ph.D. ..... Queen's University
Broderson, Hal S., M.D., M.B.A. ..... Rock Hill Ventures
Brodie, Angela M., Ph.D. ..... University of Maryland, Baltimore
Broeders, Mireille, Ph.D. ..... Radboud University Nijmegen Medical Center
Brosh, Robert M., Ph.D. ..... National Institute on Aging
Brown, Elizabeth, Ph.D., M.P.H. ..... University of Alabama, Birmingham
Brown, Kathlynn C., Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Bruce, Richard H., Ph.D. ..... Xerox Corporation
Bu, Zimei, Ph.D. ..... City College of New York
Buatti, John M., M.D. ..... The University of Iowa
Buchsbaum, Donald J., Ph.D. ..... University of Alabama at Birmingham
Budman, Simon H., Ph.D. ..... Inflexxion, Inc.
Bunn, Janice Y., Ph.D. ..... The University of Vermont & State Agricultural College
Buolamwini, John K., Ph.D. ..... University of Tennessee Health Science Center
Burdette, Everette C., Ph.D. ..... Acoustic Medical Systems, LLC
Burk, Robert D., M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Burke, Harry B., M.D., Ph.D. ..... George Washington University
Burke, Peter J., Ph.D. ..... University of California, Irvine
Burt, Randall W., M.D. ..... The University of Utah
Bush, Jason A., Ph.D. ..... California State University, Fresno
Byers, Stephen W., Ph.D. ..... Georgetown University
Bylund, Carma L., Ph.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Byrd, John C., M.D., Ph.D. ..... The Ohio State University

C

Caffrey, Michael S., Ph.D. ..... University of Illinois at Chicago
Cairns, Paul, Ph.D. ..... Fox Chase Cancer Center
Cairo, Mitchell S., M.D. ..... New York Medical College
Calado, Rodrigo, M.D., Ph.D. ..... National Heart, Lung, and Blood Institute
Calderwood, Stuart K., Ph.D. ..... Boston University Medical Campus
Calin, George A., M.D., Ph.D. ..... The Johns Hopkins University
Callas, Peter, Ph.D. ..... The University of Vermont
Campbell, Catherine E., Ph.D. ..... Noblis, Inc.
Campbell, Christine, D.Sc., M.P.H. ..... University of Edinburgh
Campbell, Janis E., Ph.D. ..... University of Oklahoma Health Sciences Center
Cancelas, Jose A., M.D., Ph.D. ..... Children's Hospital Medical Center, Cincinnati
Canto, Marcia I., M.D. ..... The Johns Hopkins University
Capobianco, Anthony J., Ph.D. ..... University of Miami School of Medicine
Carey, Robert M., B.S. ..... RPC Associates, Inc.
Carlin, Bradley P., Ph.D. ..... The University of Minnesota, Twin Cities
Carpenter, Everett E., Ph.D. ..... Virginia Commonwealth University
Carraway, Kermit L., Ph.D. ..... University of California, Davis
Carroll, Martin, M.D. ..... The Children's Hospital of Philadelphia
Carroll, William L., M.D. ..... New York University School of Medicine
Carter, Gregory W., Ph.D. ..... The Jackson Laboratory
Casillas, Jacqueline, M.D. ..... University of California, Los Angeles
Castor, Trevor P., Ph.D. ..... Aphios Corporation
Cavalli, Luciane R., Ph.D. ..... Georgetown University
Celebi, Julide T., M.D. ..... Columbia University
Chak, Amitabh, M.D. ..... Case Western Reserve University
Chambers, Setsuko K., M.D. ..... The University of Arizona
Champlin, Richard E., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Chan, Christina, Ph.D. ..... Metagenx, LLC
Chang, Chawnshang, Ph.D. ..... University of Rochester
Chang, Chien Hsing K., M.D., Ph.D. ..... Immunomedics, Inc.
Chang, Jenny C.N., M.D. ..... Methodist Hospital Research Institute
Chang, Shine, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Chaplin, David D., M.D., Ph.D. ..... University of Alabama at Birmingham
Charest, Joseph L., Ph.D. ..... Charles Stark Draper Laboratory
Chase, Diane Z., R.N., M.S.N. ..... National Breast Cancer Coalition
Chatham, John C., Ph.D. ..... University of Alabama at Birmingham
Chaurand, Pierre, Ph.D. ..... University of Montreal
Chellappan, Srikumar P., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Chen, Ming-Hui, Ph.D. ..... University of Connecticut, Storrs
Chen, Moon S.C., Ph.D., M.P.H. ..... University of California, Davis
Chen, Suzie, Ph.D. ..... Rutgers, The State University of New Jersey
Chen, Thomas C., M.D., Ph.D. ..... The University of Southern California
Chen, Wei, Ph.D. ..... The University of Minnesota, Twin Cities
Chen, Xinbin, D.V.M., Ph.D. ..... University of California, Davis
Chen, Yu, Ph.D. ..... Massachusetts Institute of Technology
Chenevert, Thomas L., Ph.D. ..... University of Michigan at Ann Arbor

Cheng, Iona, Ph.D., M.P.H. ..... University of Hawaii
Cheng, Jin Q., M.D., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Cheng, Liang, M.D. ..... Indiana University
Cheng, Shi-Yuan, Ph.D. ..... The University of Pittsburgh
Chesney, Jason A., M.D., Ph.D. ..... University of Louisville
Chia, David S., Ph.D. ..... University of California, Los Angeles
Chiles, Thomas C., Ph.D. ..... Boston College
Chilton, Beverly S., Ph.D. ..... Texas Tech University
Chiocca, E. Antonio, M.D., Ph.D. ..... The Ohio State University
Chiu, Daniel T., Ph.D. ..... University of Washington
Cho, Hyunyi, Ph.D. ..... Purdue University, West Lafayette
Cho, Michael W., Ph.D. ..... Iowa State University
Chu, Wei-Sing, M.D. ..... American Registry of Pathology, Inc.
Chung, Fung-Lung, Ph.D. ..... Georgetown University
Chung, Leland W.K., Ph.D. ..... Cedars-Sinai Medical Center
Ciccolo, Joseph T., Ph.D. ..... Brown University
Claffey, Kevin P., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Clark, Douglas P., M.D. ..... The Johns Hopkins University
Clawson, Gary A., M.D., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center
Clay, Tim, Ph.D. ..... Duke University
Cleary, Kevin R., Ph.D. ..... Children's Research Institute
Cleary, Margot P., Ph.D. ..... The University of Minnesota, Austin
Clinton, Steven K., M.D., Ph.D. ..... The Ohio State University
Cochran, Brent H., Ph.D. ..... Tufts University, Boston
Cody, Dianna D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Cohen, Eric P., M.D. ..... Medical College of Wisconsin
Cohn, Wendy F., Ph.D. ..... University of Virginia, Charlottesville
Collins, Scott D., Ph.D. ..... The University of Maine, Orono
Comenzo, Raymond L., M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Cooney, Robert, Ph.D. ..... University of Hawaii at Manoa
Cooper, Laurence J.N., M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Copland, John A., Ph.D. ..... Mayo Clinic, Jacksonville
Corey, Linda A., Ph.D. ..... Virginia Commonwealth University
Corey, Seth J., M.D., M.P.H. ..... Northwestern University
Cote, Michele L., Ph.D. ..... Wayne State University
Cote, Richard J., M.D. ..... University of Miami School of Medicine
Coups, Elliot J., Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Covey, Todd, Ph.D. ..... Nodality, Inc.
Cox, Nancy J., Ph.D. ..... The University of Chicago
Cozen, Wendy, M.P.H. ..... The University of Southern California
Craft, Noah A., M.D., Ph.D. ..... Los Angeles Biomedical Research Institute/Harbor University of California, Los Angeles Medical Center
Crawford, Howard C., Ph.D. ..... The State University of New York at Stony Brook
Crawford, Jason, Ph.D. ..... Centre for Drug Research and Development
Crawford, Sybil L., Ph.D. ..... University of Massachusetts Medical School, Worcester
Cress, Anne, Ph.D. ..... The University of Arizona
Cronan, Thereasa A., Ph.D. ..... San Diego State University

Crott, Jimmy W., Ph.D. ..... Tufts University, Boston
Crum, Lawrence A., Ph.D. ..... University of Washington
Csiszar, Katalin, Ph.D. ..... University of Hawaii at Manoa
Cui, Hengmi, Ph.D. ..... The Johns Hopkins University
Cullen, Kevin J., M.D. ..... University of Maryland, Baltimore
Cunningham, John M., M.D. ..... The University of Chicago
Curbow, Barbara A., Ph.D. ..... University of Florida
Curley, Steven A., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Czerniak, Bogdan A., M.D., Ph.D. ..... The University of Texas Health Science Center, Houston

D

Dadachova, Ekaterina, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
D'Agostino, Ralph B., Ph.D. ..... Wake Forest University Health Sciences
Dahiya, Rajvir, Ph.D. ..... Northern California Institute for Research and Education
Dai, Qi, M.D., Ph.D. ..... Vanderbilt University
Dambrosio, Steven M., Ph.D. ..... The Ohio State University
Darst, Seth A., Ph.D. ..... Rockefeller University
Dash, Srikanta, Ph.D. ..... Tulane University
Daskalakis, Constantine, Sc.D. ..... Thomas Jefferson University
Datye, Abhaya K., Ph.D. ..... The University of New Mexico
Davidian, Marie, Ph.D. ..... North Carolina State University
Davidoff, Andrew M., M.D. ..... St. Jude Children's Research Hospital
Davidson, Nancy E., M.D. ..... The University of Pittsburgh
Day, Roger S., Sc.D. ..... The University of Pittsburgh
DeAngelis, Lisa M., M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Debinski, Waldemar, M.D., Ph.D. ..... Wake Forest University Health Sciences
DeCaprio, Anthony P., Ph.D. ..... Florida International University
DeCoster, Mark A., Ph.D. ..... Louisiana State University Health Science Center, New Orleans
Deeg, H. Joachim, M.D. ..... Fred Hutchinson Cancer Research Center
Delehanty, James B., Ph.D. ..... U.S. Naval Research Laboratory
Del Valle, Juan R., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Dembo, Micah, Ph.D. ..... Boston University
Demetriou, Michael, M.D., Ph.D. ..... University of California, Irvine
Demirci, Utkan, Ph.D. ..... Brigham and Women's Hospital
Denis, Gerald V., Ph.D. ..... Boston University Medical Campus
Denko, Nicholas C., M.D., Ph.D. ..... Stanford University
Dent, Sharon R., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
DePinho, Ronald A., M.D. ..... The University of Texas M.D. Anderson Cancer Center
De Roos, Anneclaire J., Ph.D., M.P.H. ..... Fred Hutchinson Cancer Research Center
Desai, Pankaj B., Ph.D. ..... The University of Cincinnati
Deutsch, Walter A., Ph.D. ..... Louisiana State University Pennington Biomedical Research Center
De Vere White, Ralph W., M.D. ..... University of California, Davis
De Winter, Alex, Ph.D. ..... Mohr Davidow Ventures
Dhodapkar, Madhav V., M.B.B.S. ..... Yale University
Diamond, Alan, Ph.D. ..... University of Illinois at Chicago

Diehl, Michael R., Ph.D. ..... Rice University
Diem, Max, Ph.D. ..... Northeastern University
Dignan, Mark B., Ph.D., M.P.H. ..... University of Kentucky
Ding, George X., Ph.D. ..... Vanderbilt University
Ding, Wei-Qun, Ph.D. ..... University of Oklahoma Health Sciences Center
DiPersio, C. Michael, Ph.D. ..... Albany Medical College
Dittmer, Dirk P., Ph.D. ..... University of North Carolina at Chapel Hill
Divine, George W., Ph.D. ..... Henry Ford Health System
Dobkin, Carlos E., Ph.D. ..... University of California, Santa Cruz
Dobs, Adrian S., M.D., M.H.S. ..... The Johns Hopkins University
Doetsch, Paul W., Ph.D. ..... Emory University
Doherty, Gerard M., M.D. ..... Boston University
Doktycz, Mitchel, Ph.D. ..... Oak Ridge National Laboratory
Dolginow, Doug, M.D. ..... Ninth Sense
Dolnick, Bruce J., Ph.D. ..... Roswell Park Cancer Institute
D'Onofrio, Carol N., M.P.H., Ph.D. ..... University of California, Berkeley
Dooley, William C., M.D. ..... University of Oklahoma Health Sciences Center
Dorai, Haimanti, Ph.D. ..... Centocor Biologics
Dorrestein, Pieter C., Ph.D. ..... University of California, San Diego
Doyle, Terrence W., Ph.D. ..... Vion Pharmaceuticals, Inc.
Drabkin, Harry A., M.D. ..... Medical University of South Carolina
Dragnev, Konstantin H., M.D. ..... Dartmouth-Hitchcock Medical Center
Drake, Richard R., Ph.D. ..... Medical University of South Carolina
Drees, Beth E., Ph.D. ..... The University of Utah
Dritschilo, Anatoly, M.D. ..... Georgetown University
Dubbs, Robert M., M.B.A. ..... Obermayer Rebmann Maxwell & Hippel LLP
Dubeau, Louis, M.D., Ph.D. ..... The University of Southern California
Dubinett, Steven M., M.D. ..... VA Greater Los Angeles Healthcare System
Ducatman, Barbara S., M.D. ..... West Virginia University
Dudley, Donald J., M.D. ..... The University of Texas Health Science Center, San Antonio
Duffy, David C., Ph.D. ..... Twin Lights Bioscience, Inc.
Dupont, Pierre E., Ph.D. ..... Children's Hospital Boston
Dustin, Michael L., Ph.D. ..... New York University School of Medicine
Dvorak, Katerina, Ph.D. ..... The University of Arizona
Dzenis, Yuris A., Ph.D. ..... University of Nebraska, Lincoln

E

Eckert, Kristin A., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center
Eckert, Richard L., Ph.D. ..... University of Maryland, Baltimore
Eder, Joseph P., M.D. ..... Dana-Farber Cancer Institute
Edgerton, Mary E., M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Edwards, D. Scott, Ph.D. ..... Chemistry Solutions
Edwards, Jeremy S., Ph.D. ..... The University of New Mexico Health Sciences Center
Einstein, Andrew, M.D., Ph.D. ..... Columbia University
Elber, Ron, Ph.D. ..... The University of Texas, Austin
El-Deiry, Wafik S., M.D., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center

Elder, David E., M.D. ..... The University of Pennsylvania
Eliason, James F., Ph.D. ..... Wayne State University
Elkin, Elena B., Ph.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Elliott, John T., Ph.D. ..... National Institute of Standards and Technology
Elmer, Patricia J., Ph.D. ..... National College of Naturopathic Medicine
Elson, Paul J., Sc.D. ..... Cleveland Clinic Foundation
Emanuel, Peter D., M.D. ..... University of Arkansas, Little Rock
Emelianov, Stanislav Y., Ph.D. ..... The University of Texas, Austin
Emerson, Jane, M.D., Ph.D. ..... The University of Southern California
Emrick, Todd S., Ph.D. ..... University of Massachusetts, Amherst
Enders, Gregory H., M.D., Ph.D. ..... Fox Chase Cancer Center
Enns, Caroline, Ph.D. ..... Oregon Health and Science University
Erdei, Esther, Ph.D. ..... The University of New Mexico Health Sciences Center
Erdman, Susan E., D.V.M., M.P.H. ..... Massachusetts Institute of Technology
Erdmann, Christine A., Ph.D., M.P.H. ..... Medical University of the Americas
Esterowitz, Leon, Ph.D. ..... National Science Foundation
Evans, Lyndon V., R.N. ..... Cancer Centers of the Carolinas
Evers, Bernard M., M.D. ..... The University of Kentucky
Evers, Kerry, Ph.D. ..... Pro-Change Behavior Systems, Inc.

F

Fagin, James A., M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Fain, Sean B., Ph.D. ..... University of Wisconsin, Madison
Falk-Krzesinski, Holly J., Ph.D. ..... Northwestern University
Fan, Z. H., Ph.D. ..... University of Florida
Farag, Sherif S., M.D., Ph.D. ..... Indiana University-Purdue University Indianapolis
Feigelson, Heather S., Ph.D., M.P.H. ..... Kaiser Foundation Health Clinic Research Unit
Feinleib, Manning, M.D., Ph.D. ..... The Johns Hopkins Bloomberg School of Public Health
Felsburg, Peter J., D.V.M., Ph.D. ..... The University of Pennsylvania
Fennessy, Fiona, M.D., Ph.D. ..... Brigham and Women's Hospital
Fernander, Anita F., Ph.D. ..... The University of Kentucky
Fernandez-Esquer, Maria E., Ph.D. ..... The University of Texas Health Science Center, Houston
Fero, Matthew L., M.D. ..... Fred Hutchinson Cancer Research Center
Ferrando, Adolfo A., M.D., Ph.D. ..... Columbia University
Ferrone, Soldano, M.D., Ph.D. ..... The University of Pittsburgh
Fields, Alan P., Ph.D. ..... Mayo Clinic
Figueiredo, Jane C., Ph.D. ..... The University of Southern California
Fine, Jason, Sc.D. ..... University of Wisconsin, Madison
Fisher, Susan G., Ph.D. ..... University of Rochester
Fishman, David A., M.D. ..... Mount Sinai School of Medicine
Flemington, Erik K., Ph.D. ..... Tulane University
Flores, Sonia C., Ph.D. ..... University of Colorado, Denver
Fobair, Patricia A., M.P.H. ..... Stanford University
Foldvari, Marianna, Ph.D. ..... University of Waterloo
Fong, Lawrence, M.D. ..... University of California, San Francisco
Ford, John C., Ph.D. ..... Self-Employed
Foreman, Kimberly E., Ph.D. ..... Loyola University, Chicago

Forrest, Laird, Ph.D. ..... University of Kansas, Lawrence
Forry, Sam, Ph.D. ..... National Institute of Standards and Technology
Foss, Francine M., M.D. ..... Yale University
Foster, David A., Ph.D. ..... City University of New York
Fox, Bernard A., Ph.D. ..... Ubivac, LLC
Francino, Maria P., Ph.D. ..... Lawrence Berkeley National Laboratory
Franck, Richard W., Ph.D. ..... Hunter College
Frank, David A., M.D., Ph.D. ..... Dana-Farber Cancer Institute
Franklin, Wilbur A., M.D. ..... University of Colorado, Denver
Franz, Katherine J., Ph.D. ..... Duke University
Freeman, Burgess B., Pharm.D. ..... St. Jude Children's Research Hospital
Freeman, James W., Ph.D. ..... The University of Texas Health Science Center, San Antonio
Freitas, Michael A., Ph.D. ..... The Ohio State University
Freyer, James P., Ph.D. ..... The University of New Mexico
Fridman, Rafael A., Ph.D. ..... Wayne State University
Friedberg, Jonathan W., M.D. ..... University of Rochester
Friedl, Andreas, M.D. ..... University of Wisconsin, Madison
Friedman, Daniela, Ph.D. ..... University of South Carolina, Columbia
Friedman, Henry S., M.D. ..... Duke University
Fu, Bingmei M., Ph.D. ..... City College of New York
Fuchs, Serge Y., M.D., Ph.D. ..... The University of Pennsylvania
Fueyo, Juan, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Fujii, Naoaki, Ph.D. ..... St. Jude Children's Research Hospital
Fujimoto, James G., Ph.D. ..... Massachusetts Institute of Technology
Fukumura, Dai, M.D., Ph.D. ..... Massachusetts General Hospital
Fuller, Patrick M., Ph.D. ..... Beth Israel Deaconess Medical Center
Fung, Leslie W., Ph.D. ..... University of Illinois at Chicago
Fuqua, Suzanne A.W., Ph.D. ..... Baylor College of Medicine
Furdui, Cristina, Ph.D. ..... Wake Forest University
Furge, Kyle A., Ph.D. ..... Van Andel Research Institute
Furgeson, Darin Y., Ph.D. ..... The University of Utah
Furth, Priscilla A., M.D. ..... Georgetown University

G

Gabeau, Darlene, M.D., Ph.D. ..... Montefiore Medical Center
Gabrilove, Janice L., M.D. ..... Mount Sinai School of Medicine
Gafken, Philip R., Ph.D. ..... Fred Hutchinson Cancer Research Center
Galipeau, Jacques, M.D. ..... Emory University
Gallick, Gary E., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Galloway, Robert L., Ph.D. ..... Vanderbilt University
Gammon, Marilie D., Ph.D. ..... University of North Carolina, Chapel Hill
Ganapathi, Ram N., Ph.D. ..... Cleveland Clinic Foundation
Gannett, Peter M., Ph.D. ..... West Virginia University
Garbow, Joel R., Ph.D. ..... Washington University
Garcia, Benjamin A., Ph.D. ..... Princeton University
Garcia, Montse, Ph.D. ..... Catalan Institute of Oncology

Garg, Kavita, M.D. ..... University of Colorado, Denver
Gartenhaus, Ronald B., M.D. ..... University of Maryland, Baltimore
Gaskins, H. Rex, Ph.D. ..... University of Illinois at Urbana-Champaign
Gaston, Sandra M., Ph.D. ..... Beth Israel Deaconess Medical Center
Gatley, Samuel J., Ph.D. ..... Northeastern University
Gatsonis, Constantine A., Ph.D. ..... Brown University
Gau, Vincent J., Ph.D. ..... Genefluidics, Inc.
Gaudet, Mia M., Ph.D. ..... American Cancer Society, Inc.
Gavai, Ashvinikumar, Ph.D. ..... Bristol-Myers Squibb Pharmaceutical Research
Gellibolian, Robert, Ph.D. ..... N-Abl Therapeutics, Inc.
Gendler, Sandra J., Ph.D. ..... Mayo Clinic
Georganopoulou, Dimitra, Ph.D. ..... Ohmx Corporation
Gerber, Scott A., Ph.D. ..... Dartmouth College
Gerend, Mary A., Ph.D. ..... Florida State University
Gerson, Lauren B., M.D. ..... Stanford University
Geyer, Susan M., Ph.D. ..... The Ohio State University
Ghosh, Debashis, Ph.D. ..... The Pennsylvania State University, University Park
Giaccia, Amato J., Ph.D. ..... Stanford University
Gibson, Raymond E., Ph.D. ..... Gibson Consulting
Gibson, Spencer B., Ph.D. ..... University of Manitoba
Gillen, Daniel L., Ph.D. ..... University of California, Irvine
Gillies, Stephen D., Ph.D. ..... Provenance Biopharmaceuticals Corporation
Gimotty, Phyllis A., Ph.D. ..... The University of Pennsylvania
Gines, Venus M., M.A. ..... Baylor College of Medicine
Gite, Sadanand, Ph.D. ..... First Light Biosciences, Inc.
Gladson, Candece L., M.D. ..... Cleveland Clinic Foundation
Glass, Charles A., Ph.D. ..... Zacharon Pharmaceuticals, Inc.
Glazier, James A., Ph.D. ..... Indiana University, Bloomington
Glickson, Jerry D., Ph.D. ..... The University of Pennsylvania
Glorioso, Joseph C., Ph.D. ..... The University of Pittsburgh
Glucksman, Marc J., Ph.D. ..... Rosalind Franklin University of Medicine & Science
Glueck, Deborah H., Ph.D. ..... University of Colorado, Denver
Glunde, Kristine, Ph.D. ..... The Johns Hopkins University
Gmitro, Arthur F., Ph.D. ..... The University of Arizona
Godley, Lucy A., M.D., Ph.D. ..... The University of Chicago
Goggins, Michael G., M.D. ..... The Johns Hopkins University
Goldberg, Judith D., Sc.D. ..... New York University School of Medicine
Goldman, Radoslav, Ph.D. ..... Georgetown University
Gollin, Susanne M., Ph.D. ..... The University of Pittsburgh
Gollnick, Sandra O., Ph.D. ..... Roswell Park Cancer Institute
Golovlev, Val V., Ph.D. ..... Sci-Tec, Inc.
Gomez, Scarlett L., Ph.D. ..... Cancer Prevention Institute of California
Gonzales, Melissa, Ph.D. ..... The University of New Mexico
Goodrich, Glenn P., Ph.D. ..... Nanospectra Biosciences, Inc.
Goodwin, James S., M.D. ..... The University of Texas Medical Branch at Galveston
Gorlick, Richard G., M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Gotay, Carolyn C., Ph.D. ..... University of British Columbia
Gottesfeld, Joel M., Ph.D. ..... Scripps Research Institute

Govindan, Ramaswamy, M.D. ..... Washington University
Govindan, Serengulam V., Ph.D. ..... Immunomedics, Inc.
Goydos, James S., M.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Grann, Victor R., M.D., M.P.H. ..... Columbia University
Grant, Steven, M.D. ..... Virginia Commonwealth University
Graves, Kristi D., Ph.D. ..... Georgetown University
Gray, Nathanael S., Ph.D. ..... Dana-Farber Cancer Institute
Greco, William R., Ph.D. ..... The State University of New York at Buffalo
Green, Jordan J., Ph.D. ..... The Johns Hopkins University
Gregg, Jeffrey P., M.D. ..... University of California, Davis
Greis, Kenneth D., Ph.D. ..... University of Cincinnati
Griffen, Ann L., D.D.S. ..... The Ohio State University
Grimm, Jan, M.D., Ph.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Gross, Myron D., Ph.D. ..... The University of Minnesota, Twin Cities
Grossniklaus, Hans E., M.D., M.B.A. ..... Emory University
Groutas, William C., Ed.D., Ph.D. ..... Wichita State University
Grundfest, Warren S., M.D. ..... University of California, Los Angeles
Grupp, Stephan A., M.D., Ph.D. ..... Children's Hospital of Philadelphia
Gu, Jian, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Gudkov, Andrei V., Sc.D., Ph.D. ..... Roswell Park Cancer Institute
Guidry, Jeffrey J., Ph.D. ..... Texas A&M University
Gunawardana, Geewananda, Ph.D. ..... Abbott Laboratories
Gunter, Marc James, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Gupta, Kalpna, Ph.D. ..... The University of Minnesota, Twin Cities
Gupta, Sanjeev, M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Gupte, Pradeep M., M.D. ..... Rockland Technimed, Ltd.
Gusev, Yuriy, Ph.D. ..... Georgetown University
Guthold, Martin, Ph.D. ..... Wake Forest University

H

Haab, Brian B., Ph.D. ..... Van Andel Research Institute
Hagedorn, Curt H., M.D. ..... The University of Utah
Hahnfeldt, Philip, Ph.D. ..... Caritas St. Elizabeth's Medical Center
Haley, John D., Ph.D. ..... OSI Pharmaceuticals, Inc.
Hall, Nathan C., M.D., Ph.D. ..... The Ohio State University
Halligan, Brian D., Ph.D. ..... Medical College of Wisconsin
Halmos, Balazs, M.D. ..... Case Western Reserve University
Hamburger, Anne W., Ph.D. ..... University of Maryland, Baltimore
Hamilton, Thomas C., Ph.D. ..... Fox Chase Cancer Center
Hammons, George J., Ph.D. ..... Philander Smith College
Han, James, Ph.D. ..... Ambergen, Inc.
Han, Misop, M.D. ..... The Johns Hopkins University
Hannun, Yusuf A., M.D. ..... Medical University of South Carolina
Hansen, Jeffrey C., Ph.D. ..... Colorado State University at Fort Collins
Hansen, Marc F., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Hanson, Carl V., Ph.D. ..... Public Health Foundation Enterprises

Haque, Reina, Ph.D. ..... Kaiser Foundation Research Institute
Harari, Paul M., M.D. ..... University of Wisconsin, Madison
Hardy, Jerry L. ..... Self-Employed
Harlap, Susan, M.D., M.B.B.S. ..... Columbia University
Harpole, David H., M.D. ..... Duke University
Harrington, Maureen A., Ph.D. ..... Indiana University School of Medicine
Harris, Lyndsay N., M.D. ..... Dana-Farber Cancer Institute
Harris, Marcelline Ruth, R.N., Ph.D. ..... University of Michigan
Harris, Michael B., Ph.D. ..... University of Alaska, Fairbanks
Hart, Gerald W., Ph.D. ..... The Johns Hopkins University
Haugen, Bryan R., M.D. ..... University of Colorado, Denver
Haun, Randy S., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Hawk, Ernest, M.D., M.P.H. ..... The University of Texas M.D. Anderson Cancer Center
Hawthorn, Lesleyann, Ph.D. ..... Georgia Health Sciences University
Hazle, John D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
He, Chuan, Ph.D. ..... The University of Chicago
Heffernan, Patrick B., Ph.D. ..... Meddetect, Inc.
Hei, Tom K., Ph.D. ..... Columbia University
Heisterkamp, Nora C., Ph.D. ..... Children's Hospital, Los Angeles
Held, Kathryn D., Ph.D. ..... Massachusetts General Hospital
Henderson, Katherine D., Ph.D. ..... Beckman Research Institute of City of Hope
Henry, Michael D., Ph.D. ..... The University of Iowa
Herlyn, Meenhard F., D.V.M., Sc.D. ..... Wistar Institute
Herman, James G., M.D. ..... The Johns Hopkins University
Hesketh, Peter J., Ph.D. ..... Georgia Institute of Technology
Heston, Warren D., Ph.D. ..... Cleveland Clinic Foundation
Hettich, Robert L., Ph.D. ..... Oak Ridge National Laboratory
Hichwa, Richard D., Ph.D. ..... The University of Iowa
Hielscher, Andreas H., Ph.D. ..... Columbia University
Higgins, Paul J., Ph.D. ..... Albany Medical College
Highsmith, William E., Ph.D. ..... University of Maryland, Baltimore
Hilakivi-Clarke, Leena A., Ph.D. ..... Georgetown University
Hill, Richard P., Ph.D. ..... University of Toronto
Hill, Steven M., Ph.D. ..... Tulane University of Louisiana
Hillhouse, Joel J., Ph.D. ..... East Tennessee State University
Hlatky, Lynn, Ph.D. ..... Steward Research/Specialty Projects Corporation
Ho, Shuk-Mei, Ph.D. ..... The University of Cincinnati
Hock, Janet M., M.D., Ph.D. ..... Maine Institute for Human Genetics and Health
Hockenbery, David M., M.D. ..... Fred Hutchinson Cancer Research Center
Hodge, Felicia S., Ph.D., M.P.H. ..... University of California, Los Angeles
Hoffman, Barbara, Ph.D. ..... Temple University
Hoffman, Robert M., Ph.D. ..... Anticancer, Inc.
Hogan, Michael E., Ph.D. ..... The University of Arizona
Hoh, Josephine, Ph.D. ..... Yale University
Hohl, Raymond J., M.D., Ph.D. ..... The University of Iowa
Hoke, Mary M., Ph.D. ..... The New Mexico State University, Las Cruces
Holiday, David B., Ph.D. ..... Research Triangle Institute
Holl, Mark R., Ph.D. ..... Arizona State University, Tempe

Hollingsworth, Jennifer A., Ph.D. ..... Los Alamos National Laboratory
Hollingsworth, Michael A., Ph.D. ..... University of Nebraska Medical Center
Holmes, Michelle D., M.D., Ph.D. ..... Harvard School of Public Health
Holsworth, Daniel, M.D. ..... Stemnext, LLC
Holt, Jeffrey T., M.D. ..... Commonwealth Medical College
Hoque, Ashraful, M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Hord, Norman G., Ph.D., M.P.H. ..... Michigan State University
Horvath, Tamas L., D.V.M., Ph.D. ..... Yale University
Houchen, Courtney W., M.D. ..... University of Oklahoma Health Sciences Center
Houghton, Janet A., Ph.D. ..... Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Houlette, Judy K. ..... Friend for Life Cancer Support Network
Houseman, Eugene A., Sc.D. ..... Brown University
Hovmand, Peter S., Ph.D. ..... Washington University
Howe, Louise R., Ph.D. ..... Weill Medical College of Cornell University
Howell, Gillian M., Ph.D. ..... University of Nebraska Medical Center
Hrkach, Jeff, Ph.D. ..... Bind Biosciences, Inc.
Hu, Guanghui, Ph.D. ..... Merck and Company
Hu, Jennifer J., Ph.D. ..... University of Miami School of Medicine
Huang, Emina H., M.D. ..... University of Florida
Huang, Jie, D.Sc. ..... Genentech, Inc.
Huang, Lan, Ph.D. ..... University of California, Irvine
Huang, Leaf, Ph.D. ..... University of North Carolina at Chapel Hill
Huang, Sui, M.D., Ph.D. ..... Institute for Systems Biology
Hubbard, Karen, Ph.D. ..... City College of New York
Huff, Carol A., M.D. ..... The Johns Hopkins University
Huflejt, Margaret E., Ph.D. ..... New York University School of Medicine
Hughes, Daniel C., Ph.D. ..... The University of Texas Health Science Center
Hung, Chien-Fu, Ph.D. ..... The Johns Hopkins University
Hung, Mien-Chie, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Hung, Paul J., Ph.D. ..... Cellasic Corporation
Hunter, Jennifer L., Ph.D. ..... University of Missouri, Kansas City
Hunter, Joanna, Ph.D. ..... Caprion Pharmaceuticals, Inc.
Huo, Qun T., Ph.D. ..... University of Central Florida
Hurst, Robert E., Ph.D. ..... University of Oklahoma Health Sciences Center
Hutt-Fletcher, Lindsey M., Ph.D. ..... The Louisiana State University Health Science Center
Huycke, Mark M., M.D. ..... University of Oklahoma Health Sciences Center
Hyder, Dewan S. F., Ph.D. ..... Yale University
Hyslop, Terry, Ph.D. ..... Thomas Jefferson University

I

Iglehart, James D., M.D. ..... Dana-Farber Cancer Institute
Im, Eunok, Ph.D. ..... University of California, Los Angeles
Irwin, Debra E., M.P.H., Ph.D. ..... University of North Carolina at Chapel Hill
Isales, Carlos M., M.D. ..... Georgia Health Sciences University
Isom, Harriet C., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center

Issa, Jean-Pierre J., M.D. ..... Temple University
Iversen, Edwin S., Ph.D. ..... Duke University

J

Jacobs, Michael A., Ph.D. ..... The Johns Hopkins University
Jacobson, Brian C., M.D., M.P.H. ..... Boston Medical Center
Jacques, Steven L., Ph.D. ..... Oregon Health and Science University
Jadvar, Hossein, M.D., Ph.D. ..... The University of Southern California
Jagannath, Sundar, M.D. ..... St. Vincent's Medical Center
Jain, Faquir C., Ph.D. ..... University of Connecticut, Storrs
James, Aimee S., Ph.D., M.P.H. ..... Washington University
Janz, Siegfried, Sc.D., M.D. ..... The University of Iowa
Jay, Daniel G., Ph.D. ..... Tufts University
Jeddeloh, Jeffrey A., Ph.D. ..... Orion Genomics, LLC
Jeffery, Elizabeth H., Ph.D. ..... University of Illinois at Urbana-Champaign
Jensen, Roy A., M.D. ..... University of Kansas Medical Center
Jeraj, Robert, Ph.D. ..... University of Wisconsin, Madison
Jerry, D. Joseph, Ph.D. ..... University of Massachusetts, Amherst
Jewell, William R., M.D. ..... University of Kansas Medical Center
Jhala, Nirag, M.D. ..... University of Alabama at Birmingham
Ji, Hanlee, M.D. ..... Stanford University
Ji, Jiuping J., Ph.D. ..... University of Alabama at Birmingham
Ji, Yuan, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Jimeno, Antonio, M.D., Ph.D. ..... University of Colorado, Denver
Johnson, Blair T., Ph.D. ..... University of Connecticut, Storrs
Johnson, Valen E., Ph.D. ..... The University of Texas Health Science Center, Houston
Jones, Dean P., Ph.D. ..... Emory University
Jones, Judy A., M.A. ..... Cutaneous Lymphoma Foundation
Jones, Richard J., M.D. ..... The Johns Hopkins University
Joyal, John L., Ph.D. ..... Brigham and Women's Hospital
Ju, Jingfang, Ph.D. ..... The State University of New York at Stony Brook
Jurisica, Igor M., Ph.D. ..... University of Toronto

K

Kadlubar, Susan A., Ph.D. ..... Roswell Park Cancer Institute
Kam, Lance C., Ph.D. ..... Columbia University
Kameoka, Jun, Ph.D. ..... Texas Engineering Experiment Station
Kaminski, Joseph M., M.D. ..... National Institute of Allergy and Infectious Diseases
Kandel, Eugene S., Ph.D. ..... Roswell Park Cancer Institute
Kane, Agnes B., M.D., Ph.D. ..... Brown University
Kane, Madeleine A., M.D., Ph.D. ..... University of Colorado, Denver
Kane, Susan E., Ph.D. ..... Beckman Research Institute of City of Hope
Kang, Min H., Pharm.D. ..... Texas Tech University
Kang, Yibin, Ph.D. ..... Princeton University
Kannan, Raghuraman, Ph.D. ..... University of Missouri, Columbia
Kannan, Rangaramanujam M., Ph.D. ..... The Johns Hopkins University

Kao, Chinghai, Ph.D. ..... Indiana University-Purdue University Indianapolis
Kapp, Julie M., M.P.H., Ph.D. .....University of Missouri, Columbia
Kapur, Ravi, Ph.D. ..... George Mason University
Karczmar, Gregory S., Ph.D. .....The University of Chicago
Karellas, Andrew, Ph.D. .....University of Massachusetts Medical School
Karp, Joel S., Ph.D. .....The University of Pennsylvania
Karp, Seth J., M.D. .....Vanderbilt University
Kasper, Susan, Ph.D. .....University of Cincinnati
Kassis, Amin I., Ph.D. ..... Harvard Medical School
Kast, Wijbe M., Ph.D. ..... The University of Southern California
Katti, Kattesh V., D.Sc., Ph.D. .....University of Missouri, Columbia
Katz, Mira L., Ph.D., M.P.H. ..... The Ohio State University
Kaufman, Howard L., M.D. ..... Rush University Medical Center
Kaumaya, Pravin T.P., Ph.D. ..... The Ohio State University
Kay, Brian K., Ph.D. .....University of Illinois at Chicago
Kazic, Toni, Ph.D. .....University of Missouri, Columbia
Keller, Evan T., D.V.M., Ph.D. .....University of Michigan, Ann Arbor
Kelley, Mark R., Ph.D. ..... Indiana University-Purdue University Indianapolis
Kelly, Kimberly A., Ph.D. .....University of Virginia, Charlottesville
Kennedy, Ronald C., Ph.D. .....The University of Oklahoma Health Science Center
Keshamouni, Venkateshwar G., Ph.D. .....University of Michigan, Ann Arbor
Keyomarsi, Khandan, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Khorasanizadeh, Sepideh, Ph.D. .....Sanford-Burnham Medical Research Institute
Khramtsov, Valery V., D.Sc., Ph.D. ..... The Ohio State University
Kikinis, Ron, M.D. ..... Brigham and Women's Hospital
Killackey, Maureen A., M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Kilpatrick, Michael W., Ph.D. ..... Ikonisys, Inc.
Kim, Youngmee, Ph.D. .....University of Miami, Coral Gables
Kimler, Bruce F., Ph.D. ..... University of Kansas Medical Center
Kimmel, Marek, Sc.D., Ph.D. .....Rice University
Kinghorn, Alan D., D.Sc., Ph.D. .....University of Illinois at Chicago
Kinsel, Gary R., Ph.D. ..... Southern Illinois University, Carbondale
Kinter, Michael, Ph.D. .....Oklahoma Medical Research Foundation
Kirkwood, John M., M.D. ..... The University of Pittsburgh
Kirlin, Ward G., Ph.D. .....Morehouse School of Medicine
Kisker, David, Ph.D. ..... Eoptra, LLC
Klassen, Ann C., Ph.D. .....Drexel University
Klein, Alison P., Ph.D. .....The Johns Hopkins University
Klinge, Carolyn M., Ph.D. .....University of Louisville
Klinger, Katherine W., Ph.D. ..... Genzyme Corporation
Knipp, Gregory T., Ph.D. .....Purdue University, West Lafayette
Knopp, Michael V., M.D., Ph.D. ..... The Ohio State University
Knudsen, Beatrice S., M.D., Ph.D. ..... Cedars-Sinai Medical Center
Knutson, Keith L., Ph.D. .....Mayo Clinic
Koh, James, Ph.D. .....Duke University
Kohman, Leslie J., M.D. ..... The State University of New York, Health Science Center
Koide, Shohei, Ph.D. .....The University of Chicago
Komarova, Natalia L., Ph.D. ..... University of California, Irvine

Konda, Vani, M.D. .....The University of Chicago
Kong, Ah-Ng T., Ph.D. .....Rutgers University
Konieczny, Stephen F., Ph.D. .....Purdue University, West Lafayette
Kopelman, Raoul, Ph.D. .....University of Michigan, Ann Arbor
Koper, Olga B., Ph.D. .....Battelle Memorial Institute
Korc, Murray, M.D. .....Indiana University-Purdue University Indianapolis
Kornblum, Harley I., M.D., Ph.D. .....University of California, Los Angeles
Koser, Hur, Ph.D. .....Yale University
Kosik, Kenneth S., M.D. .....University of California, Santa Barbara
Kosorok, Michael R., Ph.D. .....University of North Carolina at Chapel Hill
Koumenis, Constantinos, Ph.D. .....The University of Pennsylvania
Kousoulas, Konstantin G., Ph.D. .....Louisiana State University
Kovacs, Michael S., Ph.D. .....University of Western Ontario
Kow, Yoke W., Ph.D. .....Emory University
Kraitchman, Dara L., D.V.M., Ph.D. .....The Johns Hopkins University
Kramer, Fred R., Ph.D. .....Public Health Research Institute
Kranz, David M., Ph.D. .....University of Illinois at Urbana-Champaign
Krejza, Jaroslaw, M.D., Ph.D. .....The University of Pennsylvania
Kresty, Laura A., Ph.D. .....University of Miami School of Medicine
Kriete, Andres, Ph.D. .....Drexel University
Kris, Mark G., M.D. .....Memorial Sloan-Kettering Institute for Cancer Research
Krishnamurthy, Savitri, M.D. .....The University of Texas M.D. Anderson Cancer Center
Krishnaswamy, Venkataramanan, Ph.D. .....Dartmouth College
Krohn, Kenneth A., Ph.D. .....University of Washington
Kroll, David J., Ph.D. .....North Carolina Central University
Krontiris, Theodore G., M.D., Ph.D. .....Beckman Research Institute of City of Hope
Krupinski, Elizabeth A., Ph.D. .....The University of Arizona
Kuang, Rui, Ph.D. .....University of Minnesota Twin Cities
Kudrolli, Haris, Ph.D. .....Radiation Monitoring Devices, Inc.
Kuhn, Peter, Ph.D. .....Scripps Research Institute
Kumar, Challa S., Ph.D. .....Louisiana State University Agricultural and Mechanical College
Kumar, Nagi B., Ph.D. .....H. Lee Moffitt Cancer Center & Research Institute
Kung, Hsing-Jien, Ph.D. .....University of California, Davis
Kunicki, Thomas J., Ph.D. .....Children's Hospital of Orange County
Kuo, Winston P., D.D.S., Ph.D. .....Harvard Medical School
Kurhanewicz, John, Ph.D. .....University of California, San Francisco
Kurie, Jonathan M., M.D. .....The University of Texas M.D. Anderson Cancer Center
Kurzrock, Razelle, M.D. .....The University of Texas M.D. Anderson Cancer Center
Kushi, Lawrence H., Sc.D. .....Kaiser Foundation Research Institute
Kwiatkowski, David J., M.D., Ph.D. .....Brigham and Women's Hospital
Kyprianou, Iacovos S., Ph.D. .....Food and Drug Administration
Kyprianou, Natasha, Ph.D. .....University of Kentucky

L

Labar, Kevin S., Ph.D. .....Duke University
Lacey, Michelle R., Ph.D. .....Tulane University

Ladisch, Stephan, M.D. ..... Children's National Medical Center
LaFleur, Bonnie, Ph.D., M.P.H. ..... The University of Arizona
LaFramboise, William A., Ph.D. ..... The University of Pittsburgh
Lai, Jonathan, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Laird, Beverly L., Ph.D. ..... American Cancer Society, Inc.
Lambert, Paul F., Ph.D. ..... University of Wisconsin, Madison
Lampson, Lois A., Ph.D. ..... Brigham and Women's Hospital
Land, Stephanie R., Ph.D. ..... The University of Pittsburgh
Landsittel, Douglas P., Ph.D. ..... The University of Pittsburgh
Lane, Timothy F., Ph.D. ..... University of California, Los Angeles
Lange, Julie R., M.D. ..... The Johns Hopkins University
Langer, Mark P., M.D. ..... Indiana University-Purdue University Indianapolis
Langlotz, Curtis, M.D., Ph.D. ..... The University of Pennsylvania
Languino, Lucia R., Ph.D. ..... Thomas Jefferson University
Lapotko, Dmitri O., Sc.D., Ph.D. ..... Rice University
Larson, Richard S., M.D., Ph.D. ..... The University of New Mexico
Laubenbacher, Reinhard, Ph.D. ..... Virginia Polytechnic Institute and State University
Lawrence, David A., Ph.D. ..... New York State Department of Health
Lawson, Michael J., M.D. ..... Kaiser Permanente
Layne, Elizabeth L., D.D.S., M.B.A. ..... Self-Employed
Lazo, John S., Ph.D. ..... University of Virginia, Charlottesville
Lazovich, Deann, Ph.D., M.P.H. ..... The University of Minnesota, Twin Cities
Leal, Juan A., Ph.D. ..... The University of Minnesota, Twin Cities
Leary, James F., Ph.D. ..... Purdue University, West Lafayette
Lebman, Deborah A., Ph.D. ..... Virginia Commonwealth University
Lebovitz, Russell M., M.D., Ph.D. ..... Marval Biosciences, Inc.
Ledbetter, Jeffrey A., Ph.D. ..... University of Washington
Lee, Burton H., Ph.D., M.B.A. ..... Stanford University
Lee, Cheng S., Ph.D. ..... University of Maryland, College Park
Lee, Cheryl T., M.D. ..... University of Michigan, Ann Arbor
Lee, Chung, Ph.D. ..... Northwestern University
Lee, Jae K., Ph.D. ..... University of Virginia, Charlottesville
Lee, Janie, M.D. ..... Massachusetts General Hospital
Lee, Ji-Hyun, Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Lee, Kuo-Hsiung, Ph.D. ..... University of North Carolina at Chapel Hill
Lee, Philip J., Ph.D. ..... Cellasic Corporation
Lee, Robert J., Ph.D. ..... The Ohio State University
Lee, Sam W., Ph.D. ..... Massachusetts General Hospital
Legerski, Randy J., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Lehrman, Mark, Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Leiby, Benjamin, Ph.D. ..... Thomas Jefferson University
Leng, Xiaoyan, M.D., Ph.D. ..... Wake Forest University Health Sciences
Leonard, Lori, Sc.D. ..... The Johns Hopkins University
Leong, Stanley P.L., M.D. ..... University of California, San Francisco
Le Poole, Isabelle Caroline, Ph.D. ..... Loyola University, Chicago
Leslie-Pelecky, Diandra L., Ph.D. ..... West Virginia University
Lesniak, Maciej S., M.D. ..... The University of Chicago
Lesser, Martin L., Ph.D. ..... Feinstein Institute for Medical Research

Levchenko, Andre, Ph.D. ..... The Johns Hopkins University
Levenson, Richard M., M.D. ..... Brighton Consulting Group
Levin, Albert M., Ph.D. ..... Henry Ford Health Systems
Levine, Ross L., M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Levitan, Neal, J.D. ..... The Brain Tumor Society
Levy, Mia A., M.D., Ph.D. ..... Vanderbilt University
Lewis, Brian C., Ph.D. ..... University of Massachusetts Medical School, Worcester
Lewis, Dorothy E., Ph.D. ..... The University of Texas Health Science Center, Houston
Lewis, Jason S., Ph.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Lewis, Lionel D., M.D. ..... Dartmouth College
Li, Jia, Ph.D. ..... Henry Ford Health System
Li, King C., M.D., M.B.A. ..... Methodist Hospital Research Institute
Li, Wentian, Ph.D. ..... Feinstein Institute for Medical Research
Libermann, Towia A., Ph.D. ..... Beth Israel Deaconess Medical Center
Lieberman, Howard B., Ph.D. ..... Columbia University
Lim, Megan S., M.D., Ph.D. ..... University of Michigan, Ann Arbor
Lin, Haiqun, M.D., Ph.D. ..... Yale University
Lin, Ming-Fong, Ph.D. ..... University of Nebraska Medical Center
Lin, Qiao, Ph.D. ..... Columbia University
Lin, Shili, Ph.D. ..... The Ohio State University
Lin, Weili, Ph.D. ..... University of North Carolina at Chapel Hill
Lin, Xihong, Ph.D. ..... Harvard School of Public Health
Lin, Yan, Ph.D. ..... The University of Pittsburgh
Lin, Yong, M.D., Ph.D. ..... Lovelace Biomedical & Environmental Research
Linden, Hannah M., M.D. ..... University of Washington
Link, Brian K., M.D. ..... University of Iowa
Liphardt, Jan T., Ph.D. ..... University of California, Berkeley
Lipkin, Steven M., M.D., Ph.D. ..... Weill Medical College of Cornell University
Lipscomb, Joseph, Ph.D. ..... Emory University
Listowsky, Irving, Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Litorja, Maritoni, Ph.D. ..... National Institute of Science and Technology
Little, Julian, Ph.D. ..... University of Ottawa
Liu, Fei-Fei, M.D. ..... University of Toronto
Liu, Geoffrey, M.D. ..... University Health Network
Liu, Guodong, Ph.D. ..... North Dakota State University
Liu, Shujun, Ph.D. ..... The University of Minnesota, Twin Cities
Liu, Xuedong, Ph.D. ..... University of Colorado, Boulder
Livingston, Philip O., M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Ljubimova, Julia Y., M.D., Ph.D. ..... Cedars-Sinai Medical Center
Locker, Joseph D., M.D., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Loeb, Lawrence A., M.D., Ph.D. ..... University of Washington
Logsdon, Craig D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Lokshin, Anna E., Ph.D. ..... The University of Pittsburgh
Lonial, Sagar, M.D. ..... Emory University
Loomis, Cynthia A., M.D., Ph.D. ..... New York University School of Medicine
Lorusso, Patricia M. ..... Wayne State University
Lossos, Izidore S., M.D. ..... University of Miami School of Medicine
Lothstein, Leonard, Ph.D. ..... University of Tennessee Health Science Center

Lounsbury, David W., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Lowe, Anson W., M.D. ..... Stanford University
Lowe, Val J., M.D. ..... Mayo Clinic
Lowenstein, Pedro R., M.D., Ph.D. ..... University of Michigan, Ann Arbor
Lu, Karen H., M.D. ..... The University of Texas M.D. Anderson Cancer Center
Lu, Zheng-Rong, Ph.D. ..... Case Western Reserve University
Luckmann, Roger S., M.D., M.P.H. ..... University of Massachusetts Medical School, Worcester
Lukasik, Victoria M., D.V.M. ..... Southwest Veterinary Anesthesiology
Luker, Gary D., M.D. ..... University of Michigan, Ann Arbor
Lum, Lawrence G., Sc.D., M.D. ..... Wayne State University
Luo, Dan, Ph.D. ..... Cornell University
Luo, Guangxiang G., M.D. ..... University of Kentucky
Luta, Gheorghe, Ph.D. ..... Georgetown University
Lyle, Stephen R., M.D., Ph.D. ..... University of Massachusetts Medical School, Worcester
Lynch, Patrick M., M.D., J.D. ..... The University of Texas M.D. Anderson Cancer Center
Lyn-Cook, Beverly A., Ph.D. ..... National Center for Toxicological Research
Lynge, Elsebeth, Sc.D. ..... University of Copenhagen
Lyubchenko, Yuri L., Sc.D., Ph.D. ..... University of Nebraska Medical Center

M

Ma, Grace X., Ph.D. ..... Temple University
Ma, Haiching, Ph.D. ..... Reaction Biology Corporation
Macdonald, Tobey J., M.D. ..... Emory University
Maggard-Gibbons, Melinda A., M.D. ..... University of California, Los Angeles
Maguire, Patrick D., M.D. ..... New Hanover Regional Medical Center
Mahabee-Gittens, E. Melinda, M.D. ..... Children's Hospital Medical Center, Cincinnati
Mahmood, Umar, M.D., Ph.D. ..... Massachusetts General Hospital
Mai, Volker, Ph.D., M.P.H. ..... University of Florida
Malkas, Linda H., Ph.D. ..... Beckman Research Institute of City of Hope
Maloney, David G., M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Manciu, Marian, Ph.D. ..... The University of Texas, El Paso
Mandelblatt, Jeanne, M.D., M.P.H. ..... Georgetown University
Mandrekar, Sumithra J., Ph.D. ..... Mayo Clinic
Manfredi, James J., Ph.D. ..... Mount Sinai School of Medicine
Mankoff, David A., M.D., Ph.D. ..... University of Washington
Manne, Upender, Ph.D. ..... University of Alabama at Birmingham
Manning, Henry C., Ph.D. ..... Vanderbilt University
Manor, Danny, Ph.D. ..... Case Western Reserve University
Mao, Hui, Ph.D. ..... Emory University
Mao, Li, M.D. ..... University of Maryland, Baltimore
Mapes, James P., Ph.D. ..... Rules-Based Medicine, Inc.
Marcucci, Guido, M.D. ..... The Ohio State University
Maresca, Kevin P., Ph.D. ..... Molecular Insight Pharmaceuticals, Inc.
Margulies, David H., M.D., Ph.D. ..... National Institute of Allergy and Infectious Diseases
Marks, Jeffrey R., Ph.D. ..... Duke University

Maskarinec, Gertraud, M.D., Ph.D. ..... University of Hawaii at Manoa
Mason, Joel B., M.D. ..... Tufts University
Mason, Ralph P., Ph.D. ..... The University of Texas Southwestern Medical Center, Dallas
Masoud, Osama, Ph.D. ..... Vital Images
Massion, Pierre P., M.D. ..... Vanderbilt University
Matusik, Robert J., Ph.D. ..... Vanderbilt University
Maxfield, Frederick R., Ph.D. ..... Weill Medical College of Cornell University
Mayer, Joni A., Ph.D. ..... San Diego State University
Mayo, Kevin H., Ph.D. ..... Actipep Biotechnology, Inc.
McBride, William H., Sc.D., Ph.D. ..... University of California, Los Angeles
McCabe, George P., Ph.D. ..... Purdue University, West Lafayette
McCarthy, James B., Ph.D. ..... The University of Minnesota, Twin Cities
McCarty, Owen J., Ph.D. ..... Oregon Health and Science University
McConkey, David J., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
McCormack, Valerie, Ph.D. ..... International Agency for Research on Cancer
McCracken, John L., Ph.D. ..... Michigan State University
McCrory, Megan A., Ph.D. ..... Bastyr University
McDannold, Nathan J., Ph.D. ..... Brigham and Women's Hospital
McGee, Kiaran P., Ph.D. ..... Mayo Clinic
McGinniss, Matthew J., Ph.D. ..... Caris Life Sciences
McGown, Linda B., Ph.D. ..... Rensselaer Polytechnic Institute
McGregor, William G., M.D. ..... University of Louisville
McIntyre, James O., Ph.D. ..... Vanderbilt University
McKeithan, Timothy W., M.D., Ph.D. ..... University of Nebraska Medical Center
McKeon, Frank D., Ph.D. ..... Harvard Medical School
McKeown-Longo, Paula J., Ph.D. ..... Albany Medical College
McKinley, Randolph L., Ph.D. ..... Zumatek, Inc.
McNally, James W., Ph.D. ..... University of Michigan, Ann Arbor
McWeeney, Shannon K., Ph.D. ..... Oregon Health and Science University
Meares, Claude F., Ph.D. ..... University of California, Davis
Mecozzi, Sandro, Ph.D. ..... University of Wisconsin, Madison
Mehta, Anand S., Ph.D. ..... Drexel University
Meissner, Alexander, Ph.D. ..... Harvard University
Melancon, Donald J., Ph.D. ..... Conversations!
Mell, Loren K., M.D. ..... University of California, San Diego
Mendonca, Paulo R., Ph.D. ..... General Electric Global Research Center
Menon, Usha, Ph.D. ..... Arizona State University
Merad, Miriam, M.D., Ph.D. ..... Mount Sinai School of Medicine
Merajver, Sofia D., M.D., Ph.D. ..... University of Michigan, Ann Arbor
Merchant, Nipun B., M.D. ..... Vanderbilt University
Mercola, Dan, M.D., Ph.D. ..... University of California, Irvine
Mesri, Enrique A., Ph.D. ..... University of Miami School of Medicine
Messer, Karen, Ph.D. ..... University of California, San Diego
Messersmith, Wells A., M.D. ..... University of Colorado, Denver
Messmer, Bradley T., Ph.D. ..... University of California, San Diego
Metaxas, Dimitris N., Ph.D. ..... Rutgers, The State University of New Jersey, New Brunswick
Metzger, Gregory J., Ph.D. ..... The University of Minnesota, Twin Cities
Meyer, Laurence J., M.D., Ph.D. ..... The University of Utah

Meyer, William H., M.D. ..... University of Oklahoma Health Sciences Center
Meza, Jane, Ph.D. ..... University of Nebraska Medical Center
Miele, Lucio, M.D., Ph.D. ..... University of Mississippi Medical Center
Mikkelsen, Tom, M.D. ..... Henry Ford Health System
Miller, Glenn A., Ph.D. ..... Genzyme Corporation
Miller, Jeffrey S., M.D. ..... University of Minnesota
Miller, Joseph D., Ph.D. ..... The University of Southern California
Miller, Julie M., M.D. ..... The Johns Hopkins University
Minchinton, Andrew I., Ph.D. ..... British Columbia Cancer Agency
Minden, Mark D., M.D., Ph.D. ..... University Health Network
Minn, Andy J., M.D., Ph.D. ..... The University of Pennsylvania
Miranker, Daniel, Ph.D. ..... The University of Texas, Austin
Mishra, Lopa, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Mitchell, Beverly S., M.D. ..... Stanford University
Mitchell, Edith P., M.D. ..... Thomas Jefferson University
Mitra, Sankar, Ph.D. ..... The University of Texas Medical Branch at Galveston
Modak, Shakeel, M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Modeste, Naomi N., Ph.D., M.P.H. ..... Loma Linda University
Mohammad, Ramzi M., Ph.D. ..... Wayne State University
Moll, Ute M., M.D. ..... The State University of New York, Stony Brook
Momand, Jamil A., Ph.D. ..... California State University, Los Angeles
Monks, Terrence J., Ph.D. ..... The University of Texas, Austin
Montaner, Silvia V., Ph.D., M.P.H. ..... University of Maryland, Baltimore
Mooberry, Susan L., Ph.D. ..... The University of Texas Health Science Center
Moore, Stephen C., Ph.D. ..... Brigham and Women's Hospital
Moraru, Ion I., M.D., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Morehouse, Kim M., Ph.D. ..... U.S. Food and Drug Administration
Morgan, Robin W., Ph.D. ..... University of Delaware
Moritz, Robert L., Ph.D. ..... Institute for Systems Biology
Morris, David R., Ph.D. ..... University of Washington
Morris, Michael J., M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Morrison, Sherie L., Ph.D. ..... University of California, Los Angeles
Morton, Kathryn A., M.D. ..... The University of Utah
Moseley, Martin A., Ph.D. ..... Duke University
Moses, William W., Ph.D. ..... Lawrence Berkeley National Laboratory
Moskal, Joseph R., Ph.D. ..... Northwestern University
Moskaluk, Christopher A., M.D., Ph.D. ..... University of Virginia, Charlottesville
Moss, Sue, Ph.D. ..... Institute of Cancer Research
Motamedi, Massoud, Ph.D. ..... The University of Texas Medical Branch at Galveston
Motl, Robert W., Ph.D. ..... University of Illinois at Urbana-Champaign
Motwani, Nalini M., Ph.D. ..... Apolife, Inc.
Mountz, James M., M.D., Ph.D. ..... The University of Pittsburgh
Muddiman, David C., Ph.D. ..... North Carolina State University
Mueller, Barbara M., Ph.D. ..... Torrey Pines Institute for Molecular Studies
Mukherjee, Bhramar, Ph.D. ..... University of Michigan, Ann Arbor
Mukherjee, Priyabrata, Ph.D. ..... Mayo Clinic
Mukherji, Bijay, M.D. ..... University of Connecticut School of Medicine & Dentistry
Mukhopadhyay, Debabrata, Ph.D. ..... Mayo Clinic

Mukhtar, Hasan, Ph.D. ..... University of Wisconsin, Madison
Mullan, Patricia B., Ph.D. ..... University of Michigan, Ann Arbor
Mullersman, Jerald E., M.D., Ph.D. ..... U.S. Food and Drug Administration
Munden, Reginald F., M.D., M.B.A. ..... The University of Texas M.D. Anderson Cancer Center
Munn, David H., M.D. ..... Georgia Health Sciences University
Munshi, Nikhil C., M.D. ..... Dana-Farber Cancer Institute
Munster, Pamela N., M.D. ..... University of California, San Francisco
Murnane, John P., Ph.D. ..... University of California, San Francisco
Murphy, Kate, B.A. ..... C3: Colorectal Cancer Coalition
Murphy, Michael C., Ph.D. ..... Louisiana State University A&M College, Baton Rouge
Murphy, William J., Ph.D. ..... University of Nevada, Reno
Murray, Kermit K., Ph.D. ..... Louisiana State University
Mustian, Karen M., Ph.D. ..... University of Rochester
Muthuswamy, Senthil K., Ph.D. ..... Cold Spring Harbor Laboratory
Myers, Ronald E., Ph.D. ..... Thomas Jefferson University

N

Nadkarni, Prakash M., M.D. ..... Yale University
Nairn, Rodney S., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Nakshatri, Harikrishna, Ph.D. ..... Indiana University-Purdue University Indianapolis
Napel, Sandy A., Ph.D. ..... Stanford University
Nardulli, Ann, Ph.D. ..... University of Illinois at Urbana-Champaign
Narod, Steven A., M.D. ..... University of Toronto
Naughton, Michelle J., Ph.D. ..... Wake Forest University
Navone, Nora M., M.D., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Needham, David, Ph.D. ..... Duke University
Negrin, Robert S., M.D. ..... Stanford University
Nelson, Randall W., Ph.D. ..... Arizona State University
Nelson, Sarah J., Ph.D. ..... University of California, San Francisco
Neufeld, Thomas P., Ph.D. ..... The University of Minnesota, Twin Cities
Neuhouser, Marian L., Ph.D. ..... Fred Hutchinson Cancer Research Center
Neuwelt, Edward A., M.D. ..... Vanderbilt University
Nicosia, Santo V., M.D. ..... University of South Florida
Nielsen, Hans J., Sc.D., M.D. ..... University of Copenhagen
Nikitin, Alexander Y., M.D., Ph.D. ..... Cornell University
Nilsen-Hamilton, Marit, Ph.D. ..... Iowa State University
Nishikawa, Robert M., Ph.D. ..... The University of Chicago
Nishimura, Michael I., Ph.D. ..... Loyola University Chicago
Noar, Seth M., Ph.D. ..... University of North Carolina at Chapel Hill
Norling, Gretchen, Ph.D. ..... University of West Florida
Normolle, Daniel P., Ph.D. ..... The University of Pittsburgh
Norton, Larry, M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Nunn, Adrian D., Ph.D. ..... Bracco Research USA, Inc.
Nyati, Mukesh K., Ph.D. ..... University of Michigan, Ann Arbor

O

Oberg, Ann L., Ph.D. ..... Mayo Clinic
O'Connor, Michael F., Ph.D. ..... Consultant
O'Connor, Richard J., Ph.D. ..... Roswell Park Cancer Institute
Odedina, Folakemi T., Ph.D. ..... University of Florida
O'Donnell, Joseph F., M.D. ..... Dartmouth College
O'Dorisio, M. Sue, M.D., Ph.D. ..... University of Iowa
Odunsi, Kunle O., M.D., Ph.D. ..... Roswell Park Cancer Institute
Odze, Robert D., M.D. ..... Brigham and Women's Hospital
Oeffinger, Kevin C., M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Oesterreich, Steffi, Ph.D. ..... The University of Pittsburgh
Oh, William K., M.D. ..... Mount Sinai School of Medicine
Okada, Craig Y., M.D., Ph.D. ..... Oregon Health and Science University
O'Keefe, Stephen, M.D., J.D. ..... The University of Pittsburgh
O'Leary, Timothy J., M.D., Ph.D. ..... Department of Veterans Affairs
Oliver, Janet M., Ph.D. ..... The University of New Mexico Health Sciences Center
Olshan, Andrew, Ph.D. ..... University of North Carolina at Chapel Hill
O'Malley, Michael S., Ph.D. ..... University of North Carolina at Chapel Hill
Omary, Reed A., M.D. ..... Northwestern University
Omel, James L., M.D. ..... Self-Employed
Onar-Thomas, Arzu, Ph.D. ..... St. Jude Children's Research Hospital
Onyuksel, Hayat, Ph.D. ..... University of Illinois at Chicago
Orsulic, Sandra, Ph.D. ..... Cedars-Sinai Medical Center
Osman, Iman, M.D. ..... New York University School of Medicine
Ostrowski, Michael C., Ph.D. ..... The Ohio State University
Ouchi, Toru, Ph.D. ..... Roswell Park Cancer Institute
Overhage, Joseph M., M.D., Ph.D. ..... Indiana University-Purdue University Indianapolis
Oyajobi, Babatunde O., M.D., Ph.D., M.B.A. ..... The University of Texas Health Science Center, San Antonio

P

Pacifico, Anthony M., Ph.D. ..... Battelle Memorial Institute
Paciotti, Giulio F., Ph.D. ..... Cytimmune Sciences, Inc.
Page, Rebecca, Ph.D. ..... Brown University
Pagoto, Sherry L., Ph.D. ..... University of Massachusetts Medical School, Worcester
Palecek, Sean P., Ph.D. ..... University of Wisconsin, Madison
Palesch, Yuko Y., Ph.D. ..... Medical University of South Carolina
Pallavicini, Maria G., Ph.D. ..... University of California, Merced
Palta, Jatinder R., Ph.D. ..... University of Florida
Palta, Mari, Ph.D. ..... University of Wisconsin, Madison
Panin, Vladislav M., Ph.D. ..... Texas A&M University
Pankratz, V. Shane, Ph.D. ..... Mayo Clinic
Pannell, Lewis K., Ph.D. ..... University of South Alabama
Pardo, Francisco S., M.D. ..... San Diego State University
Paris, Pamela L., Ph.D. ..... University of California, San Francisco

Park, Ben H., M.D., Ph.D. ..... The Johns Hopkins University
Park, Peter J., Ph.D. ..... Harvard Medical School
Parker, Laurie L., Ph.D. ..... Purdue University, West Lafayette
Parker, William B., Ph.D. ..... Southern Research Institute
Parsons, Ramon E., M.D., Ph.D. ..... Columbia University
Parvin, Jeffrey D., M.D., Ph.D. ..... The Ohio State University
Pasa-Tolic, Ljiljana, Ph.D. ..... Battelle Pacific Northwest Laboratories
Pasche, Boris, M.D., Ph.D. ..... University of Alabama at Birmingham
Patel, Divya A., Ph.D. ..... Yale University
Patterson, Gregory M.L., Ph.D. ..... Texas Biomedical Research Institute
Paulsen, Keith D., Ph.D. ..... Dartmouth College
Pavlidis, Ioannis, Ph.D. ..... University of Houston
Pearman, Timothy P., Ph.D. ..... Northwestern University
Peehl, Donna M., Ph.D. ..... Stanford University
Pegg, Anthony E., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center
Pejovic, Tanja, M.D., Ph.D. ..... Oregon Health and Science University
Pelizzari, Charles A., Ph.D. ..... The University of Chicago
Pellecchia, Maurizio, Ph.D. ..... Sanford-Burnham Medical Research Institute
Pelletier, Jeffrey ..... Consultant
Pence, Barbara C., Ph.D. ..... Texas Tech University Health Science Center
Pereira, Deidre B., Ph.D. ..... University of Florida
Perelman, Lev T., Ph.D. ..... Beth Israel Deaconess Medical Center
Perez-Soler, Roman, M.D. ..... Albert Einstein College of Medicine of Yeshiva University
Perkins, Susan M., Ph.D. ..... Indiana University School of Medicine
Pescosolido, Bernice A., Ph.D. ..... Indiana University, Bloomington
Peters, Edward S., D.M.D., Sc.D. ..... Louisiana State University Health Science Center
Petersen, Gloria M., Ph.D. ..... Mayo Clinic
Petrenko, Valery A., Sc.D., Ph.D. ..... Auburn University
Petrick, Nicholas, Ph.D. ..... U.S. Food and Drug Administration
Petroni, Gina R., Ph.D. ..... University of Virginia, Charlottesville
Pfefer, Josh, Ph.D. ..... U.S. Food and Drug Administration
Piazza, Gary A., Ph.D. ..... University of South Alabama
Pieper, Rembert, Ph.D. ..... J. Craig Venter Institute, Inc.
Pieper, Russell O., Ph.D. ..... University of California, San Francisco
Pierce, James M., Ph.D. ..... University of Georgia
Pincus, Seth H., M.D. ..... Louisiana State University Health Science Center
Plant, Anne L., Ph.D. ..... National Institute of Standards and Technology
Platanias, Leonidas C., M.D., Ph.D. ..... Northwestern University
Plate, Janet, M.D., Ph.D. ..... Rush University Medical Center
Pledger, Warren J., Ph.D. ..... H. Lee Moffitt Cancer Center & Research Institute
Plon, Sharon E., M.D., Ph.D. ..... Baylor College of Medicine
Podack, Eckhard R., M.D., Ph.D. ..... University of Miami, Coral Gables
Pollock, Brad H., M.P.H., Ph.D. ..... The University of Texas Health Science Center, San Antonio
Polverini, Peter J., D.D.S. ..... University of Michigan
Ponti, Antonio, M.D., M.P.H. ..... CPO-Piemonte
Postolache, Teodor T., M.D. ..... University of Maryland, Baltimore
Pounds, Kimberly L., Ph.D. ..... Texas Southern University
Pourmand, Nader, Ph.D. ..... University of California, Santa Cruz

Powell, Charles A., M.D. ..... Mount Sinai School of Medicine
Poynter, Jenny N., Ph.D., M.P.H. ..... The University of Minnesota, Twin Cities
Prabhakar, Bellur S., Ph.D. ..... University of Illinois at Chicago
Price, Richard J., Ph.D. ..... University of Virginia, Charlottesville
Primack, Brian A., M.D. ..... The University of Pittsburgh
Prins, Robert M., Ph.D. ..... University of California, Los Angeles
Prior, Fred W., Ph.D. ..... Washington University
Provan, Keith G., Ph.D. ..... University of Kentucky
Pulsipher, Michael A., M.D. ..... National Childhood Cancer Foundation

Q

Qian, Jiang, Ph.D. ..... The Johns Hopkins University
Quaranta, Vito, M.D. ..... Vanderbilt University
Quesenberry, Peter J., M.D. ..... Rhode Island Hospital
Quigley, James P., Ph.D. ..... Scripps Research Institute
Quintana, Yuri, Ph.D. ..... St. Jude Children's Research Hospital

R

Rabinowitz, Joshua D., M.D., Ph.D. ..... Princeton University
Rabius, Vance, Ph.D. ..... The University of Texas, Austin
Rader, Janet S., M.D. ..... Medical College of Wisconsin
Radhakrishnan, Ravi, Ph.D. ..... The University of Pennsylvania
Radvanyi, Laszlo G., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Ragin, Camille C., Ph.D., M.P.H. ..... Fox Chase Cancer Center
Rai, Shesh N., Ph.D. ..... University of Louisville
Rajan, Sunder S., Ph.D. ..... U.S. Food and Drug Administration
Ram, Prahlad T., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Ramakrishnan, Sundaram, Ph.D. ..... The University of Minnesota, Twin Cities
Ramakrishnan, Viswanathan, Ph.D. ..... Medical University of South Carolina
Rampersaud, Arfaan, Ph.D. ..... Columbus Nanoworks, Inc.
Ransom, Sean, Ph.D. ..... Tulane University
Rao, Chinthalapally V., Ph.D. ..... University of Oklahoma Health Sciences Center
Rao, Jianghong, Ph.D. ..... Stanford University
Rapkin, Bruce D., Ph.D. ..... Albert Einstein College of Medicine of Yeshiva University
Ratajczak, Mariusz Z., Sc.D., M.D., Ph.D. ..... University of Louisville
Rathmell, Jeffrey C., Ph.D. ..... Duke University
Ratner, Nancy, Ph.D. ..... Children's Hospital Medical Center, Cincinnati
Rauscher, Frank J., Ph.D. ..... Wistar Institute
Ray, Swapan K., Ph.D. ..... The University of South Carolina, Columbia
Reader, Steven, Ph.D. ..... University of South Florida
Reczek, Peter R., Ph.D. ..... Fertility Acoustics, Inc.
Reder, Jake, Ph.D. ..... Celdara Medical, LLC
Redmond, Carol K., Sc.D., Ph.D. ..... The University of Pittsburgh
Reeves, Anthony P., Ph.D. ..... Cornell University
Regisford, E. Gloria, Ph.D. ..... Prairie View Agricultural & Mechanical University
Reich, Daniel H., Ph.D. ..... The Johns Hopkins University

Reinhart-King, Cynthia A., Ph.D. ..... Cornell University
Reis, Isildinha M., Ph.D. ..... University of Miami School of Medicine
Rempel, Sandra A., Ph.D. ..... Henry Ford Health System
Renne, Rolf F., Ph.D. ..... University of Florida
Rennert, Gad, M.D., Ph.D. ..... Carmel Medical Center
Reshetnyak, Yana K., Ph.D. ..... University of Rhode Island
Retterer, Scott T., Ph.D. ..... Oak Ridge National Laboratory
Rhode, Peter R., Ph.D. ..... Altor Bioscience Corporation
Ribas, Antoni, M.D., Ph.D. ..... University of California, Los Angeles
Rice, John J., Ph.D. ..... IBM Research T. J. Watson Research Center
Richards, Nigel G. J., Ph.D. ..... University of Florida
Richards-Kortum, Rebecca R., Ph.D. ..... The University of Texas
Richardson, Adam D., Ph.D. ..... Sanford-Burnham Medical Research Institute
Richmond, Ann, Ph.D. ..... Vanderbilt University
Riedel-Kruse, Hans I., Ph.D. ..... Stanford University
Riethman, Harold C., Ph.D. ..... Wistar Institute
Rigas, Basil, Sc.D., M.D. ..... The State University New York, Stony Brook
Rimm, David L., M.D., Ph.D. ..... Yale University
Ringel, Matthew D., M.D. ..... The Ohio State University
Risch, Harvey A., M.D., Ph.D. ..... Yale University
Ritenbaugh, Cheryl K., Ph.D., M.P.H. ..... The University of Arizona
Rizi, Rahim R., Ph.D. ..... The University of Pennsylvania
Roberts, Charles T., Ph.D. ..... Oregon Health and Science University
Robertson, Gavin P., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center
Robertson, Keith D., Ph.D. ..... Georgia Health Sciences University
Robey, Frank A., Ph.D. ..... Ariavax, Inc.
Rodeck, Ulrich, M.D., Ph.D. ..... Thomas Jefferson University
Rodland, Karin D., Ph.D. ..... Battelle Pacific Northwest Laboratories
Rogatko, Andre, Ph.D. ..... Cedars-Sinai Medical Center
Rogers, Rick, Ph.D. ..... Harvard School of Public Health
Rollins, Andrew M., Ph.D. ..... Case Western Reserve University
Romkes, Marjorie, Ph.D. ..... The University of Pittsburgh
Rosania, Gus R., Ph.D. ..... University of Michigan
Rosenberg, Daniel W., Ph.D. ..... University of Connecticut School of Medicine & Dentistry
Rosenberg, Jonathan E., M.D., Ph.D. ..... Dana-Farber Cancer Institute
Rosenstein, Barry S., Ph.D. ..... Mount Sinai School of Medicine
Rosmarin, Alan G., M.D. ..... University of Massachusetts Medical School, Worcester
Ross, Mark M., Ph.D. ..... U.S. Food and Drug Administration
Roth, Jack, M.D. ..... Introgen Research Institute, Inc.
Roy, Hemant K., M.D. ..... Northshore University Healthsystem
Royce, Melanie E., M.D., Ph.D. ..... The University of New Mexico
Rozek, Laura, Ph.D. ..... University of Michigan
Rudek, Michelle A., Ph.D., Pharm.D. ..... The Johns Hopkins University
Ruggero, Davide, Ph.D. ..... University of California, San Francisco
Ruggiero, Laurie, Ph.D. ..... University of Illinois at Chicago
Runyan, Raymond B., Ph.D. ..... The University of Arizona
Rushton, Gerard, Ph.D. ..... University of Iowa
Russek, Stephen E., Ph.D. ..... National Institute of Standards and Technology

Russo, Jose, M.D. .....Fox Chase Cancer Center
Ruth, Thomas J., Ph.D. .....University of British Columbia
Rychak, Joshua J., Ph.D. .....Targeson, Inc.

S

Sabbadini, Roger A., Ph.D. .....LPath Therapeutics, Inc.
Saenger, Yvonne M., M.D. .....Mount Sinai School of Medicine
Saffer, Jeffrey D., Ph.D. .....Battelle Pacific Northwest Laboratories
Saiz, Leonor, Ph.D. ..... University of California, Davis
Sakamoto, Kathleen M., M.D., Ph.D. ..... Stanford University
Sakr, Wael A., M.D. .....Wayne State University
Saluja, Ashok K., Ph.D. .....The University of Minnesota, Twin Cities
Samlowski, Wolfram E., M.D. .....University of Nevada, Reno
Sanda, Martin G., M.D. .....Beth Israel Deaconess Medical Center
Sanders Thompson, Vetta L., Ph.D. ..... Washington University
Sanderson, Ralph D., Ph.D. ..... University of Alabama at Birmingham
Sandri-Goldin, Rozanne M., Ph.D. ..... University of California, Irvine
Sapsford-Medintz, Kim E., Ph.D. ..... U.S. Food and Drug Administration
Saraiya, Mona, M.D, M.P.H. .....Centers for Disease Control and Prevention
Sarkar, Fazlul H., Ph.D. .....Wayne State University
Saulnier Sholler, Giselle, M.D. ..... The University of Vermont & State Agricultural College
Sauro, Herbert M., Ph.D. .....University of Washington
Sausville, Edward A., M.D., Ph.D. ..... University of Maryland, Baltimore
Sauter, Edward R., M.D., Ph.D. .....University of North Dakota
Sayre, James W., Ph.D. ..... University of California, Los Angeles
Scadeng, Miriam, M.D. .....University of California, San Diego
Scarlata, Suzanne F., Ph.D. .....The State University of New York, Stony Brook
Scarpinato, Karin D., Ph.D. ..... Georgia Southern University
Schabath, Matthew B., Ph.D. .....H. Lee Moffitt Cancer Center & Research Institute
Schad, Peter A., Ph.D. .....Research Triangle Institute
Schellhase, Kenneth G., M.D., M.P.H. .....Medical College of Wisconsin
Schepkin, Victor D., Ph.D. ..... Florida State University
Scheurer, Michael E., Ph.D., M.P.H. ..... Baylor College of Medicine
Schiffman, Joshua D., M.D. .....The University of Utah
Schmainda, Kathleen M., Ph.D. .....Medical College of Wisconsin
Schnall, Mitchell D., M.D., Ph.D. .....American College of Radiology
Schneider, Erika, Ph.D. ..... Cleveland Clinic Foundation
Schootman, Mario, Ph.D. ..... Washington University
Schwartz, Anna L., Ph.D. .....Arizona State University
Schwartz, Joel L., D.M.D., M.D. .....University of Illinois at Chicago
Schwertfeger, Kathryn L., Ph.D. .....The University of Minnesota, Twin Cities
Seewaldt, Victoria L., M.D. .....Duke University
Segre, Daniel, Ph.D. .....Boston University
Senore, Carlo, M.D. .....CPO-Piemonte
Sethi, Ishwar K., Ph.D. ..... Oakland University
Shah, Manish A., M.D. ..... Weill Medical College of Cornell University
Shalloway, David I., Ph.D. .....Cornell University

Shannon, Jackilen, Ph.D., M.P.H. ..... Oregon Health and Science University
Shannon, Kevin M., M.D. ..... University of California, San Francisco
Shapiro, Charles L., M.D. ..... The Ohio State University
Shappell, Brian, M.B.A. ..... University of Notre Dame
Sharma, Arun K., Ph.D. ..... The Pennsylvania State University, Hershey Medical Center
Sharp, John G., Ph.D. ..... University of Nebraska Medical Center
Sharp, Stewart M., Ph.D. ..... AngioDynamics, Inc.
Sheng, Shijie, Ph.D. ..... Wayne State University
Sherry, Dean, Ph.D. ..... The University of Texas, Dallas
Shete, Sanjay, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Shi, Huidong, Ph.D. ..... Georgia Health Sciences University
Shibata, Darryl K., M.D. ..... The University of Southern California
Shields, Anthony F., M.D., Ph.D. ..... Wayne State University
Shin, Dong M., M.D. ..... Emory University
Shipp, Gregory W., M.D. ..... Nanosphere, Inc.
Shoreibah, Mohamed G., Ph.D. ..... Glycobiotics, Inc.
Short, Pamela F., Ph.D. ..... The Pennsylvania State University, University Park
Showe, Louise C., Ph.D. ..... Wistar Institute
Shreve, Andrew P., Ph.D. ..... Los Alamos National Laboratory
Shroyer, Kenneth R., M.D., Ph.D. ..... The State University of New York, Stony Brook
Shu, Xiao-Ou, M.D., Ph.D. ..... Vanderbilt University
Shuman, Ruth, Ph.D. ..... National Science Foundation
Shung, K. Kirk, Ph.D. ..... The University of Southern California
Shureiqi, Imad, M.D. ..... The University of Texas M.D. Anderson Cancer Center
Shyr, Yu, Ph.D. ..... Vanderbilt University
Silva, Matthew, Ph.D. ..... Amgen Incorporated
Silver, Robert B., Ph.D. ..... Wayne State University
Simeone, Diane M., M.D. ..... University of Michigan, Ann Arbor
Simon, George R., M.D. ..... Medical University of South Carolina
Simon, Sanford M., Ph.D. ..... Rockefeller University
Simpson, Kit N., Ph.D., M.P.H. ..... Medical University of South Carolina
Singh, Karan P., Ph.D. ..... The University of North Texas Health Science Center
Singh, Rakesh K., Ph.D. ..... University of Nebraska Medical Center
Singh, Sheila K., M.D., Ph.D. ..... McMaster University
Sinha, Samiran, Ph.D. ..... Texas A&M University System
Sinko, Patrick J., Ph.D. ..... Rutgers, The State University of New Jersey, New Brunswick
Siracusa, Linda D., Ph.D. ..... Thomas Jefferson University
Siu, Lillian L., M.D. ..... University of Toronto
Slavin, Joanne L., Ph.D. ..... The University of Minnesota, Twin Cities
Sloan, Andrew E., M.D., Ph.D. ..... Case Western Reserve University
Slovin, Susan F., M.D., Ph.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Smith, Jill P., M.D. ..... The Pennsylvania State University, Hershey Medical Center
Smith, Thomas J., M.D. ..... Virginia Commonwealth University
Smythe, William R., M.D. ..... Texas A&M University Health Science Center
Sneed, Jeannie, Ph.D. ..... U.S. Department of Agriculture
Sokolov, Konstantin V., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Soliman, Amr, M.D., Ph.D. ..... University of Michigan, Ann Arbor
Solit, David B., M.D. ..... Memorial Sloan-Kettering Institute for Cancer Research

Solomon, William B., M.D. ..... The State University of New York, Downstate Medical Center
Sondak, Vernon K., M.D. .....H. Lee Moffitt Cancer Center & Research Institute
Song, Chang W., Ph.D. .....The University of Minnesota, Twin Cities
Sorensen, Alma G., M.D. ..... Massachusetts General Hospital
Soteropoulos, Patricia, Ph.D. .....Public Health Research Institute
Sotomayor, Eduardo M., M.D. .....H. Lee Moffitt Cancer Center & Research Institute
Sousa, Karen H., Ph.D., R.N., F.A.A.N. .....University of Colorado, Denver
Sousa, Rui J., Ph.D. ..... The University of Texas Health Science Center, San Antonio
Sowers, Lawrence C., Ph.D. .....The University of Texas Medical Branch at Galveston
Spears, Patricia A., B.S. ..... North Carolina State University, Raleigh
Spiegelman, Vladimir S., M.D., Ph.D. .....AMC Cancer Research Center
Springer, Charles S., Ph.D. ..... Oregon Health and Science University
Sreekumar, Arun, Ph.D. ..... Baylor College of Medicine
Stebe, Kathleen J., Ph.D. .....The University of Pennsylvania
Steinmetz, Nicole F., Ph.D. ..... Case Western Reserve University
Sterling, Richard K., M.D. .....Virginia Commonwealth University
Stevens, Alan B., Ph.D. ..... Scott and White Memorial Hospital
Stevens, Victoria L., Ph.D. .....American Cancer Society, Inc.
Stidley, Christine A., Ph.D. .....The University of New Mexico
Stojadinovic, Alexander, M.D. .....Walter Reed Army Medical Center
Stoner, Gary, Ph.D. .....Medical College of Wisconsin
Storer, Barry E., Ph.D. .....Fred Hutchinson Cancer Research Center
Strasser, Andrew, Ph.D. .....The University of Pennsylvania
Stratton, Steven P., Ph.D. ..... The University of Arizona
Street, Richard L., Ph.D. ..... Baylor College of Medicine
Strickler, James, Ph.D. ..... Lifesensors, Inc.
Strome, Scott E., M.D. ..... University of Maryland, Baltimore
Strouse, Geoffrey F., Ph.D. ..... Florida State University
Studzinski, George P., M.D., Ph.D. .....University of Medicine and Dentistry of New Jersey-Robert W. Johnson Medical School
Sturgeon, Susan R., Dr.P.H., M.P.H. .....University of Massachusetts Amherst
Su, Gloria H.T., Ph.D. .....Columbia University
Suman, Vera J., Ph.D. .....Mayo Clinic
Sun, Duxin, Ph.D. .....University of Michigan, Ann Arbor
Sun, Xiao-Hong, Ph.D. .....Oklahoma Medical Research Foundation
Sunderland, John, Ph.D. .....University of Iowa
Svenson, Sonke, Ph.D. .....Cerulean Pharma Inc.
Swanson, Basil I., M.D., Ph.D. .....Los Alamos National Laboratory
Swartz, Harold M., M.D., Ph.D. .....Dartmouth College
Swede, Helen, Ph.D. .....University of Connecticut School of Medicine & Dentistry
Sweeney, Carol, Ph.D. .....The University of Utah
Sweetenham, John W., M.D. .....University of Colorado, Denver
Syed, Viqar, Ph.D. ..... Henry M. Jackson Foundation
Symanowski, James T., Ph.D. ..... Nevada Cancer Institute
Synold, Timothy W., Pharm.D. ..... Beckman Research Institute of City of Hope
Szmacinski, Henryk, Ph.D. ..... University of Maryland, Baltimore

T

Tackett, Alan J., Ph.D. ..... University of Arkansas Medical Sciences, Little Rock
Taichman, Russell S., D.M.D., D.M.Sc. ..... University of Michigan, Ann Arbor
Tainsky, Michael A., Ph.D. ..... Wayne State University
Taioli, Emanuela, M.D., Ph.D. ..... Feinstein Institute for Medical Research
Talcott, James A., M.D. ..... Massachusetts General Hospital
Tan, Ming T., Ph.D. ..... University of Maryland, Baltimore
Tannenbaum, Charles S., Ph.D. ..... Cleveland Clinic Foundation
Taouli, Bachir, M.D. ..... Mount Sinai School of Medicine
Tarler, Matthew D., Ph.D. ..... Cleveland Medical Devices, Inc.
Taron, Christopher, Ph.D. ..... New England Biolabs, Inc.
Tasciotti, Ennio, Ph.D. ..... Methodist Hospital Research Institute
Taylor, Ann G., Ed.D., R.N., F.A.A.N. ..... University of Virginia, Charlottesville
Taylor, D. Lansing, Ph.D. ..... Carnegie-Mellon University
Taylor, Deanne M., Ph.D. ..... Reproductive Medicine Associates of New Jersey
Taylor, Douglas D., Ph.D. ..... University of Louisville
Taylor, Maureen, Ph.D. ..... Imperial College of Science-Technology
Taylor, Richard E., Ph.D. ..... University of Notre Dame
Terrazas, Alejandro, Ph.D. ..... Mediabalance, Inc.
Testa, Joseph R., Ph.D. ..... Fox Chase Cancer Center
Tew, Kenneth D., Sc.D., Ph.D. ..... Medical University of South Carolina
Tewari, Muneesh, M.D., Ph.D. ..... Fred Hutchinson Cancer Research Center
Thomas, James P., M.D., Ph.D. ..... University of Wisconsin, Madison
Thomas, Nancy E., M.D., Ph.D. ..... University of North Carolina at Chapel Hill
Thomas-Tikhonenko, Andrei, Ph.D. ..... The University of Pennsylvania
Thompson, Cheryl L., Ph.D. ..... Case Western Reserve University
Thompson, E. Aubrey, Ph.D. ..... Mayo Clinic
Thompson, Katherine H., Ph.D., Pharm.D. ..... University of British Columbia
Threadgill, David W., Ph.D. ..... North Carolina State University
Ting, Angela H., Ph.D. ..... Cleveland Clinic Foundation
Tinmouth, Jill, M.D., Ph.D. ..... University of Toronto
Tockman, Melvyn S., M.D., Ph.D. ..... University of South Florida
Toker, Alex, Ph.D. ..... Beth Israel Deaconess Medical Center
Tomalia, Donald A., Ph.D. ..... Dendritic Nanotechnologies, Inc.
Toribara, Neil W., M.D., Ph.D. ..... Denver Health and Hospital Authority
Tosteson, Tor D., Sc.D. ..... Dartmouth College
Towner, Rheal A., Ph.D. ..... Oklahoma Medical Research Foundation
Trede, Nikolaus S., M.D., Ph.D. ..... The University of Utah
Triche, Timothy J., M.D., Ph.D. ..... Children's Hospital, Los Angeles
Tricot, Guido J., M.D., Ph.D. ..... The University of Utah
Triozzi, Pierre L., M.D. ..... Cleveland Clinic Foundation
Troyer, Dean A., M.D. ..... Eastern Virginia Medical School
Tsaprailis, George, Ph.D. ..... The University of Arizona
Tsien, Roger Y., Ph.D. ..... University of California, San Diego
Tsodikov, Alexander, Ph.D. ..... University of Michigan, Ann Arbor
Tsourkas, Andrew, Ph.D. ..... The University of Pennsylvania
Tunnell, James W., Ph.D. ..... The University of Texas, Austin

Turchi, John J., Ph.D. ..... Indiana University-Purdue University Indianapolis
Turk, Benjamin E., Ph.D. ..... Yale University
Turkheimer, Eric N., Ph.D. .....University of Virginia, Charlottesville
Turkson, James K., Ph.D. .....H. Lee Moffitt Cancer Center & Research Institute
Turner, Timothy, Ph.D. ..... Tuskegee University
Tuschl, Thomas, Ph.D. .....New York Academy of Sciences
Tyler, Douglas S., M.D. .....Duke University
Tyler, Jessica K., Ph.D. .....The University of Texas Health Science Center, Houston
Tyson, John J., Ph.D. ..... Virginia Polytechnic Institute and State University

U

Uckun, Fatih M., M.D., Ph.D. .....Children's Hospital, Los Angeles
Umar, Shahid, Ph.D. ..... University of Kansas Medical Center
Unal, Orhan, Ph.D. .....University of Wisconsin, Madison
Unger, Evan C., M.D. ..... Nuvox Pharma, LLC
Uno, Hajime, Ph.D. ..... Dana-Farber Cancer Institute

V

Vadivelu, Santhosh K., Ph.D. ..... Canaan Partners
Vaidyanathan, Ganesan, Ph.D. .....Duke University
Van Besien, Koen W., M.D., Ph.D. .....The University of Chicago
Van Golen, Cynthia M., Ph.D. ..... Delaware State University
Van Ness, Brian G., Ph.D. .....The University of Minnesota, Twin Cities
Vanness, David J., Ph.D. .....University of Wisconsin, Madison
Van Waes, Carter, M.D., Ph.D. .....National Institute on Deafness and Other Communication Disorders
Van Wijnen, Andre J., Ph.D. .....University of Massachusetts Medical School, Worcester
Varadi, Gyula, Ph.D. .....Biochemics, Inc.
Vazquez, Alexei, Ph.D. .....University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Velie, Ellen M., M.P.H., Ph.D. .....Michigan State University
Veltri, Robert W., Ph.D. .....The Johns Hopkins University
Vera, David R., Ph.D. .....University of California, San Diego
Versalovic, James, M.D., Ph.D. ..... Baylor College of Medicine
Verschraegen, Claire F., M.D. .....The University of Vermont & State Agricultural College
Viator, John A., Ph.D. .....University of Missouri-Columbia
Vidrine, Damon J., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Vieweg, Johannes W.G., M.D. ..... University of Florida
Vincek, Vladimir, M.D., Ph.D. ..... University of Miami School of Medicine
Visovsky, Constance G., Ph.D., R.N. ..... University of South Florida
Visuri, Steven R., Ph.D. ..... Prodesse, Inc.
Vogt, Andreas, Ph.D. ..... The University of Pittsburgh
Vykoukal, Jody V., Ph.D. ..... The University of Texas M.D. Anderson Cancer Center

W

Wachsman, William, M.D., Ph.D. ..... University of California, San Diego
Wagenaar, Douglas J., Ph.D. ..... Gamma Medica-Ideas, Inc.
Waggoner, Alan S., Ph.D. ..... Mellon Pitts Corporation
Wagman, Lawrence D., M.D. ..... St. Joseph Hospital
Wahl, Richard L., M.D. ..... The Johns Hopkins University
Waldrop-Valverde, Drenna, Ph.D. ..... Emory University
Wali, Ramesh K., Ph.D. ..... Northshore University Healthsystem
Walker, Barbara W., Ph.D., J.D. ..... Self-Employed
Walkosz, Barbara, Ph.D. ..... Klein Buendel, Inc.
Waller, Edmund K., M.D., Ph.D. ..... Emory University
Walsh, Judith M.E., M.D., M.P.H. ..... University of California, San Francisco
Wan, Yu-Jui Y., Ph.D. ..... University of Kansas Medical Center
Wandersman, Abraham H., Ph.D. ..... University of South Carolina, Columbia
Wang, Binghe, Ph.D. ..... Georgia State University
Wang, Catharine, Ph.D. ..... Fox Chase Cancer Center
Wang, Edwin, Ph.D. ..... National Research Council Canada
Wang, Eugenia, Ph.D. ..... University of Louisville
Wang, Ge, Ph.D. ..... Virginia Polytechnic Institute and State University
Wang, Jean C.Y., M.D., Ph.D. ..... University of Toronto
Wang, Jiwu, Ph.D. ..... Allele Biotechnology and Pharmaceuticals
Wang, Qian, Ph.D. ..... University of South Carolina, Columbia
Wang, Qingjun, Ph.D. ..... University of Kentucky
Wang, Quntian, Ph.D. ..... University of Illinois, Chicago
Wang, Shaomeng, Ph.D. ..... University of Michigan, Ann Arbor
Wang, Timothy C., M.D. ..... University of Massachusetts Medical School, Worcester
Wang, Xiao-Fan, Ph.D. ..... Duke University
Wang, Xiao-Jing, M.D., Ph.D. ..... University of Colorado Denver
Ward, Elizabeth M., Ph.D. ..... American Cancer Society, Inc.
Ward, John H., M.D. ..... The University of Utah
Wargovich, Michael, Ph.D. ..... Medical University of South Carolina
Warrick, Cynthia A., Ph.D. ..... Elizabeth City State University
Warrington, Janet A., Ph.D. ..... Affymetrix, Inc.
Washington, Mary K., M.D., Ph.D. ..... Vanderbilt University
Wasik, Mariusz A., M.D. ..... The University of Pennsylvania
Waterman, Marian L., Ph.D. ..... University of California, Irvine
Watkins, Simon C., Ph.D. ..... The University of Pittsburgh
Watson, Ronald R., Ph.D. ..... Mentors of Challenged Adults, Inc.
Webster, Thomas J., Ph.D. ..... Brown University
Wei, Esther, Sc.D. ..... California Pacific Medical Center Research Institute
Weichert, Jamey P., Ph.D. ..... University of Wisconsin, Madison
Weier, Heinz-Ulrich G., Ph.D. ..... Lawrence Berkeley National Laboratory
Weilbaecher, Katherine N., M.D. ..... Washington University
Weinberg, Andrew D., Ph.D. ..... Providence Portland Medical Center
Weinberg, Armin D., Ph.D. ..... Baylor College of Medicine
Weinberg, David S., M.D. ..... Fox Chase Cancer Center
Weinberg, Robert A., Ph.D. ..... Whitehead Institute for Biomedical Research

Weinfurt, Kevin P., Ph.D. ..... Duke University
Weinstein, Harel, Sc.D. ..... Weill Medical College of Cornell University
Weir, Hannah K., Ph.D. ..... Centers for Disease Control and Prevention
Weiss, Heidi L, Ph.D. ..... The University of Texas Medical Branch at Galveston
Weiss, Joseph F., Ph.D. ..... U.S. Department of Energy
Weiss, Robert H., M.D. ..... University of California, Davis
Wek, Ronald C., Ph.D. ..... Indiana University-Purdue University Indianapolis
Welch, Michael J., Ph.D. ..... Washington University
West, Dee W., Ph.D. ..... Cancer Prevention Institute of California
Wetzler, Meir, M.D. ..... Roswell Park Cancer Institute
Whang, Edward E., M.D. ..... Brigham and Women's Hospital
Wheatley, Barnarese P., Ed.D., M.P.H. ..... Alameda County Medical Center
Whiteside, Theresa L., Ph.D. ..... The University of Pittsburgh
Whorton, Elbert B., Ph.D. ..... The University of Texas Medical Branch at Galveston
Wickstrom, Eric, Ph.D. ..... Thomas Jefferson University
Widom, Jonathan, Ph.D. ..... Northwestern University, Chicago
Wieder, Robert, M.D., Ph.D. ..... University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School
Wiener, Erik C., Ph.D. ..... The University of Pittsburgh
Wiesenfeld, Martin, M.D. ..... Cedar Rapids Oncology Project
Wiley, Patti, M.B.A. ..... On the Wings of Angels
Wilkie, Diana J., Ph.D., R.N., F.A.A.N. ..... University of Illinois, Chicago
Willett, Christopher G., M.D. ..... Duke University
Willey, James C., M.D. ..... Medical College of Ohio
Williams, Donna L., Dr.P.H., M.P.H. ..... The Louisiana State University Health Science Center
Williams, John C., Ph.D. ..... Beckman Research Institute of City of Hope
Williard, Paul G., Ph.D. ..... Brown University
Wilson, Brian C., Ph.D. ..... University of Toronto
Wilson, Bridget S., Ph.D. ..... The University of New Mexico Health Sciences Center
Wilson, Thaddeus A., Ph.D. ..... University of Tennessee Health Science Center
Winkfield, Karen M., M.D., Ph.D. ..... Massachusetts General Hospital
Winters, Thomas A., Ph.D. ..... National Institutes of Health
Wiseman, Robert W., Ph.D. ..... Michigan State University
Wistuba, Ignacio I., M.D. ..... The University of Texas Southwestern Medical Center, Dallas
Witzig, Thomas E., M.D. ..... Mayo Clinic
Wolchok, Jedd D., M.D., Ph.D. ..... Memorial Sloan-Kettering Institute for Cancer Research
Wolff, Steven N., M.D. ..... Meharry Medical College
Wollenweber, Scott D., Ph.D. ..... Wake Forest University Health Sciences
Woloschak, Gayle E., Ph.D. ..... Northwestern University
Wong, Kwok K., M.D., Ph.D. ..... Dana-Farber Cancer Institute
Wong, Melissa H., Ph.D. ..... Oregon Health and Science University
Wong, Stephen T.C., Ph.D. ..... Methodist Hospital Research Institute
Wood, Charles, Ph.D. ..... University of Nebraska Lincoln
Wood, Marie E., M.D. ..... The University of Vermont & State Agricultural College
Woodall, W. Gill, Ph.D. ..... The University of New Mexico
Woodgett, James R., Ph.D. ..... Mount Sinai Hospital-Samuel Lunenfeld Research Institute
Woods, Erik J., Ph.D. ..... General Biotechnology, LLC

Woods, Virgil L., M.D. .....University of California, San Diego
Worsham, Maria J., Ph.D. .....Henry Ford Health System
Wright, Kenneth L., Ph.D. .....H. Lee Moffitt Cancer Center & Research Institute
Wright, Michael E., Ph.D. .....University of Iowa
Wroblewski, Dariusz, Ph.D. .....Bioformatix, Inc.
Wu, Anna M., Ph.D. .....University of California, Los Angeles
Wu, Lily, M.D., Ph.D. .....University of California, Los Angeles
Wu, Mingming, Ph.D. .....Cornell University
Wu, Xifeng, M.D., Ph.D. .....The University of Texas M.D. Anderson Cancer Center

X

Xia, Younan, Ph.D. .....Georgia Institute of Technology
Xia, Yu, Ph.D. .....Boston University
Xiao, Hua, M.D., Ph.D. .....Michigan State University
Xie, Jingwu, Ph.D. .....Indiana University-Purdue University Indianapolis
Xing, Lianping, M.D., Ph.D. .....University of Rochester
Xu, Xiangxi M., Ph.D. .....University of Miami School of Medicine
Xu, Yan, Ph.D. .....Indiana University-Purdue University Indianapolis
Xu, Yang, Ph.D. .....University of California, San Diego

Y

Yakovlev, Vladislav V., Ph.D. .....University of Wisconsin, Milwaukee
Yang, Chung S., Ph.D. .....Rutgers, The State University of New Jersey, New Brunswick
Yang, Guoliang, Ph.D. .....Drexel University
Yang, Jianguo, Ph.D. .....Genzyme Corporation
Yang, Lily, M.D., Ph.D. .....Emory University
Yang, Wancai, M.D. .....University of Illinois, Chicago
Yang, Wei T., M.B.B.S. .....The University of Texas M.D. Anderson Cancer Center
Yang, Xiao-Feng, M.D., Ph.D. .....Temple University
Yang, Yu-Chung, Ph.D. .....Case Western Reserve University
Yankeelov, Thomas E., Ph.D. .....Vanderbilt University
Yannelli, John R., Ph.D. .....University of Kentucky
Yarmush, Martin L., M.D., Ph.D. .....Biolok International, Inc.
Yeatman, Timothy J., M.D. .....H. Lee Moffitt Cancer Center & Research Institute
Yeger, Herman, Ph.D. .....University of Toronto
Yi, Qing, M.D., Ph.D. .....The University of Texas M.D. Anderson Cancer Center
Yost, David A., Ph.D. .....Innovative Biosensors, Inc.
You, Lingchong, Ph.D. .....Duke University
Younes, Anas, M.D. .....The University of Texas M.D. Anderson Cancer Center
Young, Jeanne P. .....Childhood Brain Tumor Foundation
Yuan, Jian-Min, M.D., Ph.D. .....The University of Pittsburgh
Yun, Wenbing, Ph.D. .....Xradia, Inc.

Z

Zaia, Joseph, Ph.D. ..... Boston University Medical Campus
Zamboni, William C., Ph.D., Pharm.D. ..... University of North Carolina at Chapel Hill
Zhang, Bin, M.D., Ph.D. ..... The University of Texas Health Science Center, San Antonio
Zhang, David Y., M.D., Ph.D. ..... Mount Sinai School of Medicine
Zhang, Jian-Ting, Ph.D. ..... Indiana University-Purdue University Indianapolis
Zhang, Lin, Ph.D. ..... The University of Pittsburgh
Zhang, Min, M.D., Ph.D. ..... Purdue University, West Lafayette
Zhang, Ruiwen, M.D., Ph.D. ..... Texas Tech University
Zhang, Wei, Ph.D. ..... The University of Texas M.D. Anderson Cancer Center
Zhang, Xiaoliu, M.D., Ph.D. ..... University of Houston
Zhang, Xin A., M.D. ..... University of Tennessee Health Science Center
Zhao, Zhizhuang J., Ph.D. ..... Vanderbilt University
Zheng, Bin, Ph.D. ..... The University of Pittsburgh
Zheng, Pan, M.D., Ph.D. ..... University of Michigan at Ann Arbor
Zheng, Tim, M.D., Ph.D. ..... The University of Pennsylvania
Zheng, Yi, Ph.D. ..... Children's Hospital Medical Center, Cincinnati
Zhou, Binhua P., M.D., Ph.D. ..... University of Kentucky
Zhou, Chuan, Ph.D. ..... University of Michigan, Ann Arbor
Zhou, Jin-Rong, Ph.D. ..... Beth Israel Deaconess Medical Center
Zhou, Rong, Ph.D. ..... The University of Pennsylvania
Zhou, Shibin, M.D., Ph.D. ..... The Johns Hopkins University
Zhu, Weimo, Ph.D. ..... University of Illinois, Urbana-Champaign
Zhu, Yong, Ph.D. ..... Yale University
Zi, Xiaolin, M.D., Ph.D. ..... University of California, Irvine
Zon, Robin T., M.D. ..... Memorial Hospital of South Bend
Zondlo, Neal J., Ph.D. ..... University of Delaware
Zong, Hui, Ph.D. ..... University of Oregon
Zuckerman, Kenneth S., M.D. ..... University of South Florida
Zutter, Mary M., M.D. ..... Vanderbilt University

Total Number of Reviewers: 1,600

Appendix E: NCI Grant Mechanisms and Descriptions

Below is a brief description of NIH funding mechanisms. Additional information on grants, contracts, and extramural policy notices may be found by viewing the NCI DEA Web page on Grants Guidelines and Descriptions at **http://deainfo.nci.nih.gov/flash/awards.htm**.

C Series: Research Construction Programs	
C06	**Research Facilities Construction Grants** To provide matching Federal funds, up to 75 percent, for construction or major remodeling to create new research facilities, which in addition to basic research laboratories may include, under certain circumstances, animal facilities and/or limited clinical facilities where they are an integral part of an overall research effort.
D Series: Training Projects	
D43	**International Training Grants in Epidemiology** To improve and expand epidemiologic research and the utilization of epidemiology in clinical trials and prevention research in foreign countries through support of training programs for foreign health professionals, technicians, and other health care workers.
F Series: Fellowship Programs	
F31	**Predoctoral Individual National Research Service Award (NRSA)** To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).
F31	**Predoctoral Fellowship—Minority Students** A fellowship award that provides predoctoral minority students with supervised research training in specified health and health-related areas leading toward a research degree (e.g., Ph.D.).
F31	**National Research Service Award for Individual Postdoctoral Fellows** To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F32	**National Research Service Award for Individual Postdoctoral Fellows** To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas.
F33	**National Research Service Award for Senior Fellows** To provide opportunities for experienced scientists to make major changes in the direction of research careers, broaden scientific backgrounds, acquire new research capabilities, enlarge command of an allied research field, or take time from regular professional responsibilities to increase capabilities to engage in health-related research.

K Series: Career Development Programs	
K01	**The Howard Temin Award (no longer supported through use of the K01 by the NCI; see the K99/R00 Award)** A previously used NCI-specific variant of the NIH Mentored Research Scientist Development Award that was designed to provide research scientists with an additional period of sponsored research experience as a way to gain expertise in a research area new to the applicant or in an area that would demonstrably enhance the applicant's scientific career.
K01	**Mentored Career Development Award for Underrepresented Minorities** To support scientists committed to research who are in need of both advanced research training and additional experience.
K05	**Established Investigator Award in Cancer Prevention, Control, Behavioral, and Population Research** To support scientists qualified to pursue independent research that would extend the research program of the sponsoring institution, or to direct an essential part of this program.
K07	**Cancer Prevention, Control, Behavioral, and Population Sciences Career Development Award** To support the postdoctoral career development of investigators who are committed to academic research careers in cancer prevention, control, behavioral, epidemiological, and/or the population sciences. It supports up to 5 years of combined didactic and supervised (i.e., mentored) research experiences to acquire the methodological and theoretical research skills needed to become an independent scientist. The very broad nature of the prevention, control, and population sciences makes it applicable to those individuals doctorally trained in the basic sciences, medicine, behavioral sciences, and/or public health. The K07 award has been expanded from a scope limited to "preventive oncology" to include the entire spectrum of fields that are of vital importance to cancer prevention and control such as nutrition, epidemiology, and behavioral sciences.
K08	**Mentored Clinical Scientists Development Award** To provide the opportunity for promising medical scientists with demonstrated aptitude to develop into independent investigators, or for faculty members to pursue research in categorical areas applicable to the awarding unit, and to aid in filling the academic faculty gap in specific shortage areas within U.S. health professions institutions.
K08	**Mentored Clinical Scientists Development Award—Minorities in Clinical Oncology** A specialized type of Mentored Clinical Scientist Developmental Award (K08) that supports the development of outstanding clinical research scientists, with this type being reserved for qualified individuals from underrepresented minority groups. Both types of K08 awards support periods of specialized study for clinically trained professionals who are committed to careers in research and who have the potential to develop into independent investigators. The K08 awards for Minorities in Clinical Oncology are distinct and important because they provide opportunities for promising medical scientists with demonstrated aptitudes who belong to underrepresented minority groups to develop into independent investigators, or for faculty members who belong to underrepresented minority groups to pursue research aspects of categorical areas applicable to the awarding unit(s), and aid in filling the academic faculty gaps in these shortage areas within U.S. health professions institutions.

K12	**Institutional Clinical Oncology Research Career Development Award** To support a newly trained clinician appointed by an institution for development of independent research skills and experience in a fundamental science within the framework of an interdisciplinary research and development program.
K22	**The NCI Transition Career Development Award for Underrepresented Minorities** To provide support to outstanding newly trained basic or clinical investigators to develop their independent research skills through a two-phase program: an initial period involving an intramural appointment at the NIH and a final period of support at an extramural institution. The award is intended to facilitate the establishment of a record of independent research by the investigator to sustain or promote a successful research career.
K22	**The NCI Scholars Program** To provide an opportunity for outstanding new investigators to begin their independent research careers, first within the special environment of the NCI and then at an institution of their choice. Specifically, this Program provides the necessary resources to initiate an independent research program of 3 to 4 years at the NCI, followed by an extramural funding mechanism (K22) to support their research program for 2 years at the extramural institution to which they are recruited.
K23	**Mentored Patient-Oriented Research Career Development Award** To provide support for the career development of investigators who have made a commitment to focus their research endeavors on patient-oriented research. This mechanism provides support for a 3-year minimum up to a 5-year period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators.
K23	**Mentored Patient-Oriented Research Career Development Award for Underrepresented Minorities** To support the career development of investigators who have made a commitment to focus their research on patient-oriented research. This mechanism provides support for a period of supervised study and research for clinically trained professionals who have the potential to develop into productive clinical investigators in patient-oriented research.
K24	**Mid-Career Investigator Award in Patient-Oriented Research** To provide support for clinicians to allow them protected time to devote to patient-oriented research and to act as mentors for beginning clinical investigators. The target candidates are outstanding clinical scientists engaged in patient-oriented research who are within 15 years of their specialty training, who can demonstrate the need for a period of intensive research focus as a means of enhancing their clinical research careers, and who are committed to mentoring the next generation of clinical investigators in patient-oriented research.
K25	**Mentored Quantitative Research Career Development Award** This award allows an independent scientist in a highly technical field of research to identify an appropriate mentor with extensive experience in cancer research and to receive the necessary training and career development required to become involved in multidisciplinary cancer research.

K99/ R00	**NIH Pathway to Independence (PI) Award** The Pathway to Independence Award, which is part of the NIH Roadmap Initiative but is known as the Howard Temin Award within the NCI, will provide up to 5 years of support consisting of two phases. The initial phase will provide 1 to 2 years of mentored support for highly promising postdoctoral research scientists. This phase will be followed by up to 3 years of independent support contingent on securing an independent research position. Award recipients will be expected to compete successfully for independent R01 support from the NIH during the career transition award period. The PI Award is limited to postdoctoral trainees within 5 years of completion of their training who propose research relevant to the mission of one or more of the participating NIH Institutes and Centers.
P Series: Research Program Projects and Centers	
P01	**Research Program Projects** To support multidisciplinary or multifaceted research programs that have a focused theme. Each component project should be directly related to and contribute to the common theme.
P20	**Exploratory Grants** To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers.
P30	**Center Core Grants** To support shared use of resources and facilities for categorical research by investigators from different disciplines who provide a multidisciplinary approach to a joint research effort, or by investigators from the same discipline who focus on a common research problem. The core grant is integrated with the Center's component projects or Program Projects, though funded independently from them. By providing more accessible resources, this support is expected to assure greater productivity than that provided through the separate projects and Program Projects.
P50	**Specialized Center Grants** To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. This spectrum of activities comprises a multidisciplinary attack on a specific disease or biomedical problem area. These grants differ from Program Project grants in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division, and subsequently receive continuous attention from its staff. Centers also may serve as regional or national resources for special research purposes.

R Series: Research Projects	
R01	**Research Project** Grants are awarded to institutions to allow a Principal Investigator to pursue a scientific focus or objective in his or her area of interest and competence. Institutional sponsorship assures the NIH that the institution will provide facilities necessary to conduct the research and will be accountable for the grant funds. Applications are accepted for health-related research and development in all areas within the scope of the NIH's mission.
R03	**Small Research Grants** Small grants provide research support, specifically limited in time and amount, for activities such as pilot projects, testing of new techniques, or feasibility studies of innovative, high-risk research, which would provide a basis for more extended research.
R13	**Conferences** The NIH provides funding for conferences to coordinate, exchange, and disseminate information related to its program interests. Generally, such awards are limited to participation with other organizations in supporting conferences rather than provision of sole support. Costs eligible for support include salaries, consultant services, equipment rental, travel, supplies, conference services, and publications. Prospective applicants are encouraged to inquire in advance concerning possible interest on the part of an awarding Institute/Center (IC), and to obtain more information on application procedures and costs.
R15	**The NIH Academic Research Enhancement Awards (AREA)** To enhance the research environment of educational institutions that have not been traditional recipients of NIH research funds, this award provides limited funds to those institutions' faculty members to develop new research projects or expand ongoing research activities in health sciences and to encourage students to participate in the research activity. As funds are anticipated to continue to be available each year, the NIH is now inviting applications for AREA grants through a standing, ongoing Program Announcement.
R21	**Exploratory/Developmental Grants** To encourage the development of new research activities in categorical program areas. (Support generally is restricted in the level of support and duration.)
R24	**Resource-Related Research Projects** To support research projects that will enhance the capability of resources to serve biomedical research.

R25E	**Cancer Education Grant Program (CEGP)** A flexible, curriculum-driven program aimed at developing and sustaining innovative educational approaches that ultimately will have an impact on reducing cancer incidence, mortality, and morbidity, as well as on improving the quality of life of cancer patients. The CEGP accepts investigator-initiated grant applications that pursue a wide spectrum of objectives ranging from short courses; to the development of new curricula in academic institutions; to national forums and seminar series; to hands-on workshop experiences for the continuing education of health care professionals, biomedical researchers, and the lay community; to structured short-term research experiences designed to motivate high school, college, medical, dental, and other health professional students to pursue careers in cancer research. Education grants can focus on education activities before, during, and after the completion of a doctoral-level degree, as long as they address a need that is not fulfilled adequately by any other grant mechanism available at the NIH, and are dedicated to areas of particular concern to the National Cancer Program.
R25T	**Cancer Education and Career Development Program** To support the development and implementation of curriculum-dependent, team-oriented programs to train predoctoral and postdoctoral candidates in cancer research team settings that are highly interdisciplinary and collaborative. This specialized program is not only particularly applicable to the behavioral, prevention, control, nutrition, and population sciences but also should be considered by other areas of research (e.g., imaging, pathology) that will require sustained leadership, dedicated faculty time, specialized curriculum development and implementation, interdisciplinary research environments, and more than one mentor per program participant to achieve their education and research career development objectives.
R33	**Exploratory/Developmental Grants, Phase II** To provide a second phase for support of innovative exploratory and developmental research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants who demonstrate program competency equivalent to that expected under R33.
R37	**Method to Extend Research in Time (MERIT) Award** To provide long-term grant support to investigators whose research competence and productivity are distinctly superior and who are highly likely to continue to perform in an outstanding manner. Investigators may not apply for a MERIT Award. Program staff and/or members of the cognizant National Advisory Council/Board will identify candidates for the MERIT Award during the course of review of competing research grant applications prepared and submitted in accordance with regular Public Health Service (PHS) requirements.

Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs

The NIH welcomes grant applications from small businesses in any biomedical or behavioral research area as described in the solicitations below. Support under the SBIR program is normally provided for 6 months/$100,000 for Phase I, and 2 years/$500,000 for Phase II. However, applicants may propose longer periods of time and greater amounts of funds necessary for completion of the project.

R41	**STTR Grants, Phase I** To support cooperative research and development (R&D) projects between small business concerns and research institutions, limited in time and amount; to establish the technical merit and feasibility of ideas that have potential for commercialization.
R42	**STTR Grants, Phase II** To support in-depth development of cooperative R&D projects between small business concerns and research institutions, limited in time and amount, whose feasibility has been established in Phase I and that have potential for commercial products or services.
R43	**SBIR Grants, Phase I** To support projects, limited in time and amount, to establish the technical merit and feasibility of R&D ideas that may ultimately lead to commercial products or services.
R44	**SBIR Grants, Phase II** To support in-depth development of R&D ideas whose feasibility has been established in Phase I and that are likely to result in commercial products or services.
R55	**James A. Shannon Director's Award** To provide a limited award to investigators to further develop, test, and refine research techniques; perform secondary analysis of available data sets; test the feasibility of innovative and creative approaches; and conduct other discrete projects that can demonstrate their research capabilities and lend additional weight to their already meritorious applications.
R56	**High-Priority, Short-Term Project Award** Begun in FY2005, this grant provides funds for 1- or 2-year high-priority new or competing renewal R01 applications that fall just outside the limits of funding of the participating NIH Institutes and Centers (ICs); recipients of R56 awards will be selected by IC staff from R01 applications that fall at or near the payline margins.

S Series: Research-Related Programs	
SC1	**Research Enhancement Award** Individual investigator-initiated research projects aimed at developing researchers at minority-serving institutions (MSIs) to a stage where they can transition successfully to other extramural support (R01 or equivalent).
SC2	**Pilot Research Project** Individual investigator-initiated pilot research projects for faculty at minority-serving institutions (MSIs) to generate preliminary data for a more ambitious research project.
S06	**Minority Biomedical Research Support (MBRS)** To strengthen the biomedical research and research training capability of ethnic minority institutions, and thus establish a more favorable milieu for increasing the involvement of minority faculty and students in biomedical research.
S07	**Biomedical Research Support Grants (NCRR BRSG)** As an example of this funding mechanism, the NIH issued a Request for Applications (RFA) in FY2004 to provide short-term interim support for institutional activities that will strengthen oversight of human subjects research at institutions that receive significant NIH support for clinical research. Although there is considerable flexibility in the types of activities that could be supported under the Biomedical Research Support Grant (BRSG) Program, that RFA emphasized the importance of efforts to enhance the protection of research subjects by means that would be sustained by the recipient institution after the award period ends. Awardees also are required to collaborate with other institutions conducting human subjects research and are not currently funded under this Program, and to share educational resources, computer technologies, best practices, etc. Although all NIH components supporting clinical research (including the NCI) are providing support for this Program, it is administered by the National Center for Research Resources (NCRR).
S10	**Biomedical Research Support Shared Instrumentation Grants (NCRR SIG)** The National Center for Research Resources (NCRR) initiated its competitive Shared Instrumentation Grant (SIG) Program in FY1982. The SIG Program provides support for expensive state-of-the-art instruments utilized in both basic and clinical research. This Program is designed to meet the special problems of acquisition and updating of expensive shared-use instruments that are not generally available through other NIH funding mechanisms, such as the regular research project, program project, or center grant programs. Applications for funds to design or to advance the design of new instruments are not accepted. The objective of this Program is to make available to institutions with a high concentration of NIH-supported biomedical investigators expensive research instruments that can only be justified on a shared-use basis and for which meritorious research projects are described.
S21	**Research and Institutional Resources Health Disparities Endowment Grants—Capacity Building** To strengthen the research and training infrastructure of the institution, while addressing current and emerging needs in minority health and other health disparities research.

T Series: Training Programs	
T15	**Continuing Education Training Grants** To assist professional schools and other public and nonprofit institutions in the establishment, expansion, or improvement of programs of continuing professional education, especially for programs of extensive continuation, extension, or refresher education dealing with new developments in the science and technology of the profession.
T32	**NIH National Research Service Award—Institutional Research Training Grants** To enable institutions to make National Research Service Awards to individuals selected by them for predoctoral and postdoctoral research training in specified shortage areas.
U Series: Cooperative Agreements	
U01	**Research Projects—Cooperative Agreements** To support a discrete, specified, circumscribed project to be performed by the named investigators in an area representing their specific interests and competencies.
U10	**Cooperative Clinical Research—Cooperative Agreements** To support clinical evaluation of various methods of therapy and/or prevention in specific disease areas. These represent cooperative programs between participating institutions and Principal Investigators, and are usually conducted under established protocols.
U13	**Conference—Cooperative Agreements** To coordinate, exchange, and disseminate information related to its program interests, an NIH Institute or Center can use this type of award to provide funding and direction for appropriate scientific conferences. These cooperative agreements allow the NCI to partner with one or more outside organizations to support international, national, or regional meetings, conferences, and workshops that are of value in promoting the goals of the National Cancer Program.
U19	**Research Program—Cooperative Agreements** To support a research program of multiple projects directed toward a specific major objective, basic theme, or program goal, requiring a broadly based, multidisciplinary, and often long-term approach.
U24	**Resource-Related Research Projects—Cooperative Agreements** To support research projects contributing to improvement of the capability of resources to serve biomedical research.

U54	**Specialized Center—Cooperative Agreements** To support any part of the full range of research and development from very basic to clinical; may involve ancillary supportive activities such as protracted patient care necessary to the primary research or R&D effort. The spectrum of activities comprises a multidisciplinary attack on a specific disease entity or biomedical problem area. These differ from program projects in that they are usually developed in response to an announcement of the programmatic needs of an Institute or Division and subsequently receive continual attention from its staff. Centers also may serve as regional or national resources for special research purposes, with assistance from staff of the funding component in identifying appropriate priority needs.
U56	**Exploratory Grants—Cooperative Agreements** To support planning for new programs, expansion or modification of existing resources, and feasibility studies to explore various approaches to the development of interdisciplinary programs that offer potential solutions to problems of special significance to the mission of the NIH. These exploratory studies may lead to specialized or comprehensive centers. Substantial Federal programmatic staff involvement is intended to assist investigators during performance of the research activities, as defined in the terms and conditions of award.

Appendix F: Glossary of Acronyms

AA	Annual Assessment
ADAMHA	Alcohol, Drug Abuse, and Mental Health Administration
AHRQ	Agency for Healthcare Research and Quality
AIDS	Acquired Immune Deficiency Syndrome
AISB	Applied Information Systems Branch
ARA	Awaiting Receipt of Application
AREA	Academic Research Enhancement Award
ATO	Authorization To Operate
BRSG	Biomedical Research Support Grant
BSA	Board of Scientific Advisors
BSC	Board of Scientific Counselors
C&A	Certification and Accreditation
caBIG®	Cancer Bioinformatics Grid
CBIIT	NCI Center for Biomedical Informatics and Information Technology
CCCT	Coordinating Center for Clinical Trials
CCR	Center for Cancer Research
CCSG	Cancer Center Support Grant
CCSS	Childhood Cancer Survival Study
CCT	Center for Cancer Training
CD	Career Development
CDC	Centers for Disease Control and Prevention
CEGP	Cancer Education Grant Program
CIDR	Center for Inherited Disease Research
CIT	Center for Information Technology
CMO	Committee Management Office
CoC	Council of Councils
CPTC	Clinical Proteomic Technologies for Cancer Initiative
CRCHD	Center to Reduce Cancer Health Disparities
CRECD	Clinical Research Education and Career Development
CSO	Common Scientific Outline
CSR	Center for Scientific Review
CSSI	Center for Strategic Scientific Initiatives
CTAC	Clinical Trials and Translational Research Advisory Committee
CTDD	Cancer Target Discovery and Development
DCB	Division of Cancer Biology
DCCPS	Division of Cancer Control and Population Sciences
DCEG	Division of Cancer Epidemiology and Genetics
DCLG	Director's Consumer Liaison Group
DCP	Division of Cancer Prevention
DCTD	Division of Cancer Treatment and Diagnosis
DEA	Division of Extramural Activities
DHHS	U.S. Department of Health and Human Services (now HHS)
DOC	Division/Office/Center
ELSI	Ethical Legal and Social Implications
EPMC	Extramural Program Management Committee
eRA	Electronic Research Administration
ESA	Extramural Support Assistant
EUREKA	Exceptional, Unconventional Research Enabling Knowledge Acceleration
FACA	Federal Advisory Committee Act
FDA	Food and Drug Administration
FFRDC	Federally Funded Research and Development Center
FIC	Fogarty International Center
FIRCA-BSS	Fogarty International Research Collaboration—Behavioral and Social Sciences
FIRCA-BB	Fogarty International Research Collaboration—Basic Biomedical
FLARE	Fiscal Linked Analysis of Research Emphasis
FOA	Funding Opportunity Announcements
FOIA	Freedom of Information Act

FY	Fiscal Year
GSS	General Support System
HHS	Department of Health and Human Services (replaces DHHS)
IC	Institute/Center
ICMIC	*In Vivo* Cellular and Molecular Imaging Center
ICRP	International Cancer Research Portfolio
IDeA	Institutional Development Award
IMPAC	Information for Management, Planning, Analysis, and Coordination
IOM	Institute of Medicine
IRG	Initial Review Group
IRM	Information Resources Management
IT	Information Technology
LOI	Letters of Intent
LRP	Loan Repayment Program
MBRS	Minority Biomedical Research Support
MDR	Multidrug Resistance
MERIT	Method to Extend Research in Time
MSI	Minority-Serving Institution
NCAB	National Cancer Advisory Board
NCCAM	National Center for Complementary and Alternative Medicine
NCI	National Cancer Institute
NCRR	National Center for Research Resources
NCTN	National Clinical Trials Network
NDPA	NIH Director Pioneer Award
NFAC	NCI Frederick Advisory Committee
NFRP	NCI Funded Research Portfolio
NIAID	National Institute of Allergy and Infectious Diseases
NIBIB	National Institute of Biomedical Imaging and Bioengineering
NICHD	Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDDK	National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS	National Institute of Environmental Health Sciences
NIH	National Institutes of Health
NK	Natural Killer (cells)
NRSA	National Research Service Award
OBF	Office of Budget and Finance
OBSSR	Office of Behavioral and Social Sciences Research
OCAM	Office of Complementary and Alternative Medicine
OCC	Office of Cancer Centers
OD	Office of the Director
OEA	Office of Extramural Applications
OEFIA	Office of Extramural Finance and Information Analysis
OER	Office of Extramural Research
OEWG	Operational Efficiency Working Group
OFACP	Office of Federal Advisory Committee Policy
OHAM	Office of HIV and AIDS Malignancies
OPERA	Office of Policy for Extramural Research Administration
ORRPC	Office of Referral, Review, and Program Coordination
OSHA	Occupational Safety and Health Administration
PA	Program Announcement
PAR	Reviewed Program Announcement
PCP	President's Cancer Panel
PCRB	Program Coordination and Referral Branch
PEPFAR	President's Emergency Plan for AIDS Relief
PHS	Public Health Service (HHS)
PI	Principal Investigator
PIV	Personal Identity Verification
PIN	Personal Identification Number
POA&M	Plan of Actions and Milestones
PRESTO	Program Review and Extramural Staff Training Office
PROSPR	Population-Based Research Optimizing Screening through Personalized Regimens
PRS	Peer Review Scoring
RAEB	Research Analysis and Evaluation Branch
R&D	Research and Development

RePORT	Research Portfolio Online Reporting Tools
RFA	Request for Applications
RFP	Request for Proposals
RIO	Research Integrity Officer
RM	Road Map
RO	Referral Officer
RPRB	Research Programs Review Branch
RTRB	Resources and Training Review Branch
RUG	Review Users Group
SACGHS	Secretary's Advisory Committee on Genetics, Health, and Society
SBIR	Small Business Innovation Research
SBIRDC	SBIR Development Center
SEER	Surveillance, Epidemiology, and End Results
SEP	Special Emphasis Panel
SGE	Special Government Employee
SIC	Special Interest Category
SIG	Shared Instrumentation Grant; also Special Interest Group
SITE	Organ Site Codes
SPECS	Strategic Partnering to Evaluate Cancer Signatures
SPL	Scientific Program Leadership
SPORE	Specialized Program of Research Excellence
SPRS	Secure Payee Reimbursement System
SREA	Scientific Review and Evaluation Activities
SRLB	Special Review and Logistics Branch
SRO	Scientific Review Officer (formerly Scientific Review Administrator)
SSL	Secure Sockets Layer
STTR	Small Business Technology Transfer Research
T&E	Training and Education
TEAG	Trans-NCI Extramural Awareness Group
TMEN	Tumor Microenvironment Network

Appendix G: Cancer Information Sources on the Internet

NCI Website

The National Cancer Institute maintains a number of websites containing information about the Institute and its programs. All NCI websites, including those designed to provide cancer-related information to the general public and physicians, can be reached from the NCI home page at **http://www.cancer.gov/**.

DEA Websites

The following websites are maintained by the DEA to provide detailed information to researchers and the public about NCI funding opportunities and the Advisory Boards and groups supported by the DEA.

http://deainfo.nci.nih.gov/index.htm
DEA home page links to the individual DEA Web pages listed below; mission of the Division; and contact information for DEA staff.

Advisory Boards and Groups

http://deainfo.nci.nih.gov/advisory/boards.htm
Links to the home page of each NCI Advisory Board, Committee, etc.

http://deainfo.nci.nih.gov/advisory/pcp/pcp.htm
President's Cancer Panel Charter; meeting agendas, meeting minutes, and annual reports.

http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm
National Cancer Advisory Board (NCAB) Charter; members of subcommittees, meeting agendas.

http://deainfo.nci.nih.gov/advisory/ncab/ncabmeetings.htm
NCAB meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm
Board of Scientific Advisors (BSA) Charter; members of subcommittees, meeting agendas.

http://deainfo.nci.nih.gov/advisory/bsa/bsameetings.htm
BSA meeting summaries.

http://deainfo.nci.nih.gov/advisory/fac/fac.htm
NCI Frederick Advisory Committee Charter; minutes, members, and meeting agendas.

http://deainfo.nci.nih.gov/advisory/bsc/bs/bs.htm
Board of Scientific Counselors Charter; members of subcommittees.

http://deainfo.nci.nih.gov/advisory/ctac/ctac.htm
Clinical Trials and Translational Research Advisory Committee Charter; members, minutes, and agendas.

http://deainfo.nci.nih.gov/advisory/dclg/dclg.htm
NCI Director's Consumer Liaison Group Charter; meeting schedules, agendas, minutes, and meeting summaries.

http://deainfo.nci.nih.gov/advisory/bsa/bsa_program/pogprogramfo.pdf
Program Review Groups reports.

http://deainfo.nci.nih.gov/advisory/irg/irg.htm
Initial Review Group Charter; subcommittee members.

http://deainfo.nci.nih.gov/advisory/sep/sep.htm
Special Emphasis Panel Charter; rosters of recent meetings.

Extramural Funding Opportunities/Policies

http://deainfo.nci.nih.gov/funding.htm
Comprehensive information about extramural funding for cancer research; lists of active PAs and RFAs; recently cleared concepts; grant policies and guidelines; and downloadable application forms.

http://deais.nci.nih.gov/Public/RFA-PA.jsp?nt=P
Active PAs, with links to detailed descriptions.

http://deais.nci.nih.gov/Public/RFA-PA.jsp
Active RFAs, with links to detailed descriptions.

http://deainfo.nci.nih.gov/grantspolicies/index.htm
Links to full-text NCI and NIH policies related to grants and grant review (e.g., Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research and Instructions to Reviewers for Evaluating Research Involving Human Subjects in Grant and Cooperative Agreement Applications).

http://deainfo.nci.nih.gov/flash/awards.htm
Grant Guidelines and Descriptions (descriptions of NCI funding mechanisms, with links to PAs, RFAs, guidelines, and supplemental materials).

http://fundedresearch.cancer.gov
NCI Funded Research Portfolio—A searchable database for information about research grant and contract awards made by the NCI. It includes awards for the current and past 5 fiscal years for both intramural and extramural projects. The website provides the ability to search the database in various ways, including a text search of the project abstract, and a search of the Special Interest Category (SIC), and anatomic site codes assigned to the project.

http://grants.nih.gov/grants/new_investigators/index.htm
New and Early Stage Investigator Policies.

http://www.cancer.gov/researchandfunding/training
The Center for Cancer Training (CCT).

http://report.nih.gov/index.aspx
Research Portfolio Online Reporting Tools (RePORT): reports, data, and analyses of NIH research activities.

Other NIH Websites

http://www.nih.gov
http://grants.nih.gov/grants/ElectronicReceipt/
http://grants.nih.gov/grants/policy/policy.htm
http://grants.nih.gov/grants/guide/index.html
http://grants.nih.gov/training/extramural.htm

NATIONAL® CANCER INSTITUTE

January 2013